Current model profile is worth tracking against the next run.
Baseline Rankings
Daily model-driven prospect rankings built from current performance, age-to-level context, trend movement, risk, and long-term baseline value.
Start with Median. Use Performance to see who is backing it up right now. Use High for upside, Trend for daily movement, and Risk before overreacting.
Rank is ordered by Prospect Score, the 1-100 model signal. Median is the projected value marker, so a player with a higher Median can rank below a player with a stronger all-around score if risk, performance, age-to-level context, confidence, source quality, or movement are weaker.
| Rank | Player | Org | Level | Pos | Low | Median | High | Performance | Trend | Risk | Top 100 Watch | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 95 |
SEA | AA | P | 88 | 92 | 96 | 85 |
-0.1% | Low Risk · 0 | N/A | |
| 2 | 91 |
BOS | AA | SS | 84 | 89 | 94 | 79 |
0.0% | Low Risk · 0 | N/A | |
| 3 | 89 |
SEA | AA | P | 82 | 87 | 92 | 75 |
+0.2% | Low Risk · 0 | N/A | |
| 4 | 87 |
LAD | AA | RF | 79 | 84 | 89 | 76 |
-0.7% | Low Risk · 0 | N/A | |
| 5 | 87 |
WSH | High-A | SS | 78 | 86 | 95 | 75 |
-0.1% | Low Risk · 11 | N/A | |
| 6 | 85 |
MIL | AA | SS | 78 | 83 | 88 | 66 |
+0.1% | Low Risk · 0 | N/A | |
| 7 | 84 |
MIL | Single-A | OF | 75 | 82 | 89 | 78 |
-0.1% | Low Risk · 3 | 81% Strong pressure | |
| 8 | 84 |
MIN | AAA | CF | 75 | 80 | 86 | 68 |
-0.6% | Low Risk · 0 | N/A | |
| 9 | 83 |
COL | AAA | 1B | 77 | 81 | 86 | 73 |
0.0% | Low Risk · 0 | N/A | |
| 10 | 83 |
DET | AAA | CF | 77 | 82 | 87 | 62 |
+0.1% | Low Risk · 0 | N/A | |
| 11 | 82 |
BAL | AA | P | 75 | 79 | 84 | 75 |
0.0% | Low Risk · 0 | 79% Watch closely | |
| 12 | 82 |
ATH | AA | SS | 76 | 82 | 87 | 61 |
-0.5% | Low Risk · 0 | N/A | |
| 13 | 81 |
KC | High-A | P | 71 | 80 | 89 | 73 |
0.0% | Low Risk · 11 | N/A | |
| 14 | 80 |
MIA | AA | OF | 71 | 76 | 82 | 76 |
-0.9% | Low Risk · 0 | 76% Watch closely | |
| 15 | 80 |
CLE | AAA | 3B | 72 | 76 | 81 | 65 |
-0.6% | Low Risk · 0 | N/A | |
| 16 | 80 |
CIN | AAA | LF | 73 | 77 | 82 | 67 |
-0.4% | Low Risk · 0 | 79% Watch closely | |
| 17 | 80 |
STL | AA | C | 73 | 78 | 83 | 60 |
+0.3% | Low Risk · 0 | N/A | |
| 18 | 79 |
KC | High-A | P | 70 | 75 | 81 | 69 |
+0.1% | Low Risk · 3 | 77% Watch closely | |
| 19 | 78 |
CWS | AA | SS | 69 | 77 | 85 | 68 |
+0.5% | Low Risk · 8 | N/A | |
| 20 | 78 |
MIL | High-A | SS | 70 | 80 | 90 | 71 |
0.0% | Low Risk · 21 | N/A | |
| 21 | 78 |
CLE | Single-A | OF | 70 | 75 | 80 | 71 |
+0.3% | Low Risk · 3 | 76% Watch closely | |
| 22 | 78 |
LAD | AA | CF | 73 | 78 | 83 | 60 |
+0.3% | Low Risk · 0 | N/A | |
| 23 | 78 |
LAA | AAA | CF | 71 | 76 | 81 | 62 |
-0.1% | Low Risk · 5 | 78% Watch closely | |
| 24 | 78 |
PIT | High-A | P | 75 | 82 | 88 | 62 |
0.0% | Low Risk · 17 | N/A | |
| 25 | 78 |
LAD | AA | CF | 69 | 73 | 77 | 70 |
0.0% | Low Risk · 0 | N/A | |
| 26 | 77 |
LAD | AAA | RF | 69 | 73 | 78 | 69 |
-0.2% | Low Risk · 0 | 75% Watch closely | |
| 27 | 77 |
LAA | AA | P | 69 | 74 | 81 | 72 |
-0.4% | Low Risk · 0 | 72% Watch closely | |
| 28 | 77 |
MIN | AAA | OF | 69 | 73 | 79 | 66 |
+0.2% | Low Risk · 0 | 76% Watch closely | |
| 29 | 77 |
TB | High-A | C | 67 | 73 | 78 | 65 |
-0.3% | Low Risk · 3 | N/A | |
| 30 | 77 |
CHC | High-A | OF | 68 | 73 | 79 | 65 |
-0.4% | Low Risk · 3 | N/A | |
| 31 | 77 |
STL | Single-A | SS | 64 | 71 | 80 | 71 |
0.0% | Low Risk · 3 | 71% Watch closely | |
| 32 | 76 |
MIL | High-A | OF | 68 | 73 | 79 | 66 |
-0.1% | Low Risk · 3 | 75% Watch closely | |
| 33 | 76 |
TB | AAA | P | 68 | 71 | 75 | 70 |
0.0% | Low Risk · 0 | 73% Watch closely | |
| 34 | 76 |
BOS | AA | P | 65 | 70 | 76 | 65 |
0.0% | Low Risk · 0 | N/A | |
| 35 | 76 |
SEA | AA | RF | 70 | 74 | 79 | 64 |
+0.3% | Low Risk · 12 | N/A | |
| 36 | 76 |
STL | High-A | P | 68 | 74 | 79 | 64 |
0.0% | Low Risk · 3 | 75% Watch closely | |
| 37 | 76 |
CLE | AA | CF | 67 | 72 | 77 | 65 |
-0.9% | Low Risk · 0 | 75% Watch closely | |
| 38 | 76 |
BAL | AA | P | 66 | 72 | 78 | 74 |
0.0% | Low Risk · 0 | 70% Watch closely | |
| 39 | 76 |
CLE | AAA | 1B | 67 | 72 | 78 | 58 |
+0.4% | Low Risk · 0 | N/A | |
| 40 | 76 |
SEA | AA | SS | 69 | 74 | 78 | 59 |
-0.1% | Low Risk · 0 | N/A | |
| 41 | 75 |
MIL | AA | P | 68 | 73 | 78 | 65 |
0.0% | Low Risk · 0 | 74% Watch closely | |
| 42 | 75 |
STL | AAA | RF | 66 | 71 | 76 | 61 |
-0.1% | Low Risk · 0 | N/A | |
| 43 | 75 |
STL | AAA | C | 66 | 71 | 76 | 61 |
-0.1% | Low Risk · 0 | 74% Watch closely | |
| 44 | 75 |
NYM | High-A | P | 64 | 70 | 77 | 73 |
+1.5% | Low Risk · 0 | 70% Watch closely | |
| 45 | 75 |
TB | AAA | P | 66 | 73 | 81 | 66 |
-0.5% | Low Risk · 4 | 72% Watch closely | |
| 46 | 75 |
MIL | AAA | 3B | 61 | 70 | 81 | 76 |
-0.1% | Low Risk · 15 | 69% Watch closely | |
| 47 | 75 |
CHC | AA | SS | 66 | 70 | 75 | 62 |
-0.1% | Low Risk · 0 | N/A | |
| 48 | IL(7-Day)75 |
CWS | AAA | 2BIL(7-Day) | 60 | 68 | 78 | 76 |
0.0% | Low Risk · 20 | 69% Watch closely | |
| 49 | 75 |
LAD | AAA | OF | 66 | 70 | 75 | 65 |
+0.5% | Low Risk · 0 | 73% Watch closely | |
| 50 | 75 |
WSH | AAA | P | 66 | 70 | 75 | 64 |
0.0% | Low Risk · 0 | 72% Watch closely | |
| 51 | 75 |
STL | AAA | P | 65 | 69 | 73 | 69 |
+0.6% | Low Risk · 0 | 72% Watch closely | |
| 52 | 75 |
ATL | High-A | P | 67 | 73 | 79 | 57 |
+0.4% | Low Risk · 3 | N/A | |
| 53 | 74 |
TB | AA | P | 66 | 71 | 76 | 61 |
0.0% | Low Risk · 0 | 73% Watch closely | |
| 54 | 74 |
BOS | High-A | C | 64 | 70 | 77 | 71 |
-0.8% | Low Risk · 0 | 69% Watch closely | |
| 55 | 74 |
NYM | AA | P | 65 | 71 | 78 | 69 |
+0.2% | Low Risk · 0 | 70% Watch closely | |
| 56 | 74 |
ATL | High-A | OF | 65 | 70 | 75 | 63 |
+0.1% | Low Risk · 0 | N/A | |
| 57 | 74 |
LAD | High-A | CF | 67 | 72 | 77 | 60 |
-0.2% | Low Risk · 0 | N/A | |
| 58 | 74 |
PIT | High-A | OF | 67 | 73 | 79 | 56 |
+1.0% | Low Risk · 3 | N/A | |
| 59 | 74 |
MIA | AAA | 2B | 60 | 67 | 74 | 73 |
-0.2% | Low Risk · 4 | 67% Watch closely | |
| 60 | 74 |
ATH | AA | OF | 64 | 69 | 75 | 67 |
+1.6% | Low Risk · 0 | 70% Watch closely | |
| 61 | 74 |
LAD | AA | P | 62 | 70 | 83 | 73 |
0.0% | Low Risk · 24 | 67% Watch closely | |
| 62 | 74 |
PHI | AA | SS | 65 | 69 | 73 | 65 |
+0.4% | Low Risk · 0 | 72% Watch closely | |
| 63 | 73 |
BOS | High-A | CF | 64 | 69 | 75 | 59 |
-0.2% | Low Risk · 3 | N/A | |
| 64 | 73 |
LAA | High-A | P | 65 | 72 | 78 | 61 |
-2.7% | Low Risk · 0 | N/A | |
| 65 | 73 |
SEA | High-A | SS | 64 | 68 | 73 | 63 |
-0.2% | Low Risk · 0 | N/A | |
| 66 | 73 |
PHI | AA | P | 63 | 70 | 76 | 65 |
0.0% | Low Risk · 4 | N/A | |
| 67 | 73 |
COL | Single-A | 3B | 64 | 70 | 75 | 60 |
+0.3% | Low Risk · 3 | N/A | |
| 68 | 73 |
NYY | AAA | P | 65 | 70 | 75 | 59 |
0.0% | Low Risk · 10 | N/A | |
| 69 | 73 |
TOR | Single-A | SS | 66 | 72 | 77 | 59 |
-0.3% | Low Risk · 3 | N/A | |
| 70 | 72 |
NYY | AA | P | 63 | 69 | 75 | 69 |
-0.1% | Low Risk · 0 | 68% Watch closely | |
| 71 | 72 |
STL | High-A | C | 60 | 68 | 75 | 69 |
-0.3% | Low Risk · 4 | 66% Watch closely | |
| 72 | 72 |
SEA | Single-A | P | 64 | 69 | 74 | 74 |
-0.3% | Low Risk · 12 | 68% Watch closely | |
| 73 | 72 |
COL | ACL | OF | 64 | 70 | 76 | 74 |
+0.3% | Low Risk · 24 | 69% Watch closely | |
| 74 | 72 |
TOR | AAA | 2B | 60 | 66 | 74 | 70 |
+0.9% | Low Risk · 4 | 66% Watch closely | |
| 75 | 72 |
LAD | High-A | P | 61 | 66 | 71 | 67 |
0.0% | Low Risk · 0 | 68% Watch closely | |
| 76 | 72 |
MIL | AAA | P | 62 | 66 | 70 | 64 |
0.0% | Low Risk · 0 | 70% Watch closely | |
| 77 | 72 |
LAA | Single-A | OF | 62 | 67 | 72 | 63 |
0.0% | Low Risk · 3 | 70% Watch closely | |
| 78 | 72 |
BOS | AA | P | 63 | 67 | 71 | 64 |
0.0% | Low Risk · 0 | 70% Watch closely | |
| 79 | 72 |
CHC | High-A | SS | 60 | 66 | 73 | 68 |
+0.3% | Low Risk · 0 | 66% Watch closely | |
| 80 | 71 |
TOR | High-A | P | 63 | 68 | 74 | 63 |
+1.0% | Low Risk · 17 | 69% Watch closely | |
| 81 | 71 |
ATL | AAA | P | 65 | 73 | 82 | 66 |
-0.2% | Low Risk · 24 | 69% Watch closely | |
| 82 | 71 |
SF | High-A | IF | 61 | 69 | 76 | 55 |
-0.7% | Low Risk · 3 | N/A | |
| 83 | 71 |
BAL | AAA | P | 62 | 69 | 76 | 65 |
0.0% | Low Risk · 10 | 68% Watch closely | |
| 84 | 71 |
SD | High-A | P | 61 | 65 | 70 | 64 |
+0.3% | Low Risk · 0 | 68% Watch closely | |
| 85 | 71 |
BAL | AA | 2B | 62 | 67 | 72 | 58 |
+0.2% | Low Risk · 0 | 71% Watch closely | |
| 86 | 71 |
MIA | Single-A | IF | 59 | 68 | 77 | 66 |
0.0% | Low Risk · 16 | 68% Watch closely | |
| 87 | 71 |
BAL | AA | C | 62 | 66 | 70 | 64 |
+0.1% | Low Risk · 0 | 70% Watch closely | |
| 88 | 71 |
HOU | Single-A | CF | 63 | 69 | 74 | 53 |
-0.2% | Low Risk · 3 | N/A | |
| 89 | 71 |
MIA | High-A | P | 62 | 66 | 71 | 62 |
+0.2% | Low Risk · 0 | 69% Watch closely | |
| 90 | 71 |
MIL | AA | 3B | 62 | 69 | 77 | 68 |
+2.3% | Low Risk · 20 | 67% Watch closely | |
| 91 | 71 |
LAA | AA | CF | 62 | 65 | 70 | 64 |
-0.1% | Low Risk · 0 | 69% Watch closely | |
| 92 | 71 |
MIA | Single-A | IF | 58 | 66 | 78 | 68 |
0.0% | Low Risk · 11 | 64% Emerging | |
| 93 | 71 |
CIN | High-A | C | 64 | 74 | 83 | 62 |
-2.3% | Low Risk · 18 | N/A | |
| 94 | 71 |
SF | ACL | SS | 63 | 70 | 76 | 63 |
-0.2% | Low Risk · 24 | N/A | |
| 95 | 71 |
MIL | AA | OF | 60 | 67 | 75 | 65 |
0.0% | Low Risk · 8 | 68% Watch closely | |
| 96 | 71 |
LAD | High-A | SS | 63 | 69 | 75 | 53 |
-0.5% | Low Risk · 3 | N/A | |
| 97 | 71 |
WSH | AAA | SS | 63 | 69 | 73 | 53 |
0.0% | Low Risk · 0 | N/A | |
| 98 | 71 |
SEA | High-A | OF | 63 | 68 | 73 | 59 |
+0.3% | Low Risk · 0 | N/A | |
| 99 | 71 |
ATH | AAA | 3B | 62 | 66 | 71 | 58 |
-0.3% | Low Risk · 0 | 70% Watch closely | |
| 100 | 71 |
SD | Single-A | P | 60 | 67 | 74 | 63 |
0.0% | Low Risk · 3 | 68% Watch closely | |
| 101 | 71 |
STL | AA | P | 70 | 76 | 81 | 49 |
0.0% | Low Risk · 20 | N/A | |
| 102 | 70 |
CLE | AA | RF | 63 | 67 | 72 | 61 |
-0.1% | Low Risk · 12 | 69% Watch closely | |
| 103 | 70 |
MIL | AA | CF | 61 | 65 | 70 | 63 |
0.0% | Low Risk · 0 | 67% Watch closely | |
| 104 | 70 |
DET | AAA | 2B | 61 | 65 | 69 | 61 |
-0.1% | Low Risk · 0 | 68% Watch closely | |
| 105 | 70 |
LAD | High-A | OF | 63 | 68 | 72 | 60 |
-0.4% | Low Risk · 0 | N/A | |
| 106 | 70 |
TOR | Single-A | P | 58 | 66 | 75 | 68 |
-0.3% | Low Risk · 11 | 64% Emerging | |
| 107 | 70 |
TB | High-A | P | 60 | 66 | 73 | 71 |
0.0% | Low Risk · 10 | 65% Watch closely | |
| 108 | 70 |
PIT | High-A | 3B | 61 | 65 | 70 | 65 |
+0.6% | Low Risk · 0 | 67% Watch closely | |
| 109 | IL(7-Day)70 |
CWS | AAA | PIL(7-Day) | 61 | 67 | 75 | 66 |
0.0% | Low Risk · 24 | 66% Watch closely | |
| 110 | 70 |
MIL | ACL | SS | 60 | 68 | 76 | 74 |
0.0% | Low Risk · 24 | 65% Watch closely | |
| 111 | 70 |
KC | High-A | P | 59 | 66 | 74 | 64 |
0.0% | Low Risk · 0 | 65% Watch closely | |
| 112 | 70 |
BOS | FCL | C | 60 | 68 | 78 | 73 |
+0.1% | Low Risk · 24 | 65% Watch closely | |
| 113 | 70 |
STL | AA | SS | 60 | 68 | 77 | 68 |
+0.5% | Low Risk · 18 | 66% Watch closely | |
| 114 | 70 |
LAD | High-A | 3B | 58 | 67 | 76 | 67 |
-0.4% | Low Risk · 21 | 66% Watch closely | |
| 115 | 70 |
PIT | AAA | 2B | 61 | 66 | 71 | 52 |
+0.2% | Low Risk · 0 | 70% Watch closely | |
| 116 | 70 |
DET | High-A | SS | 65 | 71 | 77 | 56 |
-0.1% | Low Risk · 16 | N/A | |
| 117 | 70 |
BAL | AAA | C | 61 | 66 | 70 | 57 |
-0.4% | Low Risk · 0 | 70% Watch closely | |
| 118 | 70 |
TEX | AA | 3B | 59 | 65 | 71 | 66 |
+1.7% | Low Risk · 0 | 65% Watch closely | |
| 119 | 70 |
HOU | Single-A | SS | 62 | 68 | 73 | 61 |
+0.1% | Low Risk · 19 | N/A | |
| 120 | 70 |
TB | AA | OF | 62 | 71 | 80 | 63 |
-1.0% | Low Risk · 32 | N/A | |
| 121 | 70 |
MIN | High-A | C | 65 | 72 | 78 | 48 |
-0.2% | Low Risk · 12 | N/A | |
| 122 | 70 |
MIL | Single-A | CF | 59 | 65 | 73 | 61 |
0.0% | Low Risk · 3 | 67% Watch closely | |
| 123 | 69 |
STL | Single-A | SS | 58 | 69 | 81 | 66 |
0.0% | Low Risk · 21 | 66% Watch closely | |
| 124 | 69 |
LAA | ACL | P | 61 | 67 | 75 | 68 |
-0.1% | Low Risk · 24 | 65% Watch closely | |
| 125 | 69 |
LAA | AA | C | 59 | 68 | 77 | 67 |
-1.8% | Low Risk · 27 | 66% Watch closely | |
| 126 | 69 |
MIA | AA | SS | 63 | 70 | 77 | 53 |
0.0% | Low Risk · 5 | N/A | |
| 127 | 69 |
LAD | Single-A | OF | 59 | 63 | 68 | 61 |
-0.3% | Low Risk · 3 | 66% Watch closely | |
| 128 | 69 |
BAL | High-A | C | 62 | 67 | 72 | 57 |
-0.1% | Low Risk · 0 | N/A | |
| 129 | 69 |
ARI | AA | 2B | 60 | 64 | 69 | 56 |
-0.4% | Low Risk · 0 | 69% Watch closely | |
| 130 | 69 |
ARI | AAA | 2B | 57 | 65 | 73 | 66 |
+0.1% | Low Risk · 9 | 64% Emerging | |
| 131 | 69 |
MIA | AA | P | 60 | 66 | 73 | 62 |
+5.6% | Low Risk · 10 | 66% Watch closely | |
| 132 | 69 |
BOS | High-A | P | 58 | 65 | 72 | 63 |
0.0% | Low Risk · 0 | 65% Watch closely | |
| 133 | 69 |
ATL | High-A | P | 58 | 67 | 77 | 68 |
-0.1% | Low Risk · 31 | 64% Emerging | |
| 134 | 69 |
WSH | AAA | 1B | 60 | 64 | 68 | 60 |
+0.6% | Low Risk · 0 | 68% Watch closely | |
| 135 | 69 |
BOS | Single-A | SS | 56 | 65 | 78 | 66 |
-0.1% | Low Risk · 21 | 62% Emerging | |
| 136 | 69 |
PIT | AAA | 3B | 56 | 65 | 74 | 70 |
0.0% | Low Risk · 14 | 62% Emerging | |
| 137 | 69 |
CHC | High-A | OF | 58 | 62 | 67 | 63 |
-1.2% | Low Risk · 0 | 66% Watch closely | |
| 138 | 69 |
PIT | High-A | C | 59 | 63 | 68 | 61 |
-0.4% | Low Risk · 0 | 67% Watch closely | |
| 139 | 69 |
PHI | AA | 2B | 60 | 65 | 70 | 51 |
-0.2% | Low Risk · 0 | 68% Watch closely | |
| 140 | 69 |
MIL | AA | 1B | 60 | 64 | 68 | 60 |
+1.4% | Low Risk · 0 | 68% Watch closely | |
| 141 | 69 |
PHI | AAA | 2B | 59 | 63 | 68 | 60 |
-0.1% | Low Risk · 0 | 65% Watch closely | |
| 142 | 68 |
HOU | AA | CF | 58 | 64 | 71 | 68 |
+0.2% | Low Risk · 10 | 63% Emerging | |
| 143 | 68 |
ATH | AA | P | 65 | 71 | 76 | 51 |
0.0% | Low Risk · 20 | N/A | |
| 144 | 68 |
KC | High-A | C | 65 | 71 | 76 | 53 |
+0.1% | Low Risk · 12 | N/A | |
| 145 | 68 |
PHI | High-A | P | 56 | 64 | 72 | 65 |
-0.1% | Low Risk · 18 | 63% Emerging | |
| 146 | 68 |
ARI | AAA | C | 59 | 64 | 69 | 58 |
-0.9% | Low Risk · 0 | 66% Watch closely | |
| 147 | 68 |
PIT | Single-A | P | 59 | 64 | 69 | 62 |
0.0% | Low Risk · 17 | 66% Watch closely | |
| 148 | 68 |
BAL | AAA | P | 58 | 62 | 66 | 58 |
+1.2% | Low Risk · 0 | 66% Watch closely | |
| 149 | 68 |
BOS | AA | C | 60 | 65 | 70 | 60 |
+1.5% | Low Risk · 12 | 65% Watch closely | |
| 150 | 68 |
STL | AA | 3B | 57 | 65 | 74 | 66 |
0.0% | Low Risk · 14 | 64% Emerging | |
| 151 | 68 |
CIN | ACL | P | 58 | 66 | 75 | 69 |
-0.1% | Low Risk · 24 | 63% Emerging | |
| 152 | 68 |
PIT | AAA | 2B | 57 | 64 | 73 | 63 |
0.0% | Low Risk · 9 | 64% Emerging | |
| 153 | 68 |
SF | High-A | P | 56 | 60 | 65 | 59 |
0.0% | Low Risk · 0 | 64% Emerging | |
| 154 | 68 |
NYY | AA | SS | 56 | 65 | 74 | 68 |
-0.3% | Low Risk · 14 | 62% Emerging | |
| 155 | 68 |
MIL | Single-A | SS | 58 | 63 | 68 | 57 |
-0.6% | Low Risk · 3 | 67% Watch closely | |
| 156 | 68 |
CHC | AAA | 2B | 59 | 63 | 67 | 55 |
-0.3% | Low Risk · 0 | 68% Watch closely | |
| 157 | 68 |
CHC | Single-A | P | 58 | 67 | 80 | 62 |
0.0% | Low Risk · 21 | 64% Emerging | |
| 158 | 68 |
LAD | AAA | SS | 59 | 63 | 67 | 56 |
0.0% | Low Risk · 0 | 68% Watch closely | |
| 159 | 68 |
STL | AAA | P | 58 | 62 | 66 | 57 |
+1.8% | Low Risk · 0 | 67% Watch closely | |
| 160 | 68 |
ATL | High-A | SS | 57 | 65 | 73 | 57 |
-0.7% | Low Risk · 11 | 65% Watch closely | |
| 161 | 68 |
ATL | Single-A | OF | 56 | 65 | 80 | 66 |
0.0% | Low Risk · 21 | 61% Emerging | |
| 162 | 67 |
KC | Single-A | 3B | 61 | 67 | 72 | 50 |
+0.3% | Low Risk · 3 | N/A | |
| 163 | 67 |
TOR | AA | P | 60 | 65 | 69 | 56 |
0.0% | Low Risk · 10 | 66% Watch closely | |
| 164 | 67 |
BAL | High-A | P | 57 | 61 | 66 | 61 |
0.0% | Low Risk · 0 | 65% Watch closely | |
| 165 | 67 |
TB | AA | P | 58 | 62 | 67 | 54 |
0.0% | Low Risk · 0 | 67% Watch closely | |
| 166 | 67 |
DET | Single-A | SS | 57 | 61 | 66 | 58 |
+0.1% | Low Risk · 3 | 65% Watch closely | |
| 167 | 67 |
TB | High-A | P | 56 | 63 | 71 | 67 |
-0.1% | Low Risk · 10 | 61% Emerging | |
| 168 | 67 |
SD | Single-A | P | 55 | 63 | 76 | 64 |
0.0% | Low Risk · 8 | 61% Emerging | |
| 169 | 67 |
WSH | High-A | P | 59 | 68 | 77 | 63 |
-3.5% | Low Risk · 35 | 65% Watch closely | |
| 170 | 67 |
CHC | AA | C | 59 | 63 | 68 | 66 |
+0.7% | Low Risk · 10 | 65% Watch closely | |
| 171 | 67 |
HOU | Single-A | P | 58 | 64 | 71 | 63 |
0.0% | Low Risk · 17 | 64% Emerging | |
| 172 | 67 |
BOS | AAA | SS | 58 | 63 | 68 | 51 |
-0.3% | Low Risk · 0 | 68% Watch closely | |
| 173 | 67 |
HOU | AAA | 2B | 56 | 62 | 69 | 63 |
-0.5% | Low Risk · 4 | 62% Emerging | |
| 174 | 67 |
SF | ACL | IF | 60 | 71 | 80 | 59 |
+0.3% | Low Risk · 32 | N/A | |
| 175 | 67 |
ATL | High-A | 3B | 56 | 61 | 67 | 55 |
-0.1% | Low Risk · 0 | 66% Watch closely | |
| 176 | 67 |
MIA | High-A | SS | 56 | 60 | 65 | 57 |
-0.7% | Low Risk · 0 | 65% Watch closely | |
| 177 | 67 |
CHC | AAA | CF | 57 | 61 | 65 | 58 |
-0.6% | Low Risk · 0 | 66% Watch closely | |
| 178 | 67 |
CIN | ACL | SS | 61 | 68 | 74 | 60 |
+0.3% | Low Risk · 24 | N/A | |
| 179 | 67 |
TB | Single-A | P | 57 | 64 | 71 | 69 |
0.0% | Low Risk · 12 | 62% Emerging | |
| 180 | 67 |
LAA | Single-A | C | 59 | 65 | 71 | 49 |
-0.1% | Low Risk · 3 | 68% Watch closely | |
| 181 | 67 |
DET | AA | C | 60 | 64 | 68 | 53 |
0.0% | Low Risk · 0 | 67% Watch closely | |
| 182 | 67 |
ATH | AAA | RF | 57 | 61 | 66 | 58 |
-1.9% | Low Risk · 0 | 63% Emerging | |
| 183 | 67 |
NYM | Single-A | P | 56 | 62 | 68 | 61 |
0.0% | Low Risk · 3 | 64% Emerging | |
| 184 | 67 |
CWS | Single-A | P | 54 | 61 | 68 | 62 |
0.0% | Low Risk · 0 | 62% Emerging | |
| 185 | 67 |
ARI | AA | P | 55 | 65 | 76 | 69 |
+0.2% | Low Risk · 29 | 61% Emerging | |
| 186 | 67 |
SEA | High-A | P | 57 | 63 | 70 | 65 |
0.0% | Low Risk · 10 | 62% Emerging | |
| 187 | 67 |
ARI | High-A | OF | 59 | 65 | 70 | 48 |
-0.2% | Low Risk · 0 | 67% Watch closely | |
| 188 | 67 |
SF | High-A | SS | 59 | 64 | 69 | 55 |
-0.2% | Low Risk · 0 | 65% Watch closely | |
| 189 | 67 |
WSH | AA | P | 56 | 62 | 68 | 58 |
+0.1% | Low Risk · 0 | 63% Emerging | |
| 190 | 67 |
ARI | Single-A | P | 54 | 63 | 73 | 63 |
0.0% | Low Risk · 21 | 62% Emerging | |
| 191 | 67 |
ARI | AAA | CF | 56 | 65 | 77 | 67 |
0.0% | Low Risk · 14 | 61% Emerging | |
| 192 | 67 |
TB | AA | SS | 55 | 61 | 69 | 65 |
-0.6% | Low Risk · 4 | 60% Emerging | |
| 193 | 67 |
NYM | Single-A | SS | 57 | 62 | 68 | 55 |
-0.5% | Low Risk · 8 | 66% Watch closely | |
| 194 | 67 |
MIA | AAA | P | 59 | 67 | 76 | 58 |
+0.1% | Low Risk · 28 | N/A | |
| 195 | 67 |
MIL | AAA | C | 56 | 65 | 78 | 68 |
-0.3% | Low Risk · 15 | 60% Emerging | |
| 196 | 66 |
MIA | Single-A | OF | 54 | 62 | 70 | 61 |
-0.1% | Low Risk · 11 | 63% Emerging | |
| 197 | 66 |
WSH | AAA | 1B | 57 | 61 | 65 | 57 |
-0.6% | Low Risk · 0 | 66% Watch closely | |
| 198 | 66 |
LAD | Single-A | P | 57 | 61 | 67 | 60 |
-0.1% | Low Risk · 0 | 64% Emerging | |
| 199 | 66 |
HOU | Single-A | P | 54 | 62 | 75 | 62 |
0.0% | Low Risk · 8 | 60% Emerging | |
| 200 | 66 |
NYY | Single-A | P | 57 | 62 | 67 | 67 |
0.0% | Low Risk · 14 | 63% Emerging | |
| 201 | 66 |
PIT | High-A | SS | 56 | 60 | 65 | 58 |
+0.1% | Low Risk · 0 | 64% Emerging | |
| 202 | 66 |
BOS | AA | C | 58 | 62 | 67 | 53 |
0.0% | Low Risk · 0 | 68% Watch closely | |
| 203 | 66 |
NYY | AA | LF | 57 | 61 | 65 | 57 |
-0.3% | Low Risk · 0 | 66% Watch closely | |
| 204 | 66 |
STL | AA | P | 62 | 67 | 71 | 50 |
+0.1% | Low Risk · 10 | N/A | |
| 205 | 66 |
MIA | Single-A | P | 55 | 61 | 67 | 62 |
+0.1% | Low Risk · 0 | 63% Emerging | |
| 206 | 66 |
CHC | High-A | SS | 56 | 60 | 65 | 60 |
-0.1% | Low Risk · 5 | 65% Watch closely | |
| 207 | 66 |
SEA | High-A | P | 56 | 62 | 70 | 64 |
+0.6% | Low Risk · 10 | 61% Emerging | |
| 208 | 66 |
SF | AA | P | 58 | 62 | 67 | 63 |
0.0% | Low Risk · 10 | 62% Emerging | |
| 209 | 66 |
CIN | High-A | P | 54 | 60 | 67 | 62 |
0.0% | Low Risk · 0 | 61% Emerging | |
| 210 | 66 |
BOS | High-A | P | 61 | 66 | 71 | 47 |
-0.1% | Low Risk · 0 | N/A | |
| 211 | 66 |
PHI | DSL | OF | 56 | 64 | 72 | 62 |
+0.5% | Low Risk · 24 | 62% Emerging | |
| 212 | 66 |
CWS | AA | 3B | 56 | 60 | 65 | 59 |
-1.4% | Low Risk · 0 | 62% Emerging | |
| 213 | 66 |
SD | AA | P | 55 | 60 | 66 | 59 |
+0.3% | Low Risk · 0 | 61% Emerging | |
| 214 | 66 |
TEX | Single-A | C | 55 | 65 | 79 | 64 |
+0.1% | Low Risk · 21 | 61% Emerging | |
| 215 | 66 |
TEX | AA | P | 55 | 59 | 63 | 59 |
0.0% | Low Risk · 0 | 63% Emerging | |
| 216 | 66 |
CHC | AA | P | 56 | 63 | 70 | 67 |
+0.1% | Low Risk · 24 | 60% Emerging | |
| 217 | 66 |
STL | AAA | P | 56 | 63 | 71 | 64 |
0.0% | Low Risk · 14 | 61% Emerging | |
| 218 | 66 |
KC | High-A | C | 54 | 59 | 63 | 56 |
+0.4% | Low Risk · 0 | 63% Emerging | |
| 219 | 66 |
MIL | AA | P | 55 | 62 | 73 | 65 |
+2.5% | Low Risk · 18 | 59% Emerging | |
| 220 | 66 |
HOU | Single-A | P | 56 | 62 | 70 | 66 |
-0.3% | Low Risk · 12 | 61% Emerging | |
| 221 | 66 |
LAA | AA | P | 54 | 60 | 66 | 55 |
0.0% | Low Risk · 0 | 64% Emerging | |
| 222 | 66 |
CIN | AA | 3B | 56 | 61 | 65 | 51 |
-0.5% | Low Risk · 0 | 66% Watch closely | |
| 223 | 66 |
NYM | High-A | 2B | 58 | 64 | 68 | 51 |
-0.4% | Low Risk · 0 | 65% Watch closely | |
| 224 | 66 |
MIL | Single-A | SS | 55 | 61 | 68 | 57 |
+0.1% | Low Risk · 3 | 64% Emerging | |
| 225 | 66 |
ATH | AA | C | 54 | 63 | 74 | 65 |
0.0% | Low Risk · 14 | 62% Emerging | |
| 226 | 66 |
BAL | AA | SS | 56 | 60 | 64 | 59 |
+0.2% | Low Risk · 0 | 62% Emerging | |
| 227 | 66 |
ARI | AA | P | 55 | 59 | 64 | 54 |
+0.1% | Low Risk · 0 | 64% Emerging | |
| 228 | 66 |
HOU | AAA | P | 56 | 60 | 64 | 53 |
-1.0% | Low Risk · 0 | 65% Watch closely | |
| 229 | 65 |
ARI | AA | C | 56 | 64 | 73 | 62 |
-0.3% | Low Risk · 23 | 63% Emerging | |
| 230 | 65 |
WSH | AA | C | 56 | 60 | 64 | 57 |
+1.0% | Low Risk · 0 | 65% Watch closely | |
| 231 | 65 |
MIA | AA | SS | 56 | 59 | 64 | 55 |
+0.8% | Low Risk · 0 | 65% Watch closely | |
| 232 | 65 |
PIT | FCL | IF | 54 | 61 | 69 | 63 |
-0.4% | Low Risk · 24 | 62% Emerging | |
| 233 | 65 |
CLE | AAA | C | 56 | 60 | 64 | 60 |
-1.2% | Low Risk · 1 | 62% Emerging | |
| 234 | 65 |
TOR | AA | P | 57 | 62 | 67 | 62 |
0.0% | Low Risk · 10 | 61% Emerging | |
| 235 | 65 |
NYY | High-A | CF | 54 | 59 | 64 | 57 |
0.0% | Low Risk · 0 | 64% Emerging | |
| 236 | 65 |
TB | Single-A | SS | 55 | 59 | 64 | 56 |
-0.6% | Low Risk · 3 | 63% Emerging | |
| 237 | 65 |
TEX | High-A | CF | 53 | 59 | 65 | 58 |
+0.3% | Low Risk · 0 | 63% Emerging | |
| 238 | 65 |
CLE | AAA | P | 56 | 65 | 73 | 66 |
-0.3% | Low Risk · 24 | 60% Emerging | |
| 239 | 65 |
ARI | AA | SS | 55 | 64 | 73 | 64 |
-0.1% | Low Risk · 30 | 60% Emerging | |
| 240 | 65 |
WSH | AAA | P | 55 | 60 | 65 | 52 |
0.0% | Low Risk · 10 | 64% Emerging | |
| 241 | 65 |
WSH | High-A | SS | 56 | 61 | 67 | 51 |
0.0% | Low Risk · 3 | 66% Watch closely | |
| 242 | 65 |
MIA | AAA | RF | 56 | 60 | 65 | 55 |
0.0% | Low Risk · 12 | 64% Emerging | |
| 243 | 65 |
TB | High-A | P | 54 | 58 | 63 | 54 |
-0.1% | Low Risk · 0 | 63% Emerging | |
| 244 | 65 |
ATL | AA | P | 56 | 60 | 64 | 57 |
0.0% | Low Risk · 10 | 64% Emerging | |
| 245 | 65 |
COL | High-A | 2B | 54 | 59 | 64 | 59 |
-0.6% | Low Risk · 0 | 62% Emerging | |
| 246 | 65 |
BAL | Single-A | SS | 53 | 61 | 70 | 62 |
0.0% | Low Risk · 11 | 61% Emerging | |
| 247 | 65 |
BAL | High-A | P | 55 | 60 | 65 | 57 |
0.0% | Low Risk · 14 | 63% Emerging | |
| 248 | 65 |
NYM | AA | P | 55 | 59 | 64 | 58 |
+0.8% | Low Risk · 10 | 62% Emerging | |
| 249 | 65 |
ARI | AAA | OF | 54 | 61 | 67 | 56 |
-0.6% | Low Risk · 0 | 62% Emerging | |
| 250 | 65 |
LAA | AA | P | 55 | 59 | 63 | 56 |
-1.0% | Low Risk · 0 | 62% Emerging | |
| 251 | 65 |
NYM | AAA | P | 59 | 63 | 68 | 49 |
0.0% | Low Risk · 10 | 64% Emerging | |
| 252 | 65 |
ARI | High-A | SS | 57 | 67 | 75 | 53 |
-0.2% | Low Risk · 20 | N/A | |
| 253 | 65 |
SF | AA | P | 54 | 60 | 66 | 56 |
0.0% | Low Risk · 0 | 63% Emerging | |
| 254 | IL(Full Season)65 |
BOS | High-A | PIL(Full Season) | 54 | 65 | 76 | 67 |
0.0% | Medium Risk · 46 | 59% Emerging | |
| 255 | 65 |
ATL | AA | 2B | 54 | 63 | 73 | 65 |
0.0% | Low Risk · 14 | 59% Emerging | |
| 256 | 65 |
BAL | AA | 3B | 55 | 59 | 64 | 55 |
-0.4% | Low Risk · 0 | 62% Emerging | |
| 257 | 65 |
BOS | AA | P | 55 | 58 | 63 | 56 |
0.0% | Low Risk · 0 | 62% Emerging | |
| 258 | 65 |
ARI | AA | OF | 55 | 58 | 63 | 55 |
-0.1% | Low Risk · 0 | 63% Emerging | |
| 259 | 65 |
WSH | AA | CF | 55 | 59 | 63 | 56 |
+1.1% | Low Risk · 0 | 64% Emerging | |
| 260 | 65 |
TOR | Single-A | P | 53 | 59 | 65 | 59 |
0.0% | Low Risk · 0 | 61% Emerging | |
| 261 | 65 |
WSH | High-A | SS | 60 | 67 | 73 | 41 |
-0.2% | Low Risk · 12 | N/A | |
| 262 | 65 |
STL | AA | C | 55 | 59 | 63 | 58 |
-0.8% | Low Risk · 0 | 61% Emerging | |
| 263 | 64 |
MIL | High-A | P | 55 | 60 | 66 | 49 |
-0.1% | Low Risk · 3 | 64% Emerging | |
| 264 | 64 |
MIN | High-A | P | 54 | 60 | 66 | 58 |
-0.1% | Low Risk · 10 | 61% Emerging | |
| 265 | 64 |
MIN | AAA | SS | 55 | 58 | 63 | 56 |
+0.3% | Low Risk · 0 | 63% Emerging | |
| 266 | 64 |
BOS | High-A | CF | 53 | 60 | 68 | 50 |
-0.8% | Low Risk · 3 | 64% Emerging | |
| 267 | 64 |
NYY | AA | P | 53 | 61 | 69 | 65 |
+1.5% | Low Risk · 18 | 58% Emerging | |
| 268 | 64 |
LAA | Single-A | P | 55 | 59 | 64 | 60 |
0.0% | Low Risk · 14 | 62% Emerging | |
| 269 | 64 |
MIL | AA | P | 55 | 59 | 64 | 52 |
0.0% | Low Risk · 10 | 63% Emerging | |
| 270 | 64 |
MIL | High-A | C | 54 | 59 | 64 | 61 |
-0.1% | Low Risk · 10 | 62% Emerging | |
| 271 | 64 |
ARI | Single-A | C | 54 | 59 | 64 | 55 |
0.0% | Low Risk · 3 | 64% Emerging | |
| 272 | 64 |
SF | AA | LF | 54 | 58 | 62 | 56 |
0.0% | Low Risk · 0 | 62% Emerging | |
| 273 | 64 |
TB | AA | 1B | 55 | 59 | 64 | 55 |
-0.3% | Low Risk · 12 | 63% Emerging | |
| 274 | 64 |
TEX | Single-A | SS | 53 | 59 | 66 | 56 |
-0.1% | Low Risk · 3 | 62% Emerging | |
| 275 | 64 |
CLE | High-A | SS | 53 | 58 | 62 | 56 |
-0.5% | Low Risk · 0 | 62% Emerging | |
| 276 | 64 |
CIN | High-A | OF | 51 | 59 | 70 | 61 |
0.0% | Low Risk · 4 | 60% Emerging | |
| 277 | 64 |
ARI | High-A | P | 55 | 59 | 66 | 60 |
0.0% | Low Risk · 10 | 61% Emerging | |
| 278 | 64 |
MIL | High-A | 3B | 54 | 59 | 65 | 56 |
-0.8% | Low Risk · 16 | 62% Emerging | |
| 279 | 64 |
LAD | AAA | P | 54 | 64 | 75 | 66 |
0.0% | Low Risk · 24 | 59% Emerging | |
| 280 | 64 |
CLE | High-A | OF | 53 | 58 | 63 | 56 |
-0.3% | Low Risk · 0 | 62% Emerging | |
| 281 | 64 |
CLE | Single-A | 2B | 54 | 59 | 64 | 52 |
+0.1% | Low Risk · 3 | 64% Emerging | |
| 282 | 64 |
BOS | Single-A | SS | 53 | 60 | 67 | 54 |
-0.1% | Low Risk · 3 | 63% Emerging | |
| 283 | 64 |
ARI | Single-A | P | 52 | 58 | 64 | 60 |
0.0% | Low Risk · 0 | 60% Emerging | |
| 284 | 64 |
CHC | Single-A | P | 51 | 59 | 69 | 61 |
+0.1% | Low Risk · 8 | 58% Emerging | |
| 285 | 64 |
PIT | Single-A | IF | 52 | 61 | 70 | 60 |
0.0% | Low Risk · 16 | 59% Emerging | |
| 286 | 64 |
PIT | AAA | P | 54 | 62 | 69 | 62 |
0.0% | Low Risk · 14 | 59% Emerging | |
| 287 | 64 |
CLE | High-A | SS | 51 | 60 | 70 | 61 |
+0.1% | Low Risk · 18 | 59% Emerging | |
| 288 | 64 |
LAD | High-A | P | 52 | 58 | 65 | 58 |
0.0% | Low Risk · 0 | 59% Emerging | |
| 289 | 64 |
LAD | AA | SS | 54 | 57 | 62 | 55 |
+0.3% | Low Risk · 0 | 63% Emerging | |
| 290 | 64 |
MIN | FCL | OF | 53 | 61 | 70 | 65 |
+2.0% | Low Risk · 24 | 60% Emerging | |
| 291 | 64 |
WSH | AA | SS | 58 | 66 | 74 | 49 |
+0.1% | Low Risk · 22 | N/A | |
| 292 | 64 |
ARI | Single-A | CF | 52 | 58 | 65 | 59 |
+0.1% | Low Risk · 0 | 60% Emerging | |
| 293 | 64 |
SF | High-A | CF | 52 | 57 | 62 | 55 |
-0.4% | Low Risk · 0 | 62% Emerging | |
| 294 | 64 |
NYM | AAA | 1B | 59 | 65 | 70 | 45 |
0.0% | Low Risk · 21 | 65% Watch closely | |
| 295 | 64 |
PIT | High-A | SS | 52 | 58 | 65 | 57 |
-0.1% | Low Risk · 12 | 61% Emerging | |
| 296 | 64 |
MIA | AAA | LF | 53 | 58 | 62 | 53 |
+0.6% | Low Risk · 0 | 61% Emerging | |
| 297 | IL(Rehab)63 |
MIA | Single-A | PIL(Rehab) | 62 | 72 | 81 | 50 |
0.0% | Low Risk · 26 | N/A | |
| 298 | 63 |
MIL | AA | P | 53 | 59 | 66 | 61 |
-0.1% | Low Risk · 10 | 59% Emerging | |
| 299 | 63 |
TB | AAA | P | 60 | 66 | 71 | 45 |
0.0% | Low Risk · 20 | N/A | |
| 300 | 63 |
SF | High-A | CF | 51 | 60 | 72 | 62 |
0.0% | Low Risk · 18 | 59% Emerging | |
| 301 | 63 |
PHI | High-A | P | 54 | 58 | 64 | 55 |
0.0% | Low Risk · 0 | 62% Emerging | |
| 302 | 63 |
COL | AA | P | 51 | 57 | 64 | 58 |
+1.5% | Low Risk · 0 | 59% Emerging | |
| 303 | 63 |
TB | AAA | P | 55 | 63 | 72 | 62 |
0.0% | Low Risk · 24 | 58% Emerging | |
| 304 | 63 |
LAD | AAA | P | 54 | 58 | 63 | 51 |
+0.2% | Low Risk · 0 | 62% Emerging | |
| 305 | 63 |
LAA | AA | P | 52 | 58 | 65 | 57 |
+0.1% | Low Risk · 0 | 59% Emerging | |
| 306 | 63 |
HOU | AAA | OF | 55 | 64 | 73 | 65 |
0.0% | Low Risk · 39 | 60% Emerging | |
| 307 | 63 |
TOR | Single-A | P | 49 | 57 | 65 | 59 |
0.0% | Low Risk · 8 | 59% Emerging | |
| 308 | 63 |
PIT | Single-A | P | 53 | 58 | 62 | 52 |
-0.2% | Low Risk · 3 | 62% Emerging | |
| 309 | 63 |
CLE | ACL | P | 52 | 60 | 70 | 66 |
0.0% | Low Risk · 24 | 58% Emerging | |
| 310 | 63 |
SF | AA | C | 52 | 61 | 72 | 64 |
0.0% | Low Risk · 14 | 57% Emerging | |
| 311 | 63 |
KC | AA | P | 53 | 60 | 67 | 52 |
-0.1% | Low Risk · 6 | 61% Emerging | |
| 312 | 63 |
SF | AA | SS | 53 | 57 | 62 | 54 |
-0.5% | Low Risk · 0 | 60% Emerging | |
| 313 | 63 |
NYY | High-A | P | 53 | 58 | 63 | 57 |
0.0% | Low Risk · 0 | 61% Emerging | |
| 314 | 63 |
PHI | AA | RF | 54 | 58 | 62 | 52 |
+0.7% | Low Risk · 0 | 63% Emerging | |
| 315 | 63 |
STL | AAA | SS | 54 | 61 | 68 | 57 |
+0.1% | Low Risk · 9 | 61% Emerging | |
| 316 | 63 |
MIN | AA | SS | 53 | 60 | 68 | 60 |
+0.1% | Low Risk · 19 | 59% Emerging | |
| 317 | 63 |
BOS | AAA | CF | 54 | 59 | 63 | 48 |
-0.2% | Low Risk · 0 | 65% Watch closely | |
| 318 | 63 |
COL | AA | 3B | 53 | 58 | 63 | 51 |
+0.2% | Low Risk · 0 | 61% Emerging | |
| 319 | 63 |
ARI | High-A | C | 51 | 59 | 68 | 60 |
+2.4% | Low Risk · 18 | 59% Emerging | |
| 320 | 63 |
PHI | Single-A | C | 53 | 57 | 62 | 56 |
-0.2% | Low Risk · 0 | 62% Emerging | |
| 321 | 63 |
TEX | AA | CF | 53 | 57 | 61 | 53 |
+0.5% | Low Risk · 0 | 62% Emerging | |
| 322 | 63 |
BAL | High-A | SS | 57 | 63 | 68 | 46 |
+0.1% | Low Risk · 0 | 63% Emerging | |
| 323 | 63 |
BAL | AA | OF | 54 | 62 | 71 | 59 |
0.0% | Low Risk · 14 | 60% Emerging | |
| 324 | 63 |
CLE | High-A | 1B | 54 | 59 | 64 | 58 |
-0.2% | Low Risk · 12 | 62% Emerging | |
| 325 | 63 |
TEX | AAA | 3B | 52 | 58 | 65 | 57 |
+2.0% | Low Risk · 0 | 59% Emerging | |
| 326 | 63 |
MIL | AA | C | 54 | 58 | 63 | 62 |
-0.1% | Low Risk · 10 | 58% Emerging | |
| 327 | 63 |
LAD | AA | P | 54 | 58 | 63 | 50 |
0.0% | Low Risk · 10 | 62% Emerging | |
| 328 | 63 |
STL | AA | RF | 52 | 61 | 70 | 64 |
-1.1% | Low Risk · 15 | 57% Emerging | |
| 329 | 63 |
PIT | AA | OF | 53 | 57 | 62 | 54 |
-0.3% | Low Risk · 0 | 60% Emerging | |
| 330 | 63 |
NYY | FCL | OF | 53 | 61 | 71 | 64 |
-0.8% | Low Risk · 24 | 60% Emerging | |
| 331 | 63 |
CWS | Single-A | C | 52 | 57 | 62 | 51 |
-0.1% | Low Risk · 3 | 61% Emerging | |
| 332 | 63 |
BAL | AA | P | 51 | 57 | 63 | 58 |
0.0% | Low Risk · 0 | 58% Emerging | |
| 333 | 63 |
CLE | ACL | C | 53 | 61 | 73 | 69 |
+0.1% | Low Risk · 32 | 57% Emerging | |
| 334 | 63 |
BOS | Single-A | P | 51 | 57 | 63 | 60 |
0.0% | Low Risk · 0 | 60% Emerging | |
| 335 | 63 |
TB | AA | 3B | 53 | 57 | 62 | 56 |
+0.5% | Low Risk · 0 | 59% Emerging | |
| 336 | 63 |
CLE | Single-A | P | 51 | 57 | 64 | 57 |
-0.3% | Low Risk · 0 | 59% Emerging | |
| 337 | 63 |
CIN | AA | SS | 53 | 57 | 62 | 49 |
-1.0% | Low Risk · 0 | 63% Emerging | |
| 338 | 63 |
MIN | AA | C | 51 | 58 | 65 | 60 |
+2.7% | Low Risk · 9 | 60% Emerging | |
| 339 | 63 |
TEX | Single-A | OF | 49 | 57 | 65 | 61 |
0.0% | Low Risk · 8 | 57% Emerging | |
| 340 | 63 |
LAD | AA | P | 53 | 57 | 61 | 49 |
0.0% | Low Risk · 0 | 63% Emerging | |
| 341 | 63 |
ATL | Single-A | CF | 52 | 56 | 61 | 55 |
-0.4% | Low Risk · 0 | 61% Emerging | |
| 342 | 63 |
BOS | AA | 3B | 52 | 60 | 68 | 63 |
-0.2% | Low Risk · 14 | 57% Emerging | |
| 343 | 63 |
SD | Single-A | P | 60 | 67 | 73 | 42 |
0.0% | Low Risk · 27 | N/A | |
| 344 | 63 |
ATL | High-A | P | 51 | 61 | 70 | 62 |
0.0% | Low Risk · 28 | 59% Emerging | |
| 345 | 63 |
BAL | High-A | P | 51 | 58 | 65 | 61 |
+3.9% | Low Risk · 10 | 58% Emerging | |
| 346 | 63 |
HOU | AA | P | 50 | 56 | 63 | 59 |
0.0% | Low Risk · 4 | 59% Emerging | |
| 347 | 63 |
MIN | High-A | P | 57 | 63 | 69 | 50 |
0.0% | Low Risk · 24 | 62% Emerging | |
| 348 | 63 |
CLE | Single-A | SS | 51 | 60 | 69 | 61 |
0.0% | Low Risk · 21 | 59% Emerging | |
| 349 | 63 |
BOS | High-A | SS | 52 | 57 | 62 | 52 |
-0.6% | Low Risk · 0 | 62% Emerging | |
| 350 | 63 |
MIL | Single-A | C | 52 | 62 | 77 | 62 |
+0.1% | Low Risk · 22 | 57% Emerging | |
| 351 | 63 |
CHC | AA | P | 54 | 58 | 64 | 61 |
0.0% | Low Risk · 10 | 58% Emerging | |
| 352 | 63 |
CLE | Single-A | IF | 52 | 58 | 64 | 54 |
-0.3% | Low Risk · 3 | 61% Emerging | |
| 353 | 63 |
SEA | High-A | C | 52 | 56 | 61 | 54 |
+0.4% | Low Risk · 0 | 61% Emerging | |
| 354 | 63 |
SF | AAA | 2B | 52 | 56 | 61 | 55 |
-0.2% | Low Risk · 0 | 59% Emerging | |
| 355 | 63 |
CHC | AAA | 3B | 52 | 56 | 60 | 51 |
0.0% | Low Risk · 0 | 61% Emerging | |
| 356 | 63 |
MIL | High-A | P | 51 | 61 | 70 | 62 |
0.0% | Low Risk · 28 | 58% Emerging | |
| 357 | 63 |
MIA | AAA | SS | 53 | 57 | 62 | 52 |
-0.6% | Low Risk · 0 | 61% Emerging | |
| 358 | 63 |
TB | AAA | 1B | 52 | 60 | 69 | 64 |
-0.2% | Low Risk · 14 | 56% Emerging | |
| 359 | 63 |
WSH | Single-A | 3B | 52 | 57 | 62 | 49 |
-1.1% | Low Risk · 3 | 62% Emerging | |
| 360 | 63 |
BAL | High-A | P | 50 | 58 | 67 | 63 |
0.0% | Low Risk · 18 | 57% Emerging | |
| 361 | 63 |
HOU | AA | P | 59 | 64 | 69 | 54 |
0.0% | Low Risk · 24 | 62% Emerging | |
| 362 | 63 |
TB | AA | P | 53 | 61 | 73 | 60 |
-0.1% | Low Risk · 14 | 57% Emerging | |
| 363 | 63 |
SD | DSL | SS | 48 | 57 | 66 | 61 |
+1.5% | Low Risk · 24 | 58% Emerging | |
| 364 | 63 |
MIL | Single-A | RF | 51 | 57 | 64 | 55 |
-1.1% | Low Risk · 3 | 60% Emerging | |
| 365 | 63 |
NYM | AA | P | 51 | 60 | 69 | 65 |
-0.1% | Low Risk · 24 | 57% Emerging | |
| 366 | 63 |
ARI | AAA | P | 53 | 62 | 74 | 66 |
0.0% | Low Risk · 25 | 57% Emerging | |
| 367 | 63 |
SF | Single-A | OF | 51 | 60 | 68 | 58 |
0.0% | Low Risk · 11 | 59% Emerging | |
| 368 | 63 |
TB | AA | 2B | 53 | 57 | 61 | 50 |
-0.1% | Low Risk · 0 | 63% Emerging | |
| 369 | 63 |
MIA | AAA | C | 52 | 63 | 74 | 69 |
0.0% | Medium Risk · 47 | 56% Emerging | |
| 370 | 63 |
BAL | DSL | C | 49 | 59 | 71 | 63 |
+1.2% | Low Risk · 32 | 57% Emerging | |
| 371 | 63 |
MIN | Single-A | 2B | 52 | 58 | 65 | 52 |
-0.5% | Low Risk · 3 | 61% Emerging | |
| 372 | 63 |
ARI | AA | 2B | 53 | 57 | 62 | 47 |
+0.1% | Low Risk · 0 | 63% Emerging | |
| 373 | 62 |
TEX | Single-A | OF | 52 | 57 | 62 | 52 |
-0.6% | Low Risk · 3 | 62% Emerging | |
| 374 | 62 |
TOR | AA | RF | 52 | 56 | 61 | 56 |
-1.7% | Low Risk · 0 | 59% Emerging | |
| 375 | 62 |
PHI | AAA | SS | 52 | 56 | 61 | 55 |
0.0% | Low Risk · 1 | 59% Emerging | |
| 376 | 62 |
MIL | DSL | SS | 50 | 59 | 73 | 62 |
-0.8% | Low Risk · 32 | 57% Emerging | |
| 377 | 62 |
SF | Single-A | P | 52 | 58 | 67 | 62 |
0.0% | Low Risk · 14 | 58% Emerging | |
| 378 | 62 |
TB | AAA | P | 51 | 57 | 64 | 56 |
0.0% | Low Risk · 0 | 58% Emerging | |
| 379 | IL(60-Day)62 |
SD | AA | PIL(60-Day) | 50 | 58 | 66 | 63 |
0.0% | Low Risk · 26 | 58% Emerging | |
| 380 | 62 |
CIN | DSL | OF | 48 | 57 | 69 | 61 |
+4.2% | Low Risk · 32 | 57% Emerging | |
| 381 | 62 |
CWS | AA | CF | 53 | 57 | 62 | 50 |
-0.1% | Low Risk · 0 | 61% Emerging | |
| 382 | 62 |
NYY | AA | P | 54 | 58 | 62 | 56 |
0.0% | Low Risk · 10 | 61% Emerging | |
| 383 | 62 |
LAA | Single-A | 3B | 49 | 58 | 68 | 59 |
-0.1% | Low Risk · 8 | 57% Emerging | |
| 384 | 62 |
NYM | AA | C | 54 | 58 | 62 | 52 |
-0.6% | Low Risk · 12 | 62% Emerging | |
| 385 | 62 |
PHI | Single-A | P | 51 | 57 | 63 | 56 |
-0.2% | Low Risk · 0 | 59% Emerging | |
| 386 | 62 |
PIT | High-A | SS | 52 | 57 | 62 | 54 |
-0.7% | Low Risk · 0 | 60% Emerging | |
| 387 | 62 |
CHC | High-A | P | 51 | 57 | 64 | 62 |
0.0% | Low Risk · 10 | 58% Emerging | |
| 388 | 62 |
MIN | Single-A | OF | 51 | 61 | 71 | 61 |
+0.1% | Low Risk · 21 | 57% Emerging | |
| 389 | 62 |
MIN | AAA | P | 51 | 57 | 63 | 56 |
+0.2% | Low Risk · 10 | 60% Emerging | |
| 390 | 62 |
TOR | High-A | 2B | 51 | 60 | 74 | 62 |
0.0% | Low Risk · 18 | 56% Emerging | |
| 391 | 62 |
PHI | AAA | 1B | 51 | 57 | 63 | 55 |
-0.6% | Low Risk · 0 | 61% Emerging | |
| 392 | 62 |
MIA | AA | SS | 51 | 57 | 63 | 51 |
+0.6% | Low Risk · 0 | 60% Emerging | |
| 393 | 62 |
CIN | Single-A | OF | 48 | 57 | 66 | 60 |
-0.1% | Low Risk · 18 | 58% Emerging | |
| 394 | 62 |
TEX | AA | P | 52 | 60 | 69 | 63 |
0.0% | Low Risk · 32 | 56% Emerging | |
| 395 | 62 |
BAL | FCL | SS | 51 | 59 | 67 | 65 |
-1.5% | Low Risk · 24 | 58% Emerging | |
| 396 | 62 |
MIA | Single-A | P | 51 | 57 | 63 | 58 |
0.0% | Low Risk · 0 | 59% Emerging | |
| 397 | 62 |
KC | High-A | P | 51 | 59 | 66 | 64 |
0.0% | Low Risk · 24 | 57% Emerging | |
| 398 | 62 |
WSH | Single-A | SS | 52 | 57 | 62 | 49 |
-0.4% | Low Risk · 3 | 62% Emerging | |
| 399 | 62 |
MIL | High-A | 3B | 50 | 56 | 63 | 54 |
-0.8% | Low Risk · 0 | 59% Emerging | |
| 400 | IL(7-Day)62 |
LAD | AA | PIL(7-Day) | 51 | 59 | 69 | 64 |
0.0% | Low Risk · 24 | N/A | |
| 401 | 62 |
CWS | High-A | OF | 51 | 57 | 66 | 61 |
+3.3% | Low Risk · 10 | 57% Emerging | |
| 402 | 62 |
LAD | Single-A | LF | 51 | 58 | 65 | 61 |
+0.6% | Low Risk · 14 | 58% Emerging | |
| 403 | 62 |
MIA | High-A | SS | 52 | 62 | 73 | 63 |
+1.1% | Low Risk · 34 | 57% Emerging | |
| 404 | 62 |
SD | Single-A | 2B | 52 | 58 | 64 | 50 |
-0.3% | Low Risk · 3 | 61% Emerging | |
| 405 | 62 |
SEA | High-A | P | 50 | 57 | 64 | 60 |
+0.1% | Low Risk · 10 | 57% Emerging | |
| 406 | 62 |
NYY | High-A | P | 51 | 56 | 61 | 51 |
-0.8% | Low Risk · 0 | 61% Emerging | |
| 407 | 62 |
TOR | AA | P | 49 | 55 | 62 | 59 |
0.0% | Low Risk · 4 | 58% Emerging | |
| 408 | 62 |
MIA | AAA | 1B | 51 | 55 | 60 | 54 |
0.0% | Low Risk · 0 | 59% Emerging | |
| 409 | 62 |
KC | AA | LF | 53 | 57 | 62 | 59 |
-0.2% | Low Risk · 10 | 58% Emerging | |
| 410 | 62 |
LAD | Single-A | 1B | 52 | 58 | 65 | 59 |
-0.3% | Low Risk · 16 | 59% Emerging | |
| 411 | 62 |
COL | AA | 2B | 52 | 56 | 60 | 54 |
+0.1% | Low Risk · 0 | 61% Emerging | |
| 412 | 62 |
HOU | AA | C | 53 | 58 | 62 | 52 |
-0.9% | Low Risk · 12 | 63% Emerging | |
| 413 | 62 |
SF | AAA | P | 51 | 56 | 62 | 53 |
-1.5% | Low Risk · 0 | 60% Emerging | |
| 414 | 62 |
SD | High-A | P | 50 | 59 | 75 | 60 |
+0.1% | Low Risk · 18 | N/A | |
| 415 | 62 |
SD | ACL | OF | 48 | 57 | 68 | 64 |
-0.5% | Low Risk · 32 | 56% Emerging | |
| 416 | 62 |
TEX | High-A | RF | 50 | 56 | 62 | 56 |
-0.3% | Low Risk · 0 | 59% Emerging | |
| 417 | 62 |
CWS | Single-A | SS | 53 | 63 | 74 | 62 |
-0.1% | Low Risk · 37 | 57% Emerging | |
| 418 | 62 |
CHC | Single-A | C | 50 | 59 | 71 | 62 |
0.0% | Low Risk · 21 | 56% Emerging | |
| 419 | 62 |
ATL | Single-A | SS | 50 | 57 | 64 | 51 |
+0.1% | Low Risk · 3 | 61% Emerging | |
| 420 | 62 |
HOU | DSL | SS | 47 | 56 | 67 | 61 |
-0.6% | Low Risk · 32 | 56% Emerging | |
| 421 | 62 |
MIN | AAA | P | 54 | 63 | 72 | 58 |
-0.1% | Low Risk · 28 | 59% Emerging | |
| 422 | 62 |
BOS | FCL | CF | 50 | 58 | 67 | 63 |
-1.1% | Low Risk · 24 | 58% Emerging | |
| 423 | 62 |
WSH | AA | P | 53 | 58 | 63 | 47 |
0.0% | Low Risk · 14 | 62% Emerging | |
| 424 | 62 |
BOS | AA | SS | 53 | 57 | 62 | 49 |
+0.7% | Low Risk · 5 | 60% Emerging | |
| 425 | 62 |
CLE | AA | 1B | 50 | 58 | 66 | 61 |
0.0% | Low Risk · 14 | N/A | |
| 426 | 62 |
NYM | AAA | P | 52 | 61 | 71 | 64 |
0.0% | Low Risk · 24 | 56% Emerging | |
| 427 | 61 |
TEX | High-A | P | 55 | 65 | 75 | 57 |
0.0% | Low Risk · 38 | N/A | |
| 428 | 61 |
BOS | FCL | P | 48 | 56 | 64 | 59 |
0.0% | Low Risk · 24 | 57% Emerging | |
| 429 | 61 |
BOS | AA | P | 53 | 58 | 65 | 61 |
+0.4% | Low Risk · 11 | 57% Emerging | |
| 430 | 61 |
COL | ACL | SS | 50 | 58 | 66 | 62 |
+0.4% | Low Risk · 24 | 59% Emerging | |
| 431 | 61 |
NYM | High-A | P | 50 | 57 | 67 | 58 |
+5.2% | Low Risk · 10 | 56% Emerging | |
| 432 | 61 |
TEX | AA | C | 50 | 57 | 64 | 56 |
-0.2% | Low Risk · 4 | 59% Emerging | |
| 433 | 61 |
TOR | AA | LF | 51 | 55 | 59 | 49 |
-1.3% | Low Risk · 0 | 61% Emerging | |
| 434 | 61 |
DET | High-A | P | 51 | 55 | 60 | 51 |
0.0% | Low Risk · 0 | 60% Emerging | |
| 435 | 61 |
NYM | AAA | P | 52 | 61 | 71 | 65 |
-0.6% | Low Risk · 38 | 56% Emerging | |
| 436 | 61 |
MIL | AAA | SS | 52 | 57 | 62 | 58 |
-2.6% | Low Risk · 11 | 58% Emerging | |
| 437 | 61 |
ATH | Single-A | OF | 50 | 56 | 63 | 51 |
+2.0% | Low Risk · 3 | 60% Emerging | |
| 438 | 61 |
ATL | High-A | P | 49 | 56 | 67 | 61 |
+0.1% | Low Risk · 10 | N/A | |
| 439 | 61 |
PHI | Single-A | OF | 50 | 55 | 59 | 53 |
-0.3% | Low Risk · 0 | 59% Emerging | |
| 440 | 61 |
SF | AA | SS | 51 | 60 | 69 | 62 |
0.0% | Low Risk · 23 | 56% Emerging | |
| 441 | 61 |
BOS | High-A | CF | 51 | 56 | 61 | 50 |
+0.1% | Low Risk · 0 | 59% Emerging | |
| 442 | 61 |
SF | High-A | OF | 57 | 63 | 68 | 47 |
+0.1% | Low Risk · 10 | 61% Emerging | |
| 443 | 61 |
NYY | AA | SS | 52 | 62 | 73 | 63 |
-0.1% | Low Risk · 33 | 56% Emerging | |
| 444 | 61 |
CLE | AA | 3B | 51 | 59 | 66 | 56 |
0.0% | Low Risk · 13 | 60% Emerging | |
| 445 | 61 |
SEA | High-A | CF | 52 | 56 | 61 | 58 |
+0.1% | Low Risk · 10 | 59% Emerging | |
| 446 | 61 |
TB | High-A | P | 51 | 61 | 76 | 61 |
-0.2% | Low Risk · 28 | N/A | |
| 447 | 61 |
MIN | AA | 3B | 52 | 55 | 60 | 51 |
+2.6% | Low Risk · 0 | 60% Emerging | |
| 448 | 61 |
ATH | AA | C | 52 | 56 | 61 | 59 |
+0.9% | Low Risk · 10 | 57% Emerging | |
| 449 | 61 |
HOU | AA | P | 52 | 56 | 60 | 55 |
0.0% | Low Risk · 10 | 59% Emerging | |
| 450 | 61 |
BAL | AA | P | 52 | 56 | 61 | 58 |
0.0% | Low Risk · 10 | 57% Emerging | |
| 451 | 61 |
TEX | AA | P | 50 | 56 | 63 | 54 |
-0.3% | Low Risk · 0 | 57% Emerging | |
| 452 | 61 |
WSH | AA | P | 50 | 55 | 61 | 53 |
-1.9% | Low Risk · 0 | 57% Emerging | |
| 453 | 61 |
ATL | AA | P | 50 | 56 | 62 | 60 |
0.0% | Low Risk · 10 | 56% Emerging | |
| 454 | 61 |
LAD | High-A | P | 50 | 56 | 63 | 61 |
0.0% | Low Risk · 10 | 56% Emerging | |
| 455 | 61 |
ATH | Single-A | OF | 51 | 56 | 62 | 46 |
-0.2% | Low Risk · 3 | 62% Emerging | |
| 456 | 61 |
NYY | High-A | P | 50 | 55 | 60 | 52 |
+0.1% | Low Risk · 0 | 60% Emerging | |
| 457 | 61 |
SD | Single-A | 3B | 48 | 56 | 64 | 58 |
0.0% | Low Risk · 8 | N/A | |
| 458 | 61 |
STL | FCL | SS | 50 | 58 | 67 | 59 |
+0.1% | Low Risk · 24 | 58% Emerging | |
| 459 | 61 |
TOR | AA | LF | 51 | 61 | 72 | 62 |
-0.1% | Low Risk · 17 | 56% Emerging | |
| 460 | 61 |
COL | Single-A | OF | 50 | 56 | 63 | 53 |
-0.9% | Low Risk · 8 | 59% Emerging | |
| 461 | 61 |
NYY | DSL | CF | 49 | 57 | 70 | 62 |
+0.8% | Low Risk · 24 | 56% Emerging | |
| 462 | 61 |
BAL | AA | CF | 52 | 57 | 62 | 45 |
-0.1% | Low Risk · 5 | 62% Emerging | |
| 463 | 61 |
CLE | ACL | SS | 50 | 58 | 66 | 60 |
+0.1% | Low Risk · 24 | 58% Emerging | |
| 464 | 61 |
MIN | High-A | OF | 49 | 55 | 62 | 53 |
0.0% | Low Risk · 0 | 58% Emerging | |
| 465 | 61 |
KC | Single-A | OF | 56 | 62 | 67 | 39 |
-0.1% | Low Risk · 3 | 62% Emerging | |
| 466 | 61 |
MIN | Single-A | OF | 50 | 60 | 69 | 59 |
0.0% | Low Risk · 21 | 57% Emerging | |
| 467 | 61 |
NYY | AA | RF | 50 | 55 | 59 | 51 |
-0.7% | Low Risk · 0 | 58% Emerging | |
| 468 | IL(7-Day)61 |
MIA | Single-A | PIL(7-Day) | 48 | 56 | 64 | 59 |
0.0% | Low Risk · 14 | N/A | |
| 469 | 61 |
MIL | DSL | SS | 47 | 56 | 65 | 61 |
+1.6% | Low Risk · 24 | 56% Emerging | |
| 470 | 61 |
CIN | Single-A | SS | 52 | 62 | 71 | 53 |
-0.1% | Low Risk · 18 | 58% Emerging | |
| 471 | 61 |
BAL | Single-A | SS | 49 | 55 | 62 | 52 |
-0.1% | Low Risk · 3 | 59% Emerging | |
| 472 | 61 |
TEX | AAA | P | 51 | 55 | 60 | 49 |
0.0% | Low Risk · 0 | 58% Emerging | |
| 473 | 61 |
SF | Single-A | P | 49 | 55 | 61 | 55 |
+0.1% | Low Risk · 0 | 57% Emerging | |
| 474 | 61 |
CIN | AA | CF | 50 | 55 | 59 | 52 |
-0.1% | Low Risk · 0 | 58% Emerging | |
| 475 | 61 |
ATL | High-A | OF | 50 | 54 | 59 | 49 |
0.0% | Low Risk · 0 | 60% Emerging | |
| 476 | 61 |
MIN | Single-A | C | 49 | 56 | 62 | 60 |
+0.3% | Low Risk · 14 | 57% Emerging | |
| 477 | 61 |
DET | AAA | LF | 49 | 56 | 64 | 59 |
-1.5% | Low Risk · 14 | 57% Emerging | |
| 478 | 60 |
LAA | High-A | P | 48 | 54 | 61 | 52 |
+0.2% | Low Risk · 0 | 58% Emerging | |
| 479 | 60 |
TEX | Single-A | P | 50 | 58 | 73 | 58 |
0.0% | Low Risk · 22 | N/A | |
| 480 | 60 |
TOR | AA | C | 50 | 55 | 59 | 51 |
-0.2% | Low Risk · 0 | 58% Emerging | |
| 481 | 60 |
TOR | Single-A | 2B | 48 | 54 | 61 | 53 |
-0.4% | Low Risk · 0 | 57% Emerging | |
| 482 | 60 |
SF | High-A | OF | 50 | 55 | 60 | 55 |
-0.3% | Low Risk · 10 | 59% Emerging | |
| 483 | 60 |
LAA | Single-A | P | 49 | 55 | 61 | 52 |
0.0% | Low Risk · 0 | 58% Emerging | |
| 484 | 60 |
BAL | Single-A | OF | 49 | 54 | 61 | 54 |
+0.4% | Low Risk · 5 | 58% Emerging | |
| 485 | 60 |
CLE | AA | OF | 50 | 54 | 59 | 50 |
+0.2% | Low Risk · 1 | 58% Emerging | |
| 486 | 60 |
TB | High-A | P | 49 | 54 | 59 | 48 |
+0.1% | Low Risk · 0 | 60% Emerging | |
| 487 | 60 |
ATL | AA | P | 52 | 61 | 74 | 61 |
0.0% | Low Risk · 24 | N/A | |
| 488 | 60 |
MIA | High-A | P | 49 | 56 | 67 | 57 |
0.0% | Low Risk · 10 | N/A | |
| 489 | 60 |
PIT | AAA | P | 52 | 60 | 67 | 58 |
+1.5% | Low Risk · 28 | 58% Emerging | |
| 490 | 60 |
ARI | AA | P | 50 | 54 | 59 | 49 |
0.0% | Low Risk · 0 | 59% Emerging | |
| 491 | 60 |
TEX | Single-A | P | 49 | 56 | 63 | 60 |
0.0% | Low Risk · 12 | 57% Emerging | |
| 492 | 60 |
MIA | AA | OF | 51 | 54 | 59 | 51 |
+0.1% | Low Risk · 0 | 59% Emerging | |
| 493 | 60 |
TEX | High-A | P | 53 | 63 | 72 | 59 |
0.0% | Low Risk · 38 | 57% Emerging | |
| 494 | 60 |
TB | AAA | C | 49 | 58 | 67 | 62 |
0.0% | Low Risk · 19 | N/A | |
| 495 | 60 |
NYY | High-A | 3B | 48 | 54 | 61 | 52 |
+0.2% | Low Risk · 0 | 57% Emerging | |
| 496 | 60 |
ARI | AA | P | 50 | 56 | 63 | 56 |
+0.8% | Low Risk · 10 | 56% Emerging | |
| 497 | 60 |
PIT | AAA | P | 53 | 62 | 73 | 63 |
-2.9% | Low Risk · 35 | N/A | |
| 498 | 60 |
MIL | High-A | OF | 48 | 57 | 72 | 59 |
0.0% | Low Risk · 14 | 56% Emerging | |
| 499 | 60 |
HOU | FCL | C | 47 | 55 | 64 | 62 |
0.0% | Low Risk · 24 | N/A | |
| 500 | 60 |
COL | ACL | RF | 50 | 59 | 70 | 67 |
-0.4% | Low Risk · 38 | 56% Emerging | |
| 501 | 60 |
MIA | AA | P | 50 | 54 | 59 | 50 |
0.0% | Low Risk · 0 | 58% Emerging | |
| 502 | 60 |
PHI | High-A | P | 47 | 55 | 65 | 58 |
-0.3% | Low Risk · 14 | N/A | |
| 503 | 60 |
LAA | Single-A | P | 50 | 55 | 61 | 52 |
-0.3% | Low Risk · 14 | 58% Emerging | |
| 504 | 60 |
WSH | Single-A | SS | 49 | 53 | 58 | 51 |
-0.2% | Low Risk · 0 | 58% Emerging | |
| 505 | 60 |
HOU | Single-A | CF | 51 | 56 | 61 | 55 |
-0.2% | Low Risk · 16 | 59% Emerging | |
| 506 | 60 |
LAD | High-A | P | 49 | 55 | 63 | 61 |
0.0% | Low Risk · 10 | N/A | |
| 507 | 60 |
PIT | High-A | C | 50 | 55 | 60 | 54 |
+0.9% | Low Risk · 10 | 59% Emerging | |
| 508 | 60 |
NYM | AAA | C | 49 | 56 | 63 | 56 |
+0.1% | Low Risk · 4 | 56% Emerging | |
| 509 | 60 |
MIA | Single-A | C | 49 | 55 | 62 | 60 |
-1.0% | Low Risk · 12 | 56% Emerging | |
| 510 | 60 |
SF | Single-A | P | 49 | 55 | 63 | 60 |
0.0% | Low Risk · 14 | N/A | |
| 511 | 60 |
LAA | Single-A | P | 48 | 53 | 58 | 49 |
+0.1% | Low Risk · 0 | 58% Emerging | |
| 512 | 60 |
MIN | High-A | SS | 49 | 53 | 58 | 49 |
-0.3% | Low Risk · 0 | 59% Emerging | |
| 513 | 60 |
BAL | Single-A | C | 48 | 58 | 72 | 59 |
+5.4% | Low Risk · 18 | N/A | |
| 514 | 60 |
ARI | High-A | SS | 48 | 55 | 63 | 55 |
-0.5% | Low Risk · 13 | 57% Emerging | |
| 515 | 60 |
MIN | Single-A | RF | 48 | 54 | 61 | 51 |
-0.2% | Low Risk · 0 | 58% Emerging | |
| 516 | 60 |
HOU | AA | C | 49 | 54 | 59 | 51 |
-0.5% | Low Risk · 0 | 57% Emerging | |
| 517 | 60 |
MIL | AAA | 3B | 50 | 54 | 58 | 46 |
-0.1% | Low Risk · 0 | 60% Emerging | |
| 518 | 60 |
COL | Single-A | P | 49 | 57 | 65 | 65 |
0.0% | Low Risk · 26 | N/A | |
| 519 | 60 |
CIN | ACL | C | 50 | 56 | 62 | 59 |
-0.1% | Low Risk · 24 | 58% Emerging | |
| 520 | IL(7-Day)60 |
WSH | Single-A | PIL(7-Day) | 47 | 56 | 64 | 59 |
0.0% | Low Risk · 27 | N/A | |
| 521 | 60 |
TEX | AAA | P | 49 | 55 | 62 | 50 |
0.0% | Low Risk · 6 | 57% Emerging | |
| 522 | 60 |
CIN | High-A | SS | 49 | 54 | 59 | 48 |
-0.1% | Low Risk · 0 | 60% Emerging | |
| 523 | 60 |
SF | AAA | SS | 49 | 56 | 62 | 47 |
-1.5% | Low Risk · 0 | 59% Emerging | |
| 524 | 60 |
MIN | FCL | OF | 49 | 56 | 64 | 59 |
+0.9% | Low Risk · 24 | 57% Emerging | |
| 525 | 60 |
TB | AA | P | 50 | 54 | 58 | 50 |
+3.1% | Low Risk · 0 | 59% Emerging | |
| 526 | 60 |
ARI | High-A | P | 50 | 54 | 59 | 51 |
-2.7% | Low Risk · 10 | 59% Emerging | |
| 527 | 60 |
MIA | FCL | IF | 47 | 56 | 70 | 57 |
+3.2% | Low Risk · 32 | N/A | |
| 528 | 60 |
BOS | AAA | P | 51 | 58 | 65 | 55 |
-0.3% | Low Risk · 20 | 57% Emerging | |
| 529 | 60 |
MIN | FCL | C | 49 | 57 | 66 | 57 |
+0.6% | Low Risk · 24 | 57% Emerging | |
| 530 | 60 |
KC | Single-A | SS | 49 | 54 | 59 | 47 |
-0.2% | Low Risk · 3 | 59% Emerging | |
| 531 | 60 |
MIL | AA | P | 48 | 55 | 63 | 60 |
0.0% | Low Risk · 14 | N/A | |
| 532 | 60 |
LAD | ACL | IF | 46 | 56 | 70 | 60 |
-0.4% | Low Risk · 32 | N/A | |
| 533 | 60 |
COL | Single-A | SS | 49 | 58 | 67 | 56 |
0.0% | Low Risk · 26 | 58% Emerging | |
| 534 | 60 |
DET | FCL | CF | 48 | 56 | 66 | 62 |
-0.4% | Low Risk · 24 | N/A | |
| 535 | 60 |
MIA | High-A | CF | 49 | 53 | 58 | 49 |
+0.2% | Low Risk · 0 | 59% Emerging | |
| 536 | 60 |
NYY | FCL | 3B | 48 | 56 | 64 | 59 |
+0.2% | Low Risk · 24 | 57% Emerging | |
| 537 | 60 |
TEX | ACL | SS | 48 | 57 | 65 | 58 |
-0.1% | Low Risk · 24 | 57% Emerging | |
| 538 | 60 |
ARI | AA | P | 52 | 61 | 69 | 54 |
0.0% | Low Risk · 32 | 59% Emerging | |
| 539 | 60 |
NYM | AAA | P | 51 | 59 | 67 | 55 |
-1.6% | Low Risk · 28 | 58% Emerging | |
| 540 | 60 |
MIL | DSL | SS | 47 | 55 | 66 | 60 |
+1.0% | Low Risk · 24 | N/A | |
| 541 | 60 |
CWS | High-A | SS | 48 | 53 | 58 | 50 |
+0.6% | Low Risk · 0 | 59% Emerging | |
| 542 | 60 |
TB | High-A | 1B | 49 | 55 | 64 | 58 |
+1.7% | Low Risk · 10 | N/A | |
| 543 | 60 |
LAD | Single-A | P | 48 | 55 | 62 | 57 |
+0.5% | Low Risk · 14 | N/A | |
| 544 | 60 |
TEX | DSL | OF | 47 | 55 | 69 | 60 |
+2.5% | Low Risk · 24 | N/A | |
| 545 | 60 |
HOU | High-A | SS | 49 | 54 | 59 | 51 |
+1.1% | Low Risk · 0 | 58% Emerging | |
| 546 | 60 |
PIT | AA | P | 49 | 53 | 58 | 49 |
+0.1% | Low Risk · 0 | 57% Emerging | |
| 547 | 59 |
TEX | High-A | 3B | 49 | 54 | 59 | 51 |
0.0% | Low Risk · 0 | 57% Emerging | |
| 548 | 59 |
DET | Single-A | P | 47 | 54 | 62 | 59 |
-0.3% | Low Risk · 14 | N/A | |
| 549 | 59 |
KC | DSL | OF | 46 | 56 | 70 | 61 |
-0.2% | Low Risk · 32 | N/A | |
| 550 | 59 |
CIN | DSL | OF | 46 | 55 | 68 | 60 |
+1.2% | Low Risk · 32 | N/A | |
| 551 | 59 |
NYY | DSL | OF | 47 | 57 | 71 | 64 |
-0.5% | Low Risk · 38 | N/A | |
| 552 | 59 |
BAL | High-A | P | 49 | 54 | 60 | 53 |
0.0% | Low Risk · 10 | 57% Emerging | |
| 553 | 59 |
BOS | High-A | P | 49 | 55 | 64 | 56 |
-4.2% | Low Risk · 10 | 56% Emerging | |
| 554 | 59 |
ARI | AA | 2B | 49 | 54 | 59 | 47 |
0.0% | Low Risk · 1 | 58% Emerging | |
| 555 | 59 |
BOS | High-A | 3B | 47 | 53 | 60 | 50 |
+0.8% | Low Risk · 0 | 57% Emerging | |
| 556 | 59 |
BOS | AA | P | 50 | 55 | 61 | 54 |
0.0% | Low Risk · 10 | 56% Emerging | |
| 557 | 59 |
DET | Single-A | OF | 49 | 54 | 59 | 46 |
+0.7% | Low Risk · 3 | 59% Emerging | |
| 558 | 59 |
ARI | ACL | P | 48 | 56 | 65 | 62 |
-0.2% | Low Risk · 24 | N/A | |
| 559 | 59 |
SD | AA | P | 49 | 53 | 57 | 50 |
0.0% | Low Risk · 0 | 59% Emerging | |
| 560 | 59 |
MIA | AAA | CF | 49 | 53 | 58 | 50 |
-0.2% | Low Risk · 0 | N/A | |
| 561 | 59 |
CWS | AA | P | 50 | 59 | 72 | 62 |
0.0% | Low Risk · 25 | N/A | |
| 562 | 59 |
ATL | High-A | LF | 48 | 57 | 67 | 58 |
0.0% | Low Risk · 23 | N/A | |
| 563 | 59 |
NYM | Single-A | P | 49 | 56 | 63 | 52 |
+0.1% | Low Risk · 17 | 58% Emerging | |
| 564 | 59 |
NYM | AA | P | 49 | 55 | 61 | 54 |
+0.2% | Low Risk · 10 | 56% Emerging | |
| 565 | 59 |
WSH | High-A | P | 49 | 53 | 58 | 54 |
0.0% | Low Risk · 10 | 57% Emerging | |
| 566 | 59 |
MIA | Single-A | P | 48 | 55 | 65 | 55 |
-0.3% | Low Risk · 14 | N/A | |
| 567 | 59 |
PIT | Single-A | P | 48 | 58 | 68 | 61 |
0.0% | Low Risk · 31 | N/A | |
| 568 | 59 |
SD | AAA | RF | 49 | 53 | 57 | 52 |
+0.1% | Low Risk · 1 | N/A | |
| 569 | 59 |
BAL | AA | 2B | 50 | 59 | 69 | 61 |
0.0% | Low Risk · 29 | N/A | |
| 570 | 59 |
SF | AA | 3B | 50 | 54 | 58 | 54 |
+1.4% | Low Risk · 10 | 57% Emerging | |
| 571 | 59 |
BOS | Single-A | C | 47 | 53 | 59 | 51 |
-0.4% | Low Risk · 0 | 57% Emerging | |
| 572 | 59 |
LAD | High-A | P | 48 | 55 | 62 | 53 |
0.0% | Low Risk · 10 | 56% Emerging | |
| 573 | 59 |
CHC | AA | OF | 49 | 53 | 58 | 50 |
+0.6% | Low Risk · 0 | N/A | |
| 574 | 59 |
BAL | AA | P | 49 | 54 | 58 | 48 |
+3.9% | Low Risk · 10 | 58% Emerging | |
| 575 | 59 |
CLE | High-A | P | 48 | 53 | 58 | 50 |
0.0% | Low Risk · 0 | 57% Emerging | |
| 576 | 59 |
BOS | High-A | SS | 48 | 54 | 61 | 54 |
+0.1% | Low Risk · 10 | N/A | |
| 577 | 59 |
SF | High-A | C | 46 | 55 | 64 | 58 |
-0.2% | Low Risk · 14 | N/A | |
| 578 | 59 |
HOU | AA | 2B | 49 | 53 | 58 | 47 |
+0.2% | Low Risk · 0 | 57% Emerging | |
| 579 | 59 |
SD | Single-A | SS | 56 | 63 | 69 | 39 |
+0.3% | Low Risk · 24 | 61% Emerging | |
| 580 | 59 |
SF | High-A | P | 48 | 54 | 62 | 54 |
-2.9% | Low Risk · 10 | N/A | |
| 581 | 59 |
MIN | High-A | C | 46 | 55 | 64 | 59 |
-0.1% | Low Risk · 23 | N/A | |
| 582 | 59 |
CWS | Single-A | SS | 48 | 57 | 67 | 58 |
0.0% | Low Risk · 21 | N/A | |
| 583 | 59 |
PIT | Single-A | OF | 49 | 57 | 66 | 57 |
0.0% | Low Risk · 27 | N/A | |
| 584 | 59 |
PHI | Single-A | 2B | 49 | 54 | 60 | 44 |
0.0% | Low Risk · 3 | 60% Emerging | |
| 585 | 59 |
CLE | ACL | 2B | 46 | 57 | 73 | 61 |
+1.3% | Low Risk · 33 | N/A | |
| 586 | 59 |
SEA | DSL | OF | 46 | 54 | 64 | 59 |
+0.6% | Low Risk · 24 | N/A | |
| 587 | 59 |
MIA | Single-A | P | 48 | 57 | 66 | 57 |
0.0% | Low Risk · 21 | N/A | |
| 588 | 59 |
NYY | DSL | SS | 46 | 55 | 69 | 61 |
-0.5% | Low Risk · 38 | N/A | |
| 589 | 59 |
DET | AA | SS | 49 | 54 | 58 | 56 |
+0.1% | Low Risk · 10 | N/A | |
| 590 | 59 |
ARI | AA | 3B | 48 | 53 | 57 | 51 |
-0.1% | Low Risk · 0 | N/A | |
| 591 | 59 |
HOU | High-A | RF | 48 | 56 | 63 | 53 |
+2.2% | Low Risk · 16 | 56% Emerging | |
| 592 | 59 |
KC | AA | P | 48 | 52 | 56 | 46 |
0.0% | Low Risk · 0 | 58% Emerging | |
| 593 | 59 |
NYM | AAA | P | 48 | 56 | 64 | 58 |
-0.1% | Low Risk · 18 | N/A | |
| 594 | 59 |
WSH | Single-A | SS | 47 | 53 | 59 | 52 |
-0.1% | Low Risk · 0 | N/A | |
| 595 | 59 |
MIA | Single-A | OF | 48 | 55 | 63 | 54 |
+0.2% | Low Risk · 19 | N/A | |
| 596 | 59 |
HOU | AA | SS | 49 | 54 | 59 | 54 |
-0.5% | Low Risk · 10 | N/A | |
| 597 | 59 |
BAL | High-A | 1B | 48 | 54 | 61 | 53 |
-0.1% | Low Risk · 12 | N/A | |
| 598 | 59 |
NYY | AA | P | 50 | 54 | 60 | 50 |
0.0% | Low Risk · 10 | 58% Emerging | |
| 599 | 59 |
MIL | ACL | OF | 47 | 56 | 66 | 58 |
-0.6% | Low Risk · 32 | N/A | |
| 600 | 59 |
CLE | AAA | SS | 49 | 54 | 59 | 50 |
+0.3% | Low Risk · 12 | N/A | |
| 601 | 59 |
SD | Single-A | P | 48 | 57 | 66 | 57 |
-0.4% | Low Risk · 35 | 56% Emerging | |
| 602 | 59 |
SEA | High-A | P | 47 | 54 | 65 | 58 |
-0.4% | Low Risk · 10 | N/A | |
| 603 | 59 |
CWS | High-A | OF | 48 | 52 | 58 | 51 |
+0.4% | Low Risk · 1 | N/A | |
| 604 | 59 |
PIT | Single-A | C | 47 | 52 | 57 | 49 |
-0.2% | Low Risk · 5 | 58% Emerging | |
| 605 | 59 |
MIL | High-A | P | 47 | 56 | 69 | 60 |
+1.7% | Low Risk · 24 | N/A | |
| 606 | 59 |
TOR | AAA | SS | 48 | 52 | 56 | 49 |
-0.1% | Low Risk · 1 | 58% Emerging | |
| 607 | 59 |
STL | AAA | P | 50 | 57 | 65 | 55 |
0.0% | Low Risk · 28 | 56% Emerging | |
| 608 | 59 |
MIN | Single-A | OF | 47 | 57 | 66 | 58 |
0.0% | Low Risk · 21 | N/A | |
| 609 | 59 |
SF | AA | 3B | 48 | 52 | 57 | 50 |
-0.5% | Low Risk · 0 | N/A | |
| 610 | 59 |
STL | Single-A | SS | 49 | 54 | 60 | 48 |
-0.6% | Low Risk · 19 | 58% Emerging | |
| 611 | 59 |
ATL | AAA | P | 49 | 59 | 68 | 63 |
0.0% | Medium Risk · 48 | N/A | |
| 612 | 59 |
CHC | AA | OF | 48 | 53 | 57 | 49 |
0.0% | Low Risk · 0 | N/A | |
| 613 | 58 |
ATL | Single-A | SS | 54 | 60 | 65 | 45 |
-0.1% | Low Risk · 12 | 58% Emerging | |
| 614 | 58 |
WSH | Single-A | LF | 47 | 56 | 69 | 57 |
0.0% | Low Risk · 18 | N/A | |
| 615 | 58 |
TEX | AAA | P | 48 | 53 | 57 | 50 |
0.0% | Low Risk · 10 | N/A | |
| 616 | 58 |
CWS | DSL | SS | 45 | 54 | 63 | 59 |
-0.4% | Low Risk · 32 | N/A | |
| 617 | 58 |
CHC | DSL | OF | 45 | 55 | 70 | 58 |
+1.6% | Low Risk · 32 | N/A | |
| 618 | 58 |
PIT | FCL | IF | 46 | 56 | 68 | 57 |
-0.7% | Low Risk · 32 | N/A | |
| 619 | 58 |
ARI | AAA | 2B | 48 | 55 | 62 | 54 |
+1.8% | Low Risk · 4 | N/A | |
| 620 | 58 |
PHI | High-A | P | 47 | 54 | 63 | 58 |
0.0% | Low Risk · 10 | N/A | |
| 621 | 58 |
MIN | FCL | OF | 48 | 56 | 64 | 55 |
-0.5% | Low Risk · 24 | 57% Emerging | |
| 622 | 58 |
TEX | DSL | SS | 44 | 54 | 63 | 60 |
+2.0% | Low Risk · 32 | N/A | |
| 623 | 58 |
TEX | Single-A | P | 47 | 54 | 65 | 56 |
+0.5% | Low Risk · 14 | N/A | |
| 624 | 58 |
HOU | High-A | OF | 51 | 61 | 71 | 55 |
0.0% | Low Risk · 35 | N/A | |
| 625 | 58 |
PIT | AA | 2B | 48 | 52 | 56 | 48 |
-0.7% | Low Risk · 0 | 58% Emerging | |
| 626 | 58 |
ATH | AAA | P | 50 | 60 | 70 | 63 |
0.0% | Medium Risk · 48 | N/A | |
| 627 | 58 |
PHI | AA | C | 50 | 54 | 59 | 46 |
0.0% | Low Risk · 12 | 59% Emerging | |
| 628 | 58 |
STL | AAA | RF | 47 | 55 | 63 | 63 |
+0.1% | Low Risk · 21 | N/A | |
| 629 | 58 |
MIA | High-A | P | 49 | 54 | 60 | 50 |
0.0% | Low Risk · 14 | N/A | |
| 630 | 58 |
LAA | Single-A | CF | 46 | 52 | 59 | 51 |
+0.3% | Low Risk · 0 | N/A | |
| 631 | 58 |
LAD | Single-A | C | 46 | 55 | 70 | 57 |
+0.2% | Low Risk · 18 | N/A | |
| 632 | 58 |
LAD | AAA | P | 51 | 57 | 62 | 40 |
0.0% | Low Risk · 20 | 60% Emerging | |
| 633 | 58 |
ARI | Single-A | P | 46 | 54 | 62 | 53 |
0.0% | Low Risk · 8 | N/A | |
| 634 | 58 |
CLE | ACL | SS | 48 | 56 | 64 | 56 |
0.0% | Low Risk · 29 | 57% Emerging | |
| 635 | 58 |
CLE | Single-A | 2B | 47 | 55 | 62 | 53 |
0.0% | Low Risk · 19 | N/A | |
| 636 | 58 |
COL | AA | P | 48 | 53 | 59 | 55 |
+1.3% | Low Risk · 10 | N/A | |
| 637 | 58 |
SF | Single-A | 2B | 48 | 54 | 61 | 55 |
-0.4% | Low Risk · 16 | N/A | |
| 638 | 58 |
TOR | AA | RF | 49 | 53 | 58 | 53 |
-0.2% | Low Risk · 10 | N/A | |
| 639 | 58 |
TEX | AA | C | 48 | 52 | 57 | 49 |
+0.2% | Low Risk · 0 | N/A | |
| 640 | 58 |
MIL | AA | P | 48 | 52 | 57 | 49 |
0.0% | Low Risk · 0 | N/A | |
| 641 | 58 |
HOU | High-A | OF | 48 | 55 | 62 | 57 |
+0.3% | Low Risk · 26 | N/A | |
| 642 | 58 |
BAL | FCL | IF | 46 | 54 | 62 | 59 |
+0.7% | Low Risk · 24 | N/A | |
| 643 | 58 |
ATL | Single-A | P | 47 | 54 | 60 | 56 |
0.0% | Low Risk · 14 | N/A | |
| 644 | 58 |
SF | High-A | P | 47 | 53 | 60 | 55 |
0.0% | Low Risk · 10 | N/A | |
| 645 | 58 |
CLE | AA | P | 49 | 53 | 58 | 55 |
0.0% | Low Risk · 10 | N/A | |
| 646 | 58 |
DET | AA | P | 48 | 57 | 69 | 59 |
-0.5% | Low Risk · 24 | N/A | |
| 647 | 58 |
KC | High-A | OF | 47 | 53 | 60 | 55 |
+0.9% | Low Risk · 10 | N/A | |
| 648 | 58 |
PIT | AA | 1B | 48 | 52 | 56 | 46 |
-0.7% | Low Risk · 0 | 59% Emerging | |
| 649 | 58 |
CLE | ACL | C | 46 | 55 | 65 | 55 |
+0.1% | Low Risk · 24 | N/A | |
| 650 | 58 |
ATL | High-A | OF | 47 | 57 | 67 | 58 |
0.0% | Low Risk · 35 | N/A | |
| 651 | 58 |
ARI | High-A | P | 47 | 57 | 70 | 57 |
0.0% | Low Risk · 24 | N/A | |
| 652 | 58 |
BAL | High-A | 2B | 47 | 52 | 57 | 49 |
-0.1% | Low Risk · 0 | N/A | |
| 653 | 58 |
MIL | DSL | SS | 45 | 55 | 72 | 58 |
0.0% | Low Risk · 32 | N/A | |
| 654 | 58 |
LAA | AA | P | 48 | 52 | 56 | 45 |
0.0% | Low Risk · 0 | 58% Emerging | |
| 655 | 58 |
NYY | AA | P | 54 | 62 | 68 | 43 |
0.0% | Low Risk · 20 | 58% Emerging | |
| 656 | 58 |
COL | AA | P | 47 | 56 | 65 | 61 |
+0.3% | Low Risk · 38 | N/A | |
| 657 | 58 |
MIA | AA | 1B | 49 | 53 | 58 | 52 |
-0.3% | Low Risk · 10 | N/A | |
| 658 | 58 |
BOS | High-A | C | 46 | 53 | 61 | 55 |
-0.4% | Low Risk · 10 | N/A | |
| 659 | 58 |
LAA | AA | 3B | 47 | 54 | 62 | 56 |
-0.9% | Low Risk · 19 | N/A | |
| 660 | 58 |
DET | Single-A | C | 47 | 53 | 60 | 56 |
-0.6% | Low Risk · 14 | N/A | |
| 661 | 58 |
MIN | High-A | P | 45 | 55 | 64 | 58 |
0.0% | Low Risk · 28 | N/A | |
| 662 | 58 |
ATL | AA | P | 48 | 55 | 65 | 55 |
0.0% | Low Risk · 18 | N/A | |
| 663 | 58 |
MIA | High-A | 3B | 45 | 52 | 59 | 52 |
-0.2% | Low Risk · 0 | N/A | |
| 664 | 58 |
CWS | High-A | OF | 48 | 54 | 59 | 47 |
-0.3% | Low Risk · 16 | 58% Emerging | |
| 665 | 58 |
PIT | AA | CF | 49 | 53 | 58 | 50 |
-0.3% | Low Risk · 12 | N/A | |
| 666 | 58 |
BOS | FCL | SS | 47 | 55 | 63 | 55 |
+0.8% | Low Risk · 24 | N/A | |
| 667 | 58 |
SD | Single-A | C | 48 | 53 | 58 | 44 |
-0.8% | Low Risk · 3 | 59% Emerging | |
| 668 | 58 |
ATH | High-A | P | 46 | 51 | 56 | 45 |
+1.2% | Low Risk · 0 | 57% Emerging | |
| 669 | 58 |
MIN | AAA | C | 48 | 58 | 68 | 61 |
0.0% | Low Risk · 29 | N/A | |
| 670 | 58 |
SD | High-A | SS | 47 | 52 | 57 | 48 |
-0.7% | Low Risk · 0 | N/A | |
| 671 | 58 |
ATL | FCL | IF | 46 | 54 | 62 | 57 |
+1.0% | Low Risk · 24 | N/A | |
| 672 | 58 |
MIA | AA | CF | 48 | 52 | 57 | 50 |
-0.3% | Low Risk · 10 | N/A | |
| 673 | 58 |
COL | Single-A | 3B | 45 | 55 | 64 | 56 |
0.0% | Low Risk · 21 | N/A | |
| 674 | 58 |
CHC | ACL | SS | 45 | 55 | 70 | 58 |
-0.1% | Low Risk · 32 | N/A | |
| 675 | 58 |
TEX | AA | P | 48 | 52 | 57 | 49 |
-1.6% | Low Risk · 0 | N/A | |
| 676 | 58 |
MIA | AAA | CF | 48 | 52 | 57 | 45 |
-0.3% | Low Risk · 1 | N/A | |
| 677 | 58 |
COL | ACL | SS | 45 | 54 | 62 | 59 |
-0.5% | Low Risk · 24 | N/A | |
| 678 | 58 |
STL | High-A | CF | 46 | 53 | 60 | 51 |
+1.6% | Low Risk · 0 | N/A | |
| 679 | 58 |
ARI | DSL | OF | 44 | 54 | 66 | 59 |
-1.1% | Low Risk · 32 | N/A | |
| 680 | 58 |
SEA | Single-A | P | 47 | 54 | 67 | 55 |
0.0% | Low Risk · 12 | N/A | |
| 681 | 58 |
STL | AA | P | 49 | 57 | 67 | 57 |
0.0% | Low Risk · 32 | N/A | |
| 682 | 58 |
NYY | High-A | SS | 48 | 52 | 58 | 51 |
-0.7% | Low Risk · 10 | N/A | |
| 683 | 58 |
ATL | High-A | P | 45 | 53 | 61 | 54 |
+0.2% | Low Risk · 4 | N/A | |
| 684 | 58 |
ATL | AA | OF | 46 | 55 | 64 | 59 |
-0.3% | Low Risk · 19 | N/A | |
| 685 | 58 |
COL | ACL | SS | 47 | 53 | 59 | 53 |
-1.0% | Low Risk · 24 | N/A | |
| 686 | 58 |
SEA | High-A | P | 46 | 54 | 63 | 55 |
0.0% | Low Risk · 24 | N/A | |
| 687 | 58 |
NYY | AA | IF | 48 | 53 | 58 | 52 |
-0.4% | Low Risk · 10 | N/A | |
| 688 | 58 |
LAA | Single-A | C | 48 | 53 | 58 | 46 |
-0.1% | Low Risk · 12 | 58% Emerging | |
| 689 | 58 |
NYY | DSL | 2B | 46 | 56 | 71 | 60 |
+1.1% | Low Risk · 38 | N/A | |
| 690 | 58 |
ARI | High-A | 2B | 45 | 51 | 58 | 47 |
-0.8% | Low Risk · 0 | N/A | |
| 691 | 58 |
ARI | AAA | LF | 47 | 51 | 56 | 49 |
+0.1% | Low Risk · 1 | N/A | |
| 692 | 57 |
BOS | Single-A | SS | 46 | 52 | 59 | 47 |
-0.8% | Low Risk · 3 | N/A | |
| 693 | 57 |
CIN | Single-A | OF | 46 | 56 | 65 | 58 |
-0.2% | Low Risk · 26 | N/A | |
| 694 | 57 |
KC | DSL | SS | 43 | 52 | 64 | 57 |
+0.8% | Low Risk · 32 | N/A | |
| 695 | 57 |
CLE | High-A | 1B | 45 | 54 | 63 | 58 |
+0.4% | Low Risk · 14 | N/A | |
| 696 | 57 |
TOR | FCL | OF | 46 | 54 | 62 | 57 |
+2.7% | Low Risk · 24 | N/A | |
| 697 | 57 |
ATH | Single-A | SS | 45 | 55 | 64 | 56 |
+0.1% | Low Risk · 26 | N/A | |
| 698 | 57 |
MIL | Single-A | 3B | 46 | 52 | 58 | 51 |
+0.1% | Low Risk · 5 | N/A | |
| 699 | 57 |
WSH | AA | OF | 49 | 57 | 65 | 53 |
-1.0% | Low Risk · 29 | 57% Emerging | |
| 700 | 57 |
SEA | ACL | P | 45 | 53 | 63 | 56 |
+0.6% | Low Risk · 24 | N/A | |
| 701 | 57 |
LAA | ACL | SS | 47 | 53 | 59 | 55 |
-0.4% | Low Risk · 24 | N/A | |
| 702 | 57 |
PHI | Single-A | SS | 46 | 52 | 58 | 51 |
+0.4% | Low Risk · 0 | N/A | |
| 703 | 57 |
COL | Single-A | P | 45 | 52 | 63 | 58 |
+0.8% | Low Risk · 12 | N/A | |
| 704 | 57 |
MIN | Single-A | P | 47 | 53 | 62 | 55 |
-0.2% | Low Risk · 12 | N/A | |
| 705 | 57 |
MIL | High-A | P | 47 | 52 | 57 | 47 |
+0.2% | Low Risk · 0 | N/A | |
| 706 | 57 |
CLE | High-A | P | 47 | 55 | 66 | 56 |
-0.1% | Low Risk · 28 | N/A | |
| 707 | 57 |
DET | High-A | P | 47 | 53 | 59 | 48 |
0.0% | Low Risk · 10 | N/A | |
| 708 | 57 |
MIL | AA | P | 46 | 53 | 61 | 56 |
+0.1% | Low Risk · 18 | N/A | |
| 709 | 57 |
CLE | AA | P | 47 | 51 | 56 | 46 |
0.0% | Low Risk · 6 | N/A | |
| 710 | 57 |
CLE | High-A | P | 47 | 52 | 57 | 48 |
0.0% | Low Risk · 10 | N/A | |
| 711 | 57 |
KC | ACL | P | 45 | 55 | 72 | 54 |
0.0% | Low Risk · 32 | N/A | |
| 712 | 57 |
HOU | High-A | 1B | 45 | 52 | 59 | 58 |
+0.1% | Low Risk · 10 | N/A | |
| 713 | 57 |
STL | AAA | 2B | 48 | 52 | 57 | 54 |
+0.2% | Low Risk · 12 | N/A | |
| 714 | 57 |
COL | AA | C | 47 | 56 | 65 | 58 |
0.0% | Low Risk · 23 | N/A | |
| 715 | 57 |
BAL | AA | P | 49 | 57 | 65 | 55 |
0.0% | Low Risk · 28 | N/A | |
| 716 | 57 |
MIA | Single-A | SS | 46 | 51 | 58 | 51 |
-0.4% | Low Risk · 0 | N/A | |
| 717 | 57 |
ARI | High-A | P | 47 | 54 | 65 | 55 |
+0.2% | Low Risk · 24 | N/A | |
| 718 | 57 |
HOU | Single-A | C | 45 | 51 | 58 | 51 |
+0.6% | Low Risk · 0 | N/A | |
| 719 | 57 |
MIN | AAA | RF | 47 | 56 | 65 | 60 |
-0.1% | Low Risk · 35 | N/A | |
| 720 | 57 |
MIN | Single-A | CF | 45 | 51 | 58 | 50 |
-0.1% | Low Risk · 0 | N/A | |
| 721 | 57 |
TOR | High-A | 3B | 46 | 52 | 59 | 52 |
-2.3% | Low Risk · 10 | N/A | |
| 722 | 57 |
BAL | High-A | C | 44 | 53 | 63 | 58 |
0.0% | Low Risk · 14 | N/A | |
| 723 | 57 |
ARI | Single-A | OF | 44 | 51 | 59 | 50 |
+0.1% | Low Risk · 0 | N/A | |
| 724 | 57 |
MIL | AA | P | 47 | 54 | 62 | 55 |
0.0% | Low Risk · 18 | N/A | |
| 725 | 57 |
PHI | Single-A | P | 45 | 53 | 62 | 54 |
0.0% | Low Risk · 22 | N/A | |
| 726 | 57 |
SEA | DSL | OF | 43 | 51 | 61 | 54 |
+1.2% | Low Risk · 24 | N/A | |
| 727 | 57 |
WSH | FCL | IF | 47 | 53 | 59 | 53 |
+0.1% | Low Risk · 24 | N/A | |
| 728 | 57 |
TOR | High-A | P | 45 | 53 | 61 | 51 |
-0.4% | Low Risk · 4 | N/A | |
| 729 | 57 |
CHC | Single-A | P | 46 | 52 | 59 | 59 |
0.0% | Low Risk · 12 | N/A | |
| 730 | 57 |
BOS | FCL | CF | 47 | 53 | 59 | 51 |
+0.3% | Low Risk · 24 | N/A | |
| 731 | 57 |
TB | AA | P | 45 | 54 | 62 | 58 |
0.0% | Low Risk · 24 | N/A | |
| 732 | 57 |
NYM | Single-A | SS | 45 | 55 | 64 | 57 |
0.0% | Low Risk · 21 | N/A | |
| 733 | 57 |
NYY | AAA | P | 47 | 53 | 59 | 53 |
0.0% | Low Risk · 11 | N/A | |
| 734 | 57 |
BOS | AA | 2B | 48 | 52 | 57 | 42 |
+0.3% | Low Risk · 0 | N/A | |
| 735 | 57 |
TB | High-A | SS | 46 | 51 | 56 | 47 |
+0.1% | Low Risk · 0 | N/A | |
| 736 | 57 |
TEX | ACL | SS | 44 | 52 | 60 | 54 |
-0.9% | Low Risk · 24 | N/A | |
| 737 | 57 |
CWS | High-A | SS | 47 | 51 | 56 | 50 |
0.0% | Low Risk · 10 | N/A | |
| 738 | 57 |
MIA | High-A | P | 46 | 51 | 56 | 51 |
0.0% | Low Risk · 10 | N/A | |
| 739 | 57 |
NYY | AA | P | 46 | 52 | 60 | 55 |
-0.9% | Low Risk · 11 | N/A | |
| 740 | 57 |
LAD | Single-A | 2B | 45 | 51 | 58 | 50 |
+0.4% | Low Risk · 0 | N/A | |
| 741 | 57 |
PHI | AA | P | 46 | 52 | 59 | 56 |
0.0% | Low Risk · 24 | N/A | |
| 742 | 57 |
TOR | AA | SS | 46 | 53 | 60 | 54 |
+1.8% | Low Risk · 4 | N/A | |
| 743 | 57 |
MIL | AA | 2B | 47 | 52 | 56 | 51 |
-0.4% | Low Risk · 10 | N/A | |
| 744 | 57 |
LAD | High-A | SS | 46 | 51 | 56 | 48 |
-0.3% | Low Risk · 5 | N/A | |
| 745 | 57 |
KC | AA | P | 46 | 50 | 55 | 44 |
0.0% | Low Risk · 0 | N/A | |
| 746 | 57 |
LAD | High-A | CF | 46 | 51 | 56 | 47 |
0.0% | Low Risk · 0 | N/A | |
| 747 | 57 |
BOS | Single-A | P | 45 | 52 | 58 | 48 |
0.0% | Low Risk · 0 | N/A | |
| 748 | 57 |
MIN | AAA | P | 46 | 52 | 59 | 47 |
-1.9% | Low Risk · 6 | N/A | |
| 749 | 57 |
PIT | High-A | OF | 45 | 53 | 63 | 56 |
-1.5% | Low Risk · 18 | N/A | |
| 750 | 57 |
SD | AA | P | 46 | 52 | 59 | 53 |
+1.3% | Low Risk · 10 | N/A | |
| 751 | 57 |
BAL | Single-A | SS | 46 | 55 | 65 | 57 |
0.0% | Low Risk · 26 | N/A | |
| 752 | 57 |
SD | AAA | 1B | 46 | 55 | 64 | 59 |
+2.7% | Low Risk · 28 | N/A | |
| 753 | 57 |
CHC | Single-A | IF | 45 | 54 | 62 | 54 |
+0.1% | Low Risk · 16 | N/A | |
| 754 | 57 |
WSH | AAA | P | 50 | 61 | 70 | 64 |
-0.4% | Medium Risk · 52 | N/A | |
| 755 | 57 |
ATH | Single-A | P | 44 | 52 | 60 | 54 |
0.0% | Low Risk · 8 | N/A | |
| 756 | 57 |
LAA | Single-A | P | 48 | 54 | 59 | 49 |
0.0% | Low Risk · 27 | N/A | |
| 757 | 57 |
CLE | DSL | IF | 44 | 53 | 63 | 57 |
+0.6% | Low Risk · 32 | N/A | |
| 758 | 57 |
SD | High-A | P | 45 | 52 | 59 | 49 |
+0.7% | Low Risk · 14 | N/A | |
| 759 | 57 |
MIN | AAA | 2B | 47 | 51 | 56 | 45 |
0.0% | Low Risk · 0 | N/A | |
| 760 | 57 |
LAD | AA | 3B | 48 | 53 | 59 | 54 |
+0.2% | Low Risk · 26 | N/A | |
| 761 | 57 |
CHC | High-A | P | 46 | 52 | 61 | 54 |
0.0% | Low Risk · 10 | N/A | |
| 762 | 57 |
MIA | AA | 2B | 47 | 51 | 56 | 47 |
+0.4% | Low Risk · 5 | N/A | |
| 763 | 57 |
TEX | High-A | OF | 46 | 51 | 56 | 48 |
+0.1% | Low Risk · 5 | N/A | |
| 764 | 57 |
BAL | AA | P | 47 | 51 | 56 | 46 |
0.0% | Low Risk · 0 | N/A | |
| 765 | 57 |
ARI | AA | CF | 47 | 51 | 56 | 46 |
-1.4% | Low Risk · 17 | N/A | |
| 766 | 57 |
MIN | Single-A | P | 43 | 51 | 59 | 55 |
0.0% | Low Risk · 8 | N/A | |
| 767 | 57 |
PIT | High-A | LF | 46 | 51 | 56 | 47 |
+2.1% | Low Risk · 0 | N/A | |
| 768 | 57 |
MIL | DSL | SS | 44 | 53 | 64 | 57 |
+3.6% | Low Risk · 32 | N/A | |
| 769 | 57 |
KC | High-A | CF | 46 | 51 | 56 | 42 |
-0.2% | Low Risk · 5 | 57% Emerging | |
| 770 | 57 |
BOS | AA | RF | 47 | 51 | 56 | 42 |
0.0% | Low Risk · 5 | 57% Emerging | |
| 771 | 57 |
CLE | AA | C | 46 | 50 | 55 | 45 |
-0.3% | Low Risk · 0 | 57% Emerging | |
| 772 | 57 |
SF | Single-A | P | 47 | 52 | 60 | 54 |
0.0% | Low Risk · 28 | N/A | |
| 773 | 57 |
HOU | FCL | P | 45 | 53 | 61 | 57 |
0.0% | Low Risk · 24 | N/A | |
| 774 | 57 |
ATL | High-A | P | 44 | 52 | 62 | 57 |
0.0% | Low Risk · 18 | N/A | |
| 775 | 57 |
STL | AA | SS | 47 | 51 | 56 | 51 |
+0.1% | Low Risk · 10 | N/A | |
| 776 | 56 |
LAD | High-A | 3B | 44 | 53 | 63 | 57 |
0.0% | Low Risk · 14 | N/A | |
| 777 | 56 |
NYM | Single-A | P | 46 | 52 | 59 | 53 |
-0.1% | Low Risk · 14 | N/A | |
| 778 | 56 |
COL | DSL | OF | 43 | 53 | 70 | 57 |
+0.5% | Low Risk · 32 | N/A | |
| 779 | 56 |
STL | AA | LF | 47 | 51 | 56 | 52 |
+0.6% | Low Risk · 10 | N/A | |
| 780 | 56 |
NYY | FCL | 3B | 45 | 53 | 61 | 55 |
-1.0% | Low Risk · 24 | N/A | |
| 781 | 56 |
ATH | Single-A | P | 46 | 52 | 64 | 56 |
0.0% | Low Risk · 12 | N/A | |
| 782 | 56 |
CLE | DSL | IF | 43 | 52 | 65 | 56 |
+1.1% | Low Risk · 32 | N/A | |
| 783 | 56 |
TEX | High-A | RF | 46 | 51 | 56 | 46 |
+1.7% | Low Risk · 9 | 57% Emerging | |
| 784 | 56 |
NYY | Single-A | C | 45 | 54 | 67 | 55 |
-0.4% | Low Risk · 18 | N/A | |
| 785 | 56 |
CLE | ACL | P | 43 | 52 | 61 | 52 |
0.0% | Low Risk · 24 | N/A | |
| 786 | 56 |
LAA | ACL | SS | 46 | 52 | 58 | 51 |
-0.8% | Low Risk · 24 | N/A | |
| 787 | 56 |
MIN | DSL | IF | 43 | 53 | 68 | 58 |
-0.8% | Low Risk · 32 | N/A | |
| 788 | 56 |
KC | Single-A | P | 47 | 52 | 58 | 56 |
+0.1% | Low Risk · 26 | N/A | |
| 789 | 56 |
TOR | FCL | C | 45 | 53 | 61 | 56 |
-0.1% | Low Risk · 24 | N/A | |
| 790 | 56 |
MIL | AAA | OF | 47 | 56 | 65 | 60 |
-0.6% | Low Risk · 35 | N/A | |
| 791 | 56 |
LAD | DSL | OF | 43 | 53 | 66 | 56 |
+1.8% | Low Risk · 32 | N/A | |
| 792 | 56 |
SF | AAA | LF | 46 | 51 | 56 | 44 |
+0.1% | Low Risk · 0 | N/A | |
| 793 | 56 |
CIN | ACL | P | 44 | 53 | 69 | 53 |
+2.3% | Low Risk · 32 | N/A | |
| 794 | 56 |
BAL | High-A | P | 44 | 52 | 61 | 56 |
+0.1% | Low Risk · 14 | N/A | |
| 795 | 56 |
PHI | Single-A | P | 45 | 52 | 58 | 48 |
0.0% | Low Risk · 10 | N/A | |
| 796 | 56 |
PHI | AA | SS | 47 | 57 | 67 | 60 |
+0.9% | Medium Risk · 44 | N/A | |
| 797 | 56 |
PHI | Single-A | OF | 44 | 53 | 62 | 55 |
0.0% | Low Risk · 18 | N/A | |
| 798 | 56 |
NYM | High-A | P | 45 | 53 | 60 | 48 |
0.0% | Low Risk · 6 | N/A | |
| 799 | 56 |
BOS | Single-A | C | 43 | 51 | 59 | 52 |
-1.7% | Low Risk · 8 | N/A | |
| 800 | 56 |
NYY | Single-A | 2B | 44 | 53 | 64 | 56 |
0.0% | Low Risk · 18 | N/A | |
| 801 | 56 |
TB | AA | SS | 48 | 53 | 58 | 43 |
-0.3% | Low Risk · 10 | N/A | |
| 802 | 56 |
DET | Single-A | P | 46 | 51 | 58 | 50 |
0.0% | Low Risk · 14 | N/A | |
| 803 | 56 |
TOR | Single-A | LF | 44 | 54 | 69 | 55 |
-0.2% | Low Risk · 18 | N/A | |
| 804 | 56 |
LAA | High-A | RF | 46 | 51 | 57 | 48 |
-0.2% | Low Risk · 16 | N/A | |
| 805 | 56 |
TB | AAA | P | 48 | 58 | 67 | 62 |
0.0% | Medium Risk · 48 | N/A | |
| 806 | 56 |
STL | High-A | SS | 44 | 54 | 65 | 56 |
-0.1% | Low Risk · 14 | N/A | |
| 807 | 56 |
ARI | AA | LF | 46 | 50 | 55 | 46 |
-0.1% | Low Risk · 0 | N/A | |
| 808 | 56 |
LAD | AAA | P | 48 | 53 | 58 | 47 |
-0.2% | Low Risk · 20 | N/A | |
| 809 | 56 |
COL | High-A | OF | 46 | 51 | 56 | 48 |
0.0% | Low Risk · 12 | N/A | |
| 810 | 56 |
SF | ACL | P | 45 | 52 | 63 | 58 |
+0.1% | Low Risk · 32 | N/A | |
| 811 | 56 |
NYM | AA | C | 46 | 56 | 66 | 60 |
-0.1% | Low Risk · 31 | N/A | |
| 812 | 56 |
ATL | High-A | P | 43 | 52 | 61 | 56 |
0.0% | Low Risk · 18 | N/A | |
| 813 | 56 |
NYM | High-A | P | 45 | 52 | 62 | 57 |
-0.1% | Low Risk · 24 | N/A | |
| 814 | 56 |
CWS | DSL | OF | 43 | 52 | 65 | 53 |
+0.2% | Low Risk · 32 | N/A | |
| 815 | 56 |
BOS | DSL | SS | 42 | 52 | 63 | 57 |
+2.8% | Low Risk · 32 | N/A | |
| 816 | 56 |
TOR | Single-A | OF | 45 | 50 | 55 | 42 |
-0.3% | Low Risk · 3 | N/A | |
| 817 | 56 |
PIT | AAA | P | 46 | 56 | 65 | 60 |
0.0% | Low Risk · 25 | N/A | |
| 818 | 56 |
TOR | Single-A | SS | 47 | 53 | 59 | 39 |
-1.5% | Low Risk · 12 | 57% Emerging | |
| 819 | 56 |
NYM | DSL | OF | 43 | 53 | 66 | 56 |
+0.6% | Low Risk · 32 | N/A | |
| 820 | 56 |
MIL | ACL | P | 45 | 53 | 64 | 53 |
0.0% | Low Risk · 24 | N/A | |
| 821 | 56 |
HOU | High-A | SS | 46 | 51 | 56 | 49 |
-0.1% | Low Risk · 10 | N/A | |
| 822 | 56 |
CIN | AA | CF | 45 | 53 | 62 | 57 |
-2.9% | Low Risk · 28 | N/A | |
| 823 | 56 |
NYY | High-A | P | 46 | 52 | 57 | 48 |
0.0% | Low Risk · 14 | N/A | |
| 824 | 56 |
WSH | DSL | OF | 42 | 52 | 65 | 56 |
+2.2% | Low Risk · 32 | N/A | |
| 825 | 56 |
HOU | AA | RF | 46 | 50 | 55 | 46 |
+0.1% | Low Risk · 0 | N/A | |
| 826 | 56 |
NYM | DSL | OF | 43 | 52 | 60 | 56 |
+1.7% | Low Risk · 24 | N/A | |
| 827 | 56 |
STL | High-A | P | 46 | 50 | 56 | 45 |
0.0% | Low Risk · 10 | N/A | |
| 828 | 56 |
LAD | AA | P | 46 | 55 | 68 | 58 |
0.0% | Low Risk · 25 | N/A | |
| 829 | 56 |
ARI | AA | P | 46 | 53 | 60 | 48 |
+2.2% | Low Risk · 4 | N/A | |
| 830 | 56 |
MIN | AA | SS | 46 | 50 | 54 | 42 |
+1.7% | Low Risk · 0 | 57% Emerging | |
| 831 | 56 |
COL | High-A | CF | 54 | 61 | 67 | 34 |
0.0% | Low Risk · 25 | 59% Emerging | |
| 832 | 56 |
TEX | ACL | OF | 44 | 52 | 60 | 56 |
-0.5% | Low Risk · 24 | N/A | |
| 833 | 56 |
LAD | Single-A | P | 45 | 52 | 62 | 54 |
0.0% | Low Risk · 26 | N/A | |
| 834 | 56 |
BOS | High-A | P | 45 | 51 | 60 | 53 |
-0.1% | Low Risk · 10 | N/A | |
| 835 | 56 |
MIL | High-A | P | 44 | 54 | 64 | 58 |
0.0% | Medium Risk · 42 | N/A | |
| 836 | 56 |
TEX | AAA | P | 46 | 56 | 65 | 61 |
0.0% | Low Risk · 38 | N/A | |
| 837 | 56 |
PIT | AA | C | 46 | 55 | 64 | 57 |
0.0% | Low Risk · 28 | N/A | |
| 838 | 56 |
ATL | AA | P | 46 | 52 | 60 | 52 |
0.0% | Low Risk · 24 | N/A | |
| 839 | 56 |
DET | FCL | IF | 45 | 53 | 61 | 52 |
-0.5% | Low Risk · 24 | N/A | |
| 840 | 56 |
ATL | AA | CF | 47 | 51 | 55 | 49 |
+0.7% | Low Risk · 10 | N/A | |
| 841 | 56 |
MIN | DSL | IF | 43 | 52 | 63 | 55 |
+3.1% | Low Risk · 32 | N/A | |
| 842 | 56 |
STL | High-A | 1B | 45 | 49 | 54 | 45 |
-0.2% | Low Risk · 0 | N/A | |
| 843 | 56 |
CIN | Single-A | LF | 44 | 50 | 56 | 48 |
-1.3% | Low Risk · 5 | N/A | |
| 844 | 56 |
ARI | AAA | P | 47 | 56 | 64 | 58 |
0.0% | Low Risk · 38 | N/A | |
| 845 | 56 |
BAL | AAA | CF | 44 | 49 | 55 | 42 |
-0.5% | Low Risk · 1 | N/A | |
| 846 | 56 |
ARI | High-A | CF | 44 | 53 | 61 | 54 |
-0.5% | Low Risk · 14 | N/A | |
| 847 | 56 |
DET | Single-A | RF | 44 | 50 | 56 | 47 |
+0.1% | Low Risk · 0 | N/A | |
| 848 | 56 |
SF | AAA | 2B | 46 | 50 | 55 | 43 |
+0.4% | Low Risk · 0 | N/A | |
| 849 | 56 |
NYY | AAA | SS | 45 | 54 | 63 | 58 |
-1.1% | Low Risk · 23 | N/A | |
| 850 | 56 |
TEX | ACL | CF | 43 | 53 | 66 | 56 |
+0.2% | Low Risk · 32 | N/A | |
| 851 | 56 |
LAD | High-A | IF | 44 | 51 | 57 | 51 |
0.0% | Low Risk · 10 | N/A | |
| 852 | 56 |
TEX | High-A | SS | 45 | 56 | 72 | 59 |
0.0% | Low Risk · 31 | N/A | |
| 853 | 56 |
PIT | Single-A | IF | 43 | 51 | 60 | 52 |
0.0% | Low Risk · 8 | N/A | |
| 854 | 56 |
SD | AA | P | 45 | 52 | 59 | 48 |
0.0% | Low Risk · 10 | N/A | |
| 855 | 56 |
HOU | Single-A | 3B | 44 | 53 | 69 | 55 |
-0.1% | Low Risk · 18 | N/A | |
| 856 | 56 |
ARI | Single-A | 2B | 44 | 50 | 56 | 46 |
0.0% | Low Risk · 0 | N/A | |
| 857 | 56 |
TB | High-A | SS | 43 | 53 | 62 | 56 |
0.0% | Low Risk · 19 | N/A | |
| 858 | 56 |
ARI | High-A | P | 44 | 52 | 61 | 54 |
+0.9% | Low Risk · 14 | N/A | |
| 859 | 56 |
WSH | AAA | LF | 46 | 50 | 55 | 48 |
-0.2% | Low Risk · 13 | N/A | |
| 860 | 56 |
CLE | High-A | P | 48 | 60 | 70 | 56 |
0.0% | Medium Risk · 53 | N/A | |
| 861 | 56 |
NYM | High-A | P | 44 | 52 | 62 | 54 |
-0.2% | Low Risk · 24 | N/A | |
| 862 | 56 |
BOS | High-A | C | 45 | 50 | 55 | 43 |
-2.0% | Low Risk · 9 | N/A | |
| 863 | 56 |
MIN | AA | 2B | 45 | 53 | 61 | 55 |
-0.6% | Low Risk · 19 | N/A | |
| 864 | 56 |
STL | AA | P | 47 | 56 | 66 | 59 |
0.0% | Medium Risk · 48 | N/A | |
| 865 | 56 |
TEX | DSL | C | 41 | 51 | 64 | 57 |
-0.1% | Low Risk · 32 | N/A | |
| 866 | 56 |
NYY | High-A | P | 43 | 51 | 59 | 53 |
0.0% | Low Risk · 10 | N/A | |
| 867 | 56 |
LAA | High-A | 2B | 45 | 55 | 71 | 57 |
+0.1% | Low Risk · 28 | N/A | |
| 868 | 56 |
CWS | Single-A | P | 43 | 50 | 58 | 56 |
+0.1% | Low Risk · 12 | N/A | |
| 869 | 55 |
BAL | High-A | CF | 44 | 49 | 56 | 47 |
-0.5% | Low Risk · 0 | N/A | |
| 870 | 55 |
ATL | High-A | 2B | 45 | 49 | 54 | 45 |
-0.2% | Low Risk · 0 | N/A | |
| 871 | 55 |
NYY | FCL | RF | 43 | 52 | 65 | 59 |
0.0% | Low Risk · 32 | N/A | |
| 872 | 55 |
BOS | High-A | OF | 45 | 50 | 55 | 45 |
+0.6% | Low Risk · 0 | N/A | |
| 873 | 55 |
COL | DSL | SS | 42 | 51 | 59 | 53 |
+0.8% | Low Risk · 32 | N/A | |
| 874 | 55 |
NYY | High-A | SS | 45 | 50 | 55 | 49 |
-0.2% | Low Risk · 10 | N/A | |
| 875 | 55 |
ARI | Single-A | IF | 46 | 53 | 60 | 45 |
+0.1% | Low Risk · 19 | N/A | |
| 876 | 55 |
MIL | ACL | SS | 42 | 52 | 63 | 56 |
+0.3% | Low Risk · 32 | N/A | |
| 877 | 55 |
TEX | High-A | P | 44 | 53 | 65 | 57 |
0.0% | Low Risk · 24 | N/A | |
| 878 | 55 |
LAA | ACL | OF | 44 | 52 | 60 | 54 |
-0.2% | Low Risk · 24 | N/A | |
| 879 | 55 |
SEA | AA | 3B | 46 | 50 | 55 | 53 |
-0.2% | Low Risk · 11 | N/A | |
| 880 | 55 |
NYY | Single-A | P | 44 | 50 | 58 | 56 |
0.0% | Low Risk · 12 | N/A | |
| 881 | 55 |
MIN | High-A | CF | 44 | 49 | 54 | 42 |
+0.4% | Low Risk · 0 | N/A | |
| 882 | 55 |
PIT | AA | CF | 45 | 50 | 54 | 44 |
-0.3% | Low Risk · 0 | N/A | |
| 883 | 55 |
TEX | High-A | 3B | 44 | 52 | 61 | 53 |
+0.1% | Low Risk · 14 | N/A | |
| 884 | 55 |
SF | Single-A | 3B | 44 | 50 | 57 | 54 |
+0.9% | Low Risk · 12 | N/A | |
| 885 | 55 |
CLE | AA | SS | 45 | 50 | 54 | 43 |
-0.2% | Low Risk · 1 | N/A | |
| 886 | 55 |
CHC | High-A | P | 42 | 52 | 61 | 56 |
+0.1% | Low Risk · 24 | N/A | |
| 887 | 55 |
STL | Single-A | P | 44 | 54 | 68 | 57 |
-0.1% | Low Risk · 29 | N/A | |
| 888 | 55 |
CLE | DSL | C | 42 | 51 | 62 | 56 |
-0.3% | Low Risk · 32 | N/A | |
| 889 | 55 |
TB | FCL | IF | 44 | 51 | 59 | 53 |
+0.8% | Low Risk · 24 | N/A | |
| 890 | 55 |
KC | ACL | P | 43 | 53 | 70 | 54 |
0.0% | Low Risk · 32 | N/A | |
| 891 | 55 |
LAA | Single-A | P | 44 | 51 | 59 | 57 |
+0.2% | Low Risk · 26 | N/A | |
| 892 | 55 |
STL | AA | P | 44 | 51 | 58 | 50 |
0.0% | Low Risk · 10 | N/A | |
| 893 | 55 |
NYM | AAA | P | 47 | 57 | 67 | 61 |
0.0% | Medium Risk · 49 | N/A | |
| 894 | 55 |
PIT | Single-A | SS | 43 | 49 | 55 | 46 |
+0.1% | Low Risk · 0 | N/A | |
| 895 | 55 |
TEX | Single-A | P | 44 | 52 | 59 | 57 |
+0.2% | Low Risk · 26 | N/A | |
| 896 | 55 |
PIT | Single-A | P | 44 | 52 | 60 | 50 |
0.0% | Low Risk · 17 | N/A | |
| 897 | 55 |
CWS | AAA | P | 45 | 49 | 53 | 43 |
0.0% | Low Risk · 0 | N/A | |
| 898 | 55 |
COL | High-A | OF | 44 | 50 | 57 | 51 |
-0.1% | Low Risk · 10 | N/A | |
| 899 | 55 |
MIN | Single-A | P | 44 | 50 | 58 | 54 |
-1.2% | Low Risk · 12 | N/A | |
| 900 | 55 |
TEX | DSL | SS | 41 | 50 | 60 | 53 |
-2.0% | Low Risk · 32 | N/A | |
| 901 | 55 |
CWS | Single-A | C | 43 | 49 | 56 | 47 |
-0.4% | Low Risk · 5 | N/A | |
| 902 | 55 |
LAA | AA | CF | 46 | 54 | 63 | 57 |
+0.2% | Low Risk · 28 | N/A | |
| 903 | 55 |
MIL | High-A | P | 43 | 53 | 62 | 57 |
0.0% | Low Risk · 24 | N/A | |
| 904 | 55 |
MIL | High-A | SS | 44 | 48 | 53 | 45 |
+0.9% | Low Risk · 1 | N/A | |
| 905 | 55 |
HOU | AA | 1B | 44 | 51 | 58 | 54 |
+0.1% | Low Risk · 18 | N/A | |
| 906 | 55 |
LAD | Single-A | SS | 43 | 54 | 68 | 56 |
0.0% | Low Risk · 34 | N/A | |
| 907 | 55 |
PHI | AA | SS | 43 | 52 | 61 | 56 |
0.0% | Low Risk · 14 | N/A | |
| 908 | 55 |
ARI | Single-A | P | 42 | 51 | 63 | 55 |
-0.4% | Low Risk · 22 | N/A | |
| 909 | 55 |
LAD | High-A | P | 44 | 50 | 57 | 51 |
0.0% | Low Risk · 10 | N/A | |
| 910 | 55 |
CLE | AAA | 3B | 46 | 51 | 56 | 42 |
0.0% | Low Risk · 10 | N/A | |
| 911 | IL(60-Day)55 |
KC | AAA | PIL(60-Day) | 47 | 58 | 68 | 62 |
0.0% | Wide Range · 61 | N/A | |
| 912 | 55 |
LAA | AA | 2B | 45 | 49 | 54 | 44 |
-0.3% | Low Risk · 0 | N/A | |
| 913 | 55 |
SEA | ACL | SS | 45 | 52 | 58 | 55 |
-0.6% | Low Risk · 40 | N/A | |
| 914 | 55 |
ARI | AAA | P | 46 | 50 | 55 | 42 |
0.0% | Low Risk · 0 | N/A | |
| 915 | 55 |
KC | High-A | 1B | 45 | 52 | 59 | 52 |
0.0% | Low Risk · 26 | N/A | |
| 916 | IL(7-Day)55 |
PHI | High-A | SSIL(7-Day) | 42 | 51 | 63 | 57 |
0.0% | Low Risk · 24 | N/A | |
| 917 | 55 |
MIA | High-A | 2B | 43 | 51 | 59 | 51 |
-0.6% | Low Risk · 9 | N/A | |
| 918 | 55 |
WSH | High-A | C | 43 | 50 | 57 | 51 |
-0.7% | Low Risk · 10 | N/A | |
| 919 | 55 |
TOR | AA | P | 45 | 52 | 60 | 50 |
+0.9% | Low Risk · 20 | N/A | |
| 920 | 55 |
STL | High-A | P | 46 | 52 | 57 | 43 |
0.0% | Low Risk · 10 | N/A | |
| 921 | 55 |
NYY | High-A | SS | 44 | 49 | 55 | 44 |
+2.7% | Low Risk · 0 | N/A | |
| 922 | 55 |
NYY | DSL | C | 41 | 51 | 61 | 55 |
-0.1% | Low Risk · 32 | N/A | |
| 923 | 55 |
CHC | AAA | P | 47 | 58 | 68 | 62 |
-0.1% | Medium Risk · 51 | N/A | |
| 924 | 55 |
BAL | AA | SS | 44 | 48 | 53 | 42 |
-0.1% | Low Risk · 0 | N/A | |
| 925 | 55 |
KC | High-A | P | 43 | 50 | 57 | 48 |
+0.5% | Low Risk · 10 | N/A | |
| 926 | 55 |
CLE | Single-A | P | 43 | 52 | 67 | 52 |
0.0% | Low Risk · 18 | N/A | |
| 927 | 55 |
TOR | FCL | SS | 44 | 51 | 59 | 54 |
-1.5% | Low Risk · 24 | N/A | |
| 928 | 55 |
ARI | High-A | P | 45 | 50 | 55 | 50 |
0.0% | Low Risk · 24 | N/A | |
| 929 | 55 |
TOR | AAA | P | 44 | 48 | 52 | 41 |
0.0% | Low Risk · 0 | N/A | |
| 930 | 55 |
SEA | AAA | P | 45 | 52 | 60 | 56 |
0.0% | Low Risk · 27 | N/A | |
| 931 | 55 |
LAD | AA | P | 45 | 49 | 54 | 44 |
0.0% | Low Risk · 0 | N/A | |
| 932 | 55 |
PHI | AA | P | 46 | 55 | 68 | 59 |
0.0% | Low Risk · 38 | N/A | |
| 933 | 55 |
CHC | AA | P | 44 | 50 | 56 | 56 |
0.0% | Low Risk · 13 | N/A | |
| 934 | 55 |
NYM | High-A | C | 44 | 49 | 54 | 43 |
+0.1% | Low Risk · 9 | N/A | |
| 935 | 55 |
TOR | AA | P | 45 | 53 | 61 | 51 |
0.0% | Low Risk · 14 | N/A | |
| 936 | 55 |
MIL | AAA | P | 45 | 51 | 58 | 49 |
+0.1% | Low Risk · 5 | N/A | |
| 937 | 55 |
ARI | AAA | P | 47 | 53 | 59 | 39 |
+0.2% | Low Risk · 20 | N/A | |
| 938 | 55 |
ARI | High-A | C | 44 | 49 | 54 | 45 |
-0.8% | Low Risk · 0 | N/A | |
| 939 | 55 |
SEA | High-A | C | 45 | 52 | 59 | 52 |
+0.2% | Low Risk · 26 | N/A | |
| 940 | 55 |
KC | High-A | OF | 43 | 49 | 56 | 49 |
+1.0% | Low Risk · 10 | N/A | |
| 941 | 55 |
COL | AA | SS | 45 | 49 | 54 | 42 |
+0.4% | Low Risk · 1 | N/A | |
| 942 | 55 |
ARI | DSL | OF | 42 | 52 | 67 | 54 |
-1.5% | Low Risk · 32 | N/A | |
| 943 | 55 |
KC | High-A | P | 44 | 49 | 54 | 44 |
-1.3% | Low Risk · 0 | N/A | |
| 944 | 55 |
KC | High-A | SS | 43 | 49 | 56 | 50 |
-0.4% | Low Risk · 10 | N/A | |
| 945 | 55 |
NYY | FCL | SS | 45 | 53 | 63 | 55 |
-1.0% | Low Risk · 40 | N/A | |
| 946 | 54 |
MIL | AA | P | 46 | 54 | 61 | 45 |
+0.1% | Low Risk · 20 | N/A | |
| 947 | 54 |
LAA | AA | P | 45 | 51 | 57 | 52 |
0.0% | Low Risk · 24 | N/A | |
| 948 | 54 |
STL | AA | SS | 45 | 50 | 54 | 48 |
-0.5% | Low Risk · 10 | N/A | |
| 949 | 54 |
DET | High-A | C | 43 | 49 | 56 | 49 |
-0.2% | Low Risk · 10 | N/A | |
| 950 | 54 |
BOS | High-A | P | 43 | 50 | 59 | 51 |
+1.4% | Low Risk · 10 | N/A | |
| 951 | 54 |
MIN | AAA | P | 47 | 52 | 57 | 38 |
0.0% | Low Risk · 20 | N/A | |
| 952 | 54 |
STL | Single-A | P | 45 | 50 | 56 | 53 |
0.0% | Low Risk · 26 | N/A | |
| 953 | 54 |
TOR | High-A | P | 43 | 51 | 61 | 51 |
+0.7% | Low Risk · 18 | N/A | |
| 954 | 54 |
TOR | High-A | RF | 43 | 50 | 56 | 50 |
-0.5% | Low Risk · 10 | N/A | |
| 955 | 54 |
STL | High-A | P | 43 | 50 | 56 | 48 |
0.0% | Low Risk · 10 | N/A | |
| 956 | 54 |
CIN | Single-A | P | 44 | 50 | 54 | 39 |
0.0% | Low Risk · 3 | N/A | |
| 957 | 54 |
MIN | Single-A | C | 42 | 49 | 55 | 46 |
-0.3% | Low Risk · 0 | N/A | |
| 958 | 54 |
SD | Single-A | C | 42 | 51 | 65 | 54 |
0.0% | Low Risk · 18 | N/A | |
| 959 | 54 |
ATL | Single-A | P | 43 | 50 | 57 | 52 |
-0.3% | Low Risk · 12 | N/A | |
| 960 | 54 |
ARI | DSL | OF | 41 | 51 | 63 | 54 |
-0.5% | Low Risk · 32 | N/A | |
| 961 | 54 |
NYM | High-A | OF | 43 | 50 | 59 | 52 |
-1.4% | Low Risk · 10 | N/A | |
| 962 | 54 |
CLE | Single-A | CF | 42 | 49 | 55 | 43 |
+0.1% | Low Risk · 0 | N/A | |
| 963 | 54 |
MIL | High-A | RF | 43 | 49 | 56 | 48 |
-0.4% | Low Risk · 10 | N/A | |
| 964 | 54 |
CHC | AA | P | 46 | 51 | 56 | 40 |
0.0% | Low Risk · 6 | N/A | |
| 965 | 54 |
HOU | Single-A | CF | 43 | 52 | 64 | 53 |
0.0% | Low Risk · 24 | N/A | |
| 966 | 54 |
CWS | ACL | IF | 43 | 52 | 61 | 49 |
-1.2% | Low Risk · 24 | N/A | |
| 967 | 54 |
PHI | FCL | C | 43 | 51 | 60 | 52 |
-0.1% | Low Risk · 29 | N/A | |
| 968 | 54 |
WSH | AA | RF | 44 | 49 | 53 | 44 |
-0.4% | Low Risk · 0 | N/A | |
| 969 | 54 |
DET | High-A | 2B | 44 | 49 | 54 | 43 |
-0.5% | Low Risk · 1 | N/A | |
| 970 | 54 |
CIN | High-A | 2B | 43 | 49 | 56 | 49 |
-0.8% | Low Risk · 10 | N/A | |
| 971 | 54 |
NYM | High-A | C | 43 | 49 | 56 | 48 |
-0.3% | Low Risk · 10 | N/A | |
| 972 | 54 |
SD | High-A | SS | 43 | 49 | 56 | 49 |
+0.3% | Low Risk · 10 | N/A | |
| 973 | 54 |
KC | ACL | 3B | 43 | 52 | 62 | 58 |
+1.1% | Low Risk · 38 | N/A | |
| 974 | 54 |
STL | AA | P | 45 | 50 | 55 | 44 |
0.0% | Low Risk · 20 | N/A | |
| 975 | 54 |
SD | AAA | C | 45 | 54 | 62 | 58 |
0.0% | Low Risk · 30 | N/A | |
| 976 | 54 |
CIN | High-A | 3B | 42 | 51 | 60 | 54 |
-0.4% | Low Risk · 23 | N/A | |
| 977 | 54 |
LAD | High-A | P | 44 | 50 | 58 | 51 |
+0.2% | Low Risk · 24 | N/A | |
| 978 | 54 |
MIA | AA | LF | 43 | 49 | 55 | 40 |
0.0% | Low Risk · 0 | N/A | |
| 979 | 54 |
CWS | DSL | C | 41 | 50 | 61 | 54 |
+0.7% | Low Risk · 32 | N/A | |
| 980 | 54 |
KC | AA | SS | 44 | 48 | 52 | 39 |
0.0% | Low Risk · 1 | N/A | |
| 981 | 54 |
MIN | High-A | 2B | 42 | 52 | 62 | 55 |
-0.3% | Low Risk · 27 | N/A | |
| 982 | 54 |
LAA | AAA | SS | 46 | 53 | 61 | 49 |
-0.6% | Low Risk · 18 | N/A | |
| 983 | 54 |
STL | DSL | C | 41 | 51 | 65 | 54 |
-1.2% | Low Risk · 32 | N/A | |
| 984 | 54 |
BAL | High-A | P | 43 | 50 | 57 | 53 |
-0.2% | Low Risk · 24 | N/A | |
| 985 | 54 |
MIN | FCL | OF | 42 | 52 | 61 | 53 |
+1.1% | Low Risk · 32 | N/A | |
| 986 | 54 |
TEX | AA | LF | 45 | 49 | 54 | 46 |
0.0% | Low Risk · 10 | N/A | |
| 987 | 54 |
CIN | AA | C | 43 | 52 | 65 | 58 |
0.0% | Low Risk · 28 | N/A | |
| 988 | 54 |
LAD | Single-A | P | 43 | 50 | 56 | 45 |
0.0% | Low Risk · 10 | N/A | |
| 989 | 54 |
TOR | AA | P | 44 | 48 | 53 | 43 |
0.0% | Low Risk · 0 | N/A | |
| 990 | 54 |
BAL | Single-A | OF | 45 | 51 | 57 | 40 |
0.0% | Low Risk · 19 | N/A | |
| 991 | 54 |
CLE | Single-A | P | 41 | 50 | 64 | 54 |
-0.4% | Low Risk · 20 | N/A | |
| 992 | 54 |
STL | Single-A | P | 43 | 51 | 59 | 54 |
+0.1% | Low Risk · 28 | N/A | |
| 993 | 54 |
MIA | AA | SS | 42 | 51 | 60 | 55 |
0.0% | Low Risk · 19 | N/A | |
| 994 | 54 |
PIT | AA | P | 43 | 49 | 56 | 45 |
0.0% | Low Risk · 0 | N/A | |
| 995 | 54 |
MIA | High-A | OF | 42 | 52 | 63 | 54 |
+3.7% | Low Risk · 28 | N/A | |
| 996 | 54 |
STL | Single-A | SS | 43 | 49 | 56 | 51 |
+0.2% | Low Risk · 14 | N/A | |
| 997 | 54 |
STL | FCL | SS | 42 | 51 | 59 | 52 |
-0.2% | Low Risk · 24 | N/A | |
| 998 | 54 |
KC | AA | CF | 46 | 50 | 55 | 48 |
-0.1% | Low Risk · 26 | N/A | |
| 999 | 54 |
STL | AAA | P | 45 | 49 | 54 | 50 |
-1.1% | Low Risk · 26 | N/A | |
| 1000 | 54 |
TEX | Single-A | SS | 43 | 49 | 56 | 42 |
-0.1% | Low Risk · 8 | N/A | |
| 1001 | 54 |
KC | High-A | IF | 43 | 49 | 54 | 43 |
+0.1% | Low Risk · 5 | N/A | |
| 1002 | 54 |
BAL | FCL | SS | 41 | 49 | 57 | 49 |
0.0% | Low Risk · 24 | N/A | |
| 1003 | 54 |
MIA | High-A | 3B | 42 | 48 | 54 | 44 |
-0.3% | Low Risk · 0 | N/A | |
| 1004 | 54 |
COL | High-A | 2B | 43 | 47 | 52 | 42 |
0.0% | Low Risk · 0 | N/A | |
| 1005 | 54 |
COL | AA | C | 43 | 47 | 52 | 40 |
-0.6% | Low Risk · 0 | N/A | |
| 1006 | 54 |
TOR | High-A | OF | 43 | 54 | 71 | 56 |
0.0% | Low Risk · 29 | N/A | |
| 1007 | 54 |
COL | High-A | CF | 42 | 49 | 55 | 49 |
+1.0% | Low Risk · 10 | N/A | |
| 1008 | 54 |
CWS | High-A | C | 43 | 51 | 62 | 55 |
-0.3% | Low Risk · 34 | N/A | |
| 1009 | 54 |
KC | ACL | OF | 42 | 50 | 58 | 54 |
-0.4% | Low Risk · 24 | N/A | |
| 1010 | 54 |
NYY | High-A | C | 42 | 49 | 55 | 47 |
0.0% | Low Risk · 10 | N/A | |
| 1011 | 54 |
TEX | Single-A | SS | 43 | 53 | 64 | 55 |
0.0% | Medium Risk · 42 | N/A | |
| 1012 | 54 |
COL | AA | P | 45 | 52 | 59 | 48 |
-2.0% | Low Risk · 28 | N/A | |
| 1013 | 54 |
TOR | High-A | SS | 43 | 49 | 54 | 43 |
+0.8% | Low Risk · 0 | N/A | |
| 1014 | 54 |
CLE | High-A | P | 43 | 51 | 59 | 54 |
0.0% | Low Risk · 32 | N/A | |
| 1015 | 54 |
HOU | High-A | SS | 42 | 48 | 55 | 48 |
+0.6% | Low Risk · 10 | N/A | |
| 1016 | 54 |
TB | High-A | OF | 41 | 50 | 60 | 54 |
-0.3% | Low Risk · 28 | N/A | |
| 1017 | 54 |
LAD | Single-A | CF | 43 | 48 | 54 | 49 |
0.0% | Low Risk · 19 | N/A | |
| 1018 | 54 |
CHC | Single-A | P | 44 | 50 | 56 | 55 |
-0.3% | Low Risk · 26 | N/A | |
| 1019 | 54 |
KC | Single-A | P | 43 | 49 | 56 | 52 |
0.0% | Low Risk · 12 | N/A | |
| 1020 | 54 |
KC | AA | 1B | 44 | 49 | 53 | 48 |
0.0% | Low Risk · 10 | N/A | |
| 1021 | 54 |
CLE | High-A | OF | 44 | 49 | 54 | 43 |
-0.1% | Low Risk · 12 | N/A | |
| 1022 | 54 |
KC | AAA | P | 44 | 49 | 54 | 40 |
0.0% | Low Risk · 0 | N/A | |
| 1023 | 54 |
TEX | DSL | IF | 41 | 51 | 67 | 53 |
-0.5% | Low Risk · 32 | N/A | |
| 1024 | 54 |
ATH | Single-A | SS | 44 | 50 | 55 | 41 |
-0.1% | Low Risk · 19 | N/A | |
| 1025 | 54 |
CWS | AA | P | 45 | 52 | 60 | 48 |
+0.7% | Low Risk · 28 | N/A | |
| 1026 | 54 |
COL | AA | P | 44 | 53 | 62 | 57 |
0.0% | Low Risk · 34 | N/A | |
| 1027 | 54 |
LAD | AA | P | 43 | 49 | 55 | 50 |
+0.1% | Low Risk · 11 | N/A | |
| 1028 | 54 |
NYM | High-A | P | 41 | 48 | 55 | 55 |
0.0% | Low Risk · 10 | N/A | |
| 1029 | 54 |
NYY | Single-A | P | 41 | 48 | 55 | 46 |
0.0% | Low Risk · 0 | N/A | |
| 1030 | 54 |
BAL | Single-A | C | 41 | 47 | 54 | 45 |
0.0% | Low Risk · 0 | N/A | |
| 1031 | 53 |
MIL | ACL | OF | 45 | 51 | 57 | 51 |
-0.3% | Low Risk · 40 | N/A | |
| 1032 | 53 |
CIN | Single-A | 2B | 42 | 48 | 54 | 45 |
0.0% | Low Risk · 0 | N/A | |
| 1033 | 53 |
TB | High-A | C | 40 | 49 | 58 | 52 |
-0.2% | Low Risk · 14 | N/A | |
| 1034 | 53 |
CIN | Single-A | P | 43 | 48 | 53 | 50 |
0.0% | Low Risk · 12 | N/A | |
| 1035 | 53 |
WSH | High-A | SS | 42 | 48 | 55 | 47 |
+0.1% | Low Risk · 10 | N/A | |
| 1036 | 53 |
MIL | ACL | C | 42 | 51 | 63 | 55 |
-0.5% | Low Risk · 40 | N/A | |
| 1037 | 53 |
ARI | DSL | C | 40 | 50 | 62 | 53 |
-0.3% | Low Risk · 32 | N/A | |
| 1038 | 53 |
BOS | Single-A | SS | 42 | 49 | 56 | 43 |
0.0% | Low Risk · 8 | N/A | |
| 1039 | 53 |
SD | Single-A | P | 43 | 49 | 56 | 49 |
0.0% | Low Risk · 14 | N/A | |
| 1040 | 53 |
LAA | High-A | P | 43 | 51 | 59 | 49 |
0.0% | Low Risk · 28 | N/A | |
| 1041 | 53 |
CHC | AAA | 3B | 46 | 50 | 55 | 62 |
-0.5% | Low Risk · 20 | N/A | |
| 1042 | 53 |
MIN | DSL | OF | 40 | 50 | 61 | 53 |
+0.4% | Low Risk · 32 | N/A | |
| 1043 | 53 |
SEA | ACL | IF | 41 | 50 | 58 | 51 |
+0.1% | Low Risk · 24 | N/A | |
| 1044 | 53 |
STL | AA | P | 45 | 49 | 54 | 48 |
0.0% | Low Risk · 24 | N/A | |
| 1045 | 53 |
ARI | High-A | 3B | 43 | 49 | 54 | 38 |
+0.2% | Low Risk · 9 | N/A | |
| 1046 | 53 |
CLE | Single-A | OF | 43 | 50 | 57 | 43 |
-1.6% | Low Risk · 17 | N/A | |
| 1047 | 53 |
PIT | AA | SS | 42 | 48 | 55 | 45 |
0.0% | Low Risk · 1 | N/A | |
| 1048 | 53 |
TB | Single-A | SS | 41 | 48 | 54 | 44 |
-0.1% | Low Risk · 5 | N/A | |
| 1049 | 53 |
LAD | High-A | C | 43 | 48 | 53 | 42 |
+0.1% | Low Risk · 1 | N/A | |
| 1050 | 53 |
CHC | ACL | IF | 41 | 51 | 60 | 52 |
0.0% | Medium Risk · 42 | N/A | |
| 1051 | 53 |
TEX | High-A | 2B | 42 | 48 | 55 | 47 |
-0.1% | Low Risk · 10 | N/A | |
| 1052 | 53 |
KC | High-A | SS | 41 | 50 | 59 | 54 |
0.0% | Low Risk · 14 | N/A | |
| 1053 | 53 |
KC | Single-A | LF | 41 | 48 | 54 | 44 |
+0.1% | Low Risk · 0 | N/A | |
| 1054 | 53 |
MIA | AA | 1B | 42 | 48 | 54 | 41 |
+0.2% | Low Risk · 0 | N/A | |
| 1055 | 53 |
KC | ACL | SS | 41 | 50 | 58 | 52 |
0.0% | Low Risk · 24 | N/A | |
| 1056 | 53 |
MIA | High-A | C | 43 | 50 | 58 | 48 |
-2.2% | Low Risk · 13 | N/A | |
| 1057 | 53 |
BOS | High-A | P | 42 | 49 | 56 | 52 |
-0.6% | Low Risk · 24 | N/A | |
| 1058 | 53 |
PIT | FCL | P | 40 | 49 | 59 | 53 |
-0.1% | Low Risk · 32 | N/A | |
| 1059 | 53 |
LAD | Single-A | SS | 42 | 47 | 52 | 41 |
0.0% | Low Risk · 0 | N/A | |
| 1060 | 53 |
CIN | AAA | SS | 44 | 52 | 60 | 52 |
-0.2% | Low Risk · 25 | N/A | |
| 1061 | 53 |
TB | FCL | C | 42 | 50 | 58 | 52 |
-0.3% | Low Risk · 29 | N/A | |
| 1062 | 53 |
LAA | AA | P | 44 | 49 | 54 | 46 |
+0.6% | Low Risk · 10 | N/A | |
| 1063 | 53 |
STL | High-A | 3B | 42 | 52 | 63 | 54 |
0.0% | Low Risk · 23 | N/A | |
| 1064 | 53 |
NYY | AA | C | 43 | 48 | 53 | 42 |
0.0% | Low Risk · 1 | N/A | |
| 1065 | 53 |
MIN | FCL | IF | 41 | 50 | 58 | 51 |
0.0% | Low Risk · 24 | N/A | |
| 1066 | 53 |
STL | FCL | OF | 41 | 50 | 59 | 51 |
-1.1% | Low Risk · 29 | N/A | |
| 1067 | 53 |
ATH | High-A | SS | 42 | 48 | 55 | 47 |
-0.3% | Low Risk · 10 | N/A | |
| 1068 | 53 |
MIL | DSL | SS | 40 | 49 | 58 | 52 |
+0.2% | Low Risk · 24 | N/A | |
| 1069 | 53 |
CWS | AA | CF | 44 | 49 | 53 | 43 |
0.0% | Low Risk · 5 | N/A | |
| 1070 | 53 |
ATL | Single-A | P | 41 | 48 | 58 | 52 |
0.0% | Low Risk · 12 | N/A | |
| 1071 | 53 |
SD | AA | RF | 43 | 48 | 52 | 42 |
-0.6% | Low Risk · 12 | N/A | |
| 1072 | 53 |
NYY | AA | 1B | 44 | 53 | 62 | 56 |
-1.7% | Low Risk · 39 | N/A | |
| 1073 | 53 |
TEX | ACL | OF | 41 | 50 | 59 | 51 |
+0.1% | Low Risk · 24 | N/A | |
| 1074 | 53 |
CIN | High-A | C | 42 | 50 | 59 | 53 |
-0.1% | Low Risk · 26 | N/A | |
| 1075 | 53 |
MIL | Single-A | CF | 44 | 51 | 59 | 45 |
-0.4% | Low Risk · 28 | N/A | |
| 1076 | 53 |
MIN | Single-A | SS | 45 | 51 | 57 | 40 |
0.0% | Low Risk · 28 | N/A | |
| 1077 | 53 |
TOR | AA | P | 44 | 49 | 54 | 42 |
0.0% | Low Risk · 10 | N/A | |
| 1078 | 53 |
MIL | Single-A | P | 43 | 50 | 57 | 42 |
-0.3% | Low Risk · 17 | N/A | |
| 1079 | 53 |
CWS | AA | SS | 44 | 49 | 54 | 41 |
+0.9% | Low Risk · 5 | N/A | |
| 1080 | 53 |
CLE | AA | P | 44 | 50 | 57 | 46 |
+2.3% | Low Risk · 14 | N/A | |
| 1081 | 53 |
ARI | AA | CF | 42 | 49 | 55 | 47 |
0.0% | Low Risk · 10 | N/A | |
| 1082 | 53 |
PHI | AA | P | 44 | 49 | 54 | 47 |
0.0% | Low Risk · 10 | N/A | |
| 1083 | 53 |
ATL | High-A | P | 41 | 49 | 60 | 50 |
0.0% | Low Risk · 10 | N/A | |
| 1084 | 53 |
CIN | ACL | OF | 40 | 48 | 57 | 50 |
+0.1% | Low Risk · 24 | N/A | |
| 1085 | 53 |
LAA | High-A | P | 43 | 47 | 53 | 46 |
-0.5% | Low Risk · 10 | N/A | |
| 1086 | 53 |
NYY | Single-A | SS | 42 | 49 | 56 | 50 |
+0.5% | Low Risk · 12 | N/A | |
| 1087 | 53 |
SD | ACL | IF | 39 | 49 | 64 | 54 |
-0.7% | Low Risk · 32 | N/A | |
| 1088 | 53 |
PIT | High-A | 2B | 41 | 50 | 59 | 53 |
+0.8% | Low Risk · 23 | N/A | |
| 1089 | 53 |
NYY | AA | SS | 42 | 48 | 54 | 42 |
+1.3% | Low Risk · 0 | N/A | |
| 1090 | 53 |
HOU | AA | CF | 44 | 48 | 53 | 44 |
+0.2% | Low Risk · 12 | N/A | |
| 1091 | 53 |
WSH | AA | C | 45 | 50 | 56 | 50 |
-1.2% | Low Risk · 26 | N/A | |
| 1092 | 53 |
SEA | High-A | P | 44 | 49 | 54 | 40 |
-0.6% | Low Risk · 6 | N/A | |
| 1093 | 53 |
SEA | High-A | P | 42 | 48 | 55 | 47 |
0.0% | Low Risk · 10 | N/A | |
| 1094 | 53 |
CLE | AAA | CF | 43 | 51 | 59 | 55 |
+0.1% | Low Risk · 24 | N/A | |
| 1095 | 53 |
HOU | Single-A | P | 43 | 48 | 54 | 52 |
0.0% | Low Risk · 26 | N/A | |
| 1096 | 53 |
ATH | Single-A | 3B | 42 | 48 | 55 | 49 |
0.0% | Low Risk · 14 | N/A | |
| 1097 | 53 |
BOS | AA | OF | 42 | 46 | 51 | 39 |
-0.5% | Low Risk · 0 | N/A | |
| 1098 | 53 |
CHC | Single-A | P | 42 | 48 | 55 | 51 |
-2.5% | Low Risk · 12 | N/A | |
| 1099 | 53 |
CHC | High-A | SS | 43 | 53 | 63 | 55 |
0.0% | Medium Risk · 43 | N/A | |
| 1100 | 53 |
HOU | Single-A | P | 42 | 48 | 55 | 50 |
-0.4% | Low Risk · 14 | N/A | |
| 1101 | 53 |
PHI | AAA | C | 42 | 52 | 62 | 57 |
0.0% | Low Risk · 29 | N/A | |
| 1102 | 53 |
SF | AA | P | 42 | 48 | 55 | 48 |
+1.0% | Low Risk · 10 | N/A | |
| 1103 | 53 |
MIN | High-A | P | 41 | 48 | 54 | 49 |
-0.2% | Low Risk · 10 | N/A | |
| 1104 | 53 |
NYM | AA | SS | 43 | 53 | 63 | 57 |
0.0% | Low Risk · 36 | N/A | |
| 1105 | 53 |
ATH | AA | P | 41 | 48 | 56 | 56 |
+0.1% | Low Risk · 20 | N/A | |
| 1106 | 53 |
LAD | AA | C | 42 | 48 | 55 | 47 |
-0.1% | Low Risk · 10 | N/A | |
| 1107 | 53 |
HOU | DSL | OF | 41 | 51 | 71 | 55 |
+0.8% | Medium Risk · 46 | N/A | |
| 1108 | 53 |
STL | AA | 2B | 43 | 50 | 58 | 52 |
+0.4% | Low Risk · 18 | N/A | |
| 1109 | 53 |
TOR | High-A | P | 41 | 49 | 58 | 52 |
+1.4% | Low Risk · 18 | N/A | |
| 1110 | 53 |
BAL | High-A | CF | 43 | 48 | 54 | 44 |
+0.1% | Low Risk · 16 | N/A | |
| 1111 | 53 |
NYM | High-A | P | 41 | 51 | 60 | 54 |
+0.2% | Low Risk · 32 | N/A | |
| 1112 | 53 |
ATH | Single-A | 3B | 41 | 47 | 53 | 44 |
0.0% | Low Risk · 0 | N/A | |
| 1113 | 53 |
PIT | AA | OF | 44 | 53 | 62 | 57 |
-0.4% | Medium Risk · 44 | N/A | |
| 1114 | 53 |
LAA | AA | P | 43 | 50 | 58 | 51 |
-1.8% | Low Risk · 28 | N/A | |
| 1115 | 53 |
PHI | High-A | C | 41 | 47 | 54 | 47 |
0.0% | Low Risk · 10 | N/A | |
| 1116 | 53 |
ATL | FCL | C | 41 | 50 | 58 | 48 |
-1.3% | Low Risk · 24 | N/A | |
| 1117 | 53 |
STL | Single-A | P | 42 | 49 | 58 | 54 |
-0.3% | Low Risk · 26 | N/A | |
| 1118 | 53 |
ATL | High-A | P | 41 | 49 | 57 | 48 |
-0.2% | Low Risk · 4 | N/A | |
| 1119 | 53 |
PHI | Single-A | SS | 41 | 48 | 54 | 49 |
0.0% | Low Risk · 12 | N/A | |
| 1120 | 53 |
STL | High-A | 3B | 42 | 48 | 54 | 47 |
-0.5% | Low Risk · 10 | N/A | |
| 1121 | 53 |
MIN | Single-A | P | 41 | 48 | 55 | 45 |
0.0% | Low Risk · 14 | N/A | |
| 1122 | 53 |
HOU | Single-A | C | 42 | 49 | 55 | 46 |
+0.2% | Low Risk · 16 | N/A | |
| 1123 | 53 |
MIA | High-A | SS | 41 | 49 | 57 | 50 |
+0.3% | Low Risk · 18 | N/A | |
| 1124 | 53 |
LAA | AA | P | 43 | 47 | 51 | 47 |
-0.2% | Low Risk · 10 | N/A | |
| 1125 | 53 |
LAA | High-A | CF | 42 | 52 | 69 | 54 |
0.0% | Low Risk · 28 | N/A | |
| 1126 | 53 |
BAL | Single-A | P | 45 | 52 | 58 | 39 |
0.0% | Low Risk · 27 | N/A | |
| 1127 | 53 |
BAL | Single-A | OF | 41 | 46 | 51 | 40 |
0.0% | Low Risk · 0 | N/A | |
| 1128 | 53 |
DET | FCL | 2B | 39 | 49 | 65 | 53 |
0.0% | Low Risk · 32 | N/A | |
| 1129 | 53 |
SD | High-A | RF | 43 | 48 | 55 | 48 |
-0.3% | Low Risk · 26 | N/A | |
| 1130 | 53 |
CHC | High-A | P | 43 | 53 | 69 | 55 |
0.0% | Low Risk · 38 | N/A | |
| 1131 | 53 |
CIN | AA | C | 41 | 48 | 54 | 43 |
0.0% | Low Risk · 0 | N/A | |
| 1132 | 53 |
CWS | Single-A | SS | 41 | 51 | 67 | 53 |
+0.1% | Low Risk · 32 | N/A | |
| 1133 | 52 |
NYY | Single-A | P | 42 | 48 | 58 | 48 |
0.0% | Low Risk · 12 | N/A | |
| 1134 | 52 |
MIN | Single-A | 1B | 41 | 48 | 55 | 48 |
-0.2% | Low Risk · 14 | N/A | |
| 1135 | 52 |
BAL | AA | LF | 43 | 48 | 53 | 45 |
0.0% | Low Risk · 10 | N/A | |
| 1136 | 52 |
CIN | Single-A | 2B | 40 | 46 | 53 | 44 |
+0.1% | Low Risk · 0 | N/A | |
| 1137 | 52 |
PHI | High-A | P | 42 | 51 | 62 | 53 |
+1.8% | Low Risk · 32 | N/A | |
| 1138 | 52 |
PHI | Single-A | OF | 41 | 48 | 55 | 52 |
+0.1% | Low Risk · 12 | N/A | |
| 1139 | 52 |
CLE | High-A | LF | 41 | 47 | 54 | 50 |
-0.1% | Low Risk · 15 | N/A | |
| 1140 | 52 |
SD | AA | LF | 43 | 51 | 60 | 54 |
-0.2% | Low Risk · 30 | N/A | |
| 1141 | 52 |
MIL | ACL | OF | 42 | 51 | 59 | 52 |
-1.1% | Low Risk · 40 | N/A | |
| 1142 | 52 |
MIL | Single-A | OF | 41 | 48 | 55 | 49 |
0.0% | Low Risk · 14 | N/A | |
| 1143 | 52 |
MIL | DSL | C | 40 | 50 | 60 | 52 |
0.0% | Low Risk · 32 | N/A | |
| 1144 | 52 |
CWS | AA | P | 42 | 52 | 61 | 57 |
+0.1% | Low Risk · 38 | N/A | |
| 1145 | 52 |
STL | Single-A | P | 41 | 48 | 55 | 50 |
+0.1% | Low Risk · 14 | N/A | |
| 1146 | 52 |
WSH | High-A | P | 43 | 54 | 70 | 55 |
0.0% | Low Risk · 35 | N/A | |
| 1147 | 52 |
SF | Single-A | P | 41 | 48 | 60 | 53 |
0.0% | Low Risk · 12 | N/A | |
| 1148 | 52 |
DET | Single-A | P | 42 | 47 | 52 | 46 |
0.0% | Low Risk · 12 | N/A | |
| 1149 | 52 |
TB | AAA | 2B | 45 | 51 | 56 | 37 |
-0.1% | Low Risk · 21 | N/A | |
| 1150 | 52 |
ATL | AA | SS | 44 | 49 | 54 | 39 |
-0.6% | Low Risk · 12 | N/A | |
| 1151 | 52 |
LAA | High-A | P | 41 | 47 | 58 | 51 |
+0.9% | Low Risk · 10 | N/A | |
| 1152 | 52 |
CLE | DSL | SS | 39 | 48 | 59 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1153 | 52 |
DET | DSL | SS | 40 | 49 | 62 | 51 |
-0.4% | Low Risk · 32 | N/A | |
| 1154 | 52 |
KC | DSL | OF | 40 | 50 | 69 | 51 |
+0.1% | Low Risk · 32 | N/A | |
| 1155 | 52 |
NYY | AA | P | 43 | 47 | 52 | 41 |
-0.9% | Low Risk · 10 | N/A | |
| 1156 | 52 |
CHC | High-A | P | 41 | 50 | 58 | 51 |
-0.1% | Low Risk · 18 | N/A | |
| 1157 | 52 |
ATH | High-A | P | 42 | 46 | 51 | 47 |
0.0% | Low Risk · 10 | N/A | |
| 1158 | 52 |
BOS | DSL | OF | 39 | 49 | 62 | 51 |
-0.1% | Low Risk · 32 | N/A | |
| 1159 | 52 |
SEA | Single-A | P | 40 | 47 | 54 | 55 |
-0.3% | Low Risk · 12 | N/A | |
| 1160 | 52 |
MIA | High-A | P | 42 | 49 | 56 | 46 |
+0.2% | Low Risk · 20 | N/A | |
| 1161 | 52 |
MIL | Single-A | P | 41 | 50 | 59 | 53 |
0.0% | Low Risk · 32 | N/A | |
| 1162 | 52 |
PIT | AA | SS | 43 | 48 | 53 | 40 |
0.0% | Low Risk · 5 | N/A | |
| 1163 | 52 |
SEA | AA | P | 44 | 49 | 55 | 65 |
+0.5% | Low Risk · 21 | N/A | |
| 1164 | 52 |
CIN | AAA | P | 44 | 52 | 61 | 54 |
-0.2% | Low Risk · 38 | N/A | |
| 1165 | 52 |
LAA | Single-A | 1B | 42 | 48 | 55 | 48 |
0.0% | Low Risk · 14 | N/A | |
| 1166 | 52 |
BAL | High-A | C | 41 | 48 | 54 | 46 |
+0.1% | Low Risk · 10 | N/A | |
| 1167 | 52 |
SD | AA | OF | 43 | 48 | 53 | 44 |
+0.6% | Low Risk · 10 | N/A | |
| 1168 | 52 |
CHC | High-A | P | 41 | 49 | 57 | 46 |
0.0% | Low Risk · 20 | N/A | |
| 1169 | 52 |
PIT | AA | P | 44 | 48 | 53 | 41 |
0.0% | Low Risk · 6 | N/A | |
| 1170 | 52 |
TOR | AA | 3B | 42 | 51 | 64 | 56 |
0.0% | Low Risk · 28 | N/A | |
| 1171 | 52 |
DET | FCL | OF | 43 | 50 | 57 | 46 |
+0.1% | Low Risk · 40 | N/A | |
| 1172 | 52 |
BOS | AAA | C | 43 | 54 | 63 | 58 |
0.0% | Medium Risk · 45 | N/A | |
| 1173 | 52 |
TEX | DSL | OF | 39 | 48 | 63 | 52 |
0.0% | Low Risk · 32 | N/A | |
| 1174 | 52 |
LAA | Single-A | 2B | 41 | 47 | 53 | 41 |
-0.5% | Low Risk · 0 | N/A | |
| 1175 | 52 |
LAA | High-A | OF | 42 | 47 | 52 | 40 |
+0.2% | Low Risk · 0 | N/A | |
| 1176 | 52 |
SEA | Single-A | OF | 42 | 46 | 51 | 47 |
-0.5% | Low Risk · 12 | N/A | |
| 1177 | 52 |
CIN | High-A | P | 40 | 47 | 54 | 48 |
0.0% | Low Risk · 10 | N/A | |
| 1178 | 52 |
STL | AAA | P | 44 | 48 | 53 | 47 |
0.0% | Low Risk · 13 | N/A | |
| 1179 | 52 |
BOS | FCL | SS | 40 | 48 | 57 | 50 |
-0.2% | Low Risk · 24 | N/A | |
| 1180 | 52 |
MIL | AA | P | 43 | 50 | 57 | 44 |
0.0% | Low Risk · 20 | N/A | |
| 1181 | 52 |
LAD | AA | P | 42 | 48 | 55 | 50 |
0.0% | Low Risk · 24 | N/A | |
| 1182 | 52 |
TOR | AA | P | 44 | 48 | 54 | 45 |
0.0% | Low Risk · 10 | N/A | |
| 1183 | 52 |
CIN | High-A | P | 44 | 55 | 72 | 55 |
+0.1% | Medium Risk · 48 | N/A | |
| 1184 | 52 |
ARI | Single-A | P | 41 | 51 | 67 | 53 |
0.0% | Low Risk · 28 | N/A | |
| 1185 | 52 |
TEX | AA | CF | 43 | 48 | 52 | 47 |
-0.3% | Low Risk · 10 | N/A | |
| 1186 | 52 |
CWS | Single-A | P | 41 | 47 | 54 | 50 |
-0.4% | Low Risk · 14 | N/A | |
| 1187 | 52 |
NYY | AAA | P | 44 | 55 | 65 | 60 |
0.0% | Medium Risk · 51 | N/A | |
| 1188 | 52 |
LAA | AAA | P | 43 | 48 | 53 | 45 |
-1.0% | Low Risk · 12 | N/A | |
| 1189 | 52 |
TEX | High-A | RF | 41 | 47 | 53 | 47 |
0.0% | Low Risk · 10 | N/A | |
| 1190 | 52 |
WSH | AA | P | 45 | 53 | 67 | 56 |
+0.1% | Low Risk · 38 | N/A | |
| 1191 | IL(7-Day)52 |
BOS | High-A | SSIL(7-Day) | 41 | 52 | 62 | 56 |
0.0% | Low Risk · 40 | N/A | |
| 1192 | 52 |
LAD | High-A | P | 43 | 54 | 71 | 55 |
0.0% | Low Risk · 39 | N/A | |
| 1193 | 52 |
COL | ACL | 1B | 41 | 49 | 59 | 57 |
-0.6% | Low Risk · 32 | N/A | |
| 1194 | 52 |
NYY | Single-A | P | 41 | 48 | 56 | 53 |
0.0% | Low Risk · 26 | N/A | |
| 1195 | 52 |
ARI | Single-A | CF | 41 | 47 | 53 | 40 |
0.0% | Low Risk · 0 | N/A | |
| 1196 | IL(7-Day)52 |
NYM | Single-A | OFIL(7-Day) | 41 | 51 | 60 | 52 |
0.0% | Low Risk · 36 | N/A | |
| 1197 | 52 |
HOU | AA | P | 42 | 48 | 55 | 50 |
0.0% | Low Risk · 24 | N/A | |
| 1198 | 52 |
COL | Single-A | P | 42 | 49 | 60 | 50 |
-2.5% | Low Risk · 28 | N/A | |
| 1199 | 52 |
KC | Single-A | RF | 39 | 48 | 57 | 51 |
0.0% | Low Risk · 18 | N/A | |
| 1200 | 52 |
SEA | AA | P | 41 | 48 | 55 | 46 |
+0.2% | Low Risk · 10 | N/A | |
| 1201 | 52 |
DET | AA | 2B | 43 | 48 | 53 | 45 |
-0.2% | Low Risk · 10 | N/A | |
| 1202 | 52 |
SEA | High-A | P | 41 | 48 | 57 | 46 |
0.0% | Low Risk · 10 | N/A | |
| 1203 | 52 |
TB | Single-A | P | 39 | 47 | 57 | 53 |
-0.1% | Low Risk · 20 | N/A | |
| 1204 | 52 |
PIT | Single-A | P | 42 | 47 | 52 | 41 |
-0.2% | Low Risk · 14 | N/A | |
| 1205 | 52 |
CIN | AA | SS | 41 | 51 | 61 | 55 |
0.0% | Low Risk · 29 | N/A | |
| 1206 | 52 |
CLE | AA | P | 42 | 52 | 62 | 57 |
0.0% | Low Risk · 38 | N/A | |
| 1207 | 52 |
MIL | AAA | C | 42 | 51 | 60 | 56 |
-0.4% | Low Risk · 29 | N/A | |
| 1208 | 52 |
SEA | ACL | OF | 42 | 48 | 54 | 43 |
+0.1% | Low Risk · 24 | N/A | |
| 1209 | 52 |
TOR | DSL | IF | 39 | 48 | 58 | 52 |
-0.1% | Low Risk · 32 | N/A | |
| 1210 | 52 |
STL | AA | P | 43 | 50 | 57 | 44 |
-2.0% | Low Risk · 20 | N/A | |
| 1211 | 52 |
SEA | DSL | OF | 39 | 49 | 59 | 52 |
0.0% | Low Risk · 32 | N/A | |
| 1212 | 52 |
TEX | Single-A | P | 39 | 46 | 54 | 53 |
0.0% | Low Risk · 12 | N/A | |
| 1213 | 52 |
CLE | DSL | C | 38 | 48 | 65 | 52 |
0.0% | Low Risk · 32 | N/A | |
| 1214 | 52 |
WSH | DSL | OF | 38 | 48 | 60 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1215 | 52 |
COL | High-A | P | 40 | 47 | 54 | 51 |
+1.0% | Low Risk · 10 | N/A | |
| 1216 | 52 |
SEA | Single-A | 2B | 41 | 47 | 54 | 48 |
+0.1% | Low Risk · 14 | N/A | |
| 1217 | 52 |
BAL | AAA | C | 42 | 51 | 60 | 56 |
+0.1% | Low Risk · 29 | N/A | |
| 1218 | 52 |
CIN | ACL | OF | 41 | 47 | 54 | 48 |
0.0% | Low Risk · 24 | N/A | |
| 1219 | 52 |
BOS | High-A | LF | 43 | 53 | 71 | 54 |
+0.1% | Low Risk · 29 | N/A | |
| 1220 | 52 |
CLE | High-A | P | 42 | 52 | 62 | 55 |
-0.1% | Medium Risk · 42 | N/A | |
| 1221 | 52 |
MIL | Single-A | SS | 41 | 48 | 55 | 38 |
0.0% | Low Risk · 8 | N/A | |
| 1222 | 52 |
MIA | AAA | C | 42 | 52 | 62 | 58 |
0.0% | Medium Risk · 45 | N/A | |
| 1223 | 52 |
WSH | FCL | OF | 41 | 47 | 54 | 47 |
+0.2% | Low Risk · 29 | N/A | |
| 1224 | 52 |
KC | Single-A | P | 40 | 47 | 54 | 49 |
0.0% | Low Risk · 12 | N/A | |
| 1225 | IL(Rehab)52 |
LAD | ACL | CIL(Rehab) | 39 | 50 | 67 | 54 |
0.0% | Medium Risk · 46 | N/A | |
| 1226 | 52 |
SD | ACL | OF | 40 | 49 | 57 | 49 |
-2.2% | Low Risk · 24 | N/A | |
| 1227 | 52 |
ATH | AA | P | 43 | 48 | 53 | 42 |
-0.1% | Low Risk · 20 | N/A | |
| 1228 | 52 |
STL | High-A | C | 41 | 47 | 53 | 46 |
+0.1% | Low Risk · 10 | N/A | |
| 1229 | 52 |
MIN | AA | P | 42 | 47 | 53 | 45 |
0.0% | Low Risk · 10 | N/A | |
| 1230 | 52 |
SD | ACL | P | 41 | 51 | 67 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1231 | 52 |
SD | AA | C | 42 | 51 | 62 | 55 |
-0.1% | Low Risk · 28 | N/A | |
| 1232 | 52 |
CWS | AA | P | 43 | 53 | 63 | 58 |
+1.8% | Medium Risk · 49 | N/A | |
| 1233 | 52 |
TB | Single-A | 2B | 39 | 49 | 58 | 51 |
-0.1% | Low Risk · 23 | N/A | |
| 1234 | 52 |
ATH | Single-A | P | 40 | 48 | 58 | 50 |
0.0% | Low Risk · 22 | N/A | |
| 1235 | 52 |
LAD | High-A | P | 43 | 48 | 53 | 41 |
0.0% | Low Risk · 24 | N/A | |
| 1236 | 52 |
COL | ACL | P | 40 | 50 | 69 | 54 |
-0.1% | Medium Risk · 46 | N/A | |
| 1237 | 52 |
ATL | DSL | SS | 38 | 48 | 57 | 50 |
-0.5% | Low Risk · 32 | N/A | |
| 1238 | 52 |
CWS | AAA | OF | 43 | 47 | 52 | 47 |
+0.4% | Low Risk · 13 | N/A | |
| 1239 | 52 |
SD | AA | P | 43 | 47 | 52 | 45 |
0.0% | Low Risk · 10 | N/A | |
| 1240 | 52 |
STL | AA | P | 42 | 49 | 56 | 43 |
-0.3% | Low Risk · 20 | N/A | |
| 1241 | 52 |
ATH | AA | P | 43 | 47 | 52 | 42 |
-3.3% | Low Risk · 20 | N/A | |
| 1242 | 52 |
CHC | Single-A | SS | 40 | 46 | 52 | 43 |
0.0% | Low Risk · 0 | N/A | |
| 1243 | 52 |
MIL | DSL | OF | 39 | 49 | 59 | 51 |
-0.1% | Low Risk · 32 | N/A | |
| 1244 | 52 |
LAA | Single-A | P | 40 | 47 | 53 | 48 |
-0.2% | Low Risk · 12 | N/A | |
| 1245 | 52 |
COL | High-A | P | 41 | 47 | 55 | 46 |
0.0% | Low Risk · 10 | N/A | |
| 1246 | 52 |
DET | Single-A | SS | 41 | 45 | 50 | 39 |
+0.1% | Low Risk · 0 | N/A | |
| 1247 | IL(Rehab)52 |
WSH | Single-A | 3BIL(Rehab) | 41 | 52 | 68 | 54 |
0.0% | Low Risk · 38 | N/A | |
| 1248 | 52 |
NYY | High-A | LF | 40 | 49 | 58 | 53 |
0.0% | Low Risk · 28 | N/A | |
| 1249 | 52 |
NYM | Single-A | SS | 39 | 49 | 59 | 53 |
-0.1% | Low Risk · 23 | N/A | |
| 1250 | 52 |
LAA | High-A | P | 40 | 49 | 57 | 52 |
0.0% | Low Risk · 32 | N/A | |
| 1251 | 52 |
NYM | FCL | C | 39 | 47 | 55 | 48 |
-0.3% | Low Risk · 24 | N/A | |
| 1252 | 52 |
MIL | Single-A | SS | 40 | 46 | 53 | 42 |
+0.2% | Low Risk · 5 | N/A | |
| 1253 | 52 |
NYY | High-A | P | 42 | 47 | 52 | 48 |
0.0% | Low Risk · 24 | N/A | |
| 1254 | 52 |
WSH | AA | 1B | 42 | 47 | 52 | 44 |
+0.1% | Low Risk · 10 | N/A | |
| 1255 | 52 |
SD | High-A | OF | 42 | 46 | 51 | 46 |
0.0% | Low Risk · 10 | N/A | |
| 1256 | 52 |
ATL | High-A | SS | 40 | 47 | 53 | 44 |
-0.2% | Low Risk · 10 | N/A | |
| 1257 | 52 |
MIA | DSL | OF | 39 | 49 | 59 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1258 | 52 |
SEA | AA | P | 42 | 46 | 51 | 41 |
0.0% | Low Risk · 10 | N/A | |
| 1259 | 51 |
LAD | High-A | P | 40 | 49 | 58 | 52 |
+0.1% | Low Risk · 28 | N/A | |
| 1260 | 51 |
ATH | Single-A | P | 42 | 47 | 53 | 41 |
+0.2% | Low Risk · 10 | N/A | |
| 1261 | 51 |
CLE | High-A | 3B | 42 | 47 | 53 | 39 |
-0.5% | Low Risk · 5 | N/A | |
| 1262 | 51 |
LAD | ACL | C | 38 | 48 | 57 | 52 |
+0.3% | Low Risk · 32 | N/A | |
| 1263 | 51 |
BOS | AA | C | 41 | 47 | 53 | 38 |
-0.3% | Low Risk · 0 | N/A | |
| 1264 | 51 |
CLE | DSL | OF | 38 | 48 | 59 | 52 |
0.0% | Low Risk · 32 | N/A | |
| 1265 | 51 |
MIL | Single-A | P | 40 | 51 | 65 | 54 |
0.0% | Medium Risk · 42 | N/A | |
| 1266 | 51 |
STL | DSL | OF | 38 | 48 | 60 | 51 |
-0.3% | Low Risk · 32 | N/A | |
| 1267 | 51 |
TOR | AA | 3B | 43 | 48 | 53 | 38 |
-1.9% | Low Risk · 21 | N/A | |
| 1268 | 51 |
CIN | Single-A | P | 42 | 47 | 53 | 43 |
-0.1% | Low Risk · 24 | N/A | |
| 1269 | 51 |
WSH | FCL | OF | 39 | 48 | 57 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1270 | 51 |
PHI | High-A | P | 41 | 52 | 68 | 55 |
0.0% | Low Risk · 38 | N/A | |
| 1271 | 51 |
TB | DSL | IF | 38 | 48 | 62 | 56 |
-0.2% | Medium Risk · 46 | N/A | |
| 1272 | 51 |
MIL | Single-A | P | 41 | 48 | 55 | 40 |
-0.4% | Low Risk · 17 | N/A | |
| 1273 | 51 |
PHI | DSL | SS | 38 | 47 | 55 | 49 |
-0.3% | Low Risk · 32 | N/A | |
| 1274 | 51 |
TEX | AA | P | 44 | 52 | 66 | 55 |
+0.5% | Low Risk · 38 | N/A | |
| 1275 | 51 |
NYY | Single-A | CF | 40 | 51 | 61 | 54 |
0.0% | Low Risk · 34 | N/A | |
| 1276 | 51 |
STL | AAA | P | 42 | 50 | 56 | 43 |
-0.2% | Low Risk · 20 | N/A | |
| 1277 | 51 |
TOR | AA | P | 43 | 52 | 65 | 55 |
-0.1% | Low Risk · 39 | N/A | |
| 1278 | 51 |
SD | Single-A | SS | 40 | 48 | 61 | 50 |
+0.6% | Low Risk · 20 | N/A | |
| 1279 | 51 |
ATH | AA | 3B | 42 | 46 | 51 | 41 |
0.0% | Low Risk · 12 | N/A | |
| 1280 | 51 |
LAD | AAA | P | 43 | 50 | 57 | 41 |
+0.1% | Low Risk · 20 | N/A | |
| 1281 | 51 |
SF | High-A | P | 42 | 47 | 53 | 44 |
-0.2% | Low Risk · 24 | N/A | |
| 1282 | 51 |
HOU | DSL | SS | 38 | 48 | 60 | 52 |
0.0% | Low Risk · 32 | N/A | |
| 1283 | 51 |
CLE | ACL | IF | 39 | 48 | 56 | 50 |
-2.2% | Low Risk · 24 | N/A | |
| 1284 | 51 |
BAL | DSL | SS | 38 | 48 | 61 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1285 | 51 |
MIL | AA | P | 41 | 46 | 52 | 51 |
0.0% | Low Risk · 13 | N/A | |
| 1286 | 51 |
CHC | ACL | OF | 40 | 49 | 59 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1287 | 51 |
ARI | AAA | P | 41 | 50 | 60 | 57 |
+1.8% | Low Risk · 38 | N/A | |
| 1288 | 51 |
HOU | High-A | P | 42 | 50 | 59 | 49 |
0.0% | Low Risk · 28 | N/A | |
| 1289 | 51 |
ATL | Single-A | C | 39 | 49 | 59 | 52 |
0.0% | Low Risk · 23 | N/A | |
| 1290 | 51 |
ATL | DSL | OF | 38 | 48 | 62 | 51 |
-0.2% | Low Risk · 32 | N/A | |
| 1291 | 51 |
NYY | AA | C | 41 | 51 | 60 | 56 |
0.0% | Low Risk · 29 | N/A | |
| 1292 | 51 |
KC | AA | P | 43 | 50 | 56 | 41 |
+0.1% | Low Risk · 20 | N/A | |
| 1293 | 51 |
SD | ACL | P | 40 | 50 | 68 | 53 |
0.0% | Medium Risk · 46 | N/A | |
| 1294 | 51 |
MIL | Single-A | P | 40 | 46 | 53 | 40 |
0.0% | Low Risk · 0 | N/A | |
| 1295 | 51 |
WSH | High-A | CF | 40 | 46 | 51 | 36 |
0.0% | Low Risk · 5 | N/A | |
| 1296 | 51 |
BAL | High-A | 3B | 40 | 45 | 50 | 38 |
-0.1% | Low Risk · 1 | N/A | |
| 1297 | 51 |
NYM | Single-A | P | 41 | 46 | 51 | 44 |
0.0% | Low Risk · 14 | N/A | |
| 1298 | 51 |
MIA | AA | P | 41 | 47 | 54 | 48 |
-0.4% | Low Risk · 24 | N/A | |
| 1299 | 51 |
PHI | AA | 2B | 43 | 47 | 52 | 44 |
-0.1% | Low Risk · 10 | N/A | |
| 1300 | 51 |
NYY | High-A | C | 40 | 46 | 53 | 47 |
-0.1% | Low Risk · 10 | N/A | |
| 1301 | 51 |
BOS | High-A | P | 41 | 48 | 57 | 49 |
-0.1% | Low Risk · 24 | N/A | |
| 1302 | 51 |
SF | Single-A | CF | 40 | 47 | 53 | 47 |
+0.1% | Low Risk · 12 | N/A | |
| 1303 | 51 |
ATL | AA | P | 42 | 51 | 60 | 55 |
0.0% | Medium Risk · 42 | N/A | |
| 1304 | 51 |
CLE | Single-A | P | 43 | 48 | 54 | 39 |
0.0% | Low Risk · 24 | N/A | |
| 1305 | 51 |
LAA | Single-A | SS | 39 | 49 | 62 | 51 |
0.0% | Low Risk · 18 | N/A | |
| 1306 | 51 |
MIL | DSL | C | 38 | 48 | 61 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1307 | 51 |
TB | AAA | CF | 42 | 46 | 51 | 36 |
0.0% | Low Risk · 10 | N/A | |
| 1308 | 51 |
TEX | ACL | P | 38 | 47 | 56 | 51 |
-0.3% | Low Risk · 24 | N/A | |
| 1309 | 51 |
BAL | Single-A | 3B | 40 | 47 | 53 | 39 |
+0.1% | Low Risk · 8 | N/A | |
| 1310 | 51 |
DET | DSL | IF | 38 | 48 | 65 | 51 |
-1.6% | Low Risk · 32 | N/A | |
| 1311 | 51 |
TB | AA | OF | 43 | 48 | 54 | 41 |
+0.5% | Low Risk · 21 | N/A | |
| 1312 | 51 |
CHC | DSL | IF | 38 | 47 | 57 | 48 |
-0.3% | Low Risk · 32 | N/A | |
| 1313 | 51 |
MIA | High-A | SS | 40 | 46 | 53 | 46 |
+0.1% | Low Risk · 10 | N/A | |
| 1314 | 51 |
NYY | Single-A | 3B | 40 | 46 | 53 | 47 |
+0.2% | Low Risk · 12 | N/A | |
| 1315 | 51 |
ARI | High-A | OF | 39 | 46 | 52 | 49 |
-0.5% | Low Risk · 10 | N/A | |
| 1316 | 51 |
PIT | AAA | P | 41 | 51 | 60 | 56 |
0.0% | Low Risk · 34 | N/A | |
| 1317 | 51 |
HOU | AA | P | 42 | 49 | 56 | 49 |
+0.1% | Low Risk · 34 | N/A | |
| 1318 | 51 |
MIA | DSL | SS | 39 | 48 | 58 | 48 |
+0.3% | Low Risk · 32 | N/A | |
| 1319 | 51 |
SEA | Single-A | P | 40 | 47 | 54 | 47 |
-0.5% | Low Risk · 12 | N/A | |
| 1320 | 51 |
HOU | High-A | 2B | 40 | 46 | 53 | 45 |
-0.5% | Low Risk · 10 | N/A | |
| 1321 | 51 |
NYM | High-A | P | 42 | 52 | 61 | 47 |
0.0% | Low Risk · 32 | N/A | |
| 1322 | 51 |
MIN | FCL | P | 39 | 49 | 63 | 52 |
0.0% | Medium Risk · 42 | N/A | |
| 1323 | 51 |
PIT | AA | RF | 41 | 48 | 54 | 44 |
+0.1% | Low Risk · 12 | N/A | |
| 1324 | 51 |
SD | AA | P | 41 | 47 | 54 | 49 |
0.0% | Low Risk · 24 | N/A | |
| 1325 | 51 |
PHI | High-A | P | 41 | 48 | 56 | 46 |
-0.1% | Low Risk · 24 | N/A | |
| 1326 | 51 |
COL | High-A | P | 40 | 46 | 53 | 46 |
0.0% | Low Risk · 10 | N/A | |
| 1327 | 51 |
SD | Single-A | P | 40 | 49 | 60 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1328 | 51 |
LAD | Single-A | SS | 39 | 48 | 57 | 50 |
0.0% | Low Risk · 18 | N/A | |
| 1329 | 51 |
ATL | Single-A | OF | 39 | 50 | 59 | 52 |
0.0% | Medium Risk · 42 | N/A | |
| 1330 | 51 |
TEX | AA | P | 41 | 48 | 55 | 49 |
0.0% | Low Risk · 24 | N/A | |
| 1331 | 51 |
KC | Single-A | P | 42 | 52 | 70 | 53 |
0.0% | Medium Risk · 42 | N/A | |
| 1332 | 51 |
MIA | FCL | IF | 38 | 48 | 59 | 55 |
+0.1% | Medium Risk · 46 | N/A | |
| 1333 | 51 |
LAD | Single-A | P | 40 | 48 | 59 | 49 |
-0.4% | Low Risk · 22 | N/A | |
| 1334 | 51 |
STL | High-A | RF | 42 | 47 | 53 | 40 |
-0.6% | Low Risk · 12 | N/A | |
| 1335 | 51 |
STL | AAA | P | 41 | 49 | 61 | 60 |
+0.3% | Low Risk · 27 | N/A | |
| 1336 | 51 |
CIN | AAA | RF | 41 | 47 | 54 | 39 |
0.0% | Low Risk · 5 | N/A | |
| 1337 | 51 |
BAL | DSL | OF | 39 | 48 | 58 | 51 |
+0.1% | Low Risk · 37 | N/A | |
| 1338 | 51 |
PIT | Single-A | SS | 40 | 47 | 54 | 43 |
-0.1% | Low Risk · 16 | N/A | |
| 1339 | 51 |
CWS | Single-A | C | 39 | 49 | 59 | 53 |
+0.1% | Low Risk · 24 | N/A | |
| 1340 | 51 |
SF | DSL | OF | 39 | 48 | 58 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1341 | 51 |
TEX | AA | 3B | 41 | 48 | 55 | 47 |
-0.2% | Low Risk · 26 | N/A | |
| 1342 | 51 |
MIA | FCL | 3B | 38 | 47 | 59 | 53 |
0.0% | Low Risk · 32 | N/A | |
| 1343 | 51 |
SF | Single-A | 3B | 40 | 46 | 54 | 51 |
0.0% | Low Risk · 12 | N/A | |
| 1344 | 51 |
BOS | Single-A | 1B | 41 | 53 | 64 | 54 |
+0.1% | Medium Risk · 51 | N/A | |
| 1345 | 51 |
CIN | ACL | OF | 39 | 47 | 55 | 47 |
0.0% | Low Risk · 24 | N/A | |
| 1346 | 51 |
TB | AA | P | 42 | 47 | 52 | 42 |
0.0% | Low Risk · 10 | N/A | |
| 1347 | 51 |
MIN | AA | RF | 40 | 47 | 53 | 39 |
0.0% | Low Risk · 0 | N/A | |
| 1348 | 51 |
CLE | Single-A | C | 40 | 46 | 53 | 47 |
0.0% | Low Risk · 12 | N/A | |
| 1349 | 51 |
KC | High-A | CF | 41 | 47 | 52 | 39 |
-0.2% | Low Risk · 10 | N/A | |
| 1350 | 51 |
TB | Single-A | P | 40 | 47 | 57 | 46 |
0.0% | Low Risk · 12 | N/A | |
| 1351 | 51 |
ATL | FCL | P | 40 | 50 | 64 | 51 |
0.0% | Medium Risk · 46 | N/A | |
| 1352 | 51 |
CWS | AA | P | 43 | 48 | 53 | 44 |
+0.1% | Low Risk · 24 | N/A | |
| 1353 | 51 |
BAL | AA | P | 43 | 47 | 53 | 42 |
+0.1% | Low Risk · 24 | N/A | |
| 1354 | 51 |
LAD | High-A | P | 41 | 50 | 58 | 47 |
-0.2% | Low Risk · 32 | N/A | |
| 1355 | 51 |
MIN | High-A | P | 40 | 50 | 63 | 55 |
0.0% | Low Risk · 38 | N/A | |
| 1356 | 51 |
CLE | DSL | OF | 38 | 48 | 59 | 52 |
0.0% | Low Risk · 32 | N/A | |
| 1357 | 51 |
STL | High-A | LF | 40 | 49 | 63 | 53 |
0.0% | Low Risk · 28 | N/A | |
| 1358 | 51 |
CLE | AA | 3B | 42 | 50 | 59 | 53 |
0.0% | Low Risk · 39 | N/A | |
| 1359 | 51 |
SEA | DSL | IF | 37 | 47 | 57 | 52 |
-0.1% | Low Risk · 37 | N/A | |
| 1360 | 51 |
ATH | High-A | OF | 39 | 46 | 54 | 42 |
+0.2% | Low Risk · 16 | N/A | |
| 1361 | 51 |
CLE | AA | SS | 42 | 47 | 51 | 38 |
0.0% | Low Risk · 5 | N/A | |
| 1362 | 51 |
PIT | AA | P | 43 | 51 | 65 | 55 |
-0.3% | Low Risk · 38 | N/A | |
| 1363 | 51 |
ATH | AAA | CF | 41 | 49 | 56 | 40 |
-2.6% | Low Risk · 21 | N/A | |
| 1364 | 51 |
LAA | AA | P | 43 | 47 | 53 | 44 |
0.0% | Low Risk · 11 | N/A | |
| 1365 | 51 |
COL | High-A | SS | 41 | 47 | 52 | 38 |
-0.1% | Low Risk · 9 | N/A | |
| 1366 | 51 |
PHI | AA | P | 42 | 50 | 58 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1367 | 51 |
PHI | High-A | P | 39 | 45 | 52 | 49 |
0.0% | Low Risk · 10 | N/A | |
| 1368 | 51 |
LAD | AA | P | 39 | 45 | 52 | 43 |
-1.5% | Low Risk · 10 | N/A | |
| 1369 | 51 |
PHI | High-A | P | 41 | 49 | 60 | 49 |
-0.4% | Low Risk · 32 | N/A | |
| 1370 | 51 |
CLE | AA | P | 44 | 52 | 66 | 55 |
-0.5% | Low Risk · 39 | N/A | |
| 1371 | 51 |
STL | FCL | OF | 39 | 48 | 56 | 45 |
+0.1% | Low Risk · 24 | N/A | |
| 1372 | 51 |
TB | AAA | CF | 42 | 47 | 52 | 38 |
0.0% | Low Risk · 12 | N/A | |
| 1373 | 51 |
LAA | Single-A | C | 39 | 46 | 54 | 46 |
0.0% | Low Risk · 8 | N/A | |
| 1374 | 51 |
BOS | Single-A | P | 41 | 51 | 64 | 51 |
0.0% | Medium Risk · 42 | N/A | |
| 1375 | 51 |
CIN | DSL | IF | 38 | 47 | 58 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1376 | 51 |
MIN | Single-A | P | 39 | 47 | 55 | 50 |
0.0% | Low Risk · 28 | N/A | |
| 1377 | 51 |
TB | Single-A | P | 40 | 47 | 55 | 52 |
-0.1% | Low Risk · 26 | N/A | |
| 1378 | 51 |
TB | DSL | IF | 38 | 47 | 57 | 50 |
+0.1% | Low Risk · 32 | N/A | |
| 1379 | 51 |
SD | High-A | P | 42 | 49 | 54 | 39 |
+0.1% | Low Risk · 24 | N/A | |
| 1380 | 51 |
BOS | FCL | P | 39 | 49 | 59 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1381 | 51 |
ATL | DSL | OF | 37 | 47 | 60 | 51 |
+0.3% | Low Risk · 32 | N/A | |
| 1382 | 50 |
COL | DSL | IF | 39 | 48 | 60 | 48 |
-0.3% | Low Risk · 32 | N/A | |
| 1383 | 50 |
CIN | AA | P | 39 | 49 | 58 | 56 |
0.0% | Low Risk · 38 | N/A | |
| 1384 | 50 |
TB | DSL | P | 38 | 48 | 58 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1385 | 50 |
SF | DSL | P | 38 | 49 | 66 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1386 | 50 |
SF | AA | P | 40 | 47 | 54 | 49 |
0.0% | Low Risk · 24 | N/A | |
| 1387 | 50 |
COL | AAA | 2B | 42 | 47 | 53 | 55 |
0.0% | Low Risk · 19 | N/A | |
| 1388 | 50 |
ATH | AA | P | 43 | 48 | 53 | 44 |
0.0% | Low Risk · 24 | N/A | |
| 1389 | 50 |
NYM | Single-A | P | 39 | 47 | 56 | 52 |
0.0% | Low Risk · 36 | N/A | |
| 1390 | 50 |
SF | Single-A | SS | 38 | 47 | 56 | 50 |
-0.5% | Low Risk · 23 | N/A | |
| 1391 | 50 |
SD | High-A | OF | 39 | 46 | 53 | 44 |
-0.2% | Low Risk · 15 | N/A | |
| 1392 | 50 |
SD | DSL | OF | 38 | 49 | 62 | 52 |
+0.1% | Medium Risk · 42 | N/A | |
| 1393 | 50 |
CHC | Single-A | CF | 38 | 45 | 51 | 41 |
-0.1% | Low Risk · 0 | N/A | |
| 1394 | 50 |
BOS | DSL | C | 37 | 48 | 64 | 52 |
+0.2% | Medium Risk · 42 | N/A | |
| 1395 | IL(7-Day)50 |
LAD | High-A | PIL(7-Day) | 39 | 49 | 61 | 53 |
0.0% | Low Risk · 34 | N/A | |
| 1396 | 50 |
NYY | AA | P | 41 | 50 | 60 | 56 |
-10.7% | Medium Risk · 52 | N/A | |
| 1397 | 50 |
TEX | High-A | P | 40 | 47 | 54 | 43 |
-2.8% | Low Risk · 10 | N/A | |
| 1398 | 50 |
LAA | AA | C | 40 | 46 | 53 | 43 |
-0.1% | Low Risk · 10 | N/A | |
| 1399 | 50 |
STL | High-A | SS | 40 | 46 | 53 | 42 |
-0.8% | Low Risk · 10 | N/A | |
| 1400 | 50 |
SEA | Single-A | OF | 40 | 45 | 50 | 45 |
-0.1% | Low Risk · 12 | N/A | |
| 1401 | 50 |
COL | Single-A | CF | 38 | 47 | 55 | 47 |
-0.1% | Low Risk · 13 | N/A | |
| 1402 | 50 |
PHI | Single-A | P | 39 | 47 | 61 | 51 |
0.0% | Low Risk · 34 | N/A | |
| 1403 | 50 |
MIL | Single-A | P | 38 | 46 | 53 | 44 |
-0.3% | Low Risk · 14 | N/A | |
| 1404 | 50 |
NYM | Single-A | C | 39 | 45 | 52 | 39 |
+0.1% | Low Risk · 5 | N/A | |
| 1405 | 50 |
TEX | Single-A | SS | 40 | 49 | 59 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1406 | 50 |
TEX | AA | 1B | 41 | 46 | 51 | 46 |
+0.1% | Low Risk · 11 | N/A | |
| 1407 | 50 |
MIA | High-A | SS | 39 | 46 | 53 | 43 |
0.0% | Low Risk · 10 | N/A | |
| 1408 | 50 |
BOS | Single-A | P | 37 | 45 | 55 | 51 |
0.0% | Low Risk · 20 | N/A | |
| 1409 | 50 |
LAA | DSL | SS | 37 | 47 | 57 | 52 |
0.0% | Low Risk · 37 | N/A | |
| 1410 | IL(Rehab)50 |
TOR | Single-A | PIL(Rehab) | 46 | 58 | 69 | 45 |
0.0% | Medium Risk · 44 | N/A | |
| 1411 | 50 |
CHC | High-A | C | 39 | 45 | 52 | 45 |
0.0% | Low Risk · 10 | N/A | |
| 1412 | 50 |
BOS | DSL | OF | 37 | 47 | 57 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1413 | 50 |
TB | FCL | SS | 39 | 47 | 54 | 48 |
+0.1% | Low Risk · 24 | N/A | |
| 1414 | 50 |
SD | High-A | C | 39 | 44 | 49 | 38 |
+0.2% | Low Risk · 1 | N/A | |
| 1415 | 50 |
KC | AA | P | 41 | 49 | 63 | 54 |
-0.1% | Low Risk · 39 | N/A | |
| 1416 | 50 |
SF | AA | 1B | 40 | 46 | 52 | 42 |
-0.1% | Low Risk · 10 | N/A | |
| 1417 | 50 |
SEA | ACL | P | 39 | 48 | 59 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1418 | 50 |
TEX | AA | P | 43 | 52 | 65 | 57 |
-0.2% | Medium Risk · 52 | N/A | |
| 1419 | 50 |
TEX | ACL | 2B | 38 | 46 | 54 | 42 |
+0.1% | Low Risk · 24 | N/A | |
| 1420 | 50 |
CHC | High-A | LF | 39 | 46 | 52 | 41 |
-0.7% | Low Risk · 10 | N/A | |
| 1421 | 50 |
BAL | Single-A | P | 39 | 45 | 54 | 50 |
-0.2% | Low Risk · 12 | N/A | |
| 1422 | 50 |
CHC | ACL | OF | 40 | 49 | 58 | 51 |
-4.0% | Low Risk · 40 | N/A | |
| 1423 | 50 |
CHC | Single-A | P | 40 | 47 | 56 | 44 |
0.0% | Low Risk · 14 | N/A | |
| 1424 | 50 |
MIL | Single-A | P | 40 | 47 | 55 | 43 |
0.0% | Low Risk · 27 | N/A | |
| 1425 | 50 |
CWS | AAA | 1B | 42 | 47 | 52 | 54 |
+0.1% | Low Risk · 19 | N/A | |
| 1426 | 50 |
COL | DSL | OF | 38 | 47 | 58 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1427 | 50 |
SF | High-A | P | 39 | 46 | 53 | 50 |
0.0% | Low Risk · 24 | N/A | |
| 1428 | 50 |
WSH | AAA | P | 41 | 49 | 57 | 48 |
0.0% | Low Risk · 28 | N/A | |
| 1429 | 50 |
ATL | High-A | 1B | 39 | 45 | 52 | 44 |
0.0% | Low Risk · 10 | N/A | |
| 1430 | 50 |
BOS | DSL | SS | 36 | 47 | 60 | 50 |
0.0% | Medium Risk · 42 | N/A | |
| 1431 | 50 |
CHC | AA | 1B | 41 | 46 | 51 | 43 |
-0.2% | Low Risk · 10 | N/A | |
| 1432 | 50 |
HOU | AA | P | 41 | 45 | 50 | 41 |
0.0% | Low Risk · 10 | N/A | |
| 1433 | 50 |
LAA | ACL | OF | 39 | 48 | 57 | 55 |
-0.1% | Medium Risk · 43 | N/A | |
| 1434 | 50 |
ARI | High-A | 1B | 39 | 45 | 52 | 44 |
+0.1% | Low Risk · 10 | N/A | |
| 1435 | 50 |
CIN | ACL | P | 37 | 47 | 65 | 53 |
0.0% | Low Risk · 40 | N/A | |
| 1436 | 50 |
SF | DSL | IF | 37 | 47 | 63 | 54 |
0.0% | Medium Risk · 46 | N/A | |
| 1437 | 50 |
TEX | Single-A | P | 39 | 45 | 52 | 46 |
0.0% | Low Risk · 12 | N/A | |
| 1438 | 50 |
SF | High-A | P | 40 | 48 | 57 | 48 |
+0.2% | Low Risk · 28 | N/A | |
| 1439 | 50 |
CHC | DSL | IF | 36 | 47 | 57 | 51 |
-0.3% | Low Risk · 32 | N/A | |
| 1440 | 50 |
PHI | High-A | OF | 40 | 45 | 50 | 36 |
-0.2% | Low Risk · 9 | N/A | |
| 1441 | 50 |
HOU | High-A | P | 40 | 50 | 60 | 51 |
0.0% | Low Risk · 38 | N/A | |
| 1442 | 50 |
BOS | Single-A | P | 39 | 47 | 54 | 49 |
-0.1% | Low Risk · 28 | N/A | |
| 1443 | 50 |
HOU | Single-A | P | 39 | 46 | 52 | 39 |
-0.3% | Low Risk · 0 | N/A | |
| 1444 | 50 |
CIN | ACL | SS | 38 | 47 | 56 | 48 |
+0.2% | Low Risk · 24 | N/A | |
| 1445 | 50 |
TEX | ACL | SS | 38 | 47 | 56 | 48 |
0.0% | Low Risk · 40 | N/A | |
| 1446 | 50 |
NYY | High-A | P | 39 | 48 | 59 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1447 | 50 |
KC | High-A | P | 39 | 46 | 52 | 42 |
0.0% | Low Risk · 10 | N/A | |
| 1448 | 50 |
SD | AA | P | 40 | 51 | 60 | 56 |
+0.3% | Medium Risk · 48 | N/A | |
| 1449 | 50 |
SF | High-A | SS | 39 | 46 | 53 | 40 |
+0.1% | Low Risk · 12 | N/A | |
| 1450 | 50 |
STL | High-A | P | 39 | 48 | 56 | 47 |
-0.2% | Low Risk · 18 | N/A | |
| 1451 | IL(7-Day)50 |
ARI | Single-A | PIL(7-Day) | 41 | 53 | 64 | 55 |
0.0% | Wide Range · 61 | N/A | |
| 1452 | 50 |
PHI | High-A | C | 39 | 45 | 52 | 43 |
0.0% | Low Risk · 10 | N/A | |
| 1453 | 50 |
CIN | AA | P | 39 | 48 | 58 | 55 |
0.0% | Low Risk · 38 | N/A | |
| 1454 | 50 |
LAD | DSL | SS | 37 | 47 | 57 | 50 |
+0.1% | Low Risk · 32 | N/A | |
| 1455 | 50 |
STL | Single-A | CF | 39 | 46 | 53 | 44 |
+0.1% | Low Risk · 14 | N/A | |
| 1456 | 50 |
MIN | FCL | IF | 38 | 47 | 56 | 48 |
+0.3% | Low Risk · 32 | N/A | |
| 1457 | 50 |
HOU | FCL | SS | 38 | 47 | 55 | 47 |
-0.3% | Low Risk · 29 | N/A | |
| 1458 | 50 |
DET | DSL | IF | 36 | 46 | 59 | 50 |
+0.1% | Low Risk · 32 | N/A | |
| 1459 | 50 |
MIA | Single-A | 1B | 38 | 46 | 53 | 46 |
-0.3% | Low Risk · 14 | N/A | |
| 1460 | 50 |
HOU | AA | SS | 41 | 46 | 51 | 39 |
0.0% | Low Risk · 12 | N/A | |
| 1461 | 50 |
SF | AA | P | 40 | 47 | 55 | 43 |
-0.1% | Low Risk · 20 | N/A | |
| 1462 | 50 |
NYM | AAA | P | 41 | 49 | 61 | 60 |
0.0% | Low Risk · 28 | N/A | |
| 1463 | 50 |
HOU | AAA | P | 41 | 49 | 56 | 45 |
0.0% | Low Risk · 28 | N/A | |
| 1464 | 50 |
WSH | FCL | CF | 38 | 47 | 56 | 49 |
-0.5% | Low Risk · 32 | N/A | |
| 1465 | 50 |
NYY | AAA | P | 41 | 51 | 61 | 57 |
0.0% | Medium Risk · 50 | N/A | |
| 1466 | 50 |
STL | DSL | OF | 38 | 50 | 68 | 50 |
-0.2% | Medium Risk · 43 | N/A | |
| 1467 | 50 |
CIN | DSL | SS | 37 | 47 | 57 | 51 |
0.0% | Low Risk · 37 | N/A | |
| 1468 | 50 |
MIL | High-A | 3B | 40 | 46 | 51 | 39 |
+0.2% | Low Risk · 14 | N/A | |
| 1469 | 50 |
WSH | Single-A | P | 38 | 47 | 56 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1470 | 50 |
TOR | High-A | P | 39 | 50 | 64 | 55 |
0.0% | Medium Risk · 52 | N/A | |
| 1471 | 50 |
LAD | ACL | C | 37 | 47 | 57 | 49 |
+0.1% | Low Risk · 32 | N/A | |
| 1472 | 50 |
ATH | AA | P | 39 | 46 | 54 | 51 |
-2.2% | Low Risk · 20 | N/A | |
| 1473 | 50 |
BOS | FCL | CF | 38 | 46 | 55 | 48 |
+0.1% | Low Risk · 24 | N/A | |
| 1474 | 50 |
LAD | ACL | SS | 40 | 48 | 57 | 49 |
-0.1% | Low Risk · 40 | N/A | |
| 1475 | 50 |
CHC | ACL | SS | 40 | 47 | 54 | 47 |
0.0% | Low Risk · 40 | N/A | |
| 1476 | 50 |
CLE | ACL | 2B | 38 | 46 | 55 | 49 |
0.0% | Low Risk · 29 | N/A | |
| 1477 | 50 |
ATH | AA | 1B | 41 | 46 | 50 | 42 |
-0.3% | Low Risk · 10 | N/A | |
| 1478 | 50 |
LAA | Single-A | LF | 38 | 45 | 51 | 49 |
0.0% | Low Risk · 12 | N/A | |
| 1479 | 50 |
KC | Single-A | P | 39 | 45 | 52 | 46 |
-0.6% | Low Risk · 12 | N/A | |
| 1480 | 50 |
MIL | AA | SS | 40 | 45 | 51 | 43 |
+0.1% | Low Risk · 10 | N/A | |
| 1481 | 50 |
CIN | DSL | SS | 36 | 46 | 59 | 50 |
-0.1% | Medium Risk · 46 | N/A | |
| 1482 | 50 |
LAD | ACL | P | 38 | 47 | 58 | 51 |
-0.3% | Low Risk · 38 | N/A | |
| 1483 | 50 |
TEX | High-A | 2B | 38 | 45 | 51 | 36 |
0.0% | Low Risk · 0 | N/A | |
| 1484 | 50 |
CHC | Single-A | P | 40 | 51 | 68 | 51 |
0.0% | Medium Risk · 42 | N/A | |
| 1485 | 50 |
ATL | FCL | P | 38 | 47 | 55 | 49 |
-0.3% | Low Risk · 38 | N/A | |
| 1486 | 50 |
CWS | AA | 3B | 41 | 46 | 51 | 46 |
0.0% | Low Risk · 12 | N/A | |
| 1487 | 50 |
MIA | High-A | P | 39 | 46 | 53 | 39 |
0.0% | Low Risk · 10 | N/A | |
| 1488 | 50 |
COL | High-A | P | 38 | 45 | 51 | 47 |
-0.2% | Low Risk · 10 | N/A | |
| 1489 | 50 |
KC | Single-A | 1B | 39 | 45 | 52 | 44 |
+0.2% | Low Risk · 14 | N/A | |
| 1490 | 50 |
LAD | Single-A | 2B | 38 | 46 | 54 | 44 |
-0.1% | Low Risk · 8 | N/A | |
| 1491 | 50 |
LAD | AA | C | 39 | 49 | 58 | 53 |
0.0% | Low Risk · 28 | N/A | |
| 1492 | 50 |
HOU | High-A | C | 38 | 48 | 58 | 52 |
-0.2% | Low Risk · 30 | N/A | |
| 1493 | 50 |
BOS | AA | C | 41 | 46 | 51 | 41 |
+0.1% | Low Risk · 10 | N/A | |
| 1494 | 50 |
ARI | AA | P | 39 | 49 | 58 | 55 |
+0.1% | Low Risk · 38 | N/A | |
| 1495 | 50 |
TB | AA | P | 39 | 46 | 53 | 48 |
0.0% | Low Risk · 18 | N/A | |
| 1496 | 50 |
MIN | Single-A | P | 39 | 45 | 53 | 45 |
-0.4% | Low Risk · 12 | N/A | |
| 1497 | 50 |
HOU | Single-A | P | 38 | 47 | 60 | 51 |
-0.2% | Low Risk · 32 | N/A | |
| 1498 | 50 |
STL | AA | C | 39 | 46 | 52 | 43 |
+0.2% | Low Risk · 10 | N/A | |
| 1499 | 49 |
CIN | Single-A | 3B | 38 | 48 | 64 | 51 |
0.0% | Low Risk · 30 | N/A | |
| 1500 | 49 |
TB | DSL | IF | 37 | 47 | 56 | 49 |
0.0% | Low Risk · 37 | N/A | |
| 1501 | 49 |
CHC | AAA | P | 41 | 50 | 60 | 55 |
0.0% | Medium Risk · 48 | N/A | |
| 1502 | 49 |
ARI | Single-A | SS | 38 | 45 | 51 | 37 |
0.0% | Low Risk · 5 | N/A | |
| 1503 | 49 |
PIT | Single-A | P | 38 | 45 | 52 | 40 |
0.0% | Low Risk · 0 | N/A | |
| 1504 | 49 |
ARI | Single-A | C | 37 | 46 | 55 | 50 |
0.0% | Low Risk · 23 | N/A | |
| 1505 | IL(7-Day)49 |
TB | Single-A | SSIL(7-Day) | 38 | 49 | 60 | 54 |
0.0% | Low Risk · 40 | N/A | |
| 1506 | 49 |
BAL | Single-A | C | 38 | 48 | 57 | 51 |
0.0% | Low Risk · 27 | N/A | |
| 1507 | 49 |
CHC | Single-A | P | 39 | 46 | 53 | 48 |
-0.1% | Low Risk · 26 | N/A | |
| 1508 | 49 |
PHI | High-A | P | 38 | 47 | 61 | 51 |
-0.1% | Low Risk · 28 | N/A | |
| 1509 | 49 |
CIN | High-A | P | 39 | 47 | 57 | 49 |
0.0% | Low Risk · 34 | N/A | |
| 1510 | 49 |
COL | High-A | P | 39 | 45 | 53 | 47 |
0.0% | Low Risk · 24 | N/A | |
| 1511 | 49 |
ARI | High-A | P | 39 | 46 | 53 | 45 |
-0.1% | Low Risk · 24 | N/A | |
| 1512 | 49 |
DET | AA | P | 41 | 51 | 60 | 55 |
0.0% | Medium Risk · 48 | N/A | |
| 1513 | 49 |
CIN | AA | P | 40 | 47 | 55 | 42 |
0.0% | Low Risk · 20 | N/A | |
| 1514 | 49 |
LAD | High-A | 3B | 38 | 46 | 54 | 47 |
0.0% | Low Risk · 18 | N/A | |
| 1515 | 49 |
ATH | AA | P | 40 | 50 | 60 | 55 |
0.0% | Medium Risk · 48 | N/A | |
| 1516 | 49 |
PIT | High-A | P | 40 | 50 | 60 | 54 |
0.0% | Medium Risk · 48 | N/A | |
| 1517 | 49 |
BOS | Single-A | P | 38 | 46 | 56 | 49 |
0.0% | Low Risk · 26 | N/A | |
| 1518 | 49 |
HOU | DSL | OF | 37 | 47 | 58 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1519 | 49 |
NYM | FCL | OF | 37 | 46 | 56 | 47 |
+0.2% | Low Risk · 24 | N/A | |
| 1520 | 49 |
ATL | AA | P | 38 | 45 | 51 | 42 |
-0.3% | Low Risk · 10 | N/A | |
| 1521 | 49 |
WSH | Single-A | P | 37 | 44 | 51 | 38 |
0.0% | Low Risk · 0 | N/A | |
| 1522 | 49 |
ARI | AA | P | 41 | 45 | 50 | 42 |
0.0% | Low Risk · 10 | N/A | |
| 1523 | 49 |
MIL | Single-A | P | 39 | 46 | 54 | 39 |
0.0% | Low Risk · 10 | N/A | |
| 1524 | 49 |
BAL | AA | P | 40 | 47 | 57 | 42 |
-0.2% | Low Risk · 20 | N/A | |
| 1525 | 49 |
COL | DSL | OF | 36 | 46 | 55 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1526 | 49 |
KC | AA | P | 41 | 46 | 51 | 36 |
-0.1% | Low Risk · 20 | N/A | |
| 1527 | 49 |
MIL | Single-A | C | 41 | 51 | 60 | 43 |
0.0% | Low Risk · 36 | N/A | |
| 1528 | 49 |
PIT | High-A | C | 37 | 45 | 53 | 49 |
0.0% | Low Risk · 23 | N/A | |
| 1529 | 49 |
CHC | ACL | SS | 37 | 46 | 55 | 49 |
-0.2% | Low Risk · 32 | N/A | |
| 1530 | 49 |
PHI | High-A | 2B | 38 | 45 | 52 | 44 |
+0.1% | Low Risk · 10 | N/A | |
| 1531 | 49 |
PHI | AA | P | 40 | 48 | 55 | 44 |
0.0% | Low Risk · 20 | N/A | |
| 1532 | 49 |
SF | DSL | C | 36 | 46 | 60 | 53 |
0.0% | Medium Risk · 46 | N/A | |
| 1533 | 49 |
CWS | AA | CF | 41 | 45 | 50 | 41 |
+0.2% | Low Risk · 10 | N/A | |
| 1534 | 49 |
COL | DSL | SS | 36 | 46 | 61 | 52 |
0.0% | Medium Risk · 46 | N/A | |
| 1535 | 49 |
ATH | High-A | CF | 38 | 48 | 58 | 53 |
-0.1% | Low Risk · 29 | N/A | |
| 1536 | 49 |
ARI | ACL | P | 37 | 48 | 64 | 50 |
0.0% | Medium Risk · 42 | N/A | |
| 1537 | 49 |
CHC | High-A | 3B | 38 | 45 | 51 | 42 |
0.0% | Low Risk · 10 | N/A | |
| 1538 | 49 |
LAD | ACL | SS | 37 | 48 | 64 | 50 |
0.0% | Medium Risk · 42 | N/A | |
| 1539 | 49 |
CHC | Single-A | OF | 38 | 45 | 52 | 41 |
-0.1% | Low Risk · 16 | N/A | |
| 1540 | 49 |
COL | AA | 1B | 41 | 46 | 51 | 42 |
0.0% | Low Risk · 19 | N/A | |
| 1541 | 49 |
CLE | Single-A | P | 40 | 46 | 58 | 46 |
0.0% | Low Risk · 26 | N/A | |
| 1542 | 49 |
COL | High-A | P | 39 | 48 | 56 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1543 | 49 |
LAD | Single-A | P | 39 | 46 | 54 | 41 |
0.0% | Low Risk · 12 | N/A | |
| 1544 | 49 |
NYM | High-A | 1B | 38 | 44 | 51 | 45 |
-0.1% | Low Risk · 10 | N/A | |
| 1545 | 49 |
PHI | Single-A | P | 38 | 47 | 62 | 50 |
0.0% | Medium Risk · 44 | N/A | |
| 1546 | 49 |
PIT | DSL | IF | 36 | 46 | 59 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1547 | 49 |
SF | AA | P | 38 | 45 | 53 | 49 |
-0.3% | Low Risk · 25 | N/A | |
| 1548 | 49 |
WSH | Single-A | RF | 37 | 48 | 58 | 51 |
-0.1% | Low Risk · 32 | N/A | |
| 1549 | 49 |
TEX | ACL | IF | 37 | 46 | 55 | 46 |
-0.5% | Low Risk · 29 | N/A | |
| 1550 | 49 |
TOR | High-A | C | 38 | 45 | 52 | 45 |
0.0% | Low Risk · 10 | N/A | |
| 1551 | 49 |
MIA | AAA | P | 41 | 47 | 60 | 55 |
0.0% | Low Risk · 21 | N/A | |
| 1552 | 49 |
HOU | FCL | SS | 38 | 46 | 54 | 46 |
+0.1% | Low Risk · 24 | N/A | |
| 1553 | IL(Full Season)49 |
MIN | Single-A | OFIL(Full Season) | 39 | 49 | 58 | 50 |
0.0% | Low Risk · 38 | N/A | |
| 1554 | 49 |
DET | High-A | P | 39 | 47 | 56 | 41 |
-0.1% | Low Risk · 20 | N/A | |
| 1555 | 49 |
TEX | Single-A | C | 37 | 46 | 56 | 49 |
0.0% | Low Risk · 18 | N/A | |
| 1556 | 49 |
ATL | AAA | C | 40 | 49 | 58 | 54 |
0.0% | Low Risk · 39 | N/A | |
| 1557 | 49 |
NYY | FCL | C | 39 | 47 | 55 | 48 |
-0.4% | Low Risk · 40 | N/A | |
| 1558 | 49 |
WSH | DSL | P | 35 | 46 | 60 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1559 | 49 |
NYM | DSL | OF | 37 | 47 | 64 | 51 |
-0.1% | Medium Risk · 46 | N/A | |
| 1560 | 49 |
MIL | AA | C | 39 | 50 | 60 | 55 |
0.0% | Medium Risk · 45 | N/A | |
| 1561 | IL(7-Day)49 |
CHC | Single-A | SSIL(7-Day) | 37 | 47 | 56 | 50 |
0.0% | Low Risk · 29 | N/A | |
| 1562 | 49 |
SEA | AA | 1B | 42 | 47 | 53 | 46 |
0.0% | Low Risk · 27 | N/A | |
| 1563 | 49 |
CWS | High-A | 3B | 39 | 44 | 49 | 34 |
0.0% | Low Risk · 5 | N/A | |
| 1564 | 49 |
PIT | FCL | P | 37 | 46 | 55 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1565 | 49 |
LAA | AA | RF | 40 | 45 | 50 | 41 |
-0.3% | Low Risk · 10 | N/A | |
| 1566 | 49 |
NYY | AA | LF | 42 | 47 | 52 | 44 |
0.0% | Low Risk · 26 | N/A | |
| 1567 | 49 |
ATL | High-A | SS | 37 | 48 | 58 | 52 |
0.0% | Low Risk · 30 | N/A | |
| 1568 | 49 |
CHC | ACL | OF | 38 | 47 | 55 | 42 |
+0.1% | Low Risk · 24 | N/A | |
| 1569 | 49 |
PIT | High-A | P | 39 | 46 | 54 | 44 |
0.0% | Low Risk · 24 | N/A | |
| 1570 | 49 |
TEX | Single-A | P | 37 | 44 | 51 | 47 |
-0.1% | Low Risk · 12 | N/A | |
| 1571 | 49 |
BOS | DSL | SS | 37 | 48 | 59 | 47 |
+0.1% | Low Risk · 32 | N/A | |
| 1572 | 49 |
TEX | Single-A | RF | 39 | 45 | 52 | 42 |
-0.2% | Low Risk · 14 | N/A | |
| 1573 | 49 |
MIL | AAA | P | 41 | 49 | 63 | 61 |
0.0% | Low Risk · 38 | N/A | |
| 1574 | 49 |
WSH | High-A | CF | 38 | 45 | 52 | 39 |
-0.3% | Low Risk · 12 | N/A | |
| 1575 | 49 |
TOR | DSL | OF | 37 | 46 | 56 | 48 |
-0.6% | Low Risk · 32 | N/A | |
| 1576 | 49 |
CWS | Single-A | P | 38 | 45 | 52 | 44 |
0.0% | Low Risk · 12 | N/A | |
| 1577 | 49 |
TEX | Single-A | P | 38 | 46 | 54 | 48 |
0.0% | Low Risk · 28 | N/A | |
| 1578 | 49 |
LAA | Single-A | SS | 37 | 46 | 54 | 46 |
0.0% | Low Risk · 13 | N/A | |
| 1579 | 49 |
CLE | ACL | SS | 37 | 48 | 63 | 49 |
-0.1% | Medium Risk · 42 | N/A | |
| 1580 | 49 |
BAL | DSL | C | 37 | 47 | 56 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1581 | 49 |
BOS | Single-A | 3B | 38 | 45 | 52 | 38 |
0.0% | Low Risk · 9 | N/A | |
| 1582 | 49 |
NYY | High-A | P | 38 | 48 | 58 | 53 |
-0.5% | Low Risk · 38 | N/A | |
| 1583 | 49 |
CLE | DSL | IF | 36 | 46 | 56 | 50 |
0.0% | Low Risk · 32 | N/A | |
| 1584 | 49 |
MIN | AA | 3B | 39 | 48 | 57 | 53 |
-1.2% | Low Risk · 33 | N/A | |
| 1585 | 49 |
PIT | Single-A | P | 36 | 44 | 51 | 40 |
0.0% | Low Risk · 0 | N/A | |
| 1586 | 49 |
NYM | AA | 2B | 39 | 49 | 58 | 54 |
0.0% | Medium Risk · 44 | N/A | |
| 1587 | 49 |
CWS | Single-A | P | 38 | 45 | 52 | 44 |
0.0% | Low Risk · 12 | N/A | |
| 1588 | 49 |
CIN | High-A | P | 39 | 47 | 54 | 39 |
+0.1% | Low Risk · 20 | N/A | |
| 1589 | 49 |
MIA | AA | C | 39 | 47 | 55 | 45 |
0.0% | Low Risk · 13 | N/A | |
| 1590 | 49 |
PIT | DSL | C | 35 | 46 | 56 | 50 |
0.0% | Low Risk · 37 | N/A | |
| 1591 | 49 |
NYY | DSL | P | 36 | 46 | 59 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1592 | 49 |
MIL | AA | P | 40 | 47 | 54 | 37 |
+0.1% | Low Risk · 20 | N/A | |
| 1593 | 49 |
SEA | AA | P | 38 | 47 | 56 | 53 |
0.0% | Low Risk · 38 | N/A | |
| 1594 | 49 |
TEX | DSL | P | 36 | 46 | 59 | 51 |
-0.3% | Medium Risk · 42 | N/A | |
| 1595 | 49 |
WSH | High-A | RF | 38 | 45 | 52 | 41 |
0.0% | Low Risk · 10 | N/A | |
| 1596 | 49 |
BOS | High-A | P | 40 | 46 | 52 | 35 |
0.0% | Low Risk · 20 | N/A | |
| 1597 | 49 |
WSH | FCL | 1B | 36 | 45 | 59 | 49 |
+0.2% | Low Risk · 32 | N/A | |
| 1598 | 49 |
CLE | High-A | P | 40 | 46 | 52 | 38 |
0.0% | Low Risk · 20 | N/A | |
| 1599 | 49 |
COL | Single-A | P | 40 | 45 | 51 | 44 |
-0.1% | Low Risk · 28 | N/A | |
| 1600 | 49 |
SEA | High-A | P | 38 | 45 | 52 | 43 |
0.0% | Low Risk · 10 | N/A | |
| 1601 | 49 |
WSH | AA | SS | 40 | 45 | 50 | 39 |
0.0% | Low Risk · 10 | N/A | |
| 1602 | 49 |
CIN | High-A | P | 37 | 43 | 50 | 52 |
0.0% | Low Risk · 13 | N/A | |
| 1603 | 49 |
STL | AAA | CF | 41 | 46 | 52 | 36 |
0.0% | Low Risk · 21 | N/A | |
| 1604 | 49 |
TOR | High-A | 2B | 38 | 44 | 51 | 41 |
-0.2% | Low Risk · 10 | N/A | |
| 1605 | 49 |
LAA | Single-A | OF | 38 | 45 | 52 | 39 |
0.0% | Low Risk · 16 | N/A | |
| 1606 | 49 |
TEX | AA | P | 41 | 51 | 62 | 56 |
0.0% | Medium Risk · 51 | N/A | |
| 1607 | 49 |
SF | Single-A | P | 38 | 44 | 53 | 46 |
-0.3% | Low Risk · 12 | N/A | |
| 1608 | 49 |
PHI | High-A | C | 38 | 44 | 51 | 43 |
-0.2% | Low Risk · 15 | N/A | |
| 1609 | 49 |
KC | High-A | P | 37 | 46 | 55 | 50 |
0.0% | Low Risk · 28 | N/A | |
| 1610 | 49 |
CHC | DSL | IF | 36 | 46 | 56 | 48 |
+0.1% | Low Risk · 32 | N/A | |
| 1611 | 49 |
BOS | AA | P | 41 | 45 | 52 | 47 |
0.0% | Low Risk · 26 | N/A | |
| 1612 | 49 |
LAA | AA | CF | 40 | 45 | 50 | 37 |
0.0% | Low Risk · 10 | N/A | |
| 1613 | 49 |
NYY | Single-A | SS | 38 | 44 | 51 | 45 |
+0.1% | Low Risk · 12 | N/A | |
| 1614 | 49 |
ATH | DSL | SS | 36 | 46 | 55 | 50 |
+0.2% | Low Risk · 37 | N/A | |
| 1615 | 49 |
ARI | Single-A | SS | 37 | 44 | 50 | 36 |
0.0% | Low Risk · 0 | N/A | |
| 1616 | 49 |
SF | AA | P | 39 | 45 | 52 | 42 |
0.0% | Low Risk · 10 | N/A | |
| 1617 | 49 |
WSH | Single-A | P | 37 | 44 | 51 | 48 |
0.0% | Low Risk · 12 | N/A | |
| 1618 | 49 |
LAA | High-A | 2B | 39 | 45 | 50 | 36 |
0.0% | Low Risk · 9 | N/A | |
| 1619 | 49 |
KC | AAA | 1B | 40 | 45 | 52 | 54 |
0.0% | Low Risk · 20 | N/A | |
| 1620 | 49 |
MIA | High-A | P | 37 | 45 | 53 | 49 |
0.0% | Low Risk · 24 | N/A | |
| 1621 | 49 |
ATH | AAA | SS | 39 | 49 | 59 | 56 |
-0.1% | Low Risk · 40 | N/A | |
| 1622 | 49 |
STL | FCL | P | 37 | 46 | 57 | 45 |
0.0% | Low Risk · 24 | N/A | |
| 1623 | 49 |
CLE | ACL | C | 36 | 47 | 62 | 51 |
0.0% | Medium Risk · 42 | N/A | |
| 1624 | 49 |
WSH | Single-A | C | 38 | 45 | 52 | 36 |
+0.1% | Low Risk · 9 | N/A | |
| 1625 | 49 |
BOS | Single-A | IF | 38 | 49 | 59 | 51 |
0.0% | Low Risk · 36 | N/A | |
| 1626 | 49 |
SD | AA | 2B | 40 | 45 | 50 | 38 |
-0.2% | Low Risk · 10 | N/A | |
| 1627 | 49 |
PIT | High-A | 3B | 37 | 48 | 58 | 53 |
0.0% | Low Risk · 36 | N/A | |
| 1628 | 48 |
HOU | Single-A | SS | 38 | 46 | 53 | 39 |
0.0% | Low Risk · 24 | N/A | |
| 1629 | 48 |
ARI | High-A | P | 38 | 48 | 65 | 53 |
0.0% | Low Risk · 39 | N/A | |
| 1630 | 48 |
TEX | High-A | P | 38 | 47 | 56 | 48 |
-0.1% | Low Risk · 34 | N/A | |
| 1631 | 48 |
BOS | Single-A | P | 37 | 44 | 51 | 43 |
0.0% | Low Risk · 14 | N/A | |
| 1632 | 48 |
STL | Single-A | P | 38 | 48 | 66 | 51 |
0.0% | Low Risk · 40 | N/A | |
| 1633 | 48 |
CIN | High-A | OF | 37 | 47 | 57 | 51 |
0.0% | Low Risk · 28 | N/A | |
| 1634 | 48 |
ARI | High-A | P | 39 | 47 | 54 | 40 |
-0.6% | Low Risk · 20 | N/A | |
| 1635 | 48 |
NYY | Single-A | C | 38 | 44 | 51 | 42 |
-0.3% | Low Risk · 14 | N/A | |
| 1636 | 48 |
HOU | DSL | SS | 36 | 46 | 55 | 49 |
0.0% | Low Risk · 37 | N/A | |
| 1637 | 48 |
ATL | DSL | C | 36 | 46 | 55 | 49 |
-0.1% | Low Risk · 32 | N/A | |
| 1638 | 48 |
LAD | High-A | P | 38 | 46 | 55 | 46 |
0.0% | Low Risk · 18 | N/A | |
| 1639 | 48 |
MIL | DSL | OF | 35 | 46 | 61 | 50 |
+0.1% | Medium Risk · 42 | N/A | |
| 1640 | 48 |
BAL | AAA | CF | 41 | 46 | 51 | 44 |
0.0% | Low Risk · 28 | N/A | |
| 1641 | 48 |
WSH | AA | 1B | 40 | 49 | 58 | 51 |
-0.1% | Medium Risk · 44 | N/A | |
| 1642 | 48 |
CWS | High-A | P | 37 | 45 | 56 | 48 |
-0.1% | Low Risk · 18 | N/A | |
| 1643 | 48 |
CWS | Single-A | SS | 37 | 44 | 51 | 38 |
0.0% | Low Risk · 9 | N/A | |
| 1644 | 48 |
CIN | Single-A | SS | 37 | 44 | 50 | 37 |
0.0% | Low Risk · 5 | N/A | |
| 1645 | 48 |
MIA | DSL | OF | 36 | 47 | 60 | 49 |
-0.3% | Medium Risk · 42 | N/A | |
| 1646 | 48 |
COL | DSL | P | 36 | 46 | 56 | 48 |
-0.2% | Low Risk · 32 | N/A | |
| 1647 | 48 |
COL | Single-A | OF | 37 | 44 | 51 | 43 |
0.0% | Low Risk · 14 | N/A | |
| 1648 | 48 |
NYY | High-A | P | 39 | 44 | 50 | 41 |
0.0% | Low Risk · 24 | N/A | |
| 1649 | 48 |
TB | Single-A | C | 37 | 45 | 53 | 43 |
0.0% | Low Risk · 8 | N/A | |
| 1650 | 48 |
DET | High-A | 3B | 37 | 43 | 50 | 36 |
0.0% | Low Risk · 1 | N/A | |
| 1651 | 48 |
ATH | DSL | C | 36 | 46 | 56 | 49 |
0.0% | Low Risk · 37 | N/A | |
| 1652 | 48 |
TOR | High-A | P | 38 | 45 | 51 | 39 |
-0.1% | Low Risk · 10 | N/A | |
| 1653 | 48 |
BAL | Single-A | P | 36 | 44 | 54 | 47 |
-0.4% | Low Risk · 12 | N/A | |
| 1654 | 48 |
CIN | ACL | P | 35 | 45 | 55 | 50 |
-0.4% | Low Risk · 32 | N/A | |
| 1655 | 48 |
MIA | DSL | C | 35 | 45 | 55 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1656 | 48 |
NYM | FCL | 2B | 35 | 45 | 57 | 51 |
0.0% | Low Risk · 40 | N/A | |
| 1657 | 48 |
BOS | FCL | C | 35 | 45 | 61 | 48 |
-0.2% | Low Risk · 32 | N/A | |
| 1658 | 48 |
ATL | FCL | OF | 38 | 47 | 56 | 38 |
+0.2% | Low Risk · 33 | N/A | |
| 1659 | 48 |
CHC | ACL | SS | 39 | 45 | 52 | 43 |
0.0% | Low Risk · 40 | N/A | |
| 1660 | 48 |
SEA | Single-A | SS | 38 | 45 | 54 | 46 |
+0.1% | Low Risk · 28 | N/A | |
| 1661 | IL(Rehab)48 |
TOR | FCL | SSIL(Rehab) | 46 | 59 | 70 | 41 |
0.0% | Wide Range · 59 | N/A | |
| 1662 | 48 |
PIT | AA | SS | 41 | 51 | 63 | 57 |
-0.2% | Medium Risk · 46 | N/A | |
| 1663 | 48 |
ATL | DSL | SS | 36 | 46 | 56 | 49 |
+0.3% | Low Risk · 37 | N/A | |
| 1664 | 48 |
DET | DSL | OF | 35 | 45 | 57 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1665 | 48 |
SF | High-A | OF | 38 | 45 | 52 | 46 |
+0.1% | Low Risk · 26 | N/A | |
| 1666 | 48 |
PIT | FCL | OF | 36 | 45 | 55 | 47 |
-0.1% | Low Risk · 32 | N/A | |
| 1667 | 48 |
SD | Single-A | C | 37 | 44 | 51 | 42 |
-0.3% | Low Risk · 14 | N/A | |
| 1668 | 48 |
KC | High-A | P | 38 | 44 | 51 | 38 |
0.0% | Low Risk · 10 | N/A | |
| 1669 | 48 |
ATH | AA | CF | 39 | 43 | 48 | 34 |
0.0% | Low Risk · 5 | N/A | |
| 1670 | 48 |
NYM | DSL | OF | 36 | 46 | 55 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1671 | 48 |
DET | High-A | C | 37 | 44 | 51 | 38 |
0.0% | Low Risk · 10 | N/A | |
| 1672 | 48 |
MIL | Single-A | P | 39 | 47 | 55 | 36 |
0.0% | Low Risk · 27 | N/A | |
| 1673 | 48 |
TEX | DSL | C | 36 | 45 | 55 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1674 | 48 |
HOU | DSL | CF | 35 | 45 | 54 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1675 | 48 |
TB | DSL | P | 34 | 44 | 57 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1676 | 48 |
HOU | High-A | OF | 37 | 47 | 57 | 51 |
+0.1% | Low Risk · 28 | N/A | |
| 1677 | 48 |
CLE | AA | P | 41 | 46 | 51 | 41 |
-0.4% | Low Risk · 24 | N/A | |
| 1678 | 48 |
NYM | AA | 3B | 40 | 45 | 50 | 44 |
-0.2% | Low Risk · 12 | N/A | |
| 1679 | 48 |
CHC | High-A | P | 38 | 44 | 51 | 43 |
0.0% | Low Risk · 10 | N/A | |
| 1680 | 48 |
TOR | FCL | P | 37 | 46 | 55 | 48 |
-0.2% | Low Risk · 38 | N/A | |
| 1681 | 48 |
ATL | FCL | P | 36 | 45 | 54 | 47 |
-0.1% | Low Risk · 32 | N/A | |
| 1682 | 48 |
PIT | Single-A | P | 39 | 51 | 62 | 53 |
0.0% | Medium Risk · 56 | N/A | |
| 1683 | 48 |
TOR | Single-A | P | 37 | 46 | 63 | 47 |
-0.3% | Low Risk · 20 | N/A | |
| 1684 | 48 |
SD | AA | P | 41 | 46 | 51 | 34 |
0.0% | Low Risk · 20 | N/A | |
| 1685 | 48 |
CHC | AA | C | 38 | 43 | 47 | 36 |
-0.1% | Low Risk · 10 | N/A | |
| 1686 | 48 |
NYY | DSL | P | 35 | 46 | 64 | 51 |
0.0% | Medium Risk · 46 | N/A | |
| 1687 | 48 |
ATL | Single-A | P | 38 | 47 | 55 | 44 |
0.0% | Low Risk · 22 | N/A | |
| 1688 | 48 |
MIL | High-A | P | 38 | 47 | 56 | 49 |
-0.1% | Low Risk · 32 | N/A | |
| 1689 | 48 |
BAL | High-A | P | 37 | 45 | 53 | 46 |
0.0% | Low Risk · 24 | N/A | |
| 1690 | 48 |
STL | High-A | P | 38 | 44 | 51 | 41 |
0.0% | Low Risk · 10 | N/A | |
| 1691 | 48 |
MIA | High-A | SS | 37 | 44 | 51 | 37 |
0.0% | Low Risk · 10 | N/A | |
| 1692 | 48 |
MIL | High-A | 1B | 37 | 48 | 61 | 50 |
0.0% | Low Risk · 28 | N/A | |
| 1693 | 48 |
PIT | DSL | C | 35 | 45 | 55 | 50 |
0.0% | Low Risk · 37 | N/A | |
| 1694 | 48 |
NYY | High-A | OF | 39 | 50 | 67 | 54 |
0.0% | Medium Risk · 45 | N/A | |
| 1695 | 48 |
PIT | FCL | IF | 39 | 46 | 53 | 42 |
+0.2% | Low Risk · 40 | N/A | |
| 1696 | 48 |
LAD | DSL | OF | 35 | 45 | 55 | 50 |
0.0% | Low Risk · 37 | N/A | |
| 1697 | 48 |
TOR | AAA | P | 39 | 47 | 55 | 44 |
0.0% | Low Risk · 28 | N/A | |
| 1698 | 48 |
STL | Single-A | C | 36 | 43 | 50 | 37 |
0.0% | Low Risk · 0 | N/A | |
| 1699 | 48 |
BAL | AAA | SS | 38 | 48 | 58 | 55 |
0.0% | Medium Risk · 45 | N/A | |
| 1700 | 48 |
ATL | DSL | C | 35 | 45 | 55 | 48 |
+0.1% | Low Risk · 32 | N/A | |
| 1701 | 48 |
TB | Single-A | C | 37 | 45 | 53 | 44 |
0.0% | Low Risk · 13 | N/A | |
| 1702 | 48 |
PHI | AA | P | 38 | 48 | 57 | 53 |
0.0% | Medium Risk · 48 | N/A | |
| 1703 | 48 |
NYY | Single-A | C | 37 | 48 | 64 | 50 |
-0.2% | Low Risk · 31 | N/A | |
| 1704 | 48 |
COL | Single-A | P | 38 | 44 | 51 | 42 |
0.0% | Low Risk · 12 | N/A | |
| 1705 | IL(60-Day)48 |
NYY | High-A | PIL(60-Day) | 37 | 47 | 64 | 53 |
0.0% | Medium Risk · 50 | N/A | |
| 1706 | 48 |
MIA | High-A | CF | 38 | 47 | 56 | 43 |
0.0% | Low Risk · 33 | N/A | |
| 1707 | 48 |
MIN | DSL | C | 35 | 45 | 56 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1708 | 48 |
ATH | High-A | P | 37 | 44 | 50 | 42 |
0.0% | Low Risk · 10 | N/A | |
| 1709 | 48 |
NYM | FCL | SS | 36 | 45 | 53 | 45 |
-0.9% | Low Risk · 24 | N/A | |
| 1710 | 48 |
LAD | Single-A | OF | 38 | 48 | 66 | 51 |
0.0% | Low Risk · 32 | N/A | |
| 1711 | 48 |
TEX | ACL | 3B | 37 | 45 | 55 | 46 |
-0.2% | Low Risk · 40 | N/A | |
| 1712 | 48 |
MIL | ACL | P | 37 | 47 | 59 | 46 |
0.0% | Low Risk · 38 | N/A | |
| 1713 | 48 |
MIN | AA | 2B | 41 | 46 | 51 | 36 |
-0.6% | Low Risk · 21 | N/A | |
| 1714 | 48 |
LAD | AA | P | 37 | 44 | 57 | 58 |
+0.1% | Low Risk · 20 | N/A | |
| 1715 | 48 |
BOS | AA | P | 42 | 50 | 64 | 53 |
0.0% | Low Risk · 39 | N/A | |
| 1716 | 48 |
CWS | High-A | P | 37 | 45 | 53 | 48 |
0.0% | Low Risk · 24 | N/A | |
| 1717 | 48 |
NYM | AA | CF | 40 | 44 | 49 | 40 |
0.0% | Low Risk · 10 | N/A | |
| 1718 | 48 |
KC | AA | C | 38 | 44 | 51 | 39 |
0.0% | Low Risk · 15 | N/A | |
| 1719 | 48 |
COL | Single-A | P | 38 | 45 | 53 | 44 |
-0.2% | Low Risk · 24 | N/A | |
| 1720 | 48 |
CLE | AAA | P | 40 | 44 | 51 | 55 |
0.0% | Low Risk · 21 | N/A | |
| 1721 | 48 |
ARI | AAA | 3B | 38 | 47 | 56 | 61 |
0.0% | Low Risk · 37 | N/A | |
| 1722 | 48 |
TOR | Single-A | P | 36 | 46 | 56 | 50 |
0.0% | Low Risk · 28 | N/A | |
| 1723 | 48 |
BOS | FCL | SS | 38 | 46 | 52 | 37 |
0.0% | Low Risk · 29 | N/A | |
| 1724 | 48 |
PIT | High-A | P | 39 | 44 | 50 | 35 |
0.0% | Low Risk · 6 | N/A | |
| 1725 | 48 |
SD | High-A | CF | 36 | 46 | 55 | 50 |
0.0% | Low Risk · 33 | N/A | |
| 1726 | 48 |
KC | AA | P | 38 | 45 | 52 | 36 |
-0.1% | Low Risk · 20 | N/A | |
| 1727 | 48 |
TEX | DSL | IF | 34 | 44 | 61 | 53 |
0.0% | Low Risk · 40 | N/A | |
| 1728 | 48 |
SEA | Single-A | CF | 37 | 43 | 50 | 44 |
0.0% | Low Risk · 12 | N/A | |
| 1729 | 48 |
MIL | AA | 2B | 38 | 48 | 58 | 54 |
0.0% | Medium Risk · 45 | N/A | |
| 1730 | 48 |
PHI | AA | 1B | 38 | 44 | 52 | 55 |
+0.1% | Low Risk · 19 | N/A | |
| 1731 | 48 |
ARI | Single-A | P | 37 | 44 | 50 | 33 |
-0.3% | Low Risk · 0 | N/A | |
| 1732 | 48 |
LAA | Single-A | P | 36 | 43 | 53 | 47 |
0.0% | Low Risk · 12 | N/A | |
| 1733 | 48 |
LAD | AA | P | 38 | 46 | 54 | 47 |
0.0% | Low Risk · 32 | N/A | |
| 1734 | 48 |
NYY | AA | P | 40 | 47 | 55 | 46 |
+0.3% | Low Risk · 34 | N/A | |
| 1735 | 48 |
NYY | AAA | P | 38 | 45 | 52 | 62 |
0.0% | Low Risk · 23 | N/A | |
| 1736 | 48 |
NYY | Single-A | P | 37 | 45 | 56 | 45 |
0.0% | Low Risk · 24 | N/A | |
| 1737 | 48 |
MIN | Single-A | C | 36 | 46 | 55 | 49 |
0.0% | Low Risk · 23 | N/A | |
| 1738 | 48 |
SEA | Single-A | P | 36 | 44 | 55 | 46 |
0.0% | Low Risk · 12 | N/A | |
| 1739 | 48 |
DET | High-A | OF | 37 | 43 | 50 | 44 |
0.0% | Low Risk · 10 | N/A | |
| 1740 | 48 |
CLE | High-A | P | 37 | 44 | 52 | 41 |
0.0% | Low Risk · 10 | N/A | |
| 1741 | 48 |
TB | High-A | P | 37 | 44 | 51 | 44 |
0.0% | Low Risk · 10 | N/A | |
| 1742 | 48 |
CIN | Single-A | P | 35 | 43 | 51 | 46 |
0.0% | Low Risk · 12 | N/A | |
| 1743 | 48 |
ATH | High-A | SS | 37 | 43 | 49 | 44 |
+0.1% | Low Risk · 10 | N/A | |
| 1744 | 48 |
PIT | Single-A | OF | 37 | 43 | 50 | 45 |
-0.1% | Low Risk · 12 | N/A | |
| 1745 | 48 |
BAL | FCL | C | 36 | 45 | 53 | 46 |
-0.3% | Low Risk · 24 | N/A | |
| 1746 | 48 |
ARI | ACL | 2B | 36 | 45 | 57 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1747 | 48 |
BOS | FCL | SS | 35 | 45 | 57 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1748 | 48 |
DET | Single-A | OF | 36 | 43 | 50 | 41 |
0.0% | Low Risk · 12 | N/A | |
| 1749 | 48 |
PIT | DSL | OF | 35 | 45 | 55 | 48 |
-0.5% | Low Risk · 37 | N/A | |
| 1750 | 48 |
SF | Single-A | 1B | 38 | 45 | 52 | 48 |
+0.1% | Low Risk · 28 | N/A | |
| 1751 | 48 |
DET | FCL | P | 35 | 45 | 58 | 50 |
-0.1% | Medium Risk · 46 | N/A | |
| 1752 | 48 |
LAA | DSL | SS | 35 | 45 | 54 | 46 |
+0.1% | Low Risk · 37 | N/A | |
| 1753 | 48 |
TOR | High-A | 2B | 37 | 43 | 50 | 41 |
+0.2% | Low Risk · 15 | N/A | |
| 1754 | 48 |
CIN | Single-A | 2B | 37 | 46 | 54 | 45 |
+0.1% | Low Risk · 18 | N/A | |
| 1755 | 48 |
LAA | Single-A | P | 38 | 44 | 56 | 44 |
0.0% | Low Risk · 12 | N/A | |
| 1756 | 48 |
CHC | DSL | C | 38 | 50 | 72 | 49 |
0.0% | Medium Risk · 56 | N/A | |
| 1757 | 48 |
NYY | Single-A | P | 37 | 48 | 65 | 50 |
0.0% | Low Risk · 40 | N/A | |
| 1758 | 48 |
CWS | DSL | P | 36 | 46 | 56 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1759 | 48 |
CHC | DSL | OF | 36 | 46 | 55 | 48 |
-0.2% | Low Risk · 37 | N/A | |
| 1760 | 48 |
TB | DSL | IF | 35 | 45 | 55 | 52 |
-0.2% | Medium Risk · 43 | N/A | |
| 1761 | 48 |
MIN | High-A | SS | 37 | 44 | 50 | 34 |
+0.1% | Low Risk · 5 | N/A | |
| 1762 | 48 |
KC | AAA | RF | 38 | 43 | 47 | 33 |
0.0% | Low Risk · 5 | N/A | |
| 1763 | 48 |
SD | Single-A | SS | 36 | 46 | 58 | 51 |
0.0% | Low Risk · 30 | N/A | |
| 1764 | 48 |
STL | DSL | P | 36 | 46 | 64 | 45 |
0.0% | Low Risk · 32 | N/A | |
| 1765 | 48 |
LAD | AA | P | 39 | 46 | 52 | 41 |
-0.1% | Low Risk · 24 | N/A | |
| 1766 | 48 |
BOS | AA | C | 38 | 46 | 55 | 49 |
0.0% | Low Risk · 28 | N/A | |
| 1767 | IL(7-Day)48 |
CIN | High-A | PIL(7-Day) | 38 | 46 | 55 | 46 |
0.0% | Low Risk · 34 | N/A | |
| 1768 | 48 |
DET | Single-A | P | 36 | 44 | 53 | 47 |
0.0% | Low Risk · 20 | N/A | |
| 1769 | 48 |
HOU | High-A | P | 37 | 44 | 51 | 35 |
0.0% | Low Risk · 6 | N/A | |
| 1770 | 48 |
MIA | High-A | OF | 37 | 43 | 50 | 43 |
-0.1% | Low Risk · 10 | N/A | |
| 1771 | 48 |
MIA | DSL | SS | 35 | 45 | 55 | 47 |
0.0% | Low Risk · 32 | N/A | |
| 1772 | 48 |
MIN | AA | RF | 40 | 44 | 49 | 43 |
+0.1% | Low Risk · 12 | N/A | |
| 1773 | 48 |
NYM | Single-A | P | 36 | 44 | 56 | 48 |
0.0% | Low Risk · 20 | N/A | |
| 1774 | 48 |
SD | AA | SS | 39 | 44 | 49 | 38 |
0.0% | Low Risk · 15 | N/A | |
| 1775 | 48 |
TEX | High-A | P | 38 | 48 | 57 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1776 | 48 |
TOR | AAA | P | 38 | 46 | 56 | 55 |
0.0% | Low Risk · 27 | N/A | |
| 1777 | 48 |
SD | DSL | C | 34 | 45 | 58 | 51 |
+0.1% | Medium Risk · 46 | N/A | |
| 1778 | 48 |
PIT | Single-A | C | 37 | 44 | 51 | 39 |
+0.2% | Low Risk · 16 | N/A | |
| 1779 | 48 |
CWS | AA | C | 37 | 46 | 54 | 51 |
+0.1% | Low Risk · 29 | N/A | |
| 1780 | 48 |
SEA | Single-A | P | 37 | 48 | 64 | 53 |
+0.1% | Medium Risk · 56 | N/A | |
| 1781 | 48 |
MIN | Single-A | P | 37 | 48 | 65 | 51 |
-0.4% | Medium Risk · 42 | N/A | |
| 1782 | 48 |
HOU | FCL | OF | 34 | 44 | 58 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1783 | 48 |
KC | ACL | SS | 35 | 44 | 52 | 40 |
+0.1% | Low Risk · 29 | N/A | |
| 1784 | 48 |
ATH | Single-A | P | 39 | 47 | 54 | 36 |
0.0% | Low Risk · 27 | N/A | |
| 1785 | 48 |
TEX | Single-A | RF | 38 | 45 | 52 | 39 |
+0.1% | Low Risk · 25 | N/A | |
| 1786 | 47 |
NYY | DSL | C | 34 | 44 | 54 | 48 |
-0.2% | Low Risk · 32 | N/A | |
| 1787 | 47 |
PIT | DSL | IF | 35 | 46 | 55 | 47 |
0.0% | Low Risk · 37 | N/A | |
| 1788 | 47 |
ATH | AAA | P | 38 | 46 | 53 | 47 |
+0.2% | Low Risk · 20 | N/A | |
| 1789 | 47 |
BAL | AAA | P | 41 | 46 | 51 | 38 |
-0.2% | Low Risk · 21 | N/A | |
| 1790 | 47 |
LAD | DSL | OF | 35 | 45 | 54 | 46 |
-0.2% | Low Risk · 32 | N/A | |
| 1791 | 47 |
TB | FCL | 3B | 36 | 44 | 53 | 48 |
+0.2% | Low Risk · 32 | N/A | |
| 1792 | 47 |
CHC | AA | P | 39 | 46 | 53 | 43 |
-0.1% | Low Risk · 34 | N/A | |
| 1793 | 47 |
MIA | High-A | P | 37 | 47 | 62 | 52 |
0.0% | Low Risk · 38 | N/A | |
| 1794 | 47 |
HOU | FCL | SS | 36 | 46 | 57 | 49 |
-0.1% | Medium Risk · 47 | N/A | |
| 1795 | 47 |
KC | Single-A | C | 37 | 43 | 50 | 42 |
0.0% | Low Risk · 14 | N/A | |
| 1796 | 47 |
CLE | AA | RF | 40 | 46 | 51 | 37 |
-0.1% | Low Risk · 21 | N/A | |
| 1797 | 47 |
SEA | High-A | 3B | 37 | 43 | 50 | 42 |
-0.1% | Low Risk · 10 | N/A | |
| 1798 | 47 |
ATH | High-A | RF | 37 | 42 | 47 | 39 |
0.0% | Low Risk · 10 | N/A | |
| 1799 | 47 |
DET | Single-A | P | 35 | 46 | 55 | 50 |
0.0% | Low Risk · 28 | N/A | |
| 1800 | 47 |
ARI | ACL | 3B | 36 | 44 | 53 | 42 |
+0.2% | Low Risk · 29 | N/A | |
| 1801 | 47 |
MIA | AA | P | 39 | 46 | 54 | 42 |
-2.5% | Low Risk · 34 | N/A | |
| 1802 | 47 |
ARI | DSL | OF | 35 | 45 | 55 | 47 |
+0.3% | Low Risk · 32 | N/A | |
| 1803 | 47 |
COL | Single-A | C | 36 | 47 | 57 | 51 |
-0.1% | Low Risk · 39 | N/A | |
| 1804 | 47 |
CIN | DSL | OF | 35 | 45 | 64 | 50 |
-0.1% | Medium Risk · 46 | N/A | |
| 1805 | 47 |
TOR | AAA | SS | 40 | 45 | 51 | 40 |
0.0% | Low Risk · 27 | N/A | |
| 1806 | 47 |
MIL | AA | P | 39 | 47 | 55 | 46 |
-0.1% | Low Risk · 28 | N/A | |
| 1807 | 47 |
ARI | Single-A | OF | 37 | 43 | 50 | 40 |
0.0% | Low Risk · 14 | N/A | |
| 1808 | 47 |
STL | High-A | P | 37 | 47 | 61 | 50 |
0.0% | Medium Risk · 42 | N/A | |
| 1809 | 47 |
ARI | DSL | C | 34 | 45 | 61 | 49 |
-0.3% | Medium Risk · 42 | N/A | |
| 1810 | IL(7-Day)47 |
NYM | AA | PIL(7-Day) | 39 | 46 | 54 | 45 |
0.0% | Low Risk · 34 | N/A | |
| 1811 | 47 |
BOS | DSL | SS | 35 | 46 | 61 | 49 |
-0.4% | Medium Risk · 42 | N/A | |
| 1812 | 47 |
NYY | DSL | C | 34 | 44 | 55 | 48 |
-0.2% | Low Risk · 32 | N/A | |
| 1813 | 47 |
HOU | High-A | RF | 38 | 45 | 52 | 44 |
0.0% | Low Risk · 26 | N/A | |
| 1814 | 47 |
COL | Single-A | P | 37 | 46 | 65 | 48 |
0.0% | Low Risk · 30 | N/A | |
| 1815 | 47 |
TEX | DSL | P | 34 | 44 | 54 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1816 | 47 |
HOU | AA | P | 38 | 46 | 53 | 45 |
0.0% | Low Risk · 18 | N/A | |
| 1817 | 47 |
BOS | Single-A | CF | 37 | 43 | 50 | 41 |
0.0% | Low Risk · 12 | N/A | |
| 1818 | 47 |
MIN | AA | P | 38 | 46 | 55 | 49 |
0.0% | Low Risk · 32 | N/A | |
| 1819 | IL(Rehab)47 |
CHC | High-A | PIL(Rehab) | 46 | 59 | 69 | 44 |
0.0% | Wide Range · 66 | N/A | |
| 1820 | 47 |
ATL | AA | OF | 38 | 46 | 53 | 43 |
0.0% | Low Risk · 18 | N/A | |
| 1821 | 47 |
TEX | ACL | P | 35 | 45 | 56 | 48 |
0.0% | Medium Risk · 46 | N/A | |
| 1822 | 47 |
KC | Single-A | CF | 37 | 43 | 50 | 40 |
+0.2% | Low Risk · 14 | N/A | |
| 1823 | 47 |
TOR | AA | 2B | 37 | 46 | 56 | 52 |
0.0% | Low Risk · 33 | N/A | |
| 1824 | 47 |
CWS | High-A | P | 36 | 46 | 61 | 50 |
0.0% | Low Risk · 38 | N/A | |
| 1825 | 47 |
HOU | FCL | C | 35 | 45 | 56 | 49 |
0.0% | Medium Risk · 42 | N/A | |
| 1826 | 47 |
SF | DSL | OF | 35 | 44 | 53 | 47 |
-0.1% | Low Risk · 32 | N/A | |
| 1827 | 47 |
DET | AA | P | 39 | 49 | 59 | 53 |
+0.1% | Medium Risk · 49 | N/A | |
| 1828 | 47 |
TEX | High-A | P | 40 | 45 | 51 | 39 |
0.0% | Low Risk · 34 | N/A | |
| 1829 | 47 |
COL | DSL | SS | 35 | 45 | 54 | 49 |
+0.1% | Low Risk · 37 | N/A | |
| 1830 | 47 |
NYM | DSL | C | 34 | 45 | 54 | 47 |
+0.1% | Low Risk · 32 | N/A | |
| 1831 | 47 |
TOR | FCL | P | 36 | 45 | 54 | 45 |
0.0% | Low Risk · 38 | N/A | |
| 1832 | 47 |
BAL | Single-A | 2B | 37 | 45 | 52 | 41 |
0.0% | Low Risk · 25 | N/A | |
| 1833 | 47 |
BAL | High-A | P | 38 | 45 | 52 | 40 |
0.0% | Low Risk · 20 | N/A | |
| 1834 | 47 |
ATL | FCL | SS | 36 | 45 | 55 | 42 |
0.0% | Low Risk · 29 | N/A | |
| 1835 | 47 |
LAA | AA | P | 36 | 43 | 54 | 59 |
+0.1% | Low Risk · 21 | N/A | |
| 1836 | 47 |
MIA | Single-A | 3B | 36 | 43 | 51 | 43 |
+0.1% | Low Risk · 19 | N/A | |
| 1837 | 47 |
SF | Single-A | P | 36 | 43 | 50 | 42 |
0.0% | Low Risk · 12 | N/A | |
| 1838 | 47 |
BOS | Single-A | P | 37 | 45 | 53 | 42 |
-0.3% | Low Risk · 24 | N/A | |
| 1839 | 47 |
STL | DSL | P | 34 | 44 | 58 | 47 |
0.0% | Low Risk · 32 | N/A | |
| 1840 | 47 |
CLE | AAA | P | 39 | 46 | 54 | 42 |
0.0% | Low Risk · 28 | N/A | |
| 1841 | IL(7-Day)47 |
HOU | Single-A | PIL(7-Day) | 35 | 43 | 53 | 47 |
0.0% | Low Risk · 26 | N/A | |
| 1842 | 47 |
STL | DSL | IF | 35 | 45 | 56 | 47 |
0.0% | Low Risk · 32 | N/A | |
| 1843 | 47 |
TEX | DSL | SS | 35 | 45 | 57 | 46 |
-0.1% | Low Risk · 32 | N/A | |
| 1844 | 47 |
ARI | DSL | SS | 35 | 45 | 54 | 47 |
0.0% | Low Risk · 37 | N/A | |
| 1845 | 47 |
CLE | DSL | SS | 34 | 44 | 53 | 48 |
-0.2% | Low Risk · 37 | N/A | |
| 1846 | 47 |
NYY | AA | P | 37 | 44 | 57 | 55 |
0.0% | Low Risk · 20 | N/A | |
| 1847 | 47 |
ARI | DSL | SS | 34 | 44 | 55 | 48 |
-0.1% | Low Risk · 37 | N/A | |
| 1848 | 47 |
ATL | Single-A | P | 34 | 41 | 49 | 47 |
0.0% | Low Risk · 12 | N/A | |
| 1849 | 47 |
BOS | AA | OF | 37 | 44 | 50 | 37 |
-0.4% | Low Risk · 10 | N/A | |
| 1850 | 47 |
CLE | DSL | SS | 34 | 44 | 55 | 47 |
+0.1% | Low Risk · 32 | N/A | |
| 1851 | 47 |
NYM | FCL | SS | 35 | 45 | 55 | 47 |
+0.1% | Low Risk · 37 | N/A | |
| 1852 | IL(7-Day)47 |
MIL | AA | PIL(7-Day) | 38 | 48 | 57 | 55 |
0.0% | Medium Risk · 54 | N/A | |
| 1853 | 47 |
MIA | DSL | C | 35 | 46 | 62 | 48 |
-0.2% | Medium Risk · 42 | N/A | |
| 1854 | 47 |
COL | DSL | P | 35 | 46 | 60 | 47 |
0.0% | Medium Risk · 42 | N/A | |
| 1855 | 47 |
SEA | AAA | 2B | 39 | 43 | 48 | 49 |
0.0% | Low Risk · 19 | N/A | |
| 1856 | 47 |
BAL | Single-A | RF | 37 | 43 | 50 | 38 |
+0.2% | Low Risk · 9 | N/A | |
| 1857 | 47 |
SD | ACL | IF | 35 | 44 | 52 | 42 |
+0.1% | Low Risk · 24 | N/A | |
| 1858 | 47 |
LAA | High-A | P | 38 | 44 | 49 | 33 |
-0.1% | Low Risk · 6 | N/A | |
| 1859 | 47 |
DET | Single-A | P | 35 | 45 | 55 | 49 |
0.0% | Low Risk · 28 | N/A | |
| 1860 | 47 |
HOU | AA | P | 38 | 46 | 55 | 49 |
0.0% | Low Risk · 38 | N/A | |
| 1861 | 47 |
LAA | DSL | P | 35 | 44 | 53 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1862 | 47 |
TEX | ACL | C | 35 | 45 | 55 | 47 |
-0.2% | Low Risk · 37 | N/A | |
| 1863 | 47 |
COL | AA | P | 37 | 46 | 56 | 53 |
0.0% | Low Risk · 38 | N/A | |
| 1864 | 47 |
KC | AA | C | 39 | 44 | 49 | 31 |
0.0% | Low Risk · 10 | N/A | |
| 1865 | 47 |
TOR | AA | P | 38 | 47 | 55 | 45 |
-0.2% | Low Risk · 28 | N/A | |
| 1866 | 47 |
HOU | AAA | P | 43 | 50 | 65 | 62 |
-0.7% | Medium Risk · 48 | N/A | |
| 1867 | 47 |
PHI | FCL | P | 36 | 47 | 61 | 47 |
0.0% | Medium Risk · 46 | N/A | |
| 1868 | 47 |
KC | AAA | P | 38 | 45 | 52 | 34 |
0.0% | Low Risk · 20 | N/A | |
| 1869 | 47 |
STL | AA | P | 39 | 47 | 57 | 46 |
0.0% | Medium Risk · 42 | N/A | |
| 1870 | 47 |
MIA | DSL | OF | 35 | 46 | 61 | 47 |
-0.1% | Medium Risk · 42 | N/A | |
| 1871 | 47 |
SEA | ACL | IF | 35 | 44 | 53 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1872 | 47 |
LAD | ACL | IF | 35 | 44 | 52 | 44 |
-0.1% | Low Risk · 24 | N/A | |
| 1873 | 47 |
MIL | AA | P | 38 | 48 | 57 | 52 |
0.0% | Medium Risk · 48 | N/A | |
| 1874 | 47 |
CLE | DSL | IF | 34 | 45 | 54 | 48 |
0.0% | Low Risk · 37 | N/A | |
| 1875 | 47 |
ATH | High-A | CF | 37 | 44 | 51 | 41 |
0.0% | Low Risk · 26 | N/A | |
| 1876 | 47 |
TOR | FCL | OF | 35 | 43 | 52 | 44 |
-0.3% | Low Risk · 24 | N/A | |
| 1877 | 47 |
CHC | AA | 3B | 39 | 43 | 48 | 37 |
0.0% | Low Risk · 10 | N/A | |
| 1878 | 47 |
SEA | Single-A | P | 36 | 43 | 50 | 41 |
0.0% | Low Risk · 12 | N/A | |
| 1879 | 47 |
LAA | ACL | C | 34 | 45 | 63 | 48 |
0.0% | Low Risk · 40 | N/A | |
| 1880 | 47 |
SEA | ACL | CF | 35 | 44 | 52 | 48 |
-0.1% | Low Risk · 32 | N/A | |
| 1881 | 47 |
PIT | Single-A | P | 37 | 47 | 57 | 49 |
+0.2% | Medium Risk · 42 | N/A | |
| 1882 | 47 |
HOU | FCL | P | 35 | 43 | 52 | 44 |
0.0% | Low Risk · 24 | N/A | |
| 1883 | 47 |
CWS | AA | SS | 39 | 43 | 48 | 39 |
-0.4% | Low Risk · 15 | N/A | |
| 1884 | 47 |
ARI | AAA | P | 37 | 47 | 57 | 57 |
0.0% | Medium Risk · 54 | N/A | |
| 1885 | 47 |
BOS | DSL | C | 35 | 45 | 56 | 45 |
0.0% | Low Risk · 32 | N/A | |
| 1886 | 47 |
NYM | FCL | C | 35 | 43 | 52 | 46 |
0.0% | Low Risk · 29 | N/A | |
| 1887 | 47 |
CIN | DSL | IF | 36 | 48 | 69 | 49 |
0.0% | Medium Risk · 56 | N/A | |
| 1888 | 47 |
PHI | FCL | IF | 38 | 45 | 51 | 38 |
+0.2% | Low Risk · 38 | N/A | |
| 1889 | 47 |
LAA | DSL | OF | 34 | 45 | 55 | 48 |
0.0% | Medium Risk · 42 | N/A | |
| 1890 | 47 |
SF | ACL | P | 36 | 45 | 54 | 44 |
0.0% | Low Risk · 34 | N/A | |
| 1891 | 47 |
TEX | Single-A | RF | 35 | 45 | 55 | 49 |
+0.1% | Low Risk · 32 | N/A | |
| 1892 | 47 |
TEX | DSL | SS | 34 | 44 | 55 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1893 | 47 |
MIA | Single-A | CF | 36 | 43 | 50 | 36 |
0.0% | Low Risk · 16 | N/A | |
| 1894 | 47 |
CWS | AA | P | 38 | 46 | 53 | 42 |
0.0% | Low Risk · 28 | N/A | |
| 1895 | 47 |
TEX | High-A | C | 35 | 43 | 50 | 40 |
-0.1% | Low Risk · 10 | N/A | |
| 1896 | 47 |
TB | Single-A | OF | 34 | 44 | 54 | 48 |
0.0% | Low Risk · 30 | N/A | |
| 1897 | 47 |
PIT | High-A | P | 38 | 49 | 65 | 52 |
-6.8% | Medium Risk · 49 | N/A | |
| 1898 | 47 |
COL | DSL | C | 34 | 45 | 59 | 49 |
0.0% | Medium Risk · 42 | N/A | |
| 1899 | 47 |
PIT | Single-A | 3B | 35 | 45 | 62 | 48 |
+0.1% | Low Risk · 30 | N/A | |
| 1900 | 47 |
DET | DSL | SS | 34 | 44 | 54 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1901 | 47 |
SEA | Single-A | P | 37 | 44 | 52 | 43 |
0.0% | Low Risk · 22 | N/A | |
| 1902 | 47 |
TOR | High-A | P | 35 | 43 | 50 | 47 |
0.0% | Low Risk · 24 | N/A | |
| 1903 | 47 |
CLE | High-A | C | 36 | 44 | 52 | 44 |
0.0% | Low Risk · 23 | N/A | |
| 1904 | 47 |
CHC | ACL | C | 34 | 44 | 54 | 48 |
0.0% | Low Risk · 32 | N/A | |
| 1905 | 47 |
SD | DSL | IF | 34 | 45 | 54 | 46 |
+0.1% | Low Risk · 32 | N/A | |
| 1906 | 47 |
ARI | Single-A | SS | 36 | 44 | 51 | 39 |
-0.4% | Low Risk · 14 | N/A | |
| 1907 | 47 |
ATH | DSL | P | 34 | 44 | 54 | 47 |
0.0% | Low Risk · 32 | N/A | |
| 1908 | 47 |
COL | AA | P | 39 | 44 | 49 | 41 |
0.0% | Low Risk · 24 | N/A | |
| 1909 | 47 |
NYM | DSL | CF | 33 | 43 | 55 | 51 |
+0.2% | Medium Risk · 46 | N/A | |
| 1910 | 47 |
DET | AA | 1B | 38 | 43 | 48 | 40 |
0.0% | Low Risk · 11 | N/A | |
| 1911 | 47 |
ARI | DSL | P | 33 | 43 | 59 | 51 |
0.0% | Medium Risk · 46 | N/A | |
| 1912 | 47 |
STL | Single-A | SS | 36 | 43 | 49 | 42 |
+0.3% | Low Risk · 12 | N/A | |
| 1913 | 47 |
CLE | AAA | P | 38 | 42 | 47 | 52 |
0.0% | Low Risk · 20 | N/A | |
| 1914 | 46 |
MIN | DSL | C | 36 | 48 | 69 | 50 |
0.0% | Medium Risk · 57 | N/A | |
| 1915 | 46 |
SF | ACL | SS | 35 | 43 | 51 | 43 |
0.0% | Low Risk · 24 | N/A | |
| 1916 | 46 |
SEA | High-A | P | 34 | 42 | 56 | 58 |
-0.2% | Low Risk · 27 | N/A | |
| 1917 | 46 |
CLE | Single-A | P | 37 | 45 | 54 | 39 |
0.0% | Low Risk · 24 | N/A | |
| 1918 | 46 |
CHC | High-A | P | 35 | 43 | 51 | 46 |
0.0% | Low Risk · 18 | N/A | |
| 1919 | 46 |
ATH | AA | RF | 38 | 42 | 47 | 38 |
+0.1% | Low Risk · 19 | N/A | |
| 1920 | 46 |
LAA | ACL | P | 35 | 47 | 58 | 50 |
0.0% | Medium Risk · 52 | N/A | |
| 1921 | 46 |
CIN | Single-A | C | 37 | 47 | 65 | 48 |
+0.1% | Low Risk · 30 | N/A | |
| 1922 | IL(7-Day)46 |
BAL | Single-A | SSIL(7-Day) | 36 | 45 | 54 | 45 |
0.0% | Low Risk · 28 | N/A | |
| 1923 | 46 |
SD | Single-A | OF | 36 | 43 | 50 | 38 |
-2.5% | Low Risk · 14 | N/A | |
| 1924 | 46 |
CLE | DSL | OF | 34 | 44 | 54 | 48 |
+0.1% | Low Risk · 37 | N/A | |
| 1925 | 46 |
BOS | DSL | SS | 33 | 44 | 54 | 48 |
0.0% | Low Risk · 37 | N/A | |
| 1926 | 46 |
TEX | High-A | P | 37 | 44 | 52 | 42 |
0.0% | Low Risk · 34 | N/A | |
| 1927 | 46 |
NYY | Single-A | OF | 35 | 42 | 48 | 44 |
-0.6% | Low Risk · 12 | N/A | |
| 1928 | 46 |
TOR | High-A | P | 35 | 42 | 50 | 43 |
0.0% | Low Risk · 10 | N/A | |
| 1929 | 46 |
TEX | AA | P | 39 | 44 | 49 | 39 |
0.0% | Low Risk · 34 | N/A | |
| 1930 | 46 |
CWS | High-A | 3B | 36 | 43 | 50 | 36 |
+0.2% | Low Risk · 10 | N/A | |
| 1931 | 46 |
BAL | DSL | OF | 34 | 44 | 54 | 46 |
-0.1% | Low Risk · 32 | N/A | |
| 1932 | 46 |
NYY | High-A | C | 37 | 49 | 61 | 47 |
0.0% | Wide Range · 59 | N/A | |
| 1933 | 46 |
MIA | FCL | C | 34 | 43 | 52 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1934 | 46 |
BAL | AAA | P | 38 | 45 | 51 | 38 |
-1.0% | Low Risk · 22 | N/A | |
| 1935 | 46 |
COL | High-A | P | 37 | 44 | 52 | 41 |
0.0% | Low Risk · 34 | N/A | |
| 1936 | 46 |
NYY | Single-A | P | 35 | 43 | 51 | 43 |
0.0% | Low Risk · 12 | N/A | |
| 1937 | 46 |
SD | Single-A | OF | 36 | 42 | 49 | 40 |
-0.2% | Low Risk · 12 | N/A | |
| 1938 | 46 |
ATH | High-A | P | 36 | 42 | 49 | 37 |
0.0% | Low Risk · 10 | N/A | |
| 1939 | 46 |
NYY | DSL | SS | 34 | 44 | 54 | 47 |
-0.1% | Low Risk · 37 | N/A | |
| 1940 | 46 |
TOR | FCL | P | 34 | 44 | 54 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1941 | 46 |
DET | AAA | C | 39 | 43 | 47 | 51 |
0.0% | Low Risk · 20 | N/A | |
| 1942 | 46 |
TEX | DSL | OF | 34 | 43 | 53 | 46 |
+0.1% | Low Risk · 32 | N/A | |
| 1943 | 46 |
SEA | ACL | P | 33 | 43 | 57 | 49 |
0.0% | Low Risk · 40 | N/A | |
| 1944 | 46 |
MIN | FCL | C | 35 | 46 | 57 | 49 |
0.0% | Medium Risk · 47 | N/A | |
| 1945 | 46 |
MIA | DSL | OF | 34 | 44 | 54 | 47 |
0.0% | Low Risk · 37 | N/A | |
| 1946 | 46 |
MIN | DSL | IF | 34 | 44 | 55 | 48 |
+0.1% | Medium Risk · 42 | N/A | |
| 1947 | 46 |
TEX | AA | P | 38 | 43 | 48 | 36 |
-0.3% | Low Risk · 10 | N/A | |
| 1948 | 46 |
KC | ACL | P | 34 | 44 | 56 | 50 |
-0.2% | Medium Risk · 46 | N/A | |
| 1949 | 46 |
ARI | DSL | OF | 34 | 44 | 57 | 48 |
0.0% | Medium Risk · 42 | N/A | |
| 1950 | 46 |
COL | AA | P | 37 | 44 | 50 | 37 |
0.0% | Low Risk · 20 | N/A | |
| 1951 | IL(60-Day)46 |
BOS | Single-A | PIL(60-Day) | 37 | 49 | 59 | 54 |
0.0% | Wide Range · 67 | N/A | |
| 1952 | IL(60-Day)46 |
TOR | AA | CIL(60-Day) | 36 | 46 | 55 | 54 |
0.0% | Medium Risk · 45 | N/A | |
| 1953 | IL(60-Day)46 |
WSH | AA | SSIL(60-Day) | 36 | 46 | 56 | 54 |
0.0% | Medium Risk · 47 | N/A | |
| 1954 | 46 |
STL | FCL | C | 34 | 44 | 53 | 45 |
-0.4% | Low Risk · 32 | N/A | |
| 1955 | 46 |
NYY | DSL | OF | 35 | 46 | 60 | 49 |
0.0% | Wide Range · 58 | N/A | |
| 1956 | 46 |
DET | High-A | SS | 35 | 45 | 55 | 51 |
-0.1% | Low Risk · 33 | N/A | |
| 1957 | 46 |
LAA | ACL | P | 35 | 44 | 52 | 41 |
-0.2% | Low Risk · 34 | N/A | |
| 1958 | 46 |
DET | High-A | P | 36 | 43 | 51 | 39 |
0.0% | Low Risk · 24 | N/A | |
| 1959 | 46 |
SEA | ACL | P | 36 | 45 | 61 | 47 |
0.0% | Medium Risk · 42 | N/A | |
| 1960 | 46 |
HOU | High-A | P | 36 | 45 | 53 | 38 |
0.0% | Low Risk · 24 | N/A | |
| 1961 | 46 |
LAD | DSL | OF | 33 | 43 | 55 | 47 |
-0.1% | Low Risk · 32 | N/A | |
| 1962 | 46 |
MIL | DSL | OF | 34 | 45 | 54 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1963 | 46 |
BOS | FCL | C | 34 | 44 | 59 | 49 |
0.0% | Medium Risk · 46 | N/A | |
| 1964 | 46 |
BOS | DSL | SS | 34 | 44 | 53 | 46 |
-0.4% | Low Risk · 32 | N/A | |
| 1965 | 46 |
NYY | High-A | P | 35 | 43 | 51 | 45 |
-0.3% | Low Risk · 18 | N/A | |
| 1966 | 46 |
CIN | DSL | OF | 34 | 45 | 58 | 48 |
0.0% | Medium Risk · 42 | N/A | |
| 1967 | 46 |
MIA | FCL | RF | 34 | 43 | 54 | 47 |
-0.3% | Low Risk · 32 | N/A | |
| 1968 | 46 |
ATH | ACL | OF | 35 | 44 | 55 | 46 |
0.0% | Low Risk · 40 | N/A | |
| 1969 | 46 |
SD | High-A | OF | 36 | 42 | 49 | 41 |
0.0% | Low Risk · 10 | N/A | |
| 1970 | 46 |
KC | AA | P | 36 | 46 | 56 | 54 |
0.0% | Medium Risk · 52 | N/A | |
| 1971 | 46 |
TB | FCL | C | 34 | 45 | 57 | 47 |
0.0% | Medium Risk · 42 | N/A | |
| 1972 | 46 |
CLE | High-A | LF | 37 | 44 | 51 | 40 |
+0.1% | Low Risk · 26 | N/A | |
| 1973 | 46 |
KC | AAA | P | 38 | 42 | 47 | 49 |
0.0% | Low Risk · 19 | N/A | |
| 1974 | 46 |
SEA | AA | P | 38 | 43 | 48 | 38 |
0.0% | Low Risk · 11 | N/A | |
| 1975 | 46 |
CLE | AA | P | 38 | 48 | 58 | 53 |
-0.1% | Medium Risk · 49 | N/A | |
| 1976 | 46 |
CLE | Single-A | P | 36 | 43 | 50 | 42 |
0.0% | Low Risk · 26 | N/A | |
| 1977 | 46 |
MIN | High-A | P | 37 | 47 | 58 | 47 |
-0.3% | Medium Risk · 42 | N/A | |
| 1978 | 46 |
PHI | AA | C | 36 | 43 | 50 | 37 |
0.0% | Low Risk · 5 | N/A | |
| 1979 | 46 |
COL | Single-A | SS | 36 | 44 | 51 | 33 |
0.0% | Low Risk · 17 | N/A | |
| 1980 | 46 |
MIA | AA | P | 35 | 42 | 55 | 56 |
-0.3% | Low Risk · 21 | N/A | |
| 1981 | 46 |
STL | Single-A | 3B | 34 | 44 | 57 | 47 |
-0.1% | Low Risk · 30 | N/A | |
| 1982 | 46 |
ATH | AA | 3B | 37 | 45 | 53 | 46 |
-0.3% | Low Risk · 32 | N/A | |
| 1983 | 46 |
STL | AA | 3B | 38 | 42 | 47 | 40 |
+0.1% | Low Risk · 11 | N/A | |
| 1984 | IL(7-Day)46 |
DET | High-A | RFIL(7-Day) | 35 | 45 | 55 | 52 |
0.0% | Low Risk · 39 | N/A | |
| 1985 | 46 |
PIT | DSL | OF | 34 | 44 | 54 | 46 |
+0.1% | Low Risk · 32 | N/A | |
| 1986 | 46 |
LAA | High-A | OF | 35 | 43 | 50 | 36 |
+0.1% | Low Risk · 17 | N/A | |
| 1987 | 46 |
WSH | Single-A | 2B | 35 | 46 | 57 | 49 |
0.0% | Medium Risk · 43 | N/A | |
| 1988 | 46 |
STL | DSL | SS | 33 | 43 | 57 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 1989 | 46 |
NYM | High-A | RF | 36 | 42 | 49 | 40 |
+0.2% | Low Risk · 10 | N/A | |
| 1990 | 46 |
CLE | Single-A | P | 37 | 44 | 51 | 41 |
0.0% | Low Risk · 28 | N/A | |
| 1991 | 46 |
MIL | DSL | SS | 34 | 45 | 55 | 48 |
+0.1% | Medium Risk · 47 | N/A | |
| 1992 | 46 |
LAD | High-A | P | 37 | 44 | 52 | 41 |
0.0% | Low Risk · 34 | N/A | |
| 1993 | 46 |
BAL | Single-A | P | 34 | 41 | 48 | 48 |
0.0% | Low Risk · 13 | N/A | |
| 1994 | 46 |
SEA | Single-A | 2B | 35 | 42 | 49 | 39 |
-0.1% | Low Risk · 12 | N/A | |
| 1995 | 46 |
NYM | Single-A | SS | 35 | 42 | 48 | 32 |
+0.1% | Low Risk · 0 | N/A | |
| 1996 | 46 |
TOR | Single-A | P | 35 | 43 | 51 | 44 |
0.0% | Low Risk · 28 | N/A | |
| 1997 | 46 |
HOU | High-A | P | 37 | 43 | 48 | 36 |
-0.2% | Low Risk · 20 | N/A | |
| 1998 | 46 |
BOS | Single-A | 3B | 35 | 42 | 49 | 40 |
+0.3% | Low Risk · 19 | N/A | |
| 1999 | 46 |
TEX | DSL | OF | 33 | 43 | 62 | 50 |
-0.2% | Medium Risk · 46 | N/A | |
| 2000 | IL(Full Season)46 |
DET | Single-A | PIL(Full Season) | 36 | 47 | 64 | 54 |
0.0% | Wide Range · 60 | N/A | |
| 2001 | 46 |
NYY | DSL | C | 33 | 44 | 55 | 48 |
-0.4% | Medium Risk · 42 | N/A | |
| 2002 | IL(Full Season)46 |
TEX | AA | CIL(Full Season) | 36 | 45 | 55 | 55 |
0.0% | Medium Risk · 46 | N/A | |
| 2003 | 46 |
MIA | Single-A | C | 35 | 45 | 55 | 49 |
0.0% | Low Risk · 33 | N/A | |
| 2004 | 46 |
TEX | ACL | C | 34 | 44 | 54 | 44 |
0.0% | Low Risk · 32 | N/A | |
| 2005 | 46 |
LAA | ACL | SS | 34 | 43 | 53 | 45 |
-0.1% | Low Risk · 37 | N/A | |
| 2006 | 46 |
SD | High-A | P | 35 | 46 | 57 | 51 |
0.0% | Medium Risk · 49 | N/A | |
| 2007 | 46 |
NYM | DSL | P | 33 | 44 | 62 | 48 |
0.0% | Medium Risk · 46 | N/A | |
| 2008 | 46 |
TB | DSL | IF | 33 | 43 | 53 | 46 |
+0.3% | Low Risk · 32 | N/A | |
| 2009 | 46 |
SD | AA | P | 37 | 48 | 58 | 54 |
+0.1% | Medium Risk · 51 | N/A | |
| 2010 | 46 |
SF | Single-A | SS | 36 | 41 | 47 | 37 |
-0.2% | Low Risk · 12 | N/A | |
| 2011 | 46 |
PIT | DSL | OF | 34 | 45 | 64 | 47 |
-0.2% | Medium Risk · 46 | N/A | |
| 2012 | 46 |
CHC | DSL | P | 34 | 45 | 63 | 46 |
-0.1% | Medium Risk · 42 | N/A | |
| 2013 | 46 |
ARI | DSL | P | 33 | 43 | 54 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 2014 | 46 |
LAA | AAA | 1B | 37 | 46 | 55 | 52 |
-1.4% | Low Risk · 40 | N/A | |
| 2015 | 46 |
LAD | High-A | LF | 36 | 46 | 56 | 49 |
-0.1% | Low Risk · 37 | N/A | |
| 2016 | 46 |
TB | Single-A | P | 35 | 43 | 50 | 43 |
0.0% | Low Risk · 28 | N/A | |
| 2017 | 46 |
SEA | AA | 3B | 37 | 43 | 50 | 46 |
+0.1% | Low Risk · 29 | N/A | |
| 2018 | 46 |
SF | ACL | C | 33 | 44 | 53 | 47 |
0.0% | Low Risk · 37 | N/A | |
| 2019 | 46 |
MIN | DSL | IF | 34 | 44 | 55 | 46 |
-0.2% | Low Risk · 32 | N/A | |
| 2020 | 46 |
TB | Single-A | 1B | 33 | 42 | 52 | 47 |
0.0% | Low Risk · 20 | N/A | |
| 2021 | 46 |
MIL | Single-A | P | 35 | 47 | 60 | 50 |
-24.9% | Medium Risk · 43 | N/A | |
| 2022 | 46 |
TOR | FCL | C | 34 | 45 | 55 | 47 |
-0.3% | Medium Risk · 42 | N/A | |
| 2023 | IL(60-Day)46 |
BAL | Single-A | PIL(60-Day) | 34 | 45 | 55 | 51 |
0.0% | Low Risk · 40 | N/A | |
| 2024 | 46 |
KC | High-A | 2B | 35 | 42 | 50 | 39 |
-0.1% | Low Risk · 15 | N/A | |
| 2025 | 46 |
DET | High-A | CF | 37 | 42 | 48 | 38 |
-0.1% | Low Risk · 26 | N/A | |
| 2026 | 46 |
LAD | Single-A | OF | 34 | 44 | 53 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 2027 | 46 |
TEX | Single-A | P | 35 | 42 | 49 | 37 |
0.0% | Low Risk · 14 | N/A | |
| 2028 | 46 |
KC | High-A | P | 35 | 43 | 51 | 36 |
0.0% | Low Risk · 20 | N/A | |
| 2029 | 46 |
SF | Single-A | P | 34 | 42 | 52 | 43 |
-0.3% | Low Risk · 12 | N/A | |
| 2030 | 46 |
BOS | Single-A | P | 36 | 42 | 50 | 42 |
0.0% | Low Risk · 26 | N/A | |
| 2031 | 46 |
BOS | High-A | P | 35 | 46 | 56 | 53 |
+0.1% | Medium Risk · 52 | N/A | |
| 2032 | 46 |
DET | Single-A | SS | 36 | 43 | 50 | 42 |
0.0% | Low Risk · 30 | N/A | |
| 2033 | 46 |
CIN | Single-A | P | 34 | 42 | 50 | 43 |
0.0% | Low Risk · 28 | N/A | |
| 2034 | 46 |
STL | AA | P | 37 | 44 | 53 | 41 |
0.0% | Low Risk · 21 | N/A | |
| 2035 | IL(Rehab)46 |
HOU | FCL | CIL(Rehab) | 44 | 57 | 71 | 38 |
0.0% | Medium Risk · 54 | N/A | |
| 2036 | 46 |
ATL | FCL | OF | 34 | 46 | 57 | 48 |
0.0% | Medium Risk · 47 | N/A | |
| 2037 | 46 |
TEX | AAA | SS | 38 | 46 | 54 | 47 |
+0.2% | Medium Risk · 44 | N/A | |
| 2038 | 46 |
MIN | Single-A | P | 33 | 41 | 50 | 47 |
0.0% | Low Risk · 13 | N/A | |
| 2039 | 46 |
ARI | High-A | P | 36 | 43 | 50 | 37 |
0.0% | Low Risk · 20 | N/A | |
| 2040 | 46 |
CLE | DSL | C | 34 | 44 | 54 | 44 |
+0.1% | Low Risk · 32 | N/A | |
| 2041 | 46 |
NYM | DSL | P | 32 | 43 | 59 | 49 |
0.0% | Medium Risk · 46 | N/A | |
| 2042 | 46 |
ATL | FCL | SS | 34 | 43 | 51 | 44 |
-0.4% | Low Risk · 29 | N/A | |
| 2043 | 46 |
NYM | DSL | P | 34 | 45 | 56 | 46 |
-0.4% | Medium Risk · 42 | N/A | |
| 2044 | 46 |
SD | Single-A | P | 36 | 43 | 50 | 41 |
0.0% | Low Risk · 28 | N/A | |
| 2045 | 46 |
ARI | High-A | C | 34 | 45 | 55 | 50 |
-0.4% | Low Risk · 33 | N/A | |
| 2046 | 46 |
PIT | Single-A | P | 34 | 45 | 55 | 50 |
+0.1% | Medium Risk · 42 | N/A | |
| 2047 | 46 |
COL | DSL | IF | 34 | 44 | 53 | 45 |
-0.2% | Low Risk · 32 | N/A | |
| 2048 | 46 |
SD | Single-A | P | 35 | 42 | 50 | 36 |
-0.1% | Low Risk · 14 | N/A | |
| 2049 | 46 |
CIN | High-A | P | 35 | 45 | 63 | 50 |
0.0% | Low Risk · 38 | N/A | |
| 2050 | 46 |
PIT | DSL | P | 33 | 43 | 55 | 45 |
0.0% | Low Risk · 32 | N/A | |
| 2051 | 46 |
ATL | FCL | CF | 34 | 43 | 51 | 41 |
-0.1% | Low Risk · 24 | N/A | |
| 2052 | 45 |
NYM | DSL | SS | 34 | 46 | 57 | 46 |
0.0% | Medium Risk · 47 | N/A | |
| 2053 | 45 |
TOR | Single-A | C | 35 | 45 | 63 | 47 |
-0.2% | Low Risk · 30 | N/A | |
| 2054 | 45 |
MIN | FCL | P | 35 | 47 | 58 | 49 |
0.0% | Medium Risk · 52 | N/A | |
| 2055 | IL(60-Day)45 |
COL | Single-A | CIL(60-Day) | 36 | 46 | 64 | 50 |
0.0% | Medium Risk · 42 | N/A | |
| 2056 | 45 |
TOR | DSL | SS | 34 | 44 | 53 | 46 |
0.0% | Low Risk · 37 | N/A | |
| 2057 | 45 |
NYM | DSL | SS | 33 | 45 | 60 | 50 |
0.0% | Medium Risk · 56 | N/A | |
| 2058 | 45 |
CLE | Single-A | P | 40 | 49 | 68 | 48 |
+0.2% | Medium Risk · 50 | N/A | |
| 2059 | 45 |
TOR | Single-A | IF | 35 | 45 | 62 | 49 |
-0.1% | Medium Risk · 46 | N/A | |
| 2060 | 45 |
KC | DSL | C | 33 | 44 | 54 | 47 |
+0.1% | Medium Risk · 42 | N/A | |
| 2061 | 45 |
MIA | DSL | OF | 33 | 44 | 61 | 46 |
0.0% | Medium Risk · 42 | N/A | |
| 2062 | 45 |
LAA | ACL | P | 36 | 45 | 56 | 45 |
0.0% | Medium Risk · 48 | N/A | |
| 2063 | 45 |
WSH | High-A | P | 35 | 43 | 51 | 44 |
-0.1% | Low Risk · 24 | N/A | |
| 2064 | IL(Full Season)45 |
LAD | AA | CIL(Full Season) | 35 | 46 | 55 | 54 |
0.0% | Medium Risk · 47 | N/A | |
| 2065 | 45 |
TEX | High-A | P | 36 | 45 | 64 | 48 |
-0.2% | Low Risk · 38 | N/A | |
| 2066 | 45 |
TOR | High-A | 2B | 34 | 45 | 55 | 49 |
-0.1% | Low Risk · 29 | N/A | |
| 2067 | 45 |
CWS | AAA | P | 37 | 43 | 58 | 58 |
-0.1% | Low Risk · 24 | N/A | |
| 2068 | 45 |
MIL | ACL | SS | 35 | 43 | 52 | 42 |
-0.3% | Low Risk · 40 | N/A | |
| 2069 | 45 |
ATL | Single-A | RF | 35 | 42 | 49 | 36 |
-0.1% | Low Risk · 16 | N/A | |
| 2070 | 45 |
HOU | DSL | C | 33 | 44 | 54 | 47 |
+0.2% | Medium Risk · 42 | N/A | |
| 2071 | 45 |
LAA | DSL | IF | 33 | 44 | 57 | 46 |
0.0% | Medium Risk · 42 | N/A | |
| 2072 | 45 |
NYY | High-A | P | 35 | 45 | 61 | 49 |
-0.1% | Low Risk · 38 | N/A | |
| 2073 | 45 |
SF | ACL | P | 35 | 45 | 53 | 39 |
0.0% | Medium Risk · 48 | N/A | |
| 2074 | 45 |
LAD | AA | CF | 39 | 44 | 50 | 41 |
-0.1% | Low Risk · 35 | N/A | |
| 2075 | 45 |
SEA | ACL | P | 33 | 42 | 53 | 50 |
-0.5% | Low Risk · 32 | N/A | |
| 2076 | 45 |
CLE | DSL | SS | 33 | 43 | 53 | 46 |
0.0% | Low Risk · 37 | N/A | |
| 2077 | 45 |
BOS | FCL | CF | 33 | 43 | 56 | 47 |
+0.1% | Low Risk · 40 | N/A | |
| 2078 | IL(Rehab)45 |
MIN | Single-A | PIL(Rehab) | 35 | 47 | 58 | 49 |
0.0% | Medium Risk · 43 | N/A | |
| 2079 | 45 |
CWS | ACL | C | 36 | 46 | 55 | 44 |
+0.1% | Medium Risk · 49 | N/A | |
| 2080 | 45 |
TB | DSL | P | 33 | 45 | 63 | 48 |
-0.1% | Medium Risk · 52 | N/A | |
| 2081 | 45 |
TB | High-A | SS | 35 | 44 | 52 | 42 |
+0.1% | Low Risk · 20 | N/A | |
| 2082 | 45 |
TB | FCL | P | 34 | 44 | 62 | 45 |
+0.1% | Low Risk · 40 | N/A | |
| 2083 | 45 |
PIT | DSL | SS | 33 | 43 | 53 | 44 |
0.0% | Low Risk · 32 | N/A | |
| 2084 | 45 |
SF | DSL | IF | 32 | 42 | 52 | 46 |
+0.2% | Low Risk · 37 | N/A | |
| 2085 | 45 |
COL | Single-A | C | 35 | 41 | 48 | 39 |
0.0% | Low Risk · 12 | N/A | |
| 2086 | 45 |
KC | DSL | SS | 32 | 42 | 52 | 47 |
0.0% | Low Risk · 37 | N/A | |
| 2087 | 45 |
MIA | High-A | P | 34 | 45 | 55 | 50 |
+0.1% | Low Risk · 38 | N/A | |
| 2088 | 45 |
ATH | High-A | C | 35 | 42 | 49 | 38 |
0.0% | Low Risk · 19 | N/A | |
| 2089 | 45 |
DET | DSL | C | 33 | 44 | 56 | 46 |
-0.4% | Medium Risk · 42 | N/A | |
| 2090 | 45 |
TB | High-A | OF | 35 | 43 | 50 | 40 |
0.0% | Low Risk · 26 | N/A | |
| 2091 | 45 |
BAL | DSL | P | 33 | 43 | 59 | 46 |
-0.1% | Medium Risk · 42 | N/A | |
| 2092 | 45 |
LAD | DSL | IF | 33 | 43 | 53 | 46 |
+0.1% | Low Risk · 37 | N/A | |
| 2093 | 45 |
DET | AA | CF | 37 | 42 | 47 | 35 |
-0.1% | Low Risk · 10 | N/A | |
| 2094 | 45 |
CHC | High-A | P | 35 | 42 | 49 | 40 |
-0.2% | Low Risk · 10 | N/A | |
| 2095 | 45 |
CIN | DSL | IF | 33 | 43 | 53 | 46 |
-0.1% | Low Risk · 37 | N/A | |
| 2096 | 45 |
TEX | AAA | LF | 37 | 41 | 47 | 46 |
0.0% | Low Risk · 19 | N/A | |
| 2097 | 45 |
CHC | ACL | LF | 35 | 44 | 58 | 50 |
-0.5% | Medium Risk · 48 | N/A | |
| 2098 | 45 |
LAA | DSL | SS | 34 | 44 | 59 | 47 |
+0.1% | Medium Risk · 48 | N/A | |
| 2099 | 45 |
BAL | DSL | OF | 32 | 43 | 53 | 48 |
-0.1% | Medium Risk · 46 | N/A | |
| 2100 | 45 |
MIA | AAA | SS | 37 | 42 | 47 | 46 |
0.0% | Low Risk · 19 | N/A | |
| 2101 | 45 |
TOR | High-A | 1B | 34 | 40 | 47 | 45 |
0.0% | Low Risk · 12 | N/A | |
| 2102 | 45 |
COL | ACL | P | 33 | 42 | 56 | 47 |
-0.1% | Low Risk · 40 | N/A | |
| 2103 | 45 |
PIT | DSL | OF | 33 | 44 | 54 | 46 |
-0.1% | Medium Risk · 42 | N/A | |
| 2104 | 45 |
TOR | DSL | IF | 33 | 43 | 53 | 45 |
0.0% | Low Risk · 37 | N/A | |
| 2105 | 45 |
ARI | DSL | 1B | 33 | 42 | 51 | 46 |
-0.3% | Low Risk · 37 | N/A | |
| 2106 | 45 |
CLE | High-A | C | 35 | 46 | 57 | 51 |
0.0% | Medium Risk · 44 | N/A | |
| 2107 | 45 |
MIN | AA | P | 37 | 45 | 52 | 37 |
+0.2% | Low Risk · 34 | N/A | |
| 2108 | 45 |
CIN | Single-A | P | 34 | 42 | 49 | 38 |
-0.2% | Low Risk · 12 | N/A | |
| 2109 | 45 |
TEX | DSL | OF | 32 | 43 | 55 | 46 |
-0.2% | Low Risk · 32 | N/A | |
| 2110 | 45 |
ATH | AA | LF | 37 | 41 | 47 | 41 |
-0.3% | Low Risk · 17 | N/A | |
| 2111 | 45 |
SEA | High-A | 3B | 35 | 41 | 48 | 37 |
+0.1% | Low Risk · 10 | N/A | |
| 2112 | 45 |
SD | High-A | P | 36 | 41 | 46 | 39 |
0.0% | Low Risk · 24 | N/A | |
| 2113 | 45 |
NYM | Single-A | P | 35 | 46 | 63 | 51 |
0.0% | Medium Risk · 56 | N/A | |
| 2114 | 45 |
ATL | DSL | SS | 32 | 43 | 58 | 47 |
0.0% | Medium Risk · 42 | N/A | |
| 2115 | 45 |
SF | Single-A | P | 35 | 41 | 49 | 42 |
0.0% | Low Risk · 12 | N/A | |
| 2116 | 45 |
PHI | FCL | P | 35 | 45 | 55 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2117 | 45 |
CLE | High-A | P | 36 | 47 | 58 | 51 |
+0.1% | Medium Risk · 49 | N/A | |
| 2118 | 45 |
KC | AA | P | 36 | 44 | 50 | 34 |
+0.1% | Low Risk · 20 | N/A | |
| 2119 | 45 |
CHC | DSL | SS | 33 | 43 | 52 | 42 |
+0.1% | Low Risk · 37 | N/A | |
| 2120 | 45 |
PIT | FCL | SS | 33 | 43 | 51 | 41 |
-0.1% | Low Risk · 29 | N/A | |
| 2121 | 45 |
CLE | DSL | OF | 33 | 43 | 53 | 44 |
-0.4% | Low Risk · 32 | N/A | |
| 2122 | 45 |
PIT | Single-A | P | 35 | 43 | 50 | 39 |
-0.1% | Low Risk · 22 | N/A | |
| 2123 | 45 |
TEX | AA | C | 37 | 42 | 47 | 34 |
0.0% | Low Risk · 10 | N/A | |
| 2124 | 45 |
TB | High-A | OF | 34 | 44 | 57 | 48 |
+0.1% | Low Risk · 28 | N/A | |
| 2125 | 45 |
SEA | Single-A | C | 36 | 42 | 50 | 42 |
0.0% | Low Risk · 28 | N/A | |
| 2126 | 45 |
LAA | ACL | LF | 33 | 43 | 57 | 48 |
-0.1% | Medium Risk · 46 | N/A | |
| 2127 | 45 |
HOU | FCL | OF | 33 | 43 | 60 | 46 |
0.0% | Low Risk · 40 | N/A | |
| 2128 | 45 |
NYM | FCL | 1B | 33 | 43 | 53 | 45 |
-0.3% | Low Risk · 37 | N/A | |
| 2129 | 45 |
TEX | Single-A | 2B | 34 | 41 | 48 | 32 |
0.0% | Low Risk · 5 | N/A | |
| 2130 | 45 |
MIA | DSL | IF | 33 | 43 | 55 | 45 |
-0.2% | Low Risk · 32 | N/A | |
| 2131 | 45 |
NYY | DSL | SS | 33 | 43 | 55 | 43 |
0.0% | Low Risk · 32 | N/A | |
| 2132 | 45 |
TOR | Single-A | OF | 35 | 42 | 50 | 41 |
0.0% | Low Risk · 28 | N/A | |
| 2133 | 45 |
LAA | DSL | SS | 33 | 44 | 57 | 47 |
+0.1% | Medium Risk · 42 | N/A | |
| 2134 | 45 |
COL | AA | P | 36 | 47 | 56 | 51 |
0.0% | Medium Risk · 48 | N/A | |
| 2135 | 45 |
TB | Single-A | P | 36 | 43 | 52 | 40 |
0.0% | Low Risk · 22 | N/A | |
| 2136 | 45 |
TB | DSL | C | 33 | 42 | 52 | 44 |
0.0% | Low Risk · 32 | N/A | |
| 2137 | 45 |
CLE | ACL | SS | 33 | 43 | 53 | 43 |
-0.1% | Low Risk · 32 | N/A | |
| 2138 | 45 |
DET | Single-A | P | 35 | 42 | 49 | 34 |
0.0% | Low Risk · 10 | N/A | |
| 2139 | 45 |
KC | Single-A | 3B | 34 | 41 | 48 | 37 |
-0.3% | Low Risk · 14 | N/A | |
| 2140 | 45 |
CHC | DSL | IF | 33 | 43 | 53 | 44 |
-0.1% | Low Risk · 37 | N/A | |
| 2141 | 45 |
PHI | High-A | P | 34 | 44 | 60 | 47 |
0.0% | Low Risk · 38 | N/A | |
| 2142 | 45 |
CIN | DSL | C | 32 | 43 | 57 | 46 |
0.0% | Medium Risk · 42 | N/A | |
| 2143 | 45 |
CIN | DSL | OF | 32 | 43 | 58 | 46 |
0.0% | Medium Risk · 42 | N/A | |
| 2144 | 45 |
SD | DSL | C | 33 | 43 | 52 | 44 |
-0.2% | Low Risk · 32 | N/A | |
| 2145 | 45 |
ARI | High-A | CF | 36 | 41 | 47 | 34 |
0.0% | Low Risk · 19 | N/A | |
| 2146 | 45 |
NYY | Single-A | CF | 34 | 41 | 48 | 31 |
0.0% | Low Risk · 5 | N/A | |
| 2147 | 45 |
HOU | DSL | OF | 34 | 47 | 67 | 49 |
-0.3% | Medium Risk · 57 | N/A | |
| 2148 | 45 |
ATL | Single-A | P | 35 | 46 | 57 | 51 |
0.0% | Medium Risk · 53 | N/A | |
| 2149 | 45 |
COL | ACL | P | 33 | 42 | 51 | 41 |
0.0% | Low Risk · 24 | N/A | |
| 2150 | 45 |
KC | ACL | 1B | 33 | 42 | 59 | 46 |
-0.2% | Low Risk · 40 | N/A | |
| 2151 | 45 |
TEX | DSL | OF | 32 | 43 | 54 | 47 |
-0.4% | Medium Risk · 47 | N/A | |
| 2152 | 45 |
BOS | Single-A | C | 34 | 42 | 50 | 43 |
0.0% | Low Risk · 20 | N/A | |
| 2153 | 45 |
DET | High-A | P | 37 | 43 | 49 | 32 |
-0.3% | Low Risk · 20 | N/A | |
| 2154 | 45 |
SF | ACL | P | 32 | 41 | 60 | 48 |
0.0% | Low Risk · 40 | N/A | |
| 2155 | 45 |
NYY | High-A | OF | 35 | 42 | 49 | 38 |
0.0% | Low Risk · 19 | N/A | |
| 2156 | 45 |
MIL | Single-A | C | 36 | 47 | 64 | 52 |
+0.1% | Medium Risk · 50 | N/A | |
| 2157 | 45 |
DET | FCL | P | 33 | 43 | 58 | 45 |
0.0% | Low Risk · 40 | N/A | |
| 2158 | 45 |
NYM | AAA | P | 38 | 46 | 54 | 47 |
0.0% | Medium Risk · 44 | N/A | |
| 2159 | 45 |
WSH | FCL | IF | 33 | 42 | 51 | 39 |
+0.1% | Low Risk · 29 | N/A | |
| 2160 | 45 |
NYY | Single-A | P | 34 | 41 | 49 | 42 |
0.0% | Low Risk · 12 | N/A | |
| 2161 | 45 |
LAD | ACL | P | 35 | 46 | 64 | 43 |
0.0% | Medium Risk · 42 | N/A | |
| 2162 | 45 |
ARI | ACL | OF | 34 | 44 | 54 | 43 |
+0.1% | Low Risk · 32 | N/A | |
| 2163 | 45 |
COL | DSL | P | 33 | 44 | 55 | 45 |
0.0% | Medium Risk · 42 | N/A | |
| 2164 | 45 |
CLE | Single-A | 2B | 33 | 45 | 56 | 52 |
+0.1% | Medium Risk · 54 | N/A | |
| 2165 | 45 |
DET | AA | 1B | 35 | 44 | 53 | 50 |
-0.1% | Low Risk · 29 | N/A | |
| 2166 | 45 |
KC | DSL | OF | 32 | 43 | 52 | 45 |
-0.4% | Low Risk · 37 | N/A | |
| 2167 | 45 |
CLE | AA | P | 34 | 44 | 53 | 49 |
-0.1% | Low Risk · 38 | N/A | |
| 2168 | 45 |
TOR | FCL | 3B | 33 | 42 | 51 | 41 |
0.0% | Low Risk · 32 | N/A | |
| 2169 | 45 |
COL | High-A | P | 37 | 42 | 48 | 37 |
0.0% | Low Risk · 34 | N/A | |
| 2170 | 45 |
PIT | FCL | C | 34 | 44 | 55 | 46 |
0.0% | Medium Risk · 48 | N/A | |
| 2171 | 45 |
SF | Single-A | C | 35 | 41 | 48 | 36 |
+0.2% | Low Risk · 14 | N/A | |
| 2172 | 45 |
STL | High-A | P | 35 | 44 | 53 | 42 |
-0.3% | Low Risk · 28 | N/A | |
| 2173 | 45 |
WSH | AA | P | 37 | 44 | 52 | 38 |
0.0% | Low Risk · 34 | N/A | |
| 2174 | 45 |
TOR | DSL | P | 32 | 43 | 54 | 46 |
0.0% | Medium Risk · 42 | N/A | |
| 2175 | 45 |
PHI | Single-A | P | 36 | 42 | 47 | 33 |
0.0% | Low Risk · 14 | N/A | |
| 2176 | 45 |
NYM | DSL | SS | 33 | 42 | 52 | 44 |
-0.3% | Low Risk · 37 | N/A | |
| 2177 | 45 |
CIN | AA | P | 37 | 41 | 46 | 39 |
-0.4% | Low Risk · 12 | N/A | |
| 2178 | 45 |
ARI | High-A | P | 36 | 47 | 64 | 50 |
0.0% | Medium Risk · 49 | N/A | |
| 2179 | 45 |
LAD | DSL | OF | 32 | 43 | 59 | 47 |
0.0% | Medium Risk · 46 | N/A | |
| 2180 | 45 |
CLE | High-A | P | 35 | 44 | 53 | 44 |
0.0% | Low Risk · 28 | N/A | |
| 2181 | 45 |
DET | Single-A | P | 35 | 42 | 49 | 37 |
0.0% | Low Risk · 12 | N/A | |
| 2182 | IL(Rehab)45 |
WSH | High-A | PIL(Rehab) | 34 | 44 | 61 | 48 |
-0.2% | Medium Risk · 42 | N/A | |
| 2183 | 45 |
TOR | DSL | P | 32 | 42 | 57 | 48 |
0.0% | Medium Risk · 46 | N/A | |
| 2184 | 45 |
HOU | DSL | P | 32 | 43 | 56 | 46 |
-0.5% | Medium Risk · 42 | N/A | |
| 2185 | 45 |
SF | ACL | IF | 33 | 42 | 50 | 36 |
0.0% | Low Risk · 29 | N/A | |
| 2186 | 45 |
TOR | AAA | P | 36 | 42 | 49 | 36 |
-0.1% | Low Risk · 25 | N/A | |
| 2187 | 45 |
CIN | High-A | 1B | 34 | 44 | 60 | 47 |
-0.1% | Low Risk · 28 | N/A | |
| 2188 | 45 |
DET | FCL | OF | 32 | 43 | 54 | 47 |
0.0% | Medium Risk · 47 | N/A | |
| 2189 | 45 |
WSH | Single-A | 1B | 35 | 42 | 50 | 40 |
-0.3% | Low Risk · 30 | N/A | |
| 2190 | 45 |
TOR | High-A | P | 35 | 45 | 54 | 47 |
0.0% | Low Risk · 38 | N/A | |
| 2191 | 45 |
COL | AA | P | 34 | 44 | 54 | 50 |
-0.4% | Low Risk · 38 | N/A | |
| 2192 | 45 |
DET | FCL | P | 33 | 42 | 52 | 41 |
0.0% | Low Risk · 32 | N/A | |
| 2193 | 45 |
CIN | Single-A | P | 34 | 42 | 50 | 42 |
-0.1% | Low Risk · 28 | N/A | |
| 2194 | 45 |
CHC | AA | P | 36 | 46 | 56 | 52 |
-0.1% | Medium Risk · 52 | N/A | |
| 2195 | 45 |
SD | AA | P | 36 | 47 | 56 | 52 |
0.0% | Wide Range · 62 | N/A | |
| 2196 | 44 |
MIN | High-A | P | 35 | 41 | 48 | 35 |
0.0% | Low Risk · 10 | N/A | |
| 2197 | 44 |
MIL | ACL | CF | 34 | 44 | 55 | 45 |
-0.1% | Medium Risk · 48 | N/A | |
| 2198 | 44 |
BOS | High-A | RF | 35 | 44 | 53 | 40 |
0.0% | Low Risk · 29 | N/A | |
| 2199 | 44 |
ATH | High-A | P | 35 | 43 | 50 | 33 |
-0.1% | Low Risk · 20 | N/A | |
| 2200 | 44 |
SEA | High-A | P | 34 | 42 | 50 | 40 |
0.0% | Low Risk · 24 | N/A | |
| 2201 | 44 |
TOR | High-A | P | 34 | 41 | 48 | 40 |
0.0% | Low Risk · 10 | N/A | |
| 2202 | 44 |
SF | AAA | P | 37 | 48 | 57 | 54 |
0.0% | Medium Risk · 53 | N/A | |
| 2203 | 44 |
DET | Single-A | 1B | 34 | 41 | 48 | 38 |
0.0% | Low Risk · 12 | N/A | |
| 2204 | 44 |
DET | AA | P | 36 | 43 | 51 | 42 |
+0.1% | Low Risk · 34 | N/A | |
| 2205 | 44 |
DET | High-A | C | 33 | 41 | 48 | 40 |
-0.1% | Low Risk · 10 | N/A | |
| 2206 | 44 |
TEX | High-A | P | 36 | 43 | 48 | 31 |
0.0% | Low Risk · 20 | N/A | |
| 2207 | 44 |
CLE | Single-A | P | 35 | 44 | 52 | 40 |
0.0% | Low Risk · 25 | N/A | |
| 2208 | IL(60-Day)44 |
SD | Single-A | 3BIL(60-Day) | 34 | 43 | 52 | 45 |
0.0% | Low Risk · 29 | N/A | |
| 2209 | 44 |
STL | DSL | IF | 33 | 43 | 52 | 43 |
-0.4% | Low Risk · 32 | N/A | |
| 2210 | 44 |
CHC | ACL | P | 32 | 41 | 54 | 47 |
0.0% | Low Risk · 32 | N/A | |
| 2211 | 44 |
HOU | DSL | IF | 32 | 42 | 51 | 43 |
+0.1% | Low Risk · 37 | N/A | |
| 2212 | 44 |
NYM | Single-A | P | 35 | 43 | 50 | 35 |
0.0% | Low Risk · 24 | N/A | |
| 2213 | 44 |
MIL | DSL | SS | 32 | 43 | 54 | 46 |
0.0% | Medium Risk · 42 | N/A | |
| 2214 | 44 |
SD | AA | 3B | 36 | 41 | 46 | 37 |
+0.1% | Low Risk · 11 | N/A | |
| 2215 | 44 |
CHC | ACL | OF | 42 | 56 | 66 | 35 |
0.0% | Medium Risk · 55 | N/A | |
| 2216 | 44 |
SF | High-A | P | 33 | 40 | 46 | 38 |
-0.2% | Low Risk · 10 | N/A | |
| 2217 | 44 |
ARI | Single-A | P | 34 | 42 | 55 | 43 |
0.0% | Low Risk · 20 | N/A | |
| 2218 | 44 |
WSH | High-A | P | 33 | 41 | 49 | 47 |
-0.8% | Low Risk · 25 | N/A | |
| 2219 | 44 |
SF | DSL | C | 32 | 43 | 57 | 45 |
0.0% | Medium Risk · 42 | N/A | |
| 2220 | 44 |
TEX | ACL | C | 33 | 43 | 53 | 44 |
0.0% | Low Risk · 32 | N/A | |
| 2221 | 44 |
NYY | DSL | OF | 32 | 43 | 55 | 47 |
0.0% | Medium Risk · 42 | N/A | |
| 2222 | 44 |
COL | High-A | P | 35 | 42 | 49 | 39 |
0.0% | Low Risk · 20 | N/A | |
| 2223 | 44 |
CLE | DSL | SS | 32 | 43 | 54 | 47 |
0.0% | Medium Risk · 47 | N/A | |
| 2224 | IL(7-Day)44 |
TOR | Single-A | OFIL(7-Day) | 33 | 44 | 54 | 48 |
-0.4% | Low Risk · 40 | N/A | |
| 2225 | 44 |
SF | High-A | P | 35 | 42 | 49 | 39 |
0.0% | Low Risk · 24 | N/A | |
| 2226 | 44 |
SF | AA | P | 36 | 46 | 55 | 51 |
0.0% | Medium Risk · 52 | N/A | |
| 2227 | 44 |
LAD | Single-A | P | 35 | 43 | 53 | 42 |
-0.3% | Low Risk · 36 | N/A | |
| 2228 | 44 |
SEA | High-A | SS | 34 | 41 | 48 | 34 |
0.0% | Low Risk · 15 | N/A | |
| 2229 | 44 |
STL | DSL | C | 32 | 43 | 60 | 45 |
-0.2% | Medium Risk · 42 | N/A | |
| 2230 | 44 |
MIL | High-A | P | 35 | 44 | 54 | 46 |
0.0% | Low Risk · 38 | N/A | |
| 2231 | 44 |
COL | DSL | OF | 33 | 43 | 53 | 44 |
+0.1% | Low Risk · 37 | N/A | |
| 2232 | 44 |
ARI | ACL | SS | 33 | 42 | 50 | 37 |
+0.3% | Low Risk · 29 | N/A | |
| 2233 | 44 |
ATL | AA | CF | 36 | 41 | 46 | 35 |
+0.1% | Low Risk · 11 | N/A | |
| 2234 | 44 |
ATH | High-A | SS | 33 | 40 | 48 | 40 |
-0.1% | Low Risk · 15 | N/A | |
| 2235 | 44 |
TEX | AAA | P | 36 | 47 | 57 | 55 |
-6.9% | Wide Range · 64 | N/A | |
| 2236 | 44 |
TOR | High-A | C | 33 | 44 | 57 | 47 |
0.0% | Low Risk · 28 | N/A | |
| 2237 | 44 |
MIN | AA | P | 36 | 42 | 47 | 30 |
-0.1% | Low Risk · 20 | N/A | |
| 2238 | 44 |
MIN | AAA | 1B | 36 | 41 | 49 | 53 |
-0.1% | Low Risk · 22 | N/A | |
| 2239 | 44 |
CWS | AA | P | 36 | 44 | 52 | 45 |
0.0% | Medium Risk · 42 | N/A | |
| 2240 | 44 |
BOS | High-A | P | 34 | 45 | 60 | 47 |
0.0% | Low Risk · 38 | N/A | |
| 2241 | 44 |
PHI | Single-A | P | 34 | 42 | 52 | 44 |
0.0% | Low Risk · 34 | N/A | |
| 2242 | 44 |
SD | High-A | C | 34 | 41 | 48 | 35 |
-0.4% | Low Risk · 19 | N/A | |
| 2243 | 44 |
TEX | DSL | P | 32 | 43 | 62 | 47 |
0.0% | Medium Risk · 46 | N/A | |
| 2244 | 44 |
PHI | Single-A | C | 33 | 41 | 49 | 39 |
0.0% | Low Risk · 13 | N/A | |
| 2245 | 44 |
SD | High-A | 3B | 33 | 43 | 53 | 47 |
-0.1% | Low Risk · 28 | N/A | |
| 2246 | 44 |
TB | DSL | SS | 32 | 43 | 54 | 44 |
0.0% | Medium Risk · 42 | N/A | |
| 2247 | 44 |
KC | ACL | C | 33 | 43 | 53 | 43 |
0.0% | Low Risk · 37 | N/A | |
| 2248 | 44 |
PIT | DSL | SS | 32 | 43 | 52 | 44 |
+0.1% | Low Risk · 37 | N/A | |
| 2249 | 44 |
HOU | FCL | C | 34 | 47 | 68 | 48 |
-0.1% | Medium Risk · 57 | N/A | |
| 2250 | 44 |
SF | ACL | P | 32 | 42 | 56 | 44 |
0.0% | Low Risk · 32 | N/A | |
| 2251 | 44 |
TB | FCL | P | 34 | 43 | 52 | 47 |
0.0% | Medium Risk · 46 | N/A | |
| 2252 | 44 |
TB | DSL | SS | 34 | 47 | 60 | 43 |
0.0% | Wide Range · 64 | N/A | |
| 2253 | 44 |
CWS | ACL | OF | 34 | 44 | 54 | 41 |
+0.1% | Low Risk · 37 | N/A | |
| 2254 | 44 |
HOU | DSL | OF | 31 | 42 | 52 | 47 |
0.0% | Medium Risk · 42 | N/A | |
| 2255 | 44 |
NYY | DSL | SS | 33 | 42 | 51 | 43 |
-0.1% | Medium Risk · 48 | N/A | |
| 2256 | 44 |
TOR | High-A | C | 33 | 44 | 55 | 49 |
0.0% | Medium Risk · 45 | N/A | |
| 2257 | 44 |
TEX | DSL | P | 33 | 44 | 64 | 47 |
-0.2% | Medium Risk · 56 | N/A | |
| 2258 | 44 |
MIA | FCL | P | 32 | 42 | 59 | 49 |
-0.3% | Medium Risk · 54 | N/A | |
| 2259 | 44 |
CIN | DSL | OF | 32 | 42 | 51 | 44 |
0.0% | Low Risk · 37 | N/A | |
| 2260 | 44 |
MIN | High-A | P | 35 | 42 | 52 | 36 |
0.0% | Low Risk · 20 | N/A | |
| 2261 | 44 |
PIT | Single-A | OF | 34 | 42 | 48 | 31 |
-0.1% | Low Risk · 16 | N/A | |
| 2262 | 44 |
BAL | AA | 3B | 35 | 42 | 49 | 36 |
+0.1% | Low Risk · 26 | N/A | |
| 2263 | 44 |
CHC | Single-A | SS | 34 | 41 | 48 | 29 |
+0.1% | Low Risk · 9 | N/A | |
| 2264 | 44 |
STL | Single-A | P | 34 | 45 | 62 | 47 |
+0.1% | Low Risk · 40 | N/A | |
| 2265 | 44 |
MIN | FCL | SS | 33 | 43 | 52 | 43 |
-0.4% | Low Risk · 40 | N/A | |
| 2266 | 44 |
SD | ACL | OF | 32 | 41 | 50 | 44 |
0.0% | Low Risk · 32 | N/A | |
| 2267 | 44 |
HOU | FCL | SS | 33 | 41 | 50 | 39 |
0.0% | Low Risk · 29 | N/A | |
| 2268 | 44 |
ARI | DSL | P | 32 | 42 | 54 | 43 |
0.0% | Low Risk · 32 | N/A | |
| 2269 | 44 |
PHI | DSL | P | 34 | 47 | 68 | 47 |
-0.2% | Wide Range · 66 | N/A | |
| 2270 | 44 |
NYM | DSL | P | 31 | 42 | 59 | 47 |
-0.1% | Medium Risk · 46 | N/A | |
| 2271 | 44 |
TB | Single-A | P | 34 | 42 | 54 | 41 |
-0.2% | Low Risk · 20 | N/A | |
| 2272 | 44 |
KC | AAA | P | 35 | 43 | 49 | 31 |
-0.3% | Low Risk · 20 | N/A | |
| 2273 | 44 |
HOU | Single-A | OF | 34 | 41 | 48 | 37 |
0.0% | Low Risk · 19 | N/A | |
| 2274 | 44 |
PHI | High-A | CF | 34 | 40 | 47 | 35 |
0.0% | Low Risk · 15 | N/A | |
| 2275 | 44 |
KC | ACL | OF | 32 | 43 | 53 | 46 |
+0.2% | Medium Risk · 42 | N/A | |
| 2276 | 44 |
NYM | Single-A | P | 35 | 42 | 50 | 39 |
0.0% | Low Risk · 26 | N/A | |
| 2277 | 44 |
NYM | High-A | SS | 36 | 42 | 48 | 32 |
-0.2% | Low Risk · 21 | N/A | |
| 2278 | 44 |
STL | High-A | P | 34 | 41 | 48 | 33 |
+0.2% | Low Risk · 10 | N/A | |
| 2279 | 44 |
TOR | High-A | 1B | 34 | 42 | 49 | 32 |
+0.1% | Low Risk · 21 | N/A | |
| 2280 | 44 |
STL | High-A | P | 35 | 42 | 53 | 38 |
-0.3% | Low Risk · 20 | N/A | |
| 2281 | 44 |
SF | DSL | SS | 31 | 41 | 54 | 48 |
0.0% | Medium Risk · 46 | N/A | |
| 2282 | 44 |
BOS | High-A | P | 35 | 46 | 57 | 48 |
0.0% | Medium Risk · 52 | N/A | |
| 2283 | 44 |
NYY | DSL | OF | 32 | 43 | 61 | 45 |
0.0% | Medium Risk · 42 | N/A | |
| 2284 | 44 |
COL | DSL | IF | 32 | 42 | 52 | 44 |
-0.2% | Low Risk · 37 | N/A | |
| 2285 | 44 |
COL | Single-A | P | 34 | 41 | 48 | 35 |
0.0% | Low Risk · 14 | N/A | |
| 2286 | 44 |
LAA | Single-A | 3B | 33 | 43 | 60 | 46 |
-0.4% | Low Risk · 30 | N/A | |
| 2287 | 44 |
KC | AA | P | 37 | 43 | 48 | 32 |
0.0% | Low Risk · 20 | N/A | |
| 2288 | 44 |
ATH | High-A | SS | 34 | 40 | 47 | 39 |
0.0% | Low Risk · 15 | N/A | |
| 2289 | 44 |
NYM | High-A | OF | 36 | 42 | 48 | 31 |
0.0% | Low Risk · 21 | N/A | |
| 2290 | 44 |
DET | Single-A | P | 33 | 40 | 48 | 41 |
-0.4% | Low Risk · 26 | N/A | |
| 2291 | 44 |
NYM | DSL | IF | 32 | 42 | 51 | 43 |
-0.1% | Low Risk · 32 | N/A | |
| 2292 | IL(Rehab)44 |
DET | High-A | PIL(Rehab) | 35 | 45 | 63 | 49 |
0.0% | Medium Risk · 42 | N/A | |
| 2293 | 44 |
HOU | AA | P | 36 | 41 | 47 | 37 |
0.0% | Low Risk · 24 | N/A | |
| 2294 | 44 |
TEX | DSL | C | 32 | 42 | 52 | 44 |
0.0% | Low Risk · 37 | N/A | |
| 2295 | 44 |
TB | DSL | OF | 32 | 41 | 51 | 44 |
0.0% | Low Risk · 37 | N/A | |
| 2296 | 44 |
CHC | Single-A | SS | 34 | 41 | 48 | 33 |
+0.6% | Low Risk · 16 | N/A | |
| 2297 | 44 |
HOU | AA | P | 35 | 43 | 52 | 44 |
+0.1% | Medium Risk · 42 | N/A | |
| 2298 | 44 |
TB | High-A | P | 31 | 40 | 49 | 47 |
0.0% | Low Risk · 19 | N/A | |
| 2299 | 44 |
CWS | Single-A | P | 36 | 46 | 64 | 48 |
0.0% | Medium Risk · 53 | N/A | |
| 2300 | 44 |
CHC | High-A | P | 34 | 41 | 48 | 36 |
0.0% | Low Risk · 24 | N/A | |
| 2301 | 44 |
CIN | Single-A | 1B | 34 | 46 | 62 | 51 |
0.0% | Medium Risk · 48 | N/A | |
| 2302 | 44 |
PHI | Single-A | P | 34 | 44 | 58 | 45 |
0.0% | Low Risk · 40 | N/A | |
| 2303 | 44 |
MIA | AA | P | 36 | 44 | 52 | 41 |
+0.3% | Low Risk · 34 | N/A | |
| 2304 | 44 |
COL | DSL | C | 31 | 41 | 54 | 48 |
0.0% | Medium Risk · 46 | N/A | |
| 2305 | 44 |
STL | High-A | P | 33 | 41 | 49 | 40 |
0.0% | Low Risk · 24 | N/A | |
| 2306 | IL(Rehab)44 |
NYY | FCL | SSIL(Rehab) | 40 | 56 | 67 | 40 |
0.0% | High Risk · 76 | N/A | |
| 2307 | 44 |
SD | DSL | OF | 33 | 45 | 60 | 47 |
0.0% | Medium Risk · 56 | N/A | |
| 2308 | 44 |
MIL | High-A | P | 34 | 42 | 49 | 36 |
0.0% | Low Risk · 24 | N/A | |
| 2309 | 44 |
NYY | AA | P | 36 | 45 | 56 | 46 |
0.0% | Medium Risk · 43 | N/A | |
| 2310 | 44 |
TOR | FCL | RF | 32 | 42 | 56 | 46 |
+0.1% | Medium Risk · 46 | N/A | |
| 2311 | 44 |
TB | Single-A | P | 33 | 41 | 50 | 45 |
+0.3% | Low Risk · 26 | N/A | |
| 2312 | 44 |
MIN | High-A | OF | 37 | 46 | 65 | 50 |
0.0% | Medium Risk · 45 | N/A | |
| 2313 | 44 |
NYM | FCL | SS | 33 | 42 | 51 | 41 |
-0.4% | Low Risk · 40 | N/A | |
| 2314 | 44 |
ATH | AAA | P | 36 | 41 | 46 | 35 |
0.0% | Low Risk · 23 | N/A | |
| 2315 | 44 |
NYY | Single-A | OF | 33 | 43 | 52 | 44 |
-0.1% | Low Risk · 32 | N/A | |
| 2316 | 44 |
NYM | High-A | P | 33 | 40 | 48 | 40 |
+0.1% | Low Risk · 10 | N/A | |
| 2317 | 44 |
WSH | AA | P | 35 | 44 | 53 | 47 |
+0.1% | Medium Risk · 42 | N/A | |
| 2318 | 44 |
ARI | ACL | SS | 32 | 43 | 53 | 46 |
0.0% | Medium Risk · 47 | N/A | |
| 2319 | 44 |
KC | DSL | SS | 31 | 42 | 54 | 47 |
+0.1% | Medium Risk · 46 | N/A | |
| 2320 | 44 |
NYM | DSL | C | 32 | 42 | 53 | 45 |
-0.1% | Medium Risk · 42 | N/A | |
| 2321 | 44 |
ARI | Single-A | P | 33 | 40 | 47 | 36 |
0.0% | Low Risk · 12 | N/A | |
| 2322 | 44 |
SD | High-A | P | 34 | 43 | 51 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2323 | 44 |
ARI | Single-A | P | 34 | 42 | 52 | 39 |
-0.3% | Low Risk · 22 | N/A | |
| 2324 | 44 |
NYM | DSL | SS | 32 | 41 | 50 | 42 |
+0.1% | Low Risk · 32 | N/A | |
| 2325 | 44 |
MIL | High-A | SS | 33 | 43 | 54 | 49 |
-0.1% | Medium Risk · 42 | N/A | |
| 2326 | 44 |
MIA | DSL | OF | 32 | 42 | 52 | 43 |
+0.1% | Low Risk · 37 | N/A | |
| 2327 | 44 |
ATH | AA | P | 34 | 43 | 53 | 50 |
-0.1% | Low Risk · 39 | N/A | |
| 2328 | 44 |
SEA | Single-A | P | 35 | 42 | 50 | 37 |
0.0% | Low Risk · 22 | N/A | |
| 2329 | 44 |
LAA | Single-A | P | 35 | 42 | 49 | 36 |
-0.4% | Low Risk · 22 | N/A | |
| 2330 | 44 |
TOR | DSL | C | 32 | 42 | 51 | 42 |
-0.1% | Low Risk · 32 | N/A | |
| 2331 | 44 |
CWS | ACL | OF | 32 | 42 | 51 | 42 |
-0.3% | Low Risk · 37 | N/A | |
| 2332 | 44 |
LAD | AA | P | 37 | 42 | 47 | 33 |
-0.4% | Low Risk · 34 | N/A | |
| 2333 | 44 |
PHI | Single-A | RF | 34 | 41 | 49 | 44 |
+0.1% | Low Risk · 28 | N/A | |
| 2334 | 44 |
PHI | High-A | P | 34 | 41 | 48 | 38 |
0.0% | Low Risk · 11 | N/A | |
| 2335 | 44 |
CWS | High-A | P | 34 | 40 | 47 | 35 |
0.0% | Low Risk · 10 | N/A | |
| 2336 | 44 |
MIA | DSL | P | 33 | 44 | 62 | 44 |
+0.1% | Medium Risk · 46 | N/A | |
| 2337 | 44 |
BAL | DSL | OF | 32 | 42 | 51 | 44 |
-0.1% | Low Risk · 37 | N/A | |
| 2338 | 44 |
SD | DSL | IF | 32 | 41 | 51 | 43 |
0.0% | Low Risk · 37 | N/A | |
| 2339 | 44 |
HOU | Single-A | SS | 32 | 43 | 53 | 47 |
0.0% | Low Risk · 35 | N/A | |
| 2340 | 44 |
LAA | High-A | P | 34 | 43 | 51 | 40 |
0.0% | Low Risk · 34 | N/A | |
| 2341 | 44 |
CWS | High-A | P | 34 | 41 | 48 | 34 |
-0.3% | Low Risk · 10 | N/A | |
| 2342 | 44 |
DET | DSL | OF | 32 | 42 | 52 | 43 |
+0.1% | Medium Risk · 48 | N/A | |
| 2343 | 44 |
LAD | DSL | SS | 32 | 42 | 51 | 42 |
+0.1% | Low Risk · 32 | N/A | |
| 2344 | 43 |
PIT | AA | C | 35 | 46 | 56 | 50 |
0.0% | Medium Risk · 53 | N/A | |
| 2345 | 43 |
BAL | DSL | IF | 33 | 43 | 53 | 45 |
0.0% | Medium Risk · 48 | N/A | |
| 2346 | 43 |
SF | DSL | C | 34 | 48 | 61 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2347 | 43 |
LAD | Single-A | P | 34 | 45 | 60 | 48 |
0.0% | Medium Risk · 52 | N/A | |
| 2348 | 43 |
DET | High-A | SS | 35 | 43 | 51 | 30 |
0.0% | Low Risk · 30 | N/A | |
| 2349 | 43 |
BOS | FCL | SS | 31 | 42 | 52 | 43 |
0.0% | Medium Risk · 47 | N/A | |
| 2350 | 43 |
PIT | High-A | P | 34 | 42 | 50 | 35 |
-0.1% | Low Risk · 20 | N/A | |
| 2351 | 43 |
CWS | High-A | P | 33 | 41 | 48 | 38 |
0.0% | Low Risk · 10 | N/A | |
| 2352 | 43 |
SEA | High-A | C | 33 | 40 | 50 | 46 |
-0.1% | Low Risk · 29 | N/A | |
| 2353 | IL(60-Day)43 |
MIN | Single-A | PIL(60-Day) | 33 | 44 | 59 | 50 |
0.0% | Medium Risk · 54 | N/A | |
| 2354 | 43 |
KC | AA | OF | 33 | 43 | 52 | 50 |
0.0% | Low Risk · 34 | N/A | |
| 2355 | 43 |
CIN | High-A | RF | 34 | 42 | 50 | 37 |
0.0% | Low Risk · 21 | N/A | |
| 2356 | 43 |
ATH | High-A | 2B | 33 | 43 | 52 | 48 |
0.0% | Low Risk · 33 | N/A | |
| 2357 | 43 |
BOS | FCL | SS | 31 | 43 | 59 | 45 |
0.0% | Medium Risk · 42 | N/A | |
| 2358 | 43 |
TB | AA | P | 37 | 47 | 59 | 52 |
+0.1% | Wide Range · 63 | N/A | |
| 2359 | 43 |
TB | AA | LF | 36 | 41 | 47 | 33 |
0.0% | Low Risk · 19 | N/A | |
| 2360 | 43 |
LAD | AA | SS | 34 | 44 | 54 | 50 |
-0.1% | Medium Risk · 43 | N/A | |
| 2361 | 43 |
CHC | Single-A | P | 34 | 44 | 62 | 47 |
0.0% | Low Risk · 40 | N/A | |
| 2362 | 43 |
CLE | ACL | C | 32 | 43 | 59 | 47 |
0.0% | Medium Risk · 56 | N/A | |
| 2363 | 43 |
NYY | DSL | SS | 31 | 42 | 55 | 45 |
+0.1% | Medium Risk · 42 | N/A | |
| 2364 | 43 |
ATH | DSL | OF | 31 | 41 | 50 | 42 |
0.0% | Low Risk · 37 | N/A | |
| 2365 | 43 |
BAL | High-A | CF | 36 | 41 | 47 | 35 |
0.0% | Low Risk · 35 | N/A | |
| 2366 | 43 |
MIL | ACL | P | 31 | 43 | 53 | 46 |
0.0% | Medium Risk · 52 | N/A | |
| 2367 | 43 |
WSH | DSL | OF | 31 | 43 | 54 | 45 |
0.0% | Medium Risk · 42 | N/A | |
| 2368 | 43 |
STL | DSL | IF | 31 | 42 | 56 | 46 |
+0.1% | Medium Risk · 46 | N/A | |
| 2369 | 43 |
MIA | DSL | C | 31 | 42 | 58 | 44 |
0.0% | Medium Risk · 42 | N/A | |
| 2370 | 43 |
BOS | AAA | P | 34 | 41 | 51 | 54 |
0.0% | Low Risk · 36 | N/A | |
| 2371 | 43 |
NYY | Single-A | P | 34 | 41 | 52 | 42 |
0.0% | Low Risk · 26 | N/A | |
| 2372 | 43 |
LAA | High-A | P | 35 | 48 | 58 | 54 |
0.0% | Wide Range · 70 | N/A | |
| 2373 | 43 |
PHI | DSL | C | 31 | 42 | 52 | 44 |
-0.1% | Medium Risk · 42 | N/A | |
| 2374 | 43 |
TB | FCL | OF | 33 | 41 | 49 | 39 |
-0.1% | Low Risk · 29 | N/A | |
| 2375 | 43 |
TOR | FCL | P | 32 | 43 | 52 | 45 |
-0.5% | Medium Risk · 46 | N/A | |
| 2376 | 43 |
LAD | ACL | 2B | 33 | 43 | 53 | 47 |
+0.2% | Medium Risk · 54 | N/A | |
| 2377 | 43 |
TOR | High-A | P | 36 | 42 | 47 | 29 |
-0.4% | Low Risk · 20 | N/A | |
| 2378 | 43 |
NYY | FCL | P | 31 | 40 | 57 | 46 |
0.0% | Low Risk · 40 | N/A | |
| 2379 | 43 |
PIT | High-A | P | 33 | 41 | 49 | 41 |
0.0% | Low Risk · 34 | N/A | |
| 2380 | 43 |
SD | High-A | P | 33 | 40 | 47 | 35 |
0.0% | Low Risk · 10 | N/A | |
| 2381 | 43 |
ATH | Single-A | C | 33 | 40 | 47 | 34 |
-0.2% | Low Risk · 16 | N/A | |
| 2382 | 43 |
CWS | ACL | IF | 32 | 43 | 53 | 45 |
0.0% | Medium Risk · 48 | N/A | |
| 2383 | 43 |
WSH | FCL | C | 31 | 41 | 51 | 43 |
0.0% | Low Risk · 32 | N/A | |
| 2384 | 43 |
CWS | AAA | 2B | 35 | 39 | 44 | 54 |
-0.2% | Low Risk · 23 | N/A | |
| 2385 | 43 |
CHC | DSL | SS | 31 | 41 | 51 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2386 | 43 |
TB | High-A | P | 35 | 43 | 52 | 39 |
0.0% | Low Risk · 34 | N/A | |
| 2387 | 43 |
SF | High-A | SS | 34 | 41 | 48 | 37 |
+0.3% | Low Risk · 26 | N/A | |
| 2388 | 43 |
MIN | AA | P | 35 | 40 | 45 | 37 |
-0.3% | Low Risk · 12 | N/A | |
| 2389 | 43 |
SD | Single-A | OF | 33 | 40 | 47 | 35 |
-0.1% | Low Risk · 12 | N/A | |
| 2390 | 43 |
MIA | DSL | P | 34 | 47 | 61 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2391 | 43 |
ATH | High-A | P | 34 | 43 | 55 | 45 |
0.0% | Medium Risk · 42 | N/A | |
| 2392 | 43 |
KC | High-A | P | 33 | 44 | 54 | 48 |
0.0% | Medium Risk · 48 | N/A | |
| 2393 | 43 |
TOR | DSL | C | 31 | 42 | 52 | 44 |
0.0% | Medium Risk · 42 | N/A | |
| 2394 | 43 |
MIL | Single-A | P | 34 | 42 | 50 | 34 |
-0.4% | Low Risk · 24 | N/A | |
| 2395 | 43 |
MIN | AA | P | 33 | 40 | 50 | 50 |
0.0% | Low Risk · 20 | N/A | |
| 2396 | 43 |
KC | Single-A | P | 33 | 41 | 49 | 36 |
0.0% | Low Risk · 24 | N/A | |
| 2397 | 43 |
CHC | AA | P | 37 | 47 | 59 | 53 |
0.0% | Wide Range · 65 | N/A | |
| 2398 | 43 |
COL | ACL | P | 33 | 44 | 54 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2399 | 43 |
COL | AA | RF | 37 | 42 | 47 | 40 |
-0.2% | Low Risk · 28 | N/A | |
| 2400 | 43 |
DET | Single-A | SS | 33 | 40 | 47 | 32 |
0.0% | Low Risk · 14 | N/A | |
| 2401 | 43 |
TOR | Single-A | P | 33 | 43 | 55 | 48 |
+0.1% | Low Risk · 41 | N/A | |
| 2402 | 43 |
CIN | High-A | P | 34 | 44 | 52 | 43 |
0.0% | Medium Risk · 42 | N/A | |
| 2403 | 43 |
LAD | AA | OF | 34 | 41 | 48 | 40 |
-0.3% | Low Risk · 26 | N/A | |
| 2404 | 43 |
DET | DSL | C | 31 | 41 | 51 | 44 |
0.0% | Low Risk · 37 | N/A | |
| 2405 | 43 |
TB | DSL | OF | 31 | 40 | 50 | 42 |
-0.2% | Low Risk · 32 | N/A | |
| 2406 | 43 |
NYM | FCL | SS | 33 | 43 | 53 | 44 |
-0.1% | Medium Risk · 48 | N/A | |
| 2407 | 43 |
LAA | High-A | P | 34 | 41 | 48 | 37 |
0.0% | Low Risk · 20 | N/A | |
| 2408 | 43 |
SEA | High-A | 1B | 33 | 41 | 48 | 33 |
+0.1% | Low Risk · 19 | N/A | |
| 2409 | 43 |
SEA | High-A | SS | 33 | 43 | 52 | 46 |
-0.1% | Low Risk · 37 | N/A | |
| 2410 | 43 |
NYY | High-A | 3B | 34 | 41 | 48 | 34 |
0.0% | Low Risk · 19 | N/A | |
| 2411 | 43 |
ARI | AA | P | 35 | 43 | 50 | 39 |
0.0% | Low Risk · 34 | N/A | |
| 2412 | 43 |
MIA | DSL | IF | 32 | 42 | 51 | 41 |
-0.1% | Low Risk · 32 | N/A | |
| 2413 | 43 |
TEX | Single-A | P | 33 | 41 | 51 | 43 |
-0.5% | Low Risk · 34 | N/A | |
| 2414 | 43 |
PIT | DSL | SS | 32 | 43 | 54 | 44 |
0.0% | Medium Risk · 48 | N/A | |
| 2415 | 43 |
TOR | High-A | P | 35 | 42 | 47 | 29 |
0.0% | Low Risk · 20 | N/A | |
| 2416 | 43 |
BAL | Single-A | P | 34 | 41 | 48 | 33 |
0.0% | Low Risk · 24 | N/A | |
| 2417 | 43 |
LAA | High-A | P | 35 | 45 | 63 | 47 |
0.0% | Medium Risk · 48 | N/A | |
| 2418 | 43 |
PIT | FCL | OF | 32 | 42 | 51 | 41 |
0.0% | Low Risk · 37 | N/A | |
| 2419 | 43 |
MIN | AA | P | 35 | 42 | 50 | 40 |
+0.2% | Low Risk · 34 | N/A | |
| 2420 | 43 |
ATL | Single-A | P | 33 | 42 | 51 | 44 |
-0.1% | Medium Risk · 46 | N/A | |
| 2421 | 43 |
CIN | High-A | P | 33 | 40 | 47 | 33 |
-0.3% | Low Risk · 10 | N/A | |
| 2422 | 43 |
HOU | FCL | P | 33 | 47 | 61 | 43 |
0.0% | Wide Range · 65 | N/A | |
| 2423 | 43 |
COL | DSL | SS | 31 | 42 | 52 | 44 |
-0.1% | Medium Risk · 42 | N/A | |
| 2424 | 43 |
ARI | ACL | OF | 32 | 41 | 50 | 40 |
-0.1% | Low Risk · 40 | N/A | |
| 2425 | 43 |
TB | Single-A | P | 34 | 41 | 48 | 37 |
0.0% | Low Risk · 28 | N/A | |
| 2426 | 43 |
KC | Single-A | P | 34 | 41 | 48 | 36 |
0.0% | Low Risk · 24 | N/A | |
| 2427 | 43 |
COL | DSL | C | 31 | 41 | 52 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2428 | 43 |
NYY | FCL | P | 32 | 41 | 51 | 42 |
-0.3% | Low Risk · 32 | N/A | |
| 2429 | 43 |
BOS | AAA | 1B | 33 | 39 | 46 | 49 |
0.0% | Low Risk · 21 | N/A | |
| 2430 | 43 |
NYY | DSL | SS | 32 | 42 | 52 | 43 |
0.0% | Low Risk · 37 | N/A | |
| 2431 | 43 |
LAD | AA | SS | 35 | 41 | 48 | 35 |
0.0% | Low Risk · 26 | N/A | |
| 2432 | 43 |
TB | DSL | P | 33 | 47 | 61 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2433 | 43 |
LAD | DSL | C | 31 | 41 | 51 | 42 |
-0.7% | Low Risk · 32 | N/A | |
| 2434 | 43 |
ATL | AA | P | 33 | 43 | 55 | 49 |
0.0% | Low Risk · 40 | N/A | |
| 2435 | 43 |
CHC | DSL | OF | 31 | 43 | 60 | 46 |
0.0% | Wide Range · 58 | N/A | |
| 2436 | 43 |
MIN | Single-A | P | 35 | 43 | 63 | 45 |
0.0% | Low Risk · 33 | N/A | |
| 2437 | 43 |
BAL | FCL | C | 31 | 41 | 51 | 43 |
+0.2% | Low Risk · 37 | N/A | |
| 2438 | 43 |
CLE | DSL | IF | 31 | 41 | 51 | 42 |
-0.1% | Low Risk · 32 | N/A | |
| 2439 | 43 |
LAD | DSL | C | 31 | 42 | 53 | 43 |
+0.1% | Medium Risk · 42 | N/A | |
| 2440 | 43 |
ATH | ACL | SS | 31 | 41 | 50 | 44 |
0.0% | Medium Risk · 43 | N/A | |
| 2441 | 43 |
SF | AAA | CF | 34 | 39 | 44 | 54 |
0.0% | Low Risk · 23 | N/A | |
| 2442 | 43 |
LAA | High-A | SS | 32 | 43 | 54 | 49 |
-0.2% | Medium Risk · 43 | N/A | |
| 2443 | 43 |
MIA | Single-A | P | 32 | 43 | 53 | 47 |
0.0% | Medium Risk · 42 | N/A | |
| 2444 | 43 |
ARI | DSL | OF | 31 | 41 | 52 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2445 | 43 |
TB | FCL | P | 31 | 40 | 50 | 44 |
0.0% | Low Risk · 40 | N/A | |
| 2446 | 43 |
TOR | DSL | SS | 31 | 40 | 50 | 43 |
+0.1% | Low Risk · 37 | N/A | |
| 2447 | 43 |
NYY | DSL | C | 31 | 42 | 54 | 44 |
0.0% | Medium Risk · 42 | N/A | |
| 2448 | 43 |
BAL | DSL | OF | 31 | 41 | 51 | 42 |
+0.1% | Low Risk · 37 | N/A | |
| 2449 | 43 |
CWS | DSL | C | 31 | 42 | 52 | 43 |
0.0% | Medium Risk · 42 | N/A | |
| 2450 | 43 |
LAA | DSL | P | 30 | 41 | 51 | 44 |
0.0% | Medium Risk · 42 | N/A | |
| 2451 | 43 |
HOU | FCL | C | 32 | 41 | 50 | 41 |
0.0% | Medium Risk · 45 | N/A | |
| 2452 | 43 |
PHI | FCL | SS | 32 | 40 | 48 | 38 |
+0.5% | Low Risk · 24 | N/A | |
| 2453 | 43 |
TB | Single-A | LF | 32 | 40 | 47 | 33 |
+0.2% | Low Risk · 9 | N/A | |
| 2454 | 43 |
CIN | DSL | P | 30 | 41 | 51 | 46 |
0.0% | Medium Risk · 46 | N/A | |
| 2455 | 43 |
ARI | DSL | SS | 30 | 41 | 51 | 44 |
-0.4% | Low Risk · 37 | N/A | |
| 2456 | 43 |
COL | ACL | C | 31 | 41 | 51 | 43 |
+0.1% | Low Risk · 37 | N/A | |
| 2457 | 43 |
TOR | AAA | 3B | 34 | 39 | 44 | 48 |
0.0% | Low Risk · 21 | N/A | |
| 2458 | 43 |
SD | DSL | SS | 31 | 41 | 50 | 41 |
-0.1% | Low Risk · 37 | N/A | |
| 2459 | 43 |
TEX | DSL | OF | 31 | 42 | 52 | 44 |
-0.2% | Medium Risk · 42 | N/A | |
| 2460 | 43 |
SD | High-A | P | 33 | 41 | 48 | 29 |
0.0% | Low Risk · 20 | N/A | |
| 2461 | 43 |
CLE | DSL | C | 31 | 41 | 55 | 44 |
-0.1% | Medium Risk · 42 | N/A | |
| 2462 | 43 |
ARI | ACL | OF | 32 | 43 | 53 | 45 |
0.0% | Medium Risk · 53 | N/A | |
| 2463 | 43 |
CHC | Single-A | P | 33 | 41 | 48 | 34 |
0.0% | Low Risk · 24 | N/A | |
| 2464 | 43 |
CHC | Single-A | P | 35 | 45 | 63 | 48 |
-0.4% | Medium Risk · 55 | N/A | |
| 2465 | 43 |
CWS | High-A | C | 32 | 43 | 54 | 51 |
0.0% | Medium Risk · 48 | N/A | |
| 2466 | 43 |
MIA | FCL | IF | 31 | 42 | 53 | 46 |
+0.1% | Medium Risk · 47 | N/A | |
| 2467 | 43 |
STL | Single-A | C | 33 | 39 | 46 | 35 |
+0.1% | Low Risk · 12 | N/A | |
| 2468 | 43 |
CHC | DSL | IF | 30 | 41 | 50 | 42 |
-0.1% | Low Risk · 32 | N/A | |
| 2469 | 43 |
ARI | ACL | P | 31 | 40 | 48 | 37 |
0.0% | Low Risk · 24 | N/A | |
| 2470 | 43 |
BAL | DSL | OF | 30 | 40 | 50 | 44 |
0.0% | Low Risk · 37 | N/A | |
| 2471 | 43 |
CIN | DSL | P | 31 | 42 | 52 | 43 |
0.0% | Medium Risk · 42 | N/A | |
| 2472 | 43 |
ATH | AA | 2B | 34 | 42 | 51 | 44 |
0.0% | Low Risk · 39 | N/A | |
| 2473 | 43 |
TEX | DSL | IF | 31 | 42 | 52 | 43 |
-0.1% | Medium Risk · 42 | N/A | |
| 2474 | 43 |
LAD | Single-A | P | 34 | 45 | 62 | 50 |
0.0% | Wide Range · 67 | N/A | |
| 2475 | 43 |
CWS | DSL | OF | 31 | 42 | 52 | 44 |
0.0% | Medium Risk · 47 | N/A | |
| 2476 | 43 |
TB | DSL | C | 30 | 41 | 52 | 47 |
0.0% | Medium Risk · 51 | N/A | |
| 2477 | 43 |
BOS | DSL | SS | 31 | 42 | 53 | 44 |
0.0% | Medium Risk · 42 | N/A | |
| 2478 | 43 |
NYM | High-A | SS | 33 | 43 | 61 | 48 |
0.0% | Low Risk · 31 | N/A | |
| 2479 | 43 |
SD | ACL | P | 32 | 42 | 59 | 45 |
0.0% | Medium Risk · 54 | N/A | |
| 2480 | IL(60-Day)43 |
LAD | AA | CIL(60-Day) | 32 | 43 | 53 | 50 |
0.0% | Medium Risk · 45 | N/A | |
| 2481 | 43 |
BAL | DSL | P | 31 | 42 | 53 | 44 |
-0.2% | Medium Risk · 46 | N/A | |
| 2482 | 42 |
MIA | Single-A | CF | 32 | 39 | 46 | 35 |
0.0% | Low Risk · 12 | N/A | |
| 2483 | 42 |
LAD | High-A | P | 34 | 44 | 53 | 42 |
-0.1% | Low Risk · 30 | N/A | |
| 2484 | 42 |
PIT | Single-A | C | 32 | 43 | 53 | 47 |
-0.1% | Low Risk · 38 | N/A | |
| 2485 | 42 |
DET | Single-A | OF | 34 | 41 | 48 | 38 |
+0.4% | Low Risk · 28 | N/A | |
| 2486 | 42 |
CIN | ACL | P | 31 | 40 | 50 | 42 |
0.0% | Low Risk · 38 | N/A | |
| 2487 | 42 |
WSH | High-A | P | 33 | 44 | 60 | 49 |
+0.1% | Medium Risk · 52 | N/A | |
| 2488 | 42 |
MIL | Single-A | OF | 32 | 43 | 54 | 48 |
-0.1% | Medium Risk · 49 | N/A | |
| 2489 | 42 |
WSH | Single-A | LF | 33 | 40 | 48 | 37 |
-0.2% | Low Risk · 30 | N/A | |
| 2490 | 42 |
LAA | ACL | SS | 32 | 42 | 52 | 38 |
0.0% | Low Risk · 37 | N/A | |
| 2491 | 42 |
ATH | Single-A | SS | 32 | 38 | 45 | 39 |
+0.2% | Low Risk · 12 | N/A | |
| 2492 | 42 |
LAD | DSL | C | 31 | 42 | 52 | 43 |
0.0% | Medium Risk · 42 | N/A | |
| 2493 | 42 |
NYY | Single-A | P | 32 | 40 | 51 | 41 |
+0.1% | Low Risk · 20 | N/A | |
| 2494 | 42 |
ARI | DSL | P | 33 | 47 | 60 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2495 | 42 |
SD | DSL | P | 33 | 47 | 60 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2496 | 42 |
CLE | DSL | SS | 33 | 47 | 60 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2497 | 42 |
DET | High-A | LF | 32 | 42 | 51 | 46 |
0.0% | Low Risk · 28 | N/A | |
| 2498 | 42 |
LAD | DSL | C | 31 | 42 | 52 | 44 |
+0.1% | Medium Risk · 47 | N/A | |
| 2499 | 42 |
KC | AA | P | 35 | 43 | 52 | 44 |
+0.1% | Medium Risk · 42 | N/A | |
| 2500 | 42 |
BOS | Single-A | P | 33 | 41 | 48 | 32 |
-0.1% | Low Risk · 24 | N/A | |
| 2501 | 42 |
CWS | High-A | SS | 32 | 40 | 48 | 39 |
0.0% | Low Risk · 18 | N/A | |
| 2502 | 42 |
MIA | Single-A | P | 33 | 40 | 47 | 34 |
-0.4% | Low Risk · 24 | N/A | |
| 2503 | 42 |
ARI | Single-A | P | 33 | 43 | 52 | 44 |
-0.2% | Medium Risk · 42 | N/A | |
| 2504 | 42 |
TB | DSL | C | 31 | 41 | 51 | 41 |
-0.2% | Low Risk · 32 | N/A | |
| 2505 | 42 |
ATL | FCL | IF | 32 | 41 | 51 | 39 |
0.0% | Low Risk · 37 | N/A | |
| 2506 | 42 |
TB | DSL | OF | 31 | 41 | 50 | 41 |
-0.1% | Low Risk · 37 | N/A | |
| 2507 | 42 |
TOR | DSL | OF | 30 | 40 | 50 | 41 |
-0.1% | Low Risk · 32 | N/A | |
| 2508 | 42 |
MIA | High-A | P | 34 | 42 | 49 | 35 |
0.0% | Low Risk · 34 | N/A | |
| 2509 | 42 |
HOU | High-A | P | 33 | 42 | 52 | 46 |
-0.2% | Medium Risk · 42 | N/A | |
| 2510 | 42 |
CHC | High-A | P | 33 | 42 | 52 | 44 |
+0.1% | Medium Risk · 42 | N/A | |
| 2511 | 42 |
BOS | Single-A | OF | 33 | 40 | 47 | 38 |
0.0% | Low Risk · 28 | N/A | |
| 2512 | 42 |
CHC | Single-A | P | 33 | 40 | 48 | 37 |
0.0% | Low Risk · 22 | N/A | |
| 2513 | 42 |
CHC | DSL | OF | 30 | 41 | 51 | 42 |
+0.1% | Low Risk · 37 | N/A | |
| 2514 | 42 |
NYM | High-A | P | 33 | 42 | 51 | 43 |
+0.1% | Medium Risk · 42 | N/A | |
| 2515 | 42 |
SF | DSL | OF | 30 | 41 | 52 | 44 |
0.0% | Medium Risk · 47 | N/A | |
| 2516 | 42 |
TB | DSL | IF | 31 | 40 | 49 | 43 |
+0.2% | Low Risk · 38 | N/A | |
| 2517 | 42 |
CWS | DSL | C | 31 | 42 | 53 | 45 |
-0.2% | Medium Risk · 47 | N/A | |
| 2518 | 42 |
SD | Single-A | P | 33 | 41 | 49 | 39 |
0.0% | Low Risk · 38 | N/A | |
| 2519 | 42 |
NYM | AA | P | 34 | 45 | 55 | 51 |
0.0% | Wide Range · 62 | N/A | |
| 2520 | 42 |
CWS | AAA | CF | 35 | 40 | 45 | 44 |
-0.1% | Low Risk · 20 | N/A | |
| 2521 | 42 |
NYY | High-A | P | 33 | 42 | 51 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2522 | 42 |
LAD | Single-A | P | 34 | 42 | 49 | 37 |
-0.2% | Low Risk · 38 | N/A | |
| 2523 | 42 |
SEA | ACL | P | 31 | 41 | 51 | 44 |
-0.3% | Medium Risk · 46 | N/A | |
| 2524 | 42 |
CHC | DSL | IF | 30 | 41 | 51 | 44 |
0.0% | Medium Risk · 42 | N/A | |
| 2525 | 42 |
CHC | High-A | P | 33 | 42 | 53 | 41 |
-0.2% | Low Risk · 28 | N/A | |
| 2526 | 42 |
PIT | High-A | P | 34 | 42 | 49 | 34 |
0.0% | Low Risk · 34 | N/A | |
| 2527 | 42 |
LAD | AA | P | 34 | 41 | 47 | 34 |
0.0% | Low Risk · 24 | N/A | |
| 2528 | 42 |
CLE | Single-A | 1B | 31 | 40 | 49 | 42 |
0.0% | Low Risk · 25 | N/A | |
| 2529 | 42 |
ATH | DSL | SS | 31 | 41 | 50 | 46 |
+0.1% | Medium Risk · 51 | N/A | |
| 2530 | 42 |
MIA | Single-A | P | 33 | 41 | 49 | 39 |
0.0% | Low Risk · 36 | N/A | |
| 2531 | 42 |
MIL | ACL | P | 30 | 41 | 55 | 43 |
0.0% | Low Risk · 40 | N/A | |
| 2532 | 42 |
DET | DSL | P | 30 | 40 | 50 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2533 | 42 |
BOS | DSL | CF | 30 | 41 | 51 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2534 | 42 |
WSH | Single-A | P | 32 | 39 | 46 | 40 |
0.0% | Low Risk · 22 | N/A | |
| 2535 | 42 |
HOU | Single-A | 3B | 31 | 41 | 52 | 48 |
0.0% | Low Risk · 36 | N/A | |
| 2536 | 42 |
PIT | FCL | SS | 30 | 42 | 53 | 46 |
0.0% | Medium Risk · 47 | N/A | |
| 2537 | 42 |
BOS | DSL | OF | 31 | 40 | 50 | 41 |
0.0% | Low Risk · 32 | N/A | |
| 2538 | 42 |
SEA | Single-A | P | 33 | 41 | 53 | 42 |
0.0% | Low Risk · 36 | N/A | |
| 2539 | 42 |
ARI | High-A | P | 33 | 40 | 47 | 36 |
0.0% | Low Risk · 24 | N/A | |
| 2540 | 42 |
CIN | Single-A | CF | 32 | 40 | 46 | 32 |
0.0% | Low Risk · 16 | N/A | |
| 2541 | 42 |
CHC | AA | P | 34 | 45 | 55 | 50 |
+0.1% | Wide Range · 63 | N/A | |
| 2542 | IL(7-Day)42 |
MIA | High-A | PIL(7-Day) | 33 | 44 | 61 | 47 |
0.0% | Medium Risk · 44 | N/A | |
| 2543 | IL(Full Season)42 |
CIN | High-A | OFIL(Full Season) | 31 | 42 | 52 | 50 |
0.0% | Medium Risk · 46 | N/A | |
| 2544 | 42 |
SF | ACL | P | 30 | 41 | 52 | 44 |
0.0% | Medium Risk · 42 | N/A | |
| 2545 | 42 |
TEX | High-A | P | 33 | 40 | 48 | 38 |
0.0% | Low Risk · 24 | N/A | |
| 2546 | 42 |
LAD | AA | P | 36 | 42 | 47 | 34 |
+0.1% | Low Risk · 34 | N/A | |
| 2547 | 42 |
SD | DSL | P | 33 | 46 | 60 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2548 | 42 |
BAL | FCL | 2B | 30 | 40 | 50 | 41 |
-0.2% | Low Risk · 32 | N/A | |
| 2549 | 42 |
PHI | FCL | C | 31 | 42 | 53 | 45 |
0.0% | Medium Risk · 47 | N/A | |
| 2550 | 42 |
SD | ACL | 2B | 31 | 40 | 49 | 43 |
-0.1% | Medium Risk · 43 | N/A | |
| 2551 | 42 |
SF | AA | SS | 35 | 40 | 45 | 33 |
0.0% | Low Risk · 35 | N/A | |
| 2552 | 42 |
SF | High-A | 3B | 32 | 40 | 48 | 37 |
-0.2% | Low Risk · 26 | N/A | |
| 2553 | IL(7-Day)42 |
MIN | Single-A | PIL(7-Day) | 32 | 43 | 57 | 47 |
0.0% | Medium Risk · 48 | N/A | |
| 2554 | 42 |
STL | High-A | P | 33 | 41 | 51 | 41 |
0.0% | Low Risk · 34 | N/A | |
| 2555 | 42 |
MIN | AAA | 2B | 33 | 40 | 48 | 51 |
0.0% | Low Risk · 28 | N/A | |
| 2556 | 42 |
ATH | ACL | C | 32 | 42 | 53 | 45 |
+0.1% | Medium Risk · 54 | N/A | |
| 2557 | 42 |
PHI | FCL | P | 32 | 42 | 56 | 43 |
0.0% | Medium Risk · 56 | N/A | |
| 2558 | 42 |
CWS | High-A | CF | 31 | 42 | 54 | 45 |
0.0% | Low Risk · 28 | N/A | |
| 2559 | 42 |
ARI | DSL | SS | 30 | 41 | 51 | 44 |
-0.1% | Medium Risk · 47 | N/A | |
| 2560 | 42 |
SF | ACL | C | 31 | 41 | 50 | 41 |
0.0% | Low Risk · 32 | N/A | |
| 2561 | 42 |
LAD | DSL | IF | 32 | 44 | 66 | 44 |
0.0% | Medium Risk · 56 | N/A | |
| 2562 | 42 |
HOU | AA | C | 35 | 40 | 46 | 32 |
-0.2% | Low Risk · 24 | N/A | |
| 2563 | 42 |
SF | ACL | RF | 32 | 41 | 49 | 38 |
-0.6% | Low Risk · 40 | N/A | |
| 2564 | 42 |
SEA | Single-A | P | 33 | 40 | 47 | 34 |
0.0% | Low Risk · 24 | N/A | |
| 2565 | 42 |
NYM | Single-A | C | 31 | 41 | 51 | 44 |
0.0% | Low Risk · 32 | N/A | |
| 2566 | 42 |
LAA | DSL | SS | 30 | 41 | 51 | 43 |
-0.1% | Medium Risk · 42 | N/A | |
| 2567 | 42 |
SF | ACL | LF | 30 | 41 | 57 | 45 |
-0.2% | Medium Risk · 50 | N/A | |
| 2568 | 42 |
STL | FCL | C | 31 | 41 | 51 | 40 |
0.0% | Low Risk · 32 | N/A | |
| 2569 | 42 |
CWS | DSL | IF | 30 | 40 | 50 | 42 |
0.0% | Low Risk · 37 | N/A | |
| 2570 | 42 |
NYM | DSL | P | 30 | 42 | 53 | 46 |
0.0% | Medium Risk · 52 | N/A | |
| 2571 | 42 |
TB | AAA | P | 32 | 39 | 47 | 55 |
0.0% | Low Risk · 36 | N/A | |
| 2572 | 42 |
TEX | AA | 2B | 32 | 38 | 46 | 55 |
0.0% | Low Risk · 22 | N/A | |
| 2573 | 42 |
CLE | Single-A | C | 31 | 40 | 48 | 38 |
+0.1% | Low Risk · 22 | N/A | |
| 2574 | 42 |
DET | FCL | IF | 30 | 39 | 48 | 42 |
+0.1% | Low Risk · 32 | N/A | |
| 2575 | 42 |
HOU | AA | P | 34 | 41 | 49 | 38 |
-0.1% | Low Risk · 34 | N/A | |
| 2576 | 42 |
CHC | ACL | OF | 31 | 40 | 50 | 41 |
0.0% | Low Risk · 32 | N/A | |
| 2577 | 42 |
ATL | High-A | P | 33 | 40 | 46 | 31 |
0.0% | Low Risk · 10 | N/A | |
| 2578 | IL(60-Day)42 |
MIA | Single-A | 1BIL(60-Day) | 32 | 44 | 60 | 50 |
0.0% | Wide Range · 59 | N/A | |
| 2579 | 42 |
PIT | High-A | P | 31 | 42 | 52 | 47 |
0.0% | Low Risk · 38 | N/A | |
| 2580 | 42 |
PIT | DSL | C | 30 | 41 | 51 | 43 |
0.0% | Medium Risk · 42 | N/A | |
| 2581 | 42 |
MIA | High-A | OF | 32 | 41 | 50 | 40 |
-0.3% | Low Risk · 27 | N/A | |
| 2582 | 42 |
COL | Single-A | P | 33 | 41 | 48 | 31 |
0.0% | Low Risk · 24 | N/A | |
| 2583 | 42 |
SD | ACL | P | 32 | 41 | 54 | 41 |
0.0% | Medium Risk · 42 | N/A | |
| 2584 | 42 |
KC | DSL | P | 29 | 39 | 49 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2585 | 42 |
TEX | DSL | OF | 31 | 41 | 51 | 42 |
0.0% | Medium Risk · 48 | N/A | |
| 2586 | 42 |
KC | DSL | C | 30 | 40 | 50 | 42 |
+0.1% | Low Risk · 37 | N/A | |
| 2587 | 42 |
ATH | ACL | SS | 30 | 40 | 50 | 41 |
0.0% | Low Risk · 32 | N/A | |
| 2588 | 42 |
MIN | FCL | C | 30 | 40 | 50 | 42 |
0.0% | Low Risk · 37 | N/A | |
| 2589 | 42 |
SD | ACL | C | 30 | 40 | 50 | 41 |
0.0% | Low Risk · 32 | N/A | |
| 2590 | 42 |
SD | DSL | C | 30 | 40 | 50 | 42 |
0.0% | Low Risk · 37 | N/A | |
| 2591 | 42 |
MIA | DSL | P | 33 | 45 | 67 | 46 |
0.0% | Wide Range · 66 | N/A | |
| 2592 | 42 |
CHC | DSL | IF | 30 | 41 | 51 | 43 |
-0.5% | Medium Risk · 42 | N/A | |
| 2593 | 42 |
LAA | ACL | P | 30 | 41 | 59 | 43 |
0.0% | Low Risk · 40 | N/A | |
| 2594 | 42 |
TB | High-A | 3B | 31 | 40 | 50 | 44 |
-0.3% | Low Risk · 28 | N/A | |
| 2595 | 42 |
MIA | Single-A | C | 31 | 42 | 53 | 46 |
0.0% | Medium Risk · 48 | N/A | |
| 2596 | 42 |
NYY | Single-A | P | 30 | 40 | 51 | 45 |
0.0% | Low Risk · 40 | N/A | |
| 2597 | 42 |
TB | Single-A | P | 31 | 41 | 51 | 47 |
0.0% | Low Risk · 40 | N/A | |
| 2598 | 42 |
BOS | FCL | P | 33 | 45 | 56 | 46 |
-0.8% | Wide Range · 66 | N/A | |
| 2599 | 42 |
CIN | DSL | P | 31 | 41 | 55 | 43 |
0.0% | Medium Risk · 46 | N/A | |
| 2600 | 42 |
TEX | ACL | P | 30 | 40 | 59 | 43 |
+0.1% | Low Risk · 40 | N/A | |
| 2601 | 42 |
CWS | Single-A | P | 32 | 40 | 54 | 42 |
0.0% | Low Risk · 30 | N/A | |
| 2602 | 42 |
CHC | DSL | SS | 32 | 46 | 60 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2603 | 42 |
COL | AAA | C | 32 | 38 | 45 | 47 |
0.0% | Low Risk · 20 | N/A | |
| 2604 | IL(7-Day)42 |
MIL | High-A | PIL(7-Day) | 32 | 44 | 55 | 51 |
0.0% | Wide Range · 61 | N/A | |
| 2605 | 42 |
PHI | DSL | P | 30 | 42 | 57 | 45 |
0.0% | Medium Risk · 52 | N/A | |
| 2606 | 42 |
MIL | ACL | 1B | 31 | 41 | 53 | 44 |
-0.2% | Medium Risk · 48 | N/A | |
| 2607 | 42 |
DET | Single-A | P | 31 | 40 | 49 | 42 |
+0.1% | Low Risk · 32 | N/A | |
| 2608 | 42 |
LAA | DSL | OF | 30 | 40 | 50 | 42 |
+0.1% | Low Risk · 37 | N/A | |
| 2609 | 42 |
CHC | High-A | P | 33 | 43 | 53 | 46 |
-0.3% | Medium Risk · 52 | N/A | |
| 2610 | 42 |
KC | Single-A | P | 32 | 42 | 51 | 44 |
0.0% | Medium Risk · 46 | N/A | |
| 2611 | 42 |
NYM | FCL | P | 32 | 41 | 51 | 37 |
0.0% | Medium Risk · 48 | N/A | |
| 2612 | 42 |
CLE | DSL | OF | 30 | 41 | 51 | 43 |
-0.1% | Medium Risk · 47 | N/A | |
| 2613 | 42 |
NYM | High-A | OF | 33 | 41 | 49 | 37 |
-0.3% | Low Risk · 35 | N/A | |
| 2614 | 42 |
SEA | DSL | OF | 30 | 40 | 54 | 45 |
0.0% | Medium Risk · 46 | N/A | |
| 2615 | 42 |
MIN | AA | P | 33 | 44 | 54 | 50 |
0.0% | Medium Risk · 53 | N/A | |
| 2616 | 42 |
WSH | DSL | IF | 30 | 41 | 50 | 41 |
0.0% | Low Risk · 37 | N/A | |
| 2617 | 42 |
CHC | DSL | C | 33 | 46 | 66 | 47 |
0.0% | Wide Range · 60 | N/A | |
| 2618 | 42 |
SEA | DSL | P | 30 | 41 | 62 | 43 |
0.0% | Medium Risk · 46 | N/A | |
| 2619 | 42 |
MIA | FCL | C | 30 | 40 | 49 | 40 |
-0.2% | Low Risk · 32 | N/A | |
| 2620 | 42 |
CIN | ACL | P | 32 | 42 | 57 | 44 |
-0.3% | Medium Risk · 56 | N/A | |
| 2621 | 42 |
ARI | ACL | OF | 31 | 40 | 49 | 36 |
0.0% | Low Risk · 33 | N/A | |
| 2622 | 42 |
CIN | ACL | SS | 31 | 39 | 47 | 35 |
0.0% | Low Risk · 24 | N/A | |
| 2623 | 42 |
SD | High-A | P | 33 | 44 | 55 | 49 |
0.0% | Wide Range · 62 | N/A | |
| 2624 | 42 |
CHC | AA | P | 32 | 39 | 49 | 54 |
0.0% | Low Risk · 34 | N/A | |
| 2625 | 42 |
HOU | High-A | SS | 31 | 39 | 48 | 41 |
0.0% | Low Risk · 18 | N/A | |
| 2626 | 42 |
WSH | AAA | P | 33 | 38 | 43 | 50 |
0.0% | Low Risk · 22 | N/A | |
| 2627 | 42 |
HOU | DSL | OF | 30 | 41 | 55 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2628 | 42 |
DET | FCL | SS | 30 | 40 | 49 | 41 |
0.0% | Low Risk · 37 | N/A | |
| 2629 | 42 |
CIN | ACL | 1B | 31 | 43 | 62 | 44 |
-0.1% | Medium Risk · 50 | N/A | |
| 2630 | 42 |
TOR | DSL | IF | 30 | 42 | 52 | 44 |
+0.1% | Medium Risk · 47 | N/A | |
| 2631 | 42 |
SF | AA | P | 36 | 42 | 47 | 31 |
0.0% | Low Risk · 34 | N/A | |
| 2632 | 42 |
ATH | DSL | P | 30 | 41 | 55 | 42 |
-0.1% | Medium Risk · 42 | N/A | |
| 2633 | 42 |
PIT | AA | P | 33 | 41 | 50 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2634 | 42 |
NYM | DSL | OF | 31 | 41 | 53 | 43 |
-0.2% | Medium Risk · 48 | N/A | |
| 2635 | 42 |
DET | AA | P | 31 | 38 | 50 | 54 |
0.0% | Low Risk · 22 | N/A | |
| 2636 | 42 |
LAA | Single-A | P | 32 | 43 | 57 | 48 |
-0.1% | Medium Risk · 54 | N/A | |
| 2637 | 42 |
SEA | Single-A | P | 31 | 42 | 53 | 49 |
0.0% | Medium Risk · 54 | N/A | |
| 2638 | 42 |
ATL | Single-A | P | 32 | 40 | 47 | 30 |
0.0% | Low Risk · 24 | N/A | |
| 2639 | 42 |
ATH | Single-A | P | 33 | 41 | 48 | 29 |
-0.1% | Low Risk · 24 | N/A | |
| 2640 | 42 |
STL | FCL | P | 30 | 39 | 49 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2641 | IL(7-Day)42 |
CHC | High-A | SSIL(7-Day) | 32 | 41 | 51 | 43 |
0.0% | Low Risk · 40 | N/A | |
| 2642 | 42 |
SD | High-A | P | 32 | 40 | 47 | 33 |
0.0% | Low Risk · 20 | N/A | |
| 2643 | 42 |
NYM | DSL | OF | 30 | 43 | 59 | 46 |
0.0% | Medium Risk · 56 | N/A | |
| 2644 | 42 |
BAL | Single-A | 2B | 31 | 42 | 53 | 47 |
0.0% | Medium Risk · 48 | N/A | |
| 2645 | 42 |
KC | DSL | IF | 30 | 40 | 50 | 41 |
0.0% | Low Risk · 37 | N/A | |
| 2646 | 42 |
CWS | High-A | P | 33 | 44 | 54 | 48 |
0.0% | Medium Risk · 49 | N/A | |
| 2647 | 42 |
KC | AA | 1B | 32 | 42 | 52 | 48 |
0.0% | Medium Risk · 43 | N/A | |
| 2648 | 42 |
TOR | Single-A | OF | 30 | 40 | 50 | 43 |
0.0% | Low Risk · 35 | N/A | |
| 2649 | 42 |
TOR | FCL | P | 29 | 39 | 53 | 44 |
0.0% | Low Risk · 40 | N/A | |
| 2650 | 42 |
CIN | DSL | P | 29 | 39 | 50 | 45 |
0.0% | Medium Risk · 46 | N/A | |
| 2651 | 42 |
SD | Single-A | SS | 31 | 38 | 45 | 36 |
-0.3% | Low Risk · 12 | N/A | |
| 2652 | 41 |
BOS | AAA | IF | 33 | 41 | 55 | 58 |
-0.3% | Low Risk · 41 | N/A | |
| 2653 | 41 |
CHC | DSL | P | 29 | 39 | 49 | 42 |
+0.1% | Low Risk · 32 | N/A | |
| 2654 | 41 |
ATL | Single-A | P | 32 | 42 | 60 | 45 |
0.0% | Low Risk · 40 | N/A | |
| 2655 | 41 |
MIL | DSL | C | 30 | 42 | 53 | 44 |
+0.1% | Medium Risk · 47 | N/A | |
| 2656 | 41 |
MIA | DSL | IF | 30 | 41 | 53 | 43 |
0.0% | Medium Risk · 46 | N/A | |
| 2657 | 41 |
WSH | FCL | P | 31 | 40 | 50 | 45 |
0.0% | Medium Risk · 46 | N/A | |
| 2658 | 41 |
ARI | ACL | P | 32 | 43 | 56 | 43 |
0.0% | Medium Risk · 56 | N/A | |
| 2659 | 41 |
BAL | FCL | P | 30 | 41 | 53 | 45 |
0.0% | Medium Risk · 54 | N/A | |
| 2660 | 41 |
ARI | ACL | C | 30 | 41 | 54 | 43 |
0.0% | Medium Risk · 48 | N/A | |
| 2661 | 41 |
WSH | DSL | IF | 30 | 41 | 55 | 43 |
-0.1% | Medium Risk · 46 | N/A | |
| 2662 | 41 |
KC | ACL | SS | 31 | 40 | 49 | 39 |
+0.1% | Medium Risk · 45 | N/A | |
| 2663 | 41 |
PHI | FCL | SS | 31 | 41 | 50 | 39 |
+0.1% | Low Risk · 40 | N/A | |
| 2664 | 41 |
TOR | FCL | P | 31 | 40 | 49 | 41 |
-0.5% | Low Risk · 38 | N/A | |
| 2665 | 41 |
ATH | AA | P | 34 | 42 | 50 | 39 |
0.0% | Low Risk · 28 | N/A | |
| 2666 | 41 |
MIA | High-A | P | 33 | 41 | 49 | 33 |
0.0% | Low Risk · 34 | N/A | |
| 2667 | 41 |
MIN | High-A | IF | 31 | 42 | 52 | 47 |
0.0% | Medium Risk · 43 | N/A | |
| 2668 | 41 |
NYY | DSL | SS | 30 | 41 | 51 | 44 |
0.0% | Medium Risk · 47 | N/A | |
| 2669 | 41 |
LAD | High-A | P | 33 | 41 | 52 | 40 |
-0.1% | Low Risk · 34 | N/A | |
| 2670 | 41 |
SD | DSL | SS | 30 | 39 | 49 | 41 |
-0.1% | Low Risk · 37 | N/A | |
| 2671 | 41 |
PHI | High-A | P | 33 | 42 | 51 | 41 |
-0.3% | Medium Risk · 42 | N/A | |
| 2672 | 41 |
ARI | AA | P | 34 | 44 | 54 | 50 |
-0.1% | Wide Range · 62 | N/A | |
| 2673 | 41 |
CHC | DSL | P | 31 | 42 | 54 | 41 |
0.0% | Medium Risk · 42 | N/A | |
| 2674 | 41 |
PHI | AA | P | 33 | 40 | 48 | 35 |
0.0% | Low Risk · 34 | N/A | |
| 2675 | 41 |
LAA | DSL | C | 30 | 42 | 55 | 46 |
0.0% | Medium Risk · 56 | N/A | |
| 2676 | 41 |
SF | Single-A | P | 31 | 39 | 50 | 41 |
0.0% | Low Risk · 20 | N/A | |
| 2677 | 41 |
SD | DSL | P | 32 | 46 | 59 | 42 |
-0.4% | Wide Range · 65 | N/A | |
| 2678 | 41 |
TEX | DSL | P | 32 | 46 | 59 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2679 | 41 |
ARI | DSL | OF | 32 | 46 | 59 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2680 | 41 |
WSH | FCL | P | 32 | 45 | 66 | 47 |
0.0% | Wide Range · 67 | N/A | |
| 2681 | 41 |
NYY | FCL | SS | 30 | 41 | 50 | 40 |
0.0% | Low Risk · 37 | N/A | |
| 2682 | 41 |
SEA | DSL | OF | 30 | 40 | 55 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2683 | 41 |
STL | DSL | OF | 29 | 40 | 50 | 42 |
+0.2% | Low Risk · 37 | N/A | |
| 2684 | 41 |
SD | High-A | 1B | 32 | 44 | 56 | 48 |
0.0% | Medium Risk · 54 | N/A | |
| 2685 | 41 |
MIN | DSL | IF | 30 | 40 | 51 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2686 | 41 |
BAL | FCL | SS | 30 | 40 | 50 | 41 |
0.0% | Low Risk · 37 | N/A | |
| 2687 | IL(7-Day)41 |
SD | AA | PIL(7-Day) | 33 | 44 | 54 | 51 |
0.0% | Wide Range · 68 | N/A | |
| 2688 | 41 |
HOU | Single-A | P | 31 | 43 | 58 | 49 |
0.0% | Medium Risk · 57 | N/A | |
| 2689 | 41 |
MIN | FCL | SS | 29 | 39 | 49 | 44 |
-0.1% | Low Risk · 40 | N/A | |
| 2690 | 41 |
CHC | AA | LF | 32 | 38 | 49 | 49 |
-0.1% | Low Risk · 21 | N/A | |
| 2691 | 41 |
PHI | DSL | IF | 30 | 41 | 51 | 43 |
-0.1% | Medium Risk · 47 | N/A | |
| 2692 | 41 |
CWS | DSL | SS | 30 | 40 | 50 | 41 |
-0.1% | Low Risk · 37 | N/A | |
| 2693 | 41 |
COL | Single-A | P | 31 | 39 | 47 | 36 |
0.0% | Low Risk · 26 | N/A | |
| 2694 | 41 |
COL | DSL | OF | 30 | 39 | 48 | 41 |
0.0% | Low Risk · 37 | N/A | |
| 2695 | 41 |
ARI | ACL | P | 31 | 43 | 62 | 44 |
+0.1% | Wide Range · 66 | N/A | |
| 2696 | 41 |
CHC | High-A | P | 30 | 38 | 46 | 41 |
0.0% | Low Risk · 24 | N/A | |
| 2697 | 41 |
ARI | DSL | SS | 30 | 42 | 59 | 46 |
0.0% | Medium Risk · 56 | N/A | |
| 2698 | 41 |
TEX | ACL | OF | 29 | 40 | 49 | 42 |
0.0% | Low Risk · 37 | N/A | |
| 2699 | 41 |
ARI | DSL | C | 30 | 41 | 51 | 43 |
-0.1% | Medium Risk · 47 | N/A | |
| 2700 | 41 |
HOU | DSL | P | 29 | 40 | 50 | 44 |
0.0% | Medium Risk · 46 | N/A | |
| 2701 | 41 |
KC | DSL | IF | 30 | 40 | 51 | 43 |
0.0% | Medium Risk · 47 | N/A | |
| 2702 | 41 |
BAL | AAA | C | 34 | 40 | 46 | 34 |
0.0% | Low Risk · 33 | N/A | |
| 2703 | 41 |
NYY | AA | P | 33 | 42 | 52 | 48 |
-0.1% | Wide Range · 62 | N/A | |
| 2704 | 41 |
CIN | DSL | C | 30 | 42 | 55 | 46 |
0.0% | Medium Risk · 56 | N/A | |
| 2705 | 41 |
ARI | ACL | IF | 31 | 40 | 49 | 40 |
+0.2% | Low Risk · 38 | N/A | |
| 2706 | 41 |
LAD | DSL | C | 29 | 41 | 55 | 43 |
+0.1% | Medium Risk · 42 | N/A | |
| 2707 | 41 |
ATL | DSL | OF | 30 | 41 | 52 | 44 |
0.0% | Medium Risk · 47 | N/A | |
| 2708 | 41 |
LAA | ACL | SS | 30 | 43 | 54 | 47 |
-0.1% | Wide Range · 61 | N/A | |
| 2709 | 41 |
LAA | ACL | SS | 30 | 41 | 52 | 44 |
0.0% | Medium Risk · 47 | N/A | |
| 2710 | 41 |
PHI | DSL | P | 30 | 41 | 53 | 44 |
0.0% | Medium Risk · 56 | N/A | |
| 2711 | 41 |
CWS | ACL | P | 30 | 41 | 51 | 42 |
-0.1% | Medium Risk · 46 | N/A | |
| 2712 | 41 |
SD | DSL | OF | 30 | 39 | 48 | 39 |
-0.1% | Low Risk · 29 | N/A | |
| 2713 | 41 |
COL | AAA | P | 35 | 43 | 51 | 41 |
-0.1% | Medium Risk · 44 | N/A | |
| 2714 | 41 |
SEA | AAA | P | 32 | 39 | 46 | 49 |
0.0% | Low Risk · 34 | N/A | |
| 2715 | 41 |
KC | High-A | 3B | 31 | 39 | 49 | 41 |
0.0% | Low Risk · 20 | N/A | |
| 2716 | 41 |
MIN | FCL | OF | 31 | 43 | 54 | 44 |
0.0% | Wide Range · 63 | N/A | |
| 2717 | 41 |
CWS | DSL | IF | 30 | 40 | 52 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2718 | 41 |
WSH | High-A | P | 30 | 37 | 45 | 50 |
0.0% | Low Risk · 19 | N/A | |
| 2719 | 41 |
NYM | High-A | P | 33 | 46 | 61 | 50 |
0.0% | Wide Range · 65 | N/A | |
| 2720 | 41 |
LAD | ACL | SS | 29 | 40 | 51 | 44 |
+0.2% | Medium Risk · 47 | N/A | |
| 2721 | 41 |
COL | Single-A | OF | 32 | 39 | 46 | 39 |
-0.1% | Low Risk · 28 | N/A | |
| 2722 | 41 |
ATH | AA | P | 32 | 39 | 46 | 34 |
+0.1% | Low Risk · 24 | N/A | |
| 2723 | 41 |
TB | FCL | P | 32 | 41 | 52 | 40 |
-3.0% | Medium Risk · 48 | N/A | |
| 2724 | 41 |
TB | Single-A | OF | 31 | 39 | 49 | 40 |
-0.2% | Low Risk · 28 | N/A | |
| 2725 | 41 |
HOU | Single-A | SS | 32 | 40 | 47 | 29 |
-0.1% | Low Risk · 25 | N/A | |
| 2726 | 41 |
PHI | FCL | C | 30 | 39 | 48 | 41 |
-0.4% | Low Risk · 32 | N/A | |
| 2727 | 41 |
MIA | AA | C | 32 | 37 | 44 | 45 |
-0.1% | Low Risk · 19 | N/A | |
| 2728 | 41 |
WSH | AA | 3B | 32 | 42 | 52 | 48 |
0.0% | Medium Risk · 43 | N/A | |
| 2729 | 41 |
CLE | AAA | P | 34 | 39 | 45 | 45 |
0.0% | Low Risk · 21 | N/A | |
| 2730 | 41 |
CIN | AA | 2B | 34 | 44 | 56 | 49 |
0.0% | Medium Risk · 54 | N/A | |
| 2731 | 41 |
TOR | FCL | P | 31 | 40 | 51 | 38 |
0.0% | Low Risk · 32 | N/A | |
| 2732 | 41 |
COL | DSL | P | 29 | 41 | 52 | 45 |
0.0% | Medium Risk · 52 | N/A | |
| 2733 | 41 |
DET | FCL | C | 31 | 40 | 49 | 38 |
+0.1% | Low Risk · 33 | N/A | |
| 2734 | 41 |
LAD | DSL | P | 32 | 45 | 59 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2735 | 41 |
BOS | DSL | P | 32 | 45 | 59 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2736 | 41 |
COL | DSL | P | 30 | 40 | 54 | 43 |
0.0% | Medium Risk · 46 | N/A | |
| 2737 | 41 |
LAA | DSL | P | 29 | 39 | 51 | 43 |
-0.2% | Medium Risk · 42 | N/A | |
| 2738 | 41 |
MIA | FCL | 2B | 30 | 39 | 49 | 40 |
0.0% | Low Risk · 37 | N/A | |
| 2739 | 41 |
LAD | ACL | P | 29 | 39 | 51 | 42 |
0.0% | Low Risk · 32 | N/A | |
| 2740 | 41 |
HOU | AA | P | 31 | 38 | 49 | 48 |
+0.2% | Low Risk · 20 | N/A | |
| 2741 | 41 |
WSH | High-A | P | 32 | 43 | 54 | 46 |
0.0% | Medium Risk · 48 | N/A | |
| 2742 | 41 |
MIL | DSL | SS | 29 | 40 | 51 | 43 |
0.0% | Medium Risk · 47 | N/A | |
| 2743 | 41 |
ARI | High-A | 2B | 31 | 39 | 45 | 29 |
+0.1% | Low Risk · 15 | N/A | |
| 2744 | 41 |
KC | AA | SS | 31 | 37 | 44 | 53 |
-0.1% | Low Risk · 22 | N/A | |
| 2745 | 41 |
CIN | AA | P | 33 | 43 | 52 | 47 |
0.0% | Medium Risk · 53 | N/A | |
| 2746 | 41 |
TOR | DSL | C | 30 | 41 | 51 | 42 |
+0.1% | Medium Risk · 47 | N/A | |
| 2747 | 41 |
CLE | ACL | C | 30 | 39 | 48 | 40 |
0.0% | Low Risk · 32 | N/A | |
| 2748 | 41 |
BAL | High-A | C | 31 | 39 | 46 | 33 |
0.0% | Low Risk · 24 | N/A | |
| 2749 | 41 |
HOU | Single-A | P | 31 | 38 | 45 | 30 |
0.0% | Low Risk · 12 | N/A | |
| 2750 | 41 |
PIT | FCL | IF | 30 | 42 | 58 | 45 |
-0.3% | Medium Risk · 56 | N/A | |
| 2751 | 41 |
KC | DSL | SS | 29 | 39 | 49 | 42 |
+0.2% | Low Risk · 37 | N/A | |
| 2752 | 41 |
MIA | DSL | OF | 29 | 39 | 49 | 40 |
0.0% | Low Risk · 32 | N/A | |
| 2753 | 41 |
KC | AAA | 2B | 31 | 41 | 52 | 57 |
+0.1% | Low Risk · 39 | N/A | |
| 2754 | 41 |
SD | ACL | C | 30 | 41 | 50 | 42 |
+0.1% | Medium Risk · 53 | N/A | |
| 2755 | 41 |
CWS | ACL | OF | 29 | 40 | 50 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2756 | 41 |
WSH | High-A | RF | 32 | 44 | 55 | 50 |
0.0% | Wide Range · 61 | N/A | |
| 2757 | 41 |
SF | Single-A | OF | 32 | 39 | 46 | 30 |
0.0% | Low Risk · 21 | N/A | |
| 2758 | 41 |
CWS | ACL | P | 31 | 44 | 64 | 43 |
0.0% | Wide Range · 66 | N/A | |
| 2759 | 41 |
NYY | DSL | CF | 29 | 40 | 51 | 43 |
-0.1% | Medium Risk · 46 | N/A | |
| 2760 | 41 |
WSH | FCL | C | 31 | 42 | 52 | 43 |
0.0% | Medium Risk · 56 | N/A | |
| 2761 | 41 |
MIA | FCL | P | 29 | 40 | 50 | 43 |
0.0% | Medium Risk · 46 | N/A | |
| 2762 | 41 |
MIN | DSL | P | 31 | 42 | 54 | 42 |
-0.5% | Medium Risk · 56 | N/A | |
| 2763 | 41 |
ATH | DSL | P | 30 | 40 | 51 | 43 |
0.0% | Medium Risk · 46 | N/A | |
| 2764 | 41 |
SEA | Single-A | P | 32 | 40 | 50 | 36 |
0.0% | Low Risk · 22 | N/A | |
| 2765 | 41 |
PIT | Single-A | P | 31 | 39 | 47 | 35 |
-0.9% | Low Risk · 28 | N/A | |
| 2766 | 41 |
WSH | AAA | LF | 32 | 36 | 41 | 45 |
0.0% | Low Risk · 21 | N/A | |
| 2767 | 41 |
STL | Single-A | CF | 30 | 40 | 51 | 45 |
0.0% | Low Risk · 35 | N/A | |
| 2768 | 41 |
BAL | FCL | OF | 29 | 40 | 51 | 43 |
0.0% | Medium Risk · 45 | N/A | |
| 2769 | 41 |
MIL | DSL | C | 29 | 41 | 57 | 46 |
+0.1% | Medium Risk · 56 | N/A | |
| 2770 | 41 |
ARI | ACL | P | 30 | 39 | 48 | 36 |
0.0% | Low Risk · 34 | N/A | |
| 2771 | 41 |
CWS | AA | P | 30 | 37 | 49 | 51 |
-0.2% | Low Risk · 21 | N/A | |
| 2772 | 41 |
SD | High-A | P | 32 | 41 | 49 | 37 |
+0.1% | Low Risk · 34 | N/A | |
| 2773 | 41 |
WSH | DSL | OF | 29 | 40 | 50 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2774 | 41 |
LAD | DSL | C | 29 | 40 | 50 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2775 | 41 |
BAL | AA | P | 33 | 40 | 48 | 41 |
0.0% | Medium Risk · 42 | N/A | |
| 2776 | 41 |
PIT | AA | P | 33 | 40 | 48 | 34 |
+0.3% | Low Risk · 34 | N/A | |
| 2777 | 41 |
CWS | High-A | P | 31 | 42 | 57 | 48 |
0.0% | Medium Risk · 52 | N/A | |
| 2778 | 41 |
NYY | High-A | P | 30 | 41 | 51 | 46 |
0.0% | Low Risk · 38 | N/A | |
| 2779 | 41 |
CIN | DSL | OF | 29 | 41 | 51 | 44 |
0.0% | Medium Risk · 47 | N/A | |
| 2780 | IL(60-Day)41 |
ARI | Single-A | PIL(60-Day) | 32 | 43 | 60 | 49 |
0.0% | Wide Range · 66 | N/A | |
| 2781 | 41 |
NYM | AA | P | 32 | 40 | 47 | 35 |
0.0% | Low Risk · 34 | N/A | |
| 2782 | 41 |
TB | DSL | C | 29 | 39 | 48 | 40 |
-0.1% | Low Risk · 37 | N/A | |
| 2783 | 41 |
SF | ACL | P | 30 | 43 | 55 | 44 |
0.0% | Wide Range · 58 | N/A | |
| 2784 | 41 |
STL | FCL | OF | 30 | 40 | 50 | 42 |
0.0% | Medium Risk · 46 | N/A | |
| 2785 | 41 |
CIN | DSL | C | 29 | 42 | 53 | 45 |
0.0% | Medium Risk · 56 | N/A | |
| 2786 | 41 |
CLE | DSL | SS | 29 | 39 | 49 | 41 |
0.0% | Low Risk · 37 | N/A | |
| 2787 | 41 |
ARI | DSL | C | 29 | 41 | 52 | 43 |
0.0% | Medium Risk · 47 | N/A | |
| 2788 | 41 |
ARI | DSL | SS | 29 | 39 | 49 | 43 |
0.0% | Medium Risk · 46 | N/A | |
| 2789 | 41 |
KC | ACL | C | 29 | 39 | 50 | 42 |
0.0% | Low Risk · 40 | N/A | |
| 2790 | 41 |
TOR | Single-A | OF | 31 | 38 | 45 | 35 |
0.0% | Low Risk · 17 | N/A | |
| 2791 | 41 |
ATH | DSL | P | 31 | 45 | 59 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2792 | 41 |
PIT | DSL | P | 31 | 45 | 59 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2793 | 41 |
BOS | DSL | P | 31 | 45 | 59 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2794 | 41 |
HOU | Single-A | P | 30 | 40 | 51 | 43 |
0.0% | Low Risk · 34 | N/A | |
| 2795 | 41 |
CHC | DSL | C | 29 | 40 | 53 | 42 |
+0.1% | Medium Risk · 42 | N/A | |
| 2796 | 41 |
KC | DSL | SS | 29 | 40 | 49 | 40 |
-0.2% | Low Risk · 37 | N/A | |
| 2797 | 41 |
SEA | Single-A | 2B | 30 | 38 | 45 | 32 |
+0.2% | Low Risk · 12 | N/A | |
| 2798 | 41 |
WSH | Single-A | P | 31 | 41 | 59 | 44 |
0.0% | Low Risk · 40 | N/A | |
| 2799 | 41 |
TB | FCL | C | 29 | 39 | 49 | 43 |
-0.1% | Medium Risk · 45 | N/A | |
| 2800 | 41 |
ATH | Single-A | OF | 31 | 38 | 45 | 33 |
0.0% | Low Risk · 12 | N/A | |
| 2801 | 41 |
WSH | High-A | P | 32 | 40 | 47 | 34 |
-0.4% | Low Risk · 24 | N/A | |
| 2802 | 41 |
DET | Single-A | P | 30 | 39 | 47 | 41 |
-0.5% | Low Risk · 34 | N/A | |
| 2803 | 41 |
PHI | FCL | SS | 31 | 41 | 50 | 38 |
+0.1% | Low Risk · 41 | N/A | |
| 2804 | 41 |
MIA | High-A | 2B | 31 | 42 | 53 | 48 |
0.0% | Wide Range · 58 | N/A | |
| 2805 | 41 |
SD | High-A | SS | 31 | 38 | 45 | 32 |
0.0% | Low Risk · 19 | N/A | |
| 2806 | 41 |
PIT | DSL | C | 29 | 40 | 50 | 43 |
-0.1% | Medium Risk · 47 | N/A | |
| 2807 | 41 |
PHI | FCL | C | 29 | 40 | 51 | 42 |
-0.2% | Medium Risk · 47 | N/A | |
| 2808 | 41 |
BAL | High-A | P | 31 | 40 | 51 | 42 |
0.0% | Low Risk · 28 | N/A | |
| 2809 | 41 |
STL | DSL | OF | 29 | 39 | 49 | 39 |
0.0% | Low Risk · 32 | N/A | |
| 2810 | 41 |
MIN | DSL | OF | 29 | 39 | 49 | 39 |
-0.2% | Low Risk · 32 | N/A | |
| 2811 | 41 |
SD | High-A | C | 31 | 39 | 47 | 36 |
0.0% | Low Risk · 24 | N/A | |
| 2812 | 41 |
BOS | High-A | C | 31 | 41 | 52 | 46 |
0.0% | Medium Risk · 44 | N/A | |
| 2813 | 41 |
COL | AAA | P | 35 | 44 | 57 | 58 |
-0.1% | Wide Range · 62 | N/A | |
| 2814 | 41 |
LAD | Single-A | P | 31 | 42 | 53 | 46 |
0.0% | Medium Risk · 52 | N/A | |
| 2815 | 41 |
CIN | DSL | OF | 29 | 39 | 49 | 40 |
0.0% | Low Risk · 37 | N/A | |
| 2816 | 41 |
NYY | AAA | RF | 33 | 43 | 54 | 57 |
0.0% | Wide Range · 62 | N/A | |
| 2817 | 41 |
KC | ACL | P | 32 | 42 | 54 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 2818 | IL(7-Day)41 |
PIT | Single-A | OFIL(7-Day) | 31 | 41 | 51 | 44 |
-0.3% | Medium Risk · 49 | N/A | |
| 2819 | 41 |
MIL | ACL | P | 31 | 40 | 49 | 39 |
0.0% | Medium Risk · 48 | N/A | |
| 2820 | 41 |
LAA | ACL | P | 31 | 42 | 56 | 41 |
0.0% | Medium Risk · 56 | N/A | |
| 2821 | 41 |
LAD | AA | 1B | 34 | 40 | 46 | 31 |
0.0% | Low Risk · 35 | N/A | |
| 2822 | 41 |
HOU | High-A | P | 32 | 40 | 46 | 27 |
0.0% | Low Risk · 20 | N/A | |
| 2823 | 41 |
KC | DSL | P | 29 | 39 | 49 | 40 |
0.0% | Low Risk · 32 | N/A | |
| 2824 | 41 |
CLE | ACL | P | 30 | 41 | 56 | 44 |
0.0% | Wide Range · 60 | N/A | |
| 2825 | 41 |
CIN | ACL | OF | 30 | 41 | 51 | 43 |
0.0% | Medium Risk · 53 | N/A | |
| 2826 | 41 |
CWS | Single-A | P | 29 | 38 | 57 | 50 |
0.0% | Low Risk · 29 | N/A | |
| 2827 | 41 |
SF | DSL | IF | 28 | 38 | 53 | 44 |
-0.2% | Low Risk · 40 | N/A | |
| 2828 | 41 |
MIL | ACL | 3B | 30 | 40 | 50 | 40 |
-0.3% | Medium Risk · 48 | N/A | |
| 2829 | 41 |
CHC | DSL | P | 31 | 43 | 58 | 44 |
0.0% | Wide Range · 66 | N/A | |
| 2830 | 41 |
CHC | Single-A | P | 31 | 42 | 59 | 46 |
0.0% | Medium Risk · 54 | N/A | |
| 2831 | 41 |
ATL | AA | 1B | 34 | 39 | 44 | 31 |
-0.1% | Low Risk · 24 | N/A | |
| 2832 | 40 |
DET | AA | P | 32 | 42 | 51 | 48 |
0.0% | Medium Risk · 52 | N/A | |
| 2833 | 40 |
STL | High-A | P | 33 | 39 | 45 | 33 |
0.0% | Low Risk · 34 | N/A | |
| 2834 | 40 |
PIT | DSL | P | 30 | 43 | 63 | 45 |
0.0% | Wide Range · 66 | N/A | |
| 2835 | 40 |
CLE | Single-A | CF | 31 | 39 | 46 | 33 |
0.0% | Low Risk · 30 | N/A | |
| 2836 | 40 |
MIL | High-A | P | 32 | 41 | 49 | 40 |
0.0% | Medium Risk · 42 | N/A | |
| 2837 | 40 |
TB | Single-A | P | 30 | 38 | 47 | 41 |
-0.4% | Low Risk · 34 | N/A | |
| 2838 | 40 |
HOU | DSL | P | 30 | 43 | 64 | 45 |
+0.8% | Wide Range · 66 | N/A | |
| 2839 | 40 |
ATL | FCL | C | 31 | 41 | 51 | 38 |
0.0% | Medium Risk · 46 | N/A | |
| 2840 | 40 |
SD | DSL | OF | 28 | 39 | 53 | 44 |
0.0% | Medium Risk · 46 | N/A | |
| 2841 | 40 |
ATL | Single-A | P | 31 | 39 | 47 | 39 |
-0.1% | Low Risk · 36 | N/A | |
| 2842 | 40 |
TB | DSL | IF | 29 | 39 | 48 | 40 |
+0.1% | Low Risk · 32 | N/A | |
| 2843 | 40 |
NYY | DSL | CF | 28 | 38 | 50 | 43 |
-0.1% | Medium Risk · 46 | N/A | |
| 2844 | 40 |
HOU | AA | P | 32 | 40 | 47 | 36 |
0.0% | Low Risk · 34 | N/A | |
| 2845 | 40 |
PHI | DSL | C | 29 | 39 | 50 | 43 |
-0.1% | Medium Risk · 46 | N/A | |
| 2846 | 40 |
DET | DSL | OF | 28 | 39 | 58 | 42 |
-0.2% | Low Risk · 40 | N/A | |
| 2847 | 40 |
MIN | High-A | P | 33 | 44 | 61 | 47 |
+0.1% | Medium Risk · 53 | N/A | |
| 2848 | 40 |
COL | DSL | P | 28 | 39 | 49 | 43 |
0.0% | Medium Risk · 46 | N/A | |
| 2849 | 40 |
NYM | DSL | SS | 29 | 41 | 55 | 45 |
0.0% | Medium Risk · 56 | N/A | |
| 2850 | 40 |
LAA | AAA | P | 33 | 40 | 48 | 37 |
0.0% | Low Risk · 36 | N/A | |
| 2851 | 40 |
CLE | AA | C | 32 | 39 | 46 | 35 |
0.0% | Low Risk · 27 | N/A | |
| 2852 | 40 |
LAD | Single-A | C | 31 | 38 | 46 | 38 |
+0.2% | Low Risk · 28 | N/A | |
| 2853 | 40 |
STL | DSL | P | 30 | 41 | 54 | 40 |
0.0% | Medium Risk · 42 | N/A | |
| 2854 | 40 |
LAA | DSL | OF | 29 | 39 | 49 | 40 |
+0.1% | Low Risk · 37 | N/A | |
| 2855 | 40 |
TEX | DSL | IF | 29 | 39 | 49 | 40 |
0.0% | Low Risk · 37 | N/A | |
| 2856 | 40 |
ATH | Single-A | P | 31 | 39 | 47 | 32 |
0.0% | Low Risk · 24 | N/A | |
| 2857 | 40 |
ATH | AAA | P | 33 | 37 | 43 | 48 |
+0.1% | Low Risk · 36 | N/A | |
| 2858 | 40 |
NYY | AAA | CF | 31 | 40 | 50 | 54 |
-0.2% | Low Risk · 42 | N/A | |
| 2859 | 40 |
ATL | DSL | SS | 29 | 40 | 50 | 42 |
-0.7% | Medium Risk · 47 | N/A | |
| 2860 | 40 |
MIA | DSL | IF | 29 | 40 | 54 | 40 |
0.0% | Medium Risk · 42 | N/A | |
| 2861 | 40 |
SEA | AAA | P | 31 | 39 | 49 | 52 |
0.0% | Low Risk · 30 | N/A | |
| 2862 | 40 |
CHC | DSL | P | 28 | 39 | 49 | 41 |
0.0% | Medium Risk · 42 | N/A | |
| 2863 | 40 |
COL | DSL | C | 31 | 45 | 58 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2864 | 40 |
COL | DSL | SS | 31 | 45 | 58 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2865 | 40 |
CHC | DSL | P | 30 | 42 | 57 | 45 |
+0.1% | Wide Range · 66 | N/A | |
| 2866 | 40 |
PHI | Single-A | SS | 30 | 41 | 52 | 46 |
0.0% | Medium Risk · 47 | N/A | |
| 2867 | IL(7-Day)40 |
NYM | High-A | PIL(7-Day) | 31 | 41 | 55 | 45 |
0.0% | Medium Risk · 44 | N/A | |
| 2868 | 40 |
BAL | DSL | OF | 29 | 39 | 49 | 39 |
0.0% | Low Risk · 32 | N/A | |
| 2869 | 40 |
ATL | Single-A | SS | 31 | 39 | 46 | 31 |
0.0% | Low Risk · 23 | N/A | |
| 2870 | 40 |
ATH | High-A | P | 31 | 40 | 48 | 37 |
+0.2% | Low Risk · 34 | N/A | |
| 2871 | 40 |
SD | AAA | RF | 34 | 39 | 44 | 45 |
-0.3% | Low Risk · 36 | N/A | |
| 2872 | 40 |
ATL | Single-A | C | 32 | 39 | 47 | 36 |
+0.2% | Low Risk · 28 | N/A | |
| 2873 | 40 |
BOS | DSL | SS | 29 | 39 | 48 | 39 |
-0.3% | Low Risk · 32 | N/A | |
| 2874 | 40 |
SEA | AAA | CF | 33 | 37 | 42 | 43 |
0.0% | Low Risk · 20 | N/A | |
| 2875 | 40 |
LAA | High-A | P | 31 | 39 | 47 | 38 |
-0.5% | Low Risk · 34 | N/A | |
| 2876 | 40 |
SD | DSL | IF | 28 | 38 | 51 | 44 |
0.0% | Medium Risk · 46 | N/A | |
| 2877 | 40 |
PIT | DSL | OF | 29 | 39 | 49 | 38 |
0.0% | Low Risk · 32 | N/A | |
| 2878 | IL(Rehab)40 |
BAL | High-A | PIL(Rehab) | 32 | 43 | 57 | 46 |
0.0% | Medium Risk · 57 | N/A | |
| 2879 | 40 |
CLE | ACL | OF | 30 | 39 | 48 | 38 |
+0.1% | Medium Risk · 45 | N/A | |
| 2880 | 40 |
MIA | Single-A | P | 31 | 42 | 52 | 44 |
0.0% | Medium Risk · 44 | N/A | |
| 2881 | 40 |
NYY | DSL | SS | 29 | 40 | 50 | 42 |
0.0% | Medium Risk · 47 | N/A | |
| 2882 | 40 |
TB | Single-A | C | 31 | 40 | 48 | 37 |
+0.1% | Low Risk · 33 | N/A | |
| 2883 | 40 |
SF | High-A | C | 30 | 40 | 51 | 45 |
0.0% | Medium Risk · 42 | N/A | |
| 2884 | 40 |
NYM | DSL | C | 29 | 40 | 53 | 41 |
+0.1% | Medium Risk · 42 | N/A | |
| 2885 | 40 |
SD | DSL | C | 29 | 39 | 50 | 42 |
-0.1% | Medium Risk · 47 | N/A | |
| 2886 | 40 |
MIL | DSL | SS | 29 | 41 | 57 | 44 |
-0.1% | Medium Risk · 56 | N/A | |
| 2887 | 40 |
SEA | AA | OF | 33 | 38 | 44 | 31 |
0.0% | Low Risk · 35 | N/A | |
| 2888 | 40 |
TB | High-A | P | 30 | 37 | 45 | 32 |
0.0% | Low Risk · 10 | N/A | |
| 2889 | 40 |
CLE | Single-A | 2B | 31 | 39 | 46 | 30 |
-0.1% | Low Risk · 30 | N/A | |
| 2890 | 40 |
TEX | Single-A | P | 29 | 40 | 51 | 44 |
-0.1% | Low Risk · 40 | N/A | |
| 2891 | 40 |
WSH | DSL | IF | 29 | 39 | 51 | 42 |
-0.1% | Medium Risk · 46 | N/A | |
| 2892 | 40 |
SF | AA | 3B | 32 | 37 | 44 | 43 |
+0.1% | Low Risk · 19 | N/A | |
| 2893 | 40 |
ATL | FCL | SS | 28 | 39 | 49 | 41 |
0.0% | Low Risk · 37 | N/A | |
| 2894 | 40 |
CLE | AA | P | 33 | 39 | 46 | 34 |
-0.1% | Low Risk · 23 | N/A | |
| 2895 | 40 |
NYY | FCL | C | 30 | 39 | 47 | 34 |
-0.1% | Low Risk · 24 | N/A | |
| 2896 | 40 |
CLE | High-A | P | 30 | 38 | 45 | 36 |
0.0% | Low Risk · 24 | N/A | |
| 2897 | 40 |
NYM | FCL | CF | 29 | 40 | 58 | 43 |
0.0% | Medium Risk · 50 | N/A | |
| 2898 | 40 |
ATL | FCL | C | 29 | 39 | 48 | 38 |
+0.1% | Low Risk · 40 | N/A | |
| 2899 | IL(Full Season)40 |
PIT | AA | PIL(Full Season) | 32 | 43 | 54 | 52 |
0.0% | Wide Range · 69 | N/A | |
| 2900 | 40 |
CWS | DSL | P | 29 | 40 | 50 | 40 |
+0.4% | Medium Risk · 42 | N/A | |
| 2901 | 40 |
MIN | AA | C | 31 | 37 | 44 | 46 |
+0.1% | Low Risk · 20 | N/A | |
| 2902 | 40 |
TOR | DSL | P | 31 | 44 | 58 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2903 | 40 |
TOR | DSL | P | 31 | 44 | 58 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2904 | 40 |
STL | DSL | P | 31 | 44 | 58 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2905 | IL(Full Season)40 |
ATL | Single-A | SSIL(Full Season) | 31 | 43 | 54 | 50 |
0.0% | Wide Range · 70 | N/A | |
| 2906 | 40 |
MIA | DSL | P | 30 | 42 | 53 | 45 |
-0.2% | Wide Range · 66 | N/A | |
| 2907 | 40 |
MIN | DSL | P | 29 | 41 | 59 | 46 |
0.0% | Wide Range · 66 | N/A | |
| 2908 | 40 |
HOU | DSL | C | 29 | 41 | 54 | 44 |
+0.1% | Medium Risk · 56 | N/A | |
| 2909 | IL(Rehab)40 |
DET | FCL | CIL(Rehab) | 28 | 40 | 51 | 44 |
0.0% | Medium Risk · 51 | N/A | |
| 2910 | 40 |
LAD | DSL | OF | 28 | 40 | 51 | 43 |
0.0% | Medium Risk · 47 | N/A | |
| 2911 | 40 |
HOU | DSL | C | 28 | 39 | 51 | 43 |
0.0% | Medium Risk · 51 | N/A | |
| 2912 | 40 |
BAL | DSL | IF | 28 | 41 | 54 | 46 |
-0.2% | Wide Range · 61 | N/A | |
| 2913 | 40 |
LAA | DSL | OF | 28 | 39 | 50 | 42 |
-0.1% | Medium Risk · 47 | N/A | |
| 2914 | 40 |
CLE | High-A | P | 31 | 39 | 47 | 31 |
0.0% | Low Risk · 34 | N/A | |
| 2915 | 40 |
COL | ACL | P | 31 | 44 | 65 | 44 |
-0.3% | Wide Range · 66 | N/A | |
| 2916 | 40 |
CLE | ACL | P | 30 | 40 | 49 | 38 |
-0.2% | Medium Risk · 48 | N/A | |
| 2917 | 40 |
SD | ACL | IF | 30 | 39 | 48 | 35 |
0.0% | Medium Risk · 49 | N/A | |
| 2918 | 40 |
SF | Single-A | 3B | 29 | 40 | 51 | 48 |
0.0% | Medium Risk · 50 | N/A | |
| 2919 | 40 |
WSH | High-A | OF | 31 | 40 | 50 | 43 |
0.0% | Medium Risk · 48 | N/A | |
| 2920 | 40 |
BOS | AA | P | 31 | 37 | 48 | 47 |
0.0% | Low Risk · 21 | N/A | |
| 2921 | 40 |
LAA | DSL | P | 29 | 41 | 55 | 46 |
0.0% | Wide Range · 66 | N/A | |
| 2922 | 40 |
CHC | Single-A | C | 30 | 41 | 54 | 45 |
-0.4% | Medium Risk · 46 | N/A | |
| 2923 | 40 |
BOS | High-A | P | 31 | 40 | 48 | 39 |
-0.4% | Low Risk · 28 | N/A | |
| 2924 | 40 |
ATH | ACL | SS | 28 | 37 | 46 | 42 |
-0.1% | Low Risk · 32 | N/A | |
| 2925 | 40 |
COL | High-A | P | 30 | 39 | 48 | 41 |
0.0% | Low Risk · 32 | N/A | |
| 2926 | 40 |
CIN | ACL | C | 28 | 40 | 50 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2927 | IL(60-Day)40 |
TB | AA | PIL(60-Day) | 31 | 41 | 52 | 50 |
0.0% | Wide Range · 64 | N/A | |
| 2928 | 40 |
NYY | AA | C | 30 | 40 | 50 | 47 |
0.0% | Medium Risk · 43 | N/A | |
| 2929 | 40 |
KC | ACL | SS | 29 | 39 | 51 | 42 |
+0.1% | Medium Risk · 46 | N/A | |
| 2930 | 40 |
ARI | DSL | OF | 28 | 39 | 50 | 41 |
0.0% | Medium Risk · 47 | N/A | |
| 2931 | 40 |
SD | AA | CF | 33 | 39 | 45 | 31 |
+0.2% | Low Risk · 31 | N/A | |
| 2932 | 40 |
WSH | AAA | OF | 32 | 37 | 42 | 44 |
-0.2% | Low Risk · 26 | N/A | |
| 2933 | 40 |
BOS | FCL | P | 29 | 40 | 51 | 43 |
0.0% | Medium Risk · 56 | N/A | |
| 2934 | 40 |
TOR | Single-A | P | 30 | 38 | 47 | 38 |
-0.2% | Low Risk · 36 | N/A | |
| 2935 | 40 |
NYY | DSL | P | 29 | 40 | 54 | 43 |
-0.1% | Medium Risk · 56 | N/A | |
| 2936 | 40 |
MIL | Single-A | P | 29 | 38 | 47 | 41 |
0.0% | Low Risk · 34 | N/A | |
| 2937 | 40 |
TOR | FCL | C | 28 | 40 | 51 | 43 |
-0.1% | Medium Risk · 47 | N/A | |
| 2938 | 40 |
STL | High-A | P | 31 | 40 | 48 | 37 |
-0.1% | Low Risk · 34 | N/A | |
| 2939 | 40 |
CHC | DSL | IF | 28 | 39 | 50 | 43 |
0.0% | Medium Risk · 51 | N/A | |
| 2940 | 40 |
NYY | High-A | P | 31 | 42 | 59 | 47 |
-0.1% | Medium Risk · 53 | N/A | |
| 2941 | 40 |
CWS | ACL | P | 30 | 40 | 50 | 40 |
-0.2% | Medium Risk · 46 | N/A | |
| 2942 | 40 |
CLE | High-A | C | 30 | 41 | 51 | 46 |
-0.3% | Medium Risk · 43 | N/A | |
| 2943 | 40 |
DET | AA | P | 32 | 40 | 48 | 38 |
-0.3% | Medium Risk · 42 | N/A | |
| 2944 | 40 |
MIL | AAA | SS | 32 | 37 | 42 | 40 |
-0.5% | Low Risk · 24 | N/A | |
| 2945 | 40 |
ATL | DSL | OF | 28 | 39 | 50 | 41 |
+0.3% | Medium Risk · 47 | N/A | |
| 2946 | 40 |
CIN | High-A | SS | 30 | 43 | 54 | 49 |
0.0% | Wide Range · 61 | N/A | |
| 2947 | 40 |
NYM | Single-A | P | 31 | 41 | 52 | 41 |
0.0% | Medium Risk · 44 | N/A | |
| 2948 | 40 |
KC | AAA | P | 32 | 40 | 48 | 37 |
-0.1% | Low Risk · 37 | N/A | |
| 2949 | 40 |
PHI | High-A | OF | 31 | 39 | 47 | 32 |
0.0% | Low Risk · 35 | N/A | |
| 2950 | 40 |
ARI | High-A | SS | 30 | 38 | 44 | 31 |
0.0% | Low Risk · 19 | N/A | |
| 2951 | 40 |
NYM | AA | P | 33 | 39 | 44 | 28 |
-0.3% | Low Risk · 34 | N/A | |
| 2952 | 40 |
CHC | AAA | 3B | 32 | 37 | 42 | 41 |
0.0% | Low Risk · 20 | N/A | |
| 2953 | 40 |
LAA | High-A | C | 29 | 37 | 45 | 36 |
-0.3% | Low Risk · 15 | N/A | |
| 2954 | 40 |
SD | DSL | P | 30 | 44 | 58 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2955 | 40 |
HOU | DSL | P | 30 | 44 | 58 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2956 | 40 |
WSH | DSL | P | 30 | 44 | 58 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2957 | 40 |
CHC | DSL | P | 30 | 44 | 58 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 2958 | 40 |
MIA | AAA | P | 32 | 37 | 44 | 60 |
-0.1% | Low Risk · 28 | N/A | |
| 2959 | 40 |
WSH | High-A | P | 30 | 38 | 45 | 36 |
0.0% | Low Risk · 24 | N/A | |
| 2960 | 40 |
NYY | AAA | 1B | 32 | 37 | 42 | 46 |
-0.2% | Low Risk · 22 | N/A | |
| 2961 | 40 |
BOS | DSL | P | 29 | 40 | 54 | 42 |
-0.1% | Medium Risk · 56 | N/A | |
| 2962 | 40 |
SEA | AAA | OF | 30 | 38 | 46 | 52 |
-0.8% | Low Risk · 30 | N/A | |
| 2963 | 40 |
DET | High-A | P | 31 | 40 | 49 | 41 |
0.0% | Low Risk · 38 | N/A | |
| 2964 | 40 |
LAD | High-A | P | 31 | 40 | 48 | 40 |
0.0% | Low Risk · 32 | N/A | |
| 2965 | 40 |
KC | ACL | P | 29 | 40 | 61 | 40 |
0.0% | Low Risk · 40 | N/A | |
| 2966 | 40 |
PHI | FCL | LF | 29 | 38 | 46 | 38 |
0.0% | Low Risk · 32 | N/A | |
| 2967 | 40 |
NYM | DSL | OF | 29 | 41 | 56 | 42 |
0.0% | Wide Range · 58 | N/A | |
| 2968 | 40 |
DET | FCL | P | 30 | 40 | 50 | 36 |
0.0% | Medium Risk · 48 | N/A | |
| 2969 | 40 |
TOR | DSL | C | 28 | 38 | 48 | 40 |
+0.1% | Low Risk · 37 | N/A | |
| 2970 | 40 |
STL | Single-A | P | 31 | 39 | 47 | 38 |
+0.3% | Low Risk · 36 | N/A | |
| 2971 | 40 |
CWS | Single-A | P | 31 | 39 | 49 | 34 |
-0.1% | Low Risk · 22 | N/A | |
| 2972 | 40 |
MIL | DSL | CF | 27 | 38 | 51 | 42 |
0.0% | Medium Risk · 46 | N/A | |
| 2973 | 40 |
PIT | DSL | P | 27 | 38 | 48 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 2974 | 40 |
COL | Single-A | 1B | 28 | 39 | 49 | 43 |
0.0% | Medium Risk · 44 | N/A | |
| 2975 | 40 |
TEX | DSL | C | 28 | 41 | 52 | 45 |
+0.1% | Wide Range · 61 | N/A | |
| 2976 | IL(7-Day)40 |
PIT | Single-A | PIL(7-Day) | 30 | 40 | 49 | 39 |
0.0% | Low Risk · 38 | N/A | |
| 2977 | 40 |
HOU | Single-A | P | 31 | 40 | 48 | 37 |
0.0% | Low Risk · 38 | N/A | |
| 2978 | 40 |
PIT | High-A | P | 31 | 39 | 46 | 32 |
-0.1% | Low Risk · 34 | N/A | |
| 2979 | 39 |
MIA | DSL | IF | 28 | 39 | 50 | 41 |
0.0% | Medium Risk · 42 | N/A | |
| 2980 | 39 |
TB | DSL | OF | 28 | 39 | 50 | 41 |
-0.1% | Medium Risk · 42 | N/A | |
| 2981 | 39 |
PIT | DSL | SS | 30 | 40 | 50 | 39 |
0.0% | Medium Risk · 48 | N/A | |
| 2982 | 39 |
KC | Single-A | C | 28 | 39 | 49 | 43 |
0.0% | Low Risk · 35 | N/A | |
| 2983 | 39 |
BOS | High-A | P | 31 | 39 | 46 | 31 |
0.0% | Low Risk · 34 | N/A | |
| 2984 | 39 |
COL | DSL | 2B | 27 | 38 | 50 | 44 |
+0.1% | Medium Risk · 51 | N/A | |
| 2985 | 39 |
COL | High-A | C | 31 | 38 | 45 | 33 |
-0.1% | Low Risk · 26 | N/A | |
| 2986 | 39 |
CIN | DSL | IF | 29 | 40 | 50 | 41 |
-0.1% | Medium Risk · 48 | N/A | |
| 2987 | 39 |
MIA | DSL | P | 29 | 40 | 53 | 41 |
0.0% | Medium Risk · 52 | N/A | |
| 2988 | 39 |
NYM | FCL | C | 29 | 39 | 49 | 40 |
+0.2% | Medium Risk · 48 | N/A | |
| 2989 | 39 |
CWS | AAA | P | 29 | 39 | 48 | 55 |
0.0% | Medium Risk · 48 | N/A | |
| 2990 | 39 |
ATL | DSL | P | 28 | 39 | 55 | 44 |
0.0% | Wide Range · 60 | N/A | |
| 2991 | 39 |
LAA | AA | P | 34 | 39 | 44 | 32 |
0.0% | Low Risk · 22 | N/A | |
| 2992 | 39 |
MIN | Single-A | P | 35 | 45 | 63 | 46 |
0.0% | Wide Range · 65 | N/A | |
| 2993 | 39 |
SF | High-A | P | 29 | 41 | 51 | 47 |
-0.2% | Medium Risk · 52 | N/A | |
| 2994 | 39 |
SF | AAA | C | 30 | 40 | 49 | 55 |
0.0% | Medium Risk · 43 | N/A | |
| 2995 | 39 |
ARI | DSL | P | 28 | 39 | 54 | 42 |
-0.2% | Medium Risk · 46 | N/A | |
| 2996 | 39 |
WSH | AA | P | 29 | 36 | 45 | 50 |
-0.2% | Low Risk · 22 | N/A | |
| 2997 | 39 |
HOU | DSL | C | 28 | 39 | 50 | 42 |
+0.1% | Medium Risk · 47 | N/A | |
| 2998 | 39 |
STL | AA | P | 33 | 42 | 51 | 43 |
0.0% | Medium Risk · 44 | N/A | |
| 2999 | 39 |
KC | Single-A | SS | 30 | 40 | 49 | 41 |
0.0% | Medium Risk · 43 | N/A | |
| 3000 | 39 |
BAL | FCL | IF | 28 | 39 | 50 | 42 |
+0.1% | Medium Risk · 47 | N/A | |
| 3001 | 39 |
ARI | High-A | P | 30 | 37 | 44 | 35 |
-0.3% | Low Risk · 24 | N/A | |
| 3002 | 39 |
CWS | AA | P | 30 | 36 | 45 | 48 |
-0.8% | Low Risk · 21 | N/A | |
| 3003 | 39 |
TOR | AA | 1B | 31 | 39 | 47 | 42 |
0.0% | Low Risk · 35 | N/A | |
| 3004 | 39 |
SF | AA | SS | 32 | 41 | 49 | 40 |
-0.2% | Medium Risk · 43 | N/A | |
| 3005 | 39 |
MIL | High-A | P | 31 | 40 | 49 | 41 |
+0.2% | Medium Risk · 42 | N/A | |
| 3006 | 39 |
CIN | DSL | IF | 28 | 38 | 48 | 37 |
0.0% | Low Risk · 32 | N/A | |
| 3007 | IL(7-Day)39 |
SEA | High-A | PIL(7-Day) | 31 | 41 | 59 | 47 |
0.0% | Medium Risk · 47 | N/A | |
| 3008 | 39 |
ARI | DSL | C | 28 | 39 | 49 | 41 |
0.0% | Medium Risk · 47 | N/A | |
| 3009 | 39 |
COL | DSL | P | 28 | 39 | 49 | 40 |
0.0% | Medium Risk · 42 | N/A | |
| 3010 | 39 |
CHC | DSL | C | 28 | 39 | 49 | 42 |
0.0% | Medium Risk · 47 | N/A | |
| 3011 | 39 |
CHC | AA | SS | 32 | 40 | 49 | 40 |
0.0% | Medium Risk · 43 | N/A | |
| 3012 | 39 |
BAL | DSL | C | 28 | 39 | 49 | 42 |
-0.1% | Medium Risk · 47 | N/A | |
| 3013 | 39 |
STL | DSL | P | 27 | 38 | 50 | 42 |
0.0% | Medium Risk · 46 | N/A | |
| 3014 | 39 |
MIL | DSL | OF | 29 | 41 | 53 | 44 |
0.0% | Medium Risk · 57 | N/A | |
| 3015 | 39 |
KC | DSL | OF | 28 | 39 | 49 | 41 |
-0.1% | Medium Risk · 47 | N/A | |
| 3016 | 39 |
DET | High-A | P | 30 | 37 | 45 | 35 |
-0.1% | Low Risk · 12 | N/A | |
| 3017 | 39 |
WSH | Single-A | P | 30 | 38 | 47 | 37 |
0.0% | Low Risk · 36 | N/A | |
| 3018 | 39 |
NYM | High-A | OF | 30 | 42 | 55 | 45 |
0.0% | Medium Risk · 53 | N/A | |
| 3019 | 39 |
PHI | High-A | P | 31 | 40 | 50 | 39 |
-0.1% | Medium Risk · 42 | N/A | |
| 3020 | 39 |
TB | DSL | SS | 30 | 44 | 57 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3021 | 39 |
LAD | DSL | SS | 30 | 44 | 57 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3022 | 39 |
TB | DSL | P | 30 | 44 | 57 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3023 | 39 |
TEX | High-A | P | 31 | 40 | 48 | 35 |
0.0% | Low Risk · 34 | N/A | |
| 3024 | 39 |
SD | DSL | OF | 28 | 38 | 48 | 42 |
+0.1% | Medium Risk · 51 | N/A | |
| 3025 | 39 |
BAL | Single-A | P | 30 | 39 | 53 | 42 |
-0.2% | Medium Risk · 44 | N/A | |
| 3026 | 39 |
NYM | Single-A | RF | 31 | 38 | 46 | 27 |
0.0% | Low Risk · 25 | N/A | |
| 3027 | 39 |
CIN | DSL | C | 29 | 42 | 62 | 45 |
0.0% | Wide Range · 72 | N/A | |
| 3028 | 39 |
SF | Single-A | SS | 28 | 38 | 48 | 42 |
0.0% | Low Risk · 35 | N/A | |
| 3029 | 39 |
LAD | ACL | OF | 29 | 38 | 46 | 36 |
+0.1% | Low Risk · 32 | N/A | |
| 3030 | 39 |
CLE | High-A | P | 31 | 39 | 47 | 34 |
0.0% | Low Risk · 34 | N/A | |
| 3031 | 39 |
CHC | High-A | P | 31 | 39 | 46 | 33 |
0.0% | Low Risk · 34 | N/A | |
| 3032 | 39 |
BOS | DSL | P | 30 | 42 | 62 | 43 |
0.0% | Wide Range · 66 | N/A | |
| 3033 | 39 |
BOS | DSL | CF | 28 | 40 | 56 | 43 |
-0.3% | Medium Risk · 56 | N/A | |
| 3034 | 39 |
KC | DSL | OF | 28 | 39 | 55 | 43 |
-0.1% | Medium Risk · 56 | N/A | |
| 3035 | 39 |
BAL | FCL | P | 28 | 38 | 47 | 40 |
0.0% | Medium Risk · 46 | N/A | |
| 3036 | IL(7-Day)39 |
NYY | High-A | OFIL(7-Day) | 29 | 39 | 49 | 45 |
0.0% | Medium Risk · 48 | N/A | |
| 3037 | 39 |
ARI | Single-A | P | 31 | 39 | 47 | 35 |
0.0% | Low Risk · 36 | N/A | |
| 3038 | 39 |
TB | High-A | P | 30 | 38 | 46 | 28 |
+0.4% | Low Risk · 20 | N/A | |
| 3039 | 39 |
DET | FCL | SS | 29 | 40 | 52 | 43 |
0.0% | Wide Range · 58 | N/A | |
| 3040 | 39 |
MIA | AA | P | 29 | 36 | 51 | 54 |
0.0% | Low Risk · 31 | N/A | |
| 3041 | 39 |
BOS | FCL | P | 29 | 41 | 56 | 43 |
0.0% | Wide Range · 66 | N/A | |
| 3042 | 39 |
CLE | High-A | P | 31 | 40 | 49 | 41 |
0.0% | Medium Risk · 42 | N/A | |
| 3043 | 39 |
TB | DSL | C | 28 | 38 | 48 | 39 |
-0.2% | Low Risk · 37 | N/A | |
| 3044 | 39 |
NYY | AAA | P | 31 | 36 | 41 | 49 |
0.0% | Low Risk · 35 | N/A | |
| 3045 | 39 |
ARI | Single-A | P | 30 | 41 | 58 | 44 |
-0.1% | Medium Risk · 54 | N/A | |
| 3046 | 39 |
MIN | DSL | SS | 28 | 38 | 48 | 38 |
-0.1% | Low Risk · 37 | N/A | |
| 3047 | 39 |
CLE | Single-A | C | 29 | 40 | 51 | 45 |
+0.1% | Medium Risk · 51 | N/A | |
| 3048 | 39 |
CHC | DSL | IF | 28 | 39 | 50 | 42 |
+0.1% | Medium Risk · 47 | N/A | |
| 3049 | 39 |
COL | DSL | P | 28 | 40 | 51 | 42 |
-0.1% | Medium Risk · 52 | N/A | |
| 3050 | 39 |
HOU | Single-A | P | 29 | 39 | 50 | 43 |
0.0% | Low Risk · 40 | N/A | |
| 3051 | 39 |
ATH | Single-A | C | 28 | 38 | 47 | 41 |
-0.2% | Low Risk · 35 | N/A | |
| 3052 | 39 |
CIN | AA | P | 32 | 43 | 54 | 49 |
0.0% | Wide Range · 65 | N/A | |
| 3053 | 39 |
LAA | DSL | P | 29 | 41 | 54 | 43 |
-0.2% | Wide Range · 62 | N/A | |
| 3054 | 39 |
KC | Single-A | C | 30 | 38 | 45 | 33 |
-0.2% | Low Risk · 28 | N/A | |
| 3055 | 39 |
PHI | DSL | P | 30 | 42 | 60 | 42 |
-0.4% | Wide Range · 62 | N/A | |
| 3056 | 39 |
COL | DSL | IF | 30 | 41 | 51 | 40 |
-0.1% | Medium Risk · 57 | N/A | |
| 3057 | 39 |
TEX | ACL | P | 29 | 38 | 50 | 39 |
0.0% | Medium Risk · 46 | N/A | |
| 3058 | 39 |
CWS | AA | 3B | 31 | 41 | 50 | 45 |
0.0% | Medium Risk · 54 | N/A | |
| 3059 | 39 |
DET | DSL | LF | 27 | 37 | 53 | 41 |
+0.1% | Low Risk · 40 | N/A | |
| 3060 | 39 |
BOS | FCL | P | 30 | 41 | 52 | 43 |
0.0% | Wide Range · 66 | N/A | |
| 3061 | 39 |
LAD | DSL | C | 28 | 38 | 49 | 41 |
+0.1% | Medium Risk · 47 | N/A | |
| 3062 | 39 |
CLE | Single-A | P | 28 | 39 | 50 | 44 |
-0.1% | Medium Risk · 42 | N/A | |
| 3063 | 39 |
LAA | Single-A | P | 30 | 38 | 50 | 35 |
+0.2% | Low Risk · 22 | N/A | |
| 3064 | 39 |
CLE | Single-A | P | 30 | 38 | 45 | 31 |
-0.1% | Low Risk · 26 | N/A | |
| 3065 | 39 |
CLE | High-A | P | 31 | 40 | 49 | 39 |
-0.3% | Medium Risk · 42 | N/A | |
| 3066 | 39 |
MIL | AA | CF | 31 | 38 | 45 | 31 |
-0.2% | Low Risk · 27 | N/A | |
| 3067 | 39 |
BAL | Single-A | P | 30 | 38 | 46 | 33 |
0.0% | Low Risk · 22 | N/A | |
| 3068 | 39 |
ATL | DSL | P | 30 | 43 | 57 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3069 | 39 |
MIA | DSL | C | 30 | 43 | 57 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3070 | 39 |
BOS | DSL | P | 30 | 43 | 57 | 42 |
-0.3% | Wide Range · 65 | N/A | |
| 3071 | 39 |
MIA | High-A | P | 31 | 40 | 49 | 40 |
-0.1% | Medium Risk · 42 | N/A | |
| 3072 | 39 |
MIN | DSL | IF | 28 | 39 | 49 | 38 |
0.0% | Low Risk · 41 | N/A | |
| 3073 | 39 |
SF | DSL | SS | 27 | 37 | 47 | 43 |
0.0% | Medium Risk · 51 | N/A | |
| 3074 | 39 |
KC | DSL | OF | 28 | 38 | 50 | 41 |
-0.1% | Medium Risk · 46 | N/A | |
| 3075 | 39 |
CLE | DSL | P | 29 | 39 | 49 | 39 |
0.0% | Medium Risk · 42 | N/A | |
| 3076 | 39 |
STL | DSL | IF | 27 | 38 | 49 | 41 |
-0.1% | Medium Risk · 42 | N/A | |
| 3077 | 39 |
SF | High-A | P | 32 | 42 | 60 | 44 |
+0.1% | Medium Risk · 49 | N/A | |
| 3078 | 39 |
CHC | Single-A | P | 30 | 38 | 46 | 36 |
0.0% | Low Risk · 36 | N/A | |
| 3079 | 39 |
CHC | High-A | P | 29 | 40 | 51 | 43 |
0.0% | Low Risk · 38 | N/A | |
| 3080 | 39 |
BOS | FCL | OF | 29 | 40 | 50 | 41 |
0.0% | Medium Risk · 53 | N/A | |
| 3081 | 39 |
BAL | DSL | C | 28 | 38 | 48 | 42 |
0.0% | Medium Risk · 51 | N/A | |
| 3082 | 39 |
MIL | DSL | CF | 28 | 38 | 51 | 41 |
0.0% | Medium Risk · 46 | N/A | |
| 3083 | 39 |
PIT | AAA | 1B | 32 | 37 | 43 | 44 |
-0.1% | Low Risk · 36 | N/A | |
| 3084 | 39 |
ATH | Single-A | P | 29 | 39 | 55 | 42 |
0.0% | Low Risk · 40 | N/A | |
| 3085 | 39 |
CIN | AA | C | 32 | 38 | 43 | 31 |
0.0% | Low Risk · 27 | N/A | |
| 3086 | 39 |
BAL | FCL | OF | 29 | 42 | 53 | 45 |
0.0% | Wide Range · 67 | N/A | |
| 3087 | 39 |
ATH | Single-A | P | 32 | 42 | 60 | 42 |
+0.1% | Medium Risk · 50 | N/A | |
| 3088 | 39 |
MIN | FCL | P | 30 | 41 | 51 | 39 |
-0.6% | Medium Risk · 56 | N/A | |
| 3089 | 39 |
MIA | Single-A | LF | 29 | 38 | 45 | 33 |
+0.2% | Low Risk · 28 | N/A | |
| 3090 | 39 |
HOU | Single-A | P | 30 | 39 | 48 | 37 |
0.0% | Low Risk · 36 | N/A | |
| 3091 | 39 |
ARI | AA | P | 31 | 43 | 53 | 49 |
+0.1% | Wide Range · 65 | N/A | |
| 3092 | 39 |
HOU | DSL | OF | 27 | 38 | 49 | 41 |
0.0% | Medium Risk · 47 | N/A | |
| 3093 | 39 |
SD | DSL | C | 28 | 40 | 51 | 43 |
-0.3% | Medium Risk · 56 | N/A | |
| 3094 | 39 |
COL | High-A | P | 31 | 40 | 50 | 40 |
0.0% | Medium Risk · 42 | N/A | |
| 3095 | 39 |
NYY | DSL | P | 28 | 40 | 57 | 41 |
0.0% | Medium Risk · 56 | N/A | |
| 3096 | 39 |
PIT | Single-A | OF | 28 | 38 | 49 | 43 |
+0.1% | Low Risk · 35 | N/A | |
| 3097 | 39 |
CWS | ACL | SS | 28 | 38 | 48 | 40 |
0.0% | Low Risk · 40 | N/A | |
| 3098 | 39 |
ATL | AA | 3B | 30 | 41 | 51 | 48 |
0.0% | Wide Range · 59 | N/A | |
| 3099 | 39 |
PIT | Single-A | P | 29 | 41 | 52 | 45 |
-0.4% | Medium Risk · 53 | N/A | |
| 3100 | 39 |
KC | DSL | C | 28 | 39 | 50 | 43 |
0.0% | Medium Risk · 56 | N/A | |
| 3101 | 39 |
CHC | Single-A | CF | 30 | 38 | 45 | 32 |
0.0% | Low Risk · 33 | N/A | |
| 3102 | 39 |
LAD | DSL | IF | 27 | 38 | 49 | 41 |
-0.1% | Medium Risk · 47 | N/A | |
| 3103 | 39 |
PIT | FCL | OF | 28 | 38 | 46 | 32 |
0.0% | Low Risk · 38 | N/A | |
| 3104 | 39 |
CIN | ACL | P | 29 | 41 | 58 | 44 |
0.0% | Wide Range · 66 | N/A | |
| 3105 | 39 |
COL | ACL | P | 27 | 37 | 47 | 41 |
0.0% | Low Risk · 40 | N/A | |
| 3106 | 39 |
SD | AA | P | 31 | 41 | 52 | 47 |
0.0% | Medium Risk · 54 | N/A | |
| 3107 | 39 |
KC | High-A | P | 30 | 38 | 45 | 35 |
-0.4% | Low Risk · 34 | N/A | |
| 3108 | 39 |
COL | Single-A | P | 30 | 41 | 57 | 45 |
0.0% | Wide Range · 64 | N/A | |
| 3109 | 39 |
NYM | DSL | SS | 28 | 39 | 50 | 42 |
0.0% | Wide Range · 58 | N/A | |
| 3110 | 39 |
PHI | FCL | OF | 29 | 38 | 46 | 40 |
0.0% | Medium Risk · 48 | N/A | |
| 3111 | 39 |
CWS | High-A | OF | 30 | 38 | 45 | 32 |
0.0% | Low Risk · 26 | N/A | |
| 3112 | 39 |
HOU | DSL | OF | 27 | 38 | 48 | 40 |
-0.1% | Medium Risk · 42 | N/A | |
| 3113 | 39 |
BOS | AA | P | 31 | 42 | 52 | 48 |
0.0% | Wide Range · 63 | N/A | |
| 3114 | 39 |
TB | Single-A | P | 29 | 39 | 48 | 41 |
0.0% | Medium Risk · 44 | N/A | |
| 3115 | 39 |
HOU | High-A | P | 31 | 39 | 48 | 34 |
0.0% | Low Risk · 34 | N/A | |
| 3116 | 39 |
STL | DSL | OF | 28 | 38 | 47 | 38 |
0.0% | Low Risk · 37 | N/A | |
| 3117 | 39 |
NYM | FCL | P | 28 | 38 | 48 | 37 |
-0.4% | Low Risk · 32 | N/A | |
| 3118 | 39 |
COL | AA | SS | 31 | 38 | 45 | 33 |
+0.1% | Low Risk · 31 | N/A | |
| 3119 | 39 |
DET | DSL | P | 28 | 39 | 50 | 41 |
0.0% | Medium Risk · 52 | N/A | |
| 3120 | 39 |
PIT | FCL | IF | 27 | 38 | 49 | 40 |
+0.1% | Medium Risk · 47 | N/A | |
| 3121 | 39 |
MIN | DSL | OF | 27 | 38 | 49 | 40 |
0.0% | Medium Risk · 47 | N/A | |
| 3122 | 39 |
ATH | ACL | 1B | 26 | 36 | 48 | 42 |
-0.1% | Low Risk · 40 | N/A | |
| 3123 | 39 |
NYM | DSL | C | 27 | 39 | 50 | 41 |
0.0% | Medium Risk · 47 | N/A | |
| 3124 | 39 |
MIL | High-A | C | 29 | 38 | 47 | 38 |
0.0% | Low Risk · 32 | N/A | |
| 3125 | IL(7-Day)39 |
WSH | Single-A | PIL(7-Day) | 29 | 40 | 56 | 46 |
0.0% | Wide Range · 60 | N/A | |
| 3126 | 39 |
NYM | AA | OF | 30 | 38 | 45 | 38 |
+0.1% | Low Risk · 29 | N/A | |
| 3127 | 39 |
CWS | Single-A | P | 31 | 39 | 46 | 32 |
0.0% | Low Risk · 36 | N/A | |
| 3128 | 39 |
SD | Single-A | P | 29 | 37 | 45 | 37 |
0.0% | Low Risk · 26 | N/A | |
| 3129 | 38 |
TEX | AA | P | 29 | 36 | 45 | 49 |
0.0% | Low Risk · 34 | N/A | |
| 3130 | 38 |
TB | Single-A | P | 30 | 38 | 46 | 32 |
0.0% | Low Risk · 38 | N/A | |
| 3131 | 38 |
CIN | Single-A | P | 32 | 38 | 44 | 29 |
0.0% | Low Risk · 36 | N/A | |
| 3132 | IL(7-Day)38 |
CHC | Single-A | PIL(7-Day) | 28 | 39 | 49 | 44 |
0.0% | Medium Risk · 48 | N/A | |
| 3133 | 38 |
ATL | DSL | P | 27 | 38 | 48 | 40 |
-0.6% | Medium Risk · 46 | N/A | |
| 3134 | 38 |
ATL | FCL | P | 28 | 37 | 49 | 39 |
0.0% | Low Risk · 32 | N/A | |
| 3135 | 38 |
CWS | Single-A | P | 28 | 37 | 45 | 38 |
0.0% | Low Risk · 20 | N/A | |
| 3136 | 38 |
PHI | DSL | OF | 27 | 37 | 47 | 38 |
0.0% | Low Risk · 37 | N/A | |
| 3137 | 38 |
MIA | DSL | C | 28 | 41 | 61 | 45 |
-0.2% | Wide Range · 70 | N/A | |
| 3138 | 38 |
CHC | Single-A | P | 30 | 37 | 44 | 33 |
0.0% | Low Risk · 26 | N/A | |
| 3139 | 38 |
MIN | DSL | C | 27 | 38 | 49 | 41 |
0.0% | Medium Risk · 47 | N/A | |
| 3140 | 38 |
SD | DSL | OF | 27 | 38 | 49 | 41 |
0.0% | Medium Risk · 47 | N/A | |
| 3141 | 38 |
CHC | ACL | LF | 27 | 38 | 51 | 40 |
0.0% | Low Risk · 40 | N/A | |
| 3142 | 38 |
HOU | Single-A | P | 29 | 37 | 44 | 33 |
0.0% | Low Risk · 26 | N/A | |
| 3143 | 38 |
LAA | ACL | P | 29 | 42 | 55 | 43 |
-0.2% | High Risk · 76 | N/A | |
| 3144 | 38 |
CLE | DSL | OF | 27 | 39 | 55 | 42 |
0.0% | Medium Risk · 56 | N/A | |
| 3145 | 38 |
ATL | High-A | C | 29 | 37 | 45 | 34 |
0.0% | Low Risk · 24 | N/A | |
| 3146 | 38 |
ATL | High-A | P | 29 | 39 | 48 | 41 |
0.0% | Medium Risk · 42 | N/A | |
| 3147 | 38 |
HOU | AAA | P | 28 | 35 | 45 | 51 |
0.0% | Low Risk · 24 | N/A | |
| 3148 | 38 |
CLE | DSL | P | 28 | 39 | 49 | 38 |
0.0% | Medium Risk · 42 | N/A | |
| 3149 | 38 |
LAD | DSL | IF | 27 | 37 | 47 | 39 |
-0.1% | Low Risk · 37 | N/A | |
| 3150 | 38 |
DET | High-A | P | 31 | 42 | 59 | 43 |
0.0% | Medium Risk · 48 | N/A | |
| 3151 | 38 |
SEA | DSL | OF | 27 | 39 | 54 | 44 |
-0.1% | Wide Range · 62 | N/A | |
| 3152 | 38 |
ATL | DSL | SS | 27 | 39 | 50 | 42 |
0.0% | Medium Risk · 56 | N/A | |
| 3153 | 38 |
PHI | DSL | C | 28 | 38 | 47 | 37 |
0.0% | Low Risk · 37 | N/A | |
| 3154 | 38 |
DET | AA | C | 31 | 38 | 46 | 30 |
+0.1% | Low Risk · 40 | N/A | |
| 3155 | 38 |
TEX | ACL | P | 28 | 39 | 58 | 37 |
0.0% | Low Risk · 40 | N/A | |
| 3156 | 38 |
NYY | Single-A | C | 29 | 37 | 45 | 27 |
+0.3% | Low Risk · 30 | N/A | |
| 3157 | 38 |
MIA | FCL | C | 29 | 43 | 63 | 47 |
0.0% | Wide Range · 75 | N/A | |
| 3158 | 38 |
TEX | DSL | IF | 27 | 40 | 51 | 44 |
-0.5% | Wide Range · 61 | N/A | |
| 3159 | 38 |
NYY | High-A | P | 28 | 37 | 53 | 47 |
+0.2% | Low Risk · 27 | N/A | |
| 3160 | 38 |
BOS | FCL | P | 29 | 40 | 50 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3161 | 38 |
PHI | FCL | OF | 27 | 38 | 51 | 41 |
+0.1% | Medium Risk · 50 | N/A | |
| 3162 | 38 |
WSH | Single-A | CF | 27 | 35 | 45 | 47 |
+0.2% | Low Risk · 21 | N/A | |
| 3163 | 38 |
TEX | DSL | IF | 27 | 40 | 51 | 43 |
-0.1% | Wide Range · 61 | N/A | |
| 3164 | 38 |
MIL | AAA | P | 28 | 35 | 44 | 51 |
0.0% | Low Risk · 24 | N/A | |
| 3165 | 38 |
CHC | DSL | SS | 27 | 40 | 54 | 44 |
0.0% | Wide Range · 62 | N/A | |
| 3166 | 38 |
CLE | ACL | P | 27 | 38 | 49 | 42 |
0.0% | Medium Risk · 54 | N/A | |
| 3167 | 38 |
MIA | FCL | P | 29 | 40 | 50 | 41 |
0.0% | Medium Risk · 56 | N/A | |
| 3168 | 38 |
TOR | DSL | P | 27 | 37 | 47 | 41 |
0.0% | Medium Risk · 46 | N/A | |
| 3169 | 38 |
TEX | AA | P | 29 | 36 | 49 | 56 |
-0.3% | Low Risk · 39 | N/A | |
| 3170 | 38 |
COL | Single-A | 2B | 29 | 36 | 43 | 31 |
+0.2% | Low Risk · 17 | N/A | |
| 3171 | 38 |
MIL | Single-A | P | 29 | 41 | 54 | 45 |
-0.1% | Medium Risk · 57 | N/A | |
| 3172 | 38 |
PHI | AA | P | 29 | 35 | 47 | 51 |
-0.5% | Low Risk · 24 | N/A | |
| 3173 | IL(Rehab)38 |
MIA | Single-A | PIL(Rehab) | 29 | 41 | 52 | 45 |
0.0% | Medium Risk · 57 | N/A | |
| 3174 | 38 |
KC | DSL | OF | 27 | 38 | 48 | 40 |
+0.1% | Medium Risk · 47 | N/A | |
| 3175 | 38 |
TB | DSL | P | 27 | 40 | 58 | 44 |
0.0% | Wide Range · 66 | N/A | |
| 3176 | 38 |
WSH | Single-A | P | 29 | 38 | 49 | 36 |
-0.3% | Low Risk · 30 | N/A | |
| 3177 | 38 |
BOS | High-A | P | 29 | 40 | 53 | 44 |
-0.4% | Medium Risk · 48 | N/A | |
| 3178 | 38 |
WSH | DSL | 3B | 27 | 38 | 49 | 41 |
+0.1% | Medium Risk · 47 | N/A | |
| 3179 | 38 |
SF | AA | P | 32 | 40 | 54 | 53 |
0.0% | Medium Risk · 47 | N/A | |
| 3180 | 38 |
NYM | Single-A | C | 29 | 36 | 42 | 29 |
0.0% | Low Risk · 12 | N/A | |
| 3181 | 38 |
ATH | High-A | 2B | 28 | 39 | 48 | 44 |
0.0% | Medium Risk · 49 | N/A | |
| 3182 | 38 |
PIT | FCL | C | 28 | 38 | 49 | 40 |
+0.1% | Medium Risk · 48 | N/A | |
| 3183 | 38 |
SD | ACL | LF | 27 | 37 | 46 | 38 |
0.0% | Low Risk · 37 | N/A | |
| 3184 | 38 |
BOS | DSL | SS | 28 | 40 | 58 | 43 |
0.0% | Medium Risk · 57 | N/A | |
| 3185 | 38 |
SD | AAA | 2B | 31 | 35 | 41 | 46 |
0.0% | Low Risk · 23 | N/A | |
| 3186 | 38 |
HOU | DSL | P | 29 | 42 | 56 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3187 | 38 |
NYY | Single-A | P | 29 | 38 | 51 | 40 |
0.0% | Medium Risk · 44 | N/A | |
| 3188 | 38 |
CIN | High-A | P | 30 | 37 | 44 | 31 |
0.0% | Low Risk · 24 | N/A | |
| 3189 | 38 |
DET | FCL | C | 27 | 36 | 45 | 38 |
0.0% | Low Risk · 32 | N/A | |
| 3190 | 38 |
PHI | Single-A | LF | 28 | 39 | 49 | 43 |
0.0% | Medium Risk · 48 | N/A | |
| 3191 | 38 |
KC | DSL | IF | 27 | 38 | 48 | 40 |
0.0% | Medium Risk · 47 | N/A | |
| 3192 | 38 |
MIA | DSL | SS | 28 | 39 | 51 | 39 |
0.0% | Medium Risk · 48 | N/A | |
| 3193 | 38 |
COL | AAA | P | 29 | 37 | 45 | 50 |
0.0% | Low Risk · 29 | N/A | |
| 3194 | 38 |
ARI | ACL | C | 27 | 38 | 49 | 41 |
0.0% | Medium Risk · 47 | N/A | |
| 3195 | 38 |
DET | DSL | C | 27 | 38 | 49 | 40 |
-0.2% | Medium Risk · 46 | N/A | |
| 3196 | 38 |
NYM | DSL | C | 28 | 38 | 48 | 39 |
-0.1% | Medium Risk · 48 | N/A | |
| 3197 | 38 |
TB | DSL | OF | 28 | 38 | 47 | 39 |
-0.3% | Medium Risk · 48 | N/A | |
| 3198 | 38 |
NYY | FCL | P | 26 | 37 | 52 | 41 |
0.0% | Low Risk · 40 | N/A | |
| 3199 | 38 |
BOS | DSL | P | 29 | 43 | 58 | 45 |
-0.2% | High Risk · 77 | N/A | |
| 3200 | 38 |
CIN | DSL | P | 27 | 38 | 51 | 42 |
0.0% | Medium Risk · 52 | N/A | |
| 3201 | 38 |
BOS | AA | P | 31 | 37 | 47 | 42 |
-0.2% | Low Risk · 33 | N/A | |
| 3202 | 38 |
ATH | High-A | P | 30 | 39 | 48 | 38 |
0.0% | Medium Risk · 42 | N/A | |
| 3203 | 38 |
CHC | ACL | OF | 27 | 37 | 47 | 39 |
-0.4% | Low Risk · 40 | N/A | |
| 3204 | 38 |
SF | ACL | CF | 27 | 36 | 45 | 38 |
+0.2% | Low Risk · 32 | N/A | |
| 3205 | 38 |
BOS | AAA | P | 30 | 40 | 52 | 56 |
0.0% | Medium Risk · 50 | N/A | |
| 3206 | 38 |
HOU | DSL | P | 26 | 37 | 47 | 41 |
0.0% | Medium Risk · 46 | N/A | |
| 3207 | 38 |
PHI | AA | P | 28 | 34 | 40 | 49 |
0.0% | Low Risk · 22 | N/A | |
| 3208 | 38 |
KC | ACL | P | 29 | 42 | 58 | 43 |
0.0% | High Risk · 76 | N/A | |
| 3209 | 38 |
PIT | High-A | P | 30 | 39 | 49 | 38 |
0.0% | Medium Risk · 42 | N/A | |
| 3210 | 38 |
ATH | ACL | P | 27 | 38 | 50 | 41 |
+0.1% | Medium Risk · 54 | N/A | |
| 3211 | 38 |
MIL | High-A | P | 28 | 39 | 50 | 45 |
0.0% | Medium Risk · 52 | N/A | |
| 3212 | 38 |
SEA | DSL | SS | 27 | 37 | 46 | 38 |
+0.1% | Medium Risk · 51 | N/A | |
| 3213 | 38 |
MIA | High-A | P | 30 | 39 | 50 | 40 |
+0.1% | Medium Risk · 42 | N/A | |
| 3214 | 38 |
NYM | Single-A | P | 30 | 39 | 51 | 39 |
-0.2% | Medium Risk · 44 | N/A | |
| 3215 | 38 |
CWS | Single-A | C | 28 | 39 | 50 | 44 |
0.0% | Medium Risk · 53 | N/A | |
| 3216 | 38 |
CHC | DSL | OF | 27 | 38 | 48 | 39 |
+0.1% | Medium Risk · 42 | N/A | |
| 3217 | 38 |
BAL | DSL | C | 26 | 37 | 47 | 38 |
0.0% | Low Risk · 37 | N/A | |
| 3218 | 38 |
SEA | ACL | SS | 28 | 37 | 46 | 34 |
0.0% | Low Risk · 40 | N/A | |
| 3219 | 38 |
CWS | ACL | C | 28 | 38 | 47 | 36 |
+0.1% | Medium Risk · 53 | N/A | |
| 3220 | 38 |
TOR | AA | OF | 32 | 38 | 44 | 30 |
+0.1% | Low Risk · 35 | N/A | |
| 3221 | 38 |
BOS | Single-A | OF | 28 | 36 | 44 | 29 |
0.0% | Low Risk · 25 | N/A | |
| 3222 | 38 |
CHC | ACL | P | 28 | 39 | 50 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 3223 | 38 |
CWS | DSL | IF | 27 | 37 | 47 | 37 |
0.0% | Low Risk · 37 | N/A | |
| 3224 | 38 |
ATL | Single-A | OF | 29 | 41 | 56 | 44 |
0.0% | Medium Risk · 54 | N/A | |
| 3225 | 38 |
NYY | DSL | P | 26 | 37 | 51 | 41 |
-0.4% | Medium Risk · 46 | N/A | |
| 3226 | 38 |
NYY | Single-A | P | 28 | 36 | 44 | 35 |
0.0% | Low Risk · 26 | N/A | |
| 3227 | 38 |
COL | DSL | P | 29 | 40 | 62 | 39 |
0.0% | Medium Risk · 56 | N/A | |
| 3228 | 38 |
CWS | High-A | P | 28 | 38 | 48 | 43 |
+0.1% | Low Risk · 38 | N/A | |
| 3229 | 38 |
CWS | Single-A | P | 28 | 40 | 55 | 44 |
0.0% | Medium Risk · 54 | N/A | |
| 3230 | 38 |
HOU | DSL | C | 27 | 39 | 51 | 42 |
+0.1% | Wide Range · 58 | N/A | |
| 3231 | 38 |
NYY | FCL | RF | 27 | 37 | 45 | 33 |
+0.2% | Low Risk · 29 | N/A | |
| 3232 | 38 |
MIA | FCL | P | 28 | 39 | 49 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 3233 | 38 |
ATL | FCL | P | 29 | 39 | 49 | 39 |
-0.4% | Medium Risk · 56 | N/A | |
| 3234 | 38 |
TOR | DSL | C | 26 | 38 | 49 | 41 |
-0.1% | Medium Risk · 47 | N/A | |
| 3235 | 38 |
MIN | DSL | IF | 27 | 39 | 51 | 44 |
-0.4% | Wide Range · 61 | N/A | |
| 3236 | 38 |
ARI | DSL | OF | 27 | 38 | 50 | 42 |
-0.1% | Medium Risk · 56 | N/A | |
| 3237 | 38 |
LAD | ACL | C | 27 | 39 | 50 | 43 |
+0.1% | Wide Range · 58 | N/A | |
| 3238 | 38 |
LAD | ACL | RF | 28 | 37 | 47 | 40 |
+0.2% | Medium Risk · 48 | N/A | |
| 3239 | 38 |
TB | High-A | P | 29 | 40 | 50 | 45 |
-0.2% | Medium Risk · 52 | N/A | |
| 3240 | 38 |
KC | High-A | 3B | 29 | 40 | 49 | 41 |
0.0% | Medium Risk · 48 | N/A | |
| 3241 | 38 |
TEX | DSL | P | 27 | 37 | 50 | 40 |
-0.1% | Medium Risk · 46 | N/A | |
| 3242 | 38 |
CHC | Single-A | C | 28 | 37 | 46 | 38 |
0.0% | Medium Risk · 43 | N/A | |
| 3243 | 38 |
STL | High-A | P | 29 | 37 | 46 | 36 |
+0.1% | Low Risk · 34 | N/A | |
| 3244 | 38 |
TB | AA | P | 31 | 40 | 49 | 43 |
0.0% | Medium Risk · 53 | N/A | |
| 3245 | 38 |
ATL | FCL | P | 28 | 38 | 47 | 34 |
-0.1% | Medium Risk · 48 | N/A | |
| 3246 | 38 |
TEX | DSL | P | 26 | 37 | 48 | 41 |
0.0% | Medium Risk · 46 | N/A | |
| 3247 | 38 |
ATH | High-A | P | 30 | 40 | 51 | 43 |
0.0% | Medium Risk · 53 | N/A | |
| 3248 | 38 |
NYM | DSL | OF | 27 | 38 | 48 | 39 |
-0.1% | Medium Risk · 48 | N/A | |
| 3249 | 38 |
CIN | Single-A | P | 29 | 39 | 52 | 42 |
-0.5% | Medium Risk · 54 | N/A | |
| 3250 | 38 |
ATH | ACL | CF | 26 | 35 | 46 | 39 |
+0.1% | Low Risk · 32 | N/A | |
| 3251 | 38 |
COL | DSL | P | 31 | 44 | 65 | 45 |
0.0% | High Risk · 80 | N/A | |
| 3252 | 38 |
ATH | DSL | SS | 28 | 40 | 52 | 42 |
0.0% | Wide Range · 64 | N/A | |
| 3253 | 38 |
PIT | DSL | C | 27 | 38 | 56 | 41 |
-0.2% | Medium Risk · 56 | N/A | |
| 3254 | 38 |
SD | DSL | P | 27 | 37 | 47 | 38 |
-0.3% | Medium Risk · 42 | N/A | |
| 3255 | 38 |
MIA | Single-A | P | 29 | 37 | 45 | 35 |
0.0% | Low Risk · 36 | N/A | |
| 3256 | 38 |
BOS | Single-A | P | 29 | 38 | 46 | 34 |
-0.2% | Low Risk · 36 | N/A | |
| 3257 | 38 |
ATH | Single-A | P | 29 | 37 | 46 | 34 |
+0.2% | Low Risk · 38 | N/A | |
| 3258 | 38 |
TOR | DSL | OF | 28 | 38 | 48 | 38 |
-0.2% | Medium Risk · 48 | N/A | |
| 3259 | 38 |
CLE | Single-A | P | 30 | 38 | 46 | 32 |
0.0% | Low Risk · 38 | N/A | |
| 3260 | 38 |
LAD | DSL | SS | 27 | 39 | 50 | 42 |
+0.1% | Wide Range · 63 | N/A | |
| 3261 | 38 |
CWS | AA | P | 28 | 37 | 47 | 49 |
0.0% | Low Risk · 41 | N/A | |
| 3262 | 38 |
SF | Single-A | P | 29 | 36 | 43 | 34 |
-0.4% | Low Risk · 26 | N/A | |
| 3263 | 38 |
LAD | Single-A | P | 29 | 38 | 46 | 31 |
0.0% | Low Risk · 38 | N/A | |
| 3264 | 38 |
MIA | FCL | P | 28 | 39 | 50 | 40 |
+0.3% | Medium Risk · 56 | N/A | |
| 3265 | 38 |
BAL | AA | C | 31 | 35 | 40 | 32 |
0.0% | Low Risk · 29 | N/A | |
| 3266 | 38 |
WSH | High-A | P | 29 | 38 | 47 | 37 |
-0.3% | Medium Risk · 42 | N/A | |
| 3267 | 38 |
SF | ACL | P | 27 | 39 | 56 | 40 |
0.0% | Medium Risk · 54 | N/A | |
| 3268 | 38 |
ATH | AA | P | 28 | 38 | 50 | 53 |
-0.1% | Medium Risk · 47 | N/A | |
| 3269 | 38 |
SD | High-A | P | 29 | 38 | 47 | 36 |
-0.1% | Low Risk · 34 | N/A | |
| 3270 | 38 |
PHI | High-A | 2B | 28 | 35 | 42 | 30 |
0.0% | Low Risk · 15 | N/A | |
| 3271 | 38 |
TOR | DSL | SS | 26 | 38 | 51 | 42 |
0.0% | Wide Range · 61 | N/A | |
| 3272 | 38 |
BOS | DSL | OF | 26 | 38 | 49 | 41 |
-0.1% | Medium Risk · 56 | N/A | |
| 3273 | 38 |
LAA | AA | 3B | 32 | 38 | 44 | 28 |
+0.1% | Low Risk · 40 | N/A | |
| 3274 | 38 |
CIN | High-A | P | 29 | 39 | 48 | 37 |
0.0% | Medium Risk · 42 | N/A | |
| 3275 | 38 |
SEA | AA | P | 27 | 34 | 47 | 51 |
0.0% | Low Risk · 24 | N/A | |
| 3276 | 38 |
NYM | DSL | P | 28 | 42 | 56 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3277 | 38 |
LAA | DSL | P | 28 | 42 | 56 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3278 | 37 |
ATH | Single-A | P | 29 | 39 | 50 | 38 |
0.0% | Medium Risk · 44 | N/A | |
| 3279 | 37 |
BOS | Single-A | P | 28 | 37 | 45 | 29 |
0.0% | Low Risk · 24 | N/A | |
| 3280 | 37 |
HOU | AA | P | 28 | 34 | 40 | 47 |
0.0% | Low Risk · 21 | N/A | |
| 3281 | 37 |
PHI | Single-A | P | 27 | 35 | 43 | 36 |
-0.1% | Low Risk · 26 | N/A | |
| 3282 | 37 |
DET | DSL | OF | 29 | 42 | 63 | 45 |
0.0% | Wide Range · 75 | N/A | |
| 3283 | 37 |
LAA | DSL | C | 29 | 42 | 63 | 43 |
0.0% | Wide Range · 71 | N/A | |
| 3284 | 37 |
DET | DSL | OF | 27 | 38 | 48 | 37 |
0.0% | Low Risk · 41 | N/A | |
| 3285 | 37 |
CWS | Single-A | P | 30 | 39 | 49 | 36 |
0.0% | Medium Risk · 44 | N/A | |
| 3286 | 37 |
ATL | Single-A | OF | 27 | 38 | 48 | 42 |
0.0% | Medium Risk · 46 | N/A | |
| 3287 | 37 |
BOS | FCL | P | 29 | 39 | 50 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3288 | 37 |
KC | DSL | SS | 26 | 37 | 48 | 40 |
0.0% | Medium Risk · 47 | N/A | |
| 3289 | 37 |
BOS | DSL | C | 26 | 39 | 50 | 43 |
0.0% | Wide Range · 61 | N/A | |
| 3290 | 37 |
WSH | FCL | C | 26 | 36 | 52 | 40 |
0.0% | Low Risk · 40 | N/A | |
| 3291 | 37 |
TB | DSL | OF | 26 | 38 | 51 | 42 |
0.0% | Wide Range · 62 | N/A | |
| 3292 | 37 |
ATH | ACL | C | 27 | 38 | 49 | 41 |
0.0% | Medium Risk · 56 | N/A | |
| 3293 | 37 |
MIN | FCL | IF | 27 | 40 | 52 | 44 |
0.0% | Wide Range · 72 | N/A | |
| 3294 | 37 |
MIL | ACL | P | 28 | 38 | 48 | 35 |
0.0% | Medium Risk · 48 | N/A | |
| 3295 | 37 |
TOR | DSL | P | 27 | 39 | 50 | 42 |
0.0% | Wide Range · 62 | N/A | |
| 3296 | 37 |
KC | ACL | P | 28 | 39 | 53 | 40 |
-0.1% | Wide Range · 60 | N/A | |
| 3297 | 37 |
TB | Single-A | C | 27 | 38 | 48 | 42 |
0.0% | Medium Risk · 44 | N/A | |
| 3298 | 37 |
LAA | AA | P | 27 | 34 | 46 | 55 |
0.0% | Low Risk · 27 | N/A | |
| 3299 | 37 |
TB | FCL | CF | 27 | 37 | 46 | 38 |
0.0% | Medium Risk · 45 | N/A | |
| 3300 | 37 |
CWS | Single-A | OF | 27 | 37 | 47 | 41 |
+0.1% | Low Risk · 35 | N/A | |
| 3301 | 37 |
MIN | High-A | SS | 27 | 37 | 46 | 41 |
-0.1% | Low Risk · 28 | N/A | |
| 3302 | 37 |
NYM | DSL | OF | 26 | 37 | 49 | 40 |
0.0% | Medium Risk · 46 | N/A | |
| 3303 | 37 |
STL | High-A | OF | 29 | 37 | 46 | 33 |
+0.2% | Low Risk · 35 | N/A | |
| 3304 | 37 |
NYM | AAA | P | 28 | 38 | 49 | 56 |
0.0% | Medium Risk · 50 | N/A | |
| 3305 | 37 |
BOS | AA | P | 29 | 40 | 51 | 47 |
0.0% | Wide Range · 63 | N/A | |
| 3306 | 37 |
CWS | DSL | OF | 26 | 38 | 49 | 41 |
0.0% | Medium Risk · 56 | N/A | |
| 3307 | 37 |
TOR | FCL | IF | 27 | 36 | 45 | 33 |
+0.1% | Low Risk · 38 | N/A | |
| 3308 | 37 |
BAL | FCL | IF | 27 | 38 | 49 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 3309 | 37 |
ATH | DSL | SS | 26 | 36 | 46 | 37 |
-0.1% | Low Risk · 37 | N/A | |
| 3310 | IL(Full Season)37 |
PIT | High-A | PIL(Full Season) | 28 | 40 | 55 | 49 |
0.0% | Wide Range · 70 | N/A | |
| 3311 | 37 |
LAD | DSL | C | 27 | 39 | 52 | 43 |
+0.1% | Wide Range · 62 | N/A | |
| 3312 | 37 |
CWS | High-A | P | 29 | 40 | 50 | 45 |
-0.1% | Wide Range · 62 | N/A | |
| 3313 | 37 |
KC | ACL | P | 27 | 37 | 47 | 38 |
0.0% | Medium Risk · 46 | N/A | |
| 3314 | 37 |
BAL | Single-A | P | 28 | 37 | 45 | 29 |
-0.1% | Low Risk · 24 | N/A | |
| 3315 | 37 |
NYY | FCL | P | 27 | 36 | 48 | 36 |
-0.4% | Low Risk · 32 | N/A | |
| 3316 | IL(7-Day)37 |
NYM | FCL | SSIL(7-Day) | 27 | 39 | 54 | 43 |
0.0% | Wide Range · 62 | N/A | |
| 3317 | 37 |
KC | Single-A | SS | 30 | 39 | 48 | 36 |
0.0% | Medium Risk · 47 | N/A | |
| 3318 | 37 |
KC | ACL | P | 27 | 37 | 47 | 39 |
0.0% | Medium Risk · 52 | N/A | |
| 3319 | 37 |
HOU | DSL | P | 26 | 39 | 53 | 44 |
0.0% | Wide Range · 66 | N/A | |
| 3320 | 37 |
PIT | Single-A | P | 27 | 38 | 49 | 42 |
-0.1% | Medium Risk · 52 | N/A | |
| 3321 | 37 |
MIA | FCL | SS | 27 | 38 | 52 | 39 |
0.0% | Medium Risk · 50 | N/A | |
| 3322 | 37 |
CIN | Single-A | C | 28 | 36 | 44 | 32 |
0.0% | Low Risk · 28 | N/A | |
| 3323 | 37 |
COL | DSL | P | 28 | 41 | 55 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3324 | 37 |
CHC | DSL | P | 28 | 41 | 55 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3325 | 37 |
SEA | DSL | SS | 27 | 36 | 45 | 38 |
-0.3% | Medium Risk · 43 | N/A | |
| 3326 | 37 |
KC | DSL | SS | 27 | 37 | 47 | 37 |
0.0% | Medium Risk · 51 | N/A | |
| 3327 | 37 |
COL | High-A | C | 29 | 40 | 57 | 46 |
0.0% | Wide Range · 59 | N/A | |
| 3328 | 37 |
SD | ACL | P | 27 | 38 | 49 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 3329 | 37 |
ATL | FCL | C | 27 | 37 | 47 | 37 |
0.0% | Medium Risk · 46 | N/A | |
| 3330 | 37 |
CWS | DSL | P | 27 | 39 | 51 | 41 |
0.0% | Wide Range · 66 | N/A | |
| 3331 | 37 |
PIT | DSL | C | 26 | 37 | 47 | 39 |
0.0% | Medium Risk · 47 | N/A | |
| 3332 | 37 |
BOS | AA | P | 28 | 34 | 45 | 48 |
+0.2% | Low Risk · 24 | N/A | |
| 3333 | 37 |
LAD | Single-A | P | 29 | 37 | 45 | 30 |
-0.3% | Low Risk · 38 | N/A | |
| 3334 | 37 |
MIN | Single-A | P | 28 | 40 | 54 | 44 |
0.0% | Wide Range · 64 | N/A | |
| 3335 | 37 |
MIA | DSL | P | 27 | 39 | 51 | 41 |
0.0% | Wide Range · 66 | N/A | |
| 3336 | 37 |
DET | DSL | OF | 27 | 38 | 48 | 39 |
+0.2% | Medium Risk · 53 | N/A | |
| 3337 | 37 |
SEA | ACL | 3B | 26 | 35 | 44 | 37 |
+0.1% | Low Risk · 32 | N/A | |
| 3338 | 37 |
STL | FCL | IF | 26 | 39 | 51 | 45 |
0.0% | Wide Range · 62 | N/A | |
| 3339 | 37 |
WSH | High-A | P | 29 | 38 | 47 | 36 |
0.0% | Medium Risk · 42 | N/A | |
| 3340 | 37 |
MIN | Single-A | P | 28 | 41 | 53 | 46 |
-0.1% | Wide Range · 71 | N/A | |
| 3341 | 37 |
LAA | Single-A | C | 32 | 40 | 60 | 44 |
-0.1% | Medium Risk · 48 | N/A | |
| 3342 | 37 |
BAL | Single-A | P | 28 | 38 | 49 | 40 |
0.0% | Medium Risk · 44 | N/A | |
| 3343 | 37 |
MIL | DSL | CF | 26 | 37 | 50 | 41 |
-0.1% | Medium Risk · 56 | N/A | |
| 3344 | 37 |
MIA | FCL | CF | 27 | 38 | 51 | 41 |
0.0% | Wide Range · 62 | N/A | |
| 3345 | 37 |
CWS | Single-A | CF | 26 | 37 | 46 | 41 |
0.0% | Low Risk · 35 | N/A | |
| 3346 | 37 |
SD | High-A | P | 27 | 38 | 49 | 45 |
-0.5% | Medium Risk · 53 | N/A | |
| 3347 | 37 |
MIA | DSL | SS | 28 | 38 | 48 | 36 |
-0.6% | Medium Risk · 57 | N/A | |
| 3348 | 37 |
COL | ACL | C | 27 | 37 | 46 | 37 |
-0.1% | Medium Risk · 46 | N/A | |
| 3349 | 37 |
PHI | High-A | IF | 28 | 34 | 41 | 32 |
-0.2% | Low Risk · 13 | N/A | |
| 3350 | 37 |
CIN | Single-A | P | 28 | 38 | 50 | 40 |
0.0% | Medium Risk · 44 | N/A | |
| 3351 | 37 |
HOU | DSL | P | 25 | 35 | 45 | 41 |
-0.4% | Medium Risk · 46 | N/A | |
| 3352 | IL(Full Season)37 |
MIA | AA | PIL(Full Season) | 31 | 42 | 53 | 51 |
0.0% | High Risk · 80 | N/A | |
| 3353 | 37 |
NYM | FCL | P | 28 | 40 | 50 | 41 |
-0.3% | Wide Range · 66 | N/A | |
| 3354 | 37 |
CIN | ACL | 3B | 26 | 37 | 48 | 40 |
0.0% | Medium Risk · 47 | N/A | |
| 3355 | 37 |
PHI | FCL | P | 28 | 37 | 48 | 33 |
+0.1% | Medium Risk · 42 | N/A | |
| 3356 | 37 |
COL | DSL | P | 25 | 35 | 46 | 40 |
0.0% | Medium Risk · 46 | N/A | |
| 3357 | 37 |
PHI | Single-A | P | 28 | 37 | 47 | 32 |
0.0% | Low Risk · 22 | N/A | |
| 3358 | 37 |
SF | DSL | CF | 25 | 36 | 47 | 41 |
-0.1% | Medium Risk · 51 | N/A | |
| 3359 | 37 |
ARI | Single-A | SS | 28 | 36 | 44 | 32 |
-0.1% | Low Risk · 26 | N/A | |
| 3360 | 37 |
MIN | FCL | P | 27 | 42 | 53 | 45 |
0.0% | High Risk · 78 | N/A | |
| 3361 | 37 |
SF | DSL | C | 26 | 38 | 49 | 41 |
0.0% | Medium Risk · 56 | N/A | |
| 3362 | 37 |
ATH | High-A | P | 28 | 36 | 44 | 34 |
0.0% | Low Risk · 24 | N/A | |
| 3363 | 37 |
ATL | Single-A | P | 28 | 36 | 44 | 30 |
0.0% | Low Risk · 38 | N/A | |
| 3364 | 37 |
TOR | DSL | IF | 26 | 38 | 48 | 40 |
-0.1% | Medium Risk · 56 | N/A | |
| 3365 | 37 |
BAL | DSL | P | 25 | 37 | 48 | 42 |
-0.2% | Medium Risk · 52 | N/A | |
| 3366 | 37 |
TB | AA | C | 28 | 35 | 42 | 42 |
0.0% | Low Risk · 19 | N/A | |
| 3367 | 37 |
HOU | Single-A | C | 28 | 36 | 44 | 28 |
0.0% | Low Risk · 28 | N/A | |
| 3368 | 37 |
BAL | AA | CF | 27 | 38 | 47 | 46 |
-0.1% | Medium Risk · 44 | N/A | |
| 3369 | 37 |
HOU | DSL | OF | 26 | 37 | 48 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 3370 | 37 |
MIN | High-A | OF | 27 | 37 | 48 | 42 |
0.0% | Medium Risk · 42 | N/A | |
| 3371 | 37 |
PIT | AAA | P | 28 | 35 | 42 | 43 |
0.0% | Low Risk · 35 | N/A | |
| 3372 | 37 |
SD | DSL | OF | 27 | 38 | 49 | 39 |
0.0% | Wide Range · 58 | N/A | |
| 3373 | 37 |
CLE | AA | 2B | 31 | 37 | 43 | 28 |
0.0% | Low Risk · 40 | N/A | |
| 3374 | 37 |
LAD | ACL | CF | 29 | 40 | 63 | 42 |
0.0% | Wide Range · 64 | N/A | |
| 3375 | 37 |
LAD | AA | P | 29 | 39 | 48 | 44 |
-0.3% | Medium Risk · 54 | N/A | |
| 3376 | 37 |
ARI | AAA | P | 31 | 35 | 40 | 33 |
0.0% | Low Risk · 29 | N/A | |
| 3377 | 37 |
CIN | DSL | OF | 26 | 38 | 50 | 41 |
0.0% | Medium Risk · 56 | N/A | |
| 3378 | 37 |
PHI | AA | P | 28 | 35 | 45 | 47 |
-0.2% | Low Risk · 28 | N/A | |
| 3379 | 37 |
LAA | DSL | P | 28 | 41 | 55 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3380 | 37 |
CHC | DSL | SS | 28 | 41 | 55 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3381 | 37 |
ARI | DSL | OF | 28 | 41 | 55 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3382 | 37 |
KC | DSL | SS | 28 | 41 | 55 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3383 | 37 |
COL | DSL | P | 28 | 41 | 55 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3384 | 37 |
TEX | DSL | P | 28 | 41 | 55 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3385 | 37 |
COL | DSL | OF | 28 | 41 | 55 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3386 | 37 |
DET | High-A | P | 27 | 39 | 50 | 45 |
+0.2% | Wide Range · 62 | N/A | |
| 3387 | 37 |
SD | High-A | P | 28 | 40 | 51 | 45 |
0.0% | Wide Range · 63 | N/A | |
| 3388 | 37 |
LAD | DSL | P | 25 | 36 | 46 | 38 |
0.0% | Medium Risk · 42 | N/A | |
| 3389 | 37 |
SEA | High-A | P | 26 | 33 | 43 | 46 |
0.0% | Low Risk · 21 | N/A | |
| 3390 | 37 |
SEA | DSL | OF | 26 | 38 | 49 | 42 |
0.0% | Wide Range · 61 | N/A | |
| 3391 | 37 |
TOR | DSL | OF | 26 | 37 | 47 | 38 |
0.0% | Medium Risk · 48 | N/A | |
| 3392 | 37 |
TB | DSL | P | 27 | 37 | 47 | 37 |
0.0% | Medium Risk · 46 | N/A | |
| 3393 | 37 |
ARI | DSL | OF | 26 | 38 | 49 | 41 |
0.0% | Medium Risk · 56 | N/A | |
| 3394 | 37 |
MIL | High-A | P | 29 | 37 | 45 | 30 |
0.0% | Low Risk · 34 | N/A | |
| 3395 | IL(60-Day)37 |
MIA | Single-A | PIL(60-Day) | 26 | 37 | 47 | 45 |
0.0% | Medium Risk · 52 | N/A | |
| 3396 | 37 |
MIA | Single-A | P | 26 | 38 | 49 | 44 |
0.0% | Medium Risk · 56 | N/A | |
| 3397 | 37 |
ARI | ACL | OF | 26 | 38 | 50 | 43 |
0.0% | Wide Range · 61 | N/A | |
| 3398 | 37 |
LAA | AAA | 3B | 29 | 39 | 51 | 55 |
0.0% | Medium Risk · 55 | N/A | |
| 3399 | 37 |
BAL | FCL | OF | 27 | 39 | 50 | 40 |
-0.1% | Wide Range · 62 | N/A | |
| 3400 | 37 |
SEA | Single-A | 2B | 27 | 34 | 41 | 30 |
0.0% | Low Risk · 17 | N/A | |
| 3401 | 37 |
BOS | Single-A | P | 31 | 41 | 59 | 43 |
0.0% | Medium Risk · 55 | N/A | |
| 3402 | 37 |
BAL | DSL | P | 27 | 39 | 55 | 42 |
0.0% | Wide Range · 66 | N/A | |
| 3403 | 37 |
ATL | FCL | P | 28 | 39 | 50 | 38 |
0.0% | Medium Risk · 56 | N/A | |
| 3404 | 37 |
TEX | DSL | P | 26 | 38 | 49 | 41 |
-0.1% | Wide Range · 66 | N/A | |
| 3405 | 37 |
CHC | High-A | P | 28 | 38 | 48 | 38 |
-0.1% | Medium Risk · 42 | N/A | |
| 3406 | 37 |
ATH | Single-A | P | 28 | 38 | 48 | 39 |
0.0% | Medium Risk · 44 | N/A | |
| 3407 | 37 |
MIL | ACL | C | 27 | 37 | 47 | 37 |
0.0% | Medium Risk · 53 | N/A | |
| 3408 | 37 |
CWS | ACL | IF | 27 | 37 | 45 | 31 |
-0.3% | Low Risk · 33 | N/A | |
| 3409 | 37 |
STL | Single-A | P | 26 | 38 | 48 | 43 |
0.0% | Medium Risk · 54 | N/A | |
| 3410 | 37 |
CIN | DSL | IF | 26 | 38 | 49 | 42 |
+0.1% | Wide Range · 61 | N/A | |
| 3411 | 37 |
MIL | DSL | SS | 26 | 38 | 51 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 3412 | 37 |
TB | High-A | P | 28 | 35 | 45 | 39 |
0.0% | Low Risk · 19 | N/A | |
| 3413 | 37 |
DET | High-A | P | 27 | 35 | 43 | 38 |
0.0% | Low Risk · 27 | N/A | |
| 3414 | 37 |
SEA | AA | P | 26 | 33 | 41 | 50 |
-0.2% | Low Risk · 23 | N/A | |
| 3415 | 37 |
SF | DSL | C | 27 | 40 | 54 | 43 |
0.0% | Wide Range · 72 | N/A | |
| 3416 | 37 |
CIN | DSL | P | 25 | 37 | 50 | 41 |
-0.2% | Medium Risk · 56 | N/A | |
| 3417 | 37 |
TOR | DSL | OF | 26 | 37 | 49 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 3418 | 37 |
CIN | DSL | 1B | 26 | 37 | 48 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 3419 | 37 |
DET | FCL | P | 25 | 35 | 45 | 39 |
-0.6% | Low Risk · 40 | N/A | |
| 3420 | 37 |
WSH | DSL | P | 26 | 39 | 50 | 42 |
0.0% | Wide Range · 66 | N/A | |
| 3421 | 37 |
PHI | Single-A | P | 28 | 37 | 45 | 33 |
0.0% | Low Risk · 36 | N/A | |
| 3422 | 37 |
ATL | Single-A | 1B | 28 | 35 | 42 | 34 |
-0.2% | Low Risk · 28 | N/A | |
| 3423 | 37 |
ATL | AA | P | 31 | 39 | 53 | 52 |
0.0% | Medium Risk · 48 | N/A | |
| 3424 | 37 |
ATH | DSL | SS | 26 | 38 | 49 | 42 |
+0.1% | Wide Range · 61 | N/A | |
| 3425 | 37 |
PIT | DSL | OF | 26 | 37 | 47 | 39 |
+0.1% | Medium Risk · 51 | N/A | |
| 3426 | 37 |
BOS | DSL | C | 26 | 37 | 48 | 38 |
0.0% | Medium Risk · 51 | N/A | |
| 3427 | 37 |
CWS | ACL | 1B | 26 | 37 | 47 | 38 |
0.0% | Medium Risk · 48 | N/A | |
| 3428 | 36 |
PHI | DSL | OF | 26 | 38 | 50 | 42 |
0.0% | Wide Range · 61 | N/A | |
| 3429 | 36 |
PHI | DSL | C | 26 | 38 | 52 | 40 |
-0.1% | Wide Range · 62 | N/A | |
| 3430 | 36 |
STL | DSL | P | 26 | 37 | 48 | 39 |
-0.2% | Medium Risk · 56 | N/A | |
| 3431 | 36 |
TB | AA | P | 31 | 38 | 53 | 53 |
0.0% | Medium Risk · 49 | N/A | |
| 3432 | 36 |
WSH | AA | P | 27 | 34 | 42 | 43 |
0.0% | Low Risk · 33 | N/A | |
| 3433 | 36 |
MIA | High-A | P | 28 | 39 | 50 | 45 |
+0.2% | Wide Range · 62 | N/A | |
| 3434 | 36 |
LAA | DSL | 1B | 26 | 37 | 52 | 40 |
0.0% | Medium Risk · 56 | N/A | |
| 3435 | IL(Rehab)36 |
SD | ACL | PIL(Rehab) | 26 | 36 | 54 | 38 |
0.0% | Medium Risk · 44 | N/A | |
| 3436 | 36 |
HOU | FCL | RF | 26 | 35 | 45 | 37 |
+0.1% | Low Risk · 40 | N/A | |
| 3437 | 36 |
HOU | DSL | C | 26 | 38 | 49 | 42 |
0.0% | Wide Range · 61 | N/A | |
| 3438 | 36 |
SEA | AAA | P | 27 | 35 | 42 | 48 |
-0.3% | Low Risk · 31 | N/A | |
| 3439 | 36 |
CIN | Single-A | P | 28 | 37 | 46 | 36 |
-0.1% | Medium Risk · 46 | N/A | |
| 3440 | 36 |
HOU | FCL | P | 28 | 39 | 49 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3441 | 36 |
DET | High-A | OF | 27 | 35 | 43 | 32 |
0.0% | Low Risk · 24 | N/A | |
| 3442 | 36 |
BOS | DSL | CF | 25 | 36 | 47 | 39 |
0.0% | Medium Risk · 51 | N/A | |
| 3443 | 36 |
PHI | FCL | P | 28 | 38 | 48 | 33 |
+0.1% | Medium Risk · 48 | N/A | |
| 3444 | 36 |
CWS | ACL | OF | 27 | 39 | 51 | 43 |
+0.1% | Wide Range · 72 | N/A | |
| 3445 | 36 |
TEX | DSL | P | 27 | 39 | 51 | 40 |
0.0% | Wide Range · 66 | N/A | |
| 3446 | 36 |
COL | DSL | OF | 26 | 36 | 46 | 39 |
-0.2% | Medium Risk · 51 | N/A | |
| 3447 | 36 |
TEX | ACL | P | 28 | 39 | 54 | 40 |
0.0% | Wide Range · 66 | N/A | |
| 3448 | 36 |
HOU | DSL | P | 25 | 35 | 45 | 39 |
0.0% | Medium Risk · 46 | N/A | |
| 3449 | 36 |
LAA | Single-A | P | 29 | 37 | 48 | 33 |
+0.2% | Low Risk · 36 | N/A | |
| 3450 | 36 |
DET | Single-A | P | 26 | 35 | 44 | 39 |
0.0% | Low Risk · 34 | N/A | |
| 3451 | 36 |
TB | AA | P | 28 | 39 | 49 | 45 |
0.0% | Wide Range · 62 | N/A | |
| 3452 | 36 |
KC | Single-A | P | 28 | 37 | 45 | 36 |
+0.1% | Medium Risk · 46 | N/A | |
| 3453 | 36 |
BAL | FCL | P | 27 | 39 | 50 | 40 |
-0.1% | Wide Range · 66 | N/A | |
| 3454 | 36 |
SF | DSL | IF | 25 | 36 | 46 | 40 |
-0.1% | Medium Risk · 51 | N/A | |
| 3455 | 36 |
TOR | Single-A | P | 27 | 36 | 44 | 32 |
0.0% | Low Risk · 38 | N/A | |
| 3456 | 36 |
SF | Single-A | C | 27 | 35 | 43 | 35 |
+0.2% | Low Risk · 25 | N/A | |
| 3457 | 36 |
ARI | ACL | P | 27 | 40 | 53 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 3458 | 36 |
ATH | ACL | P | 27 | 40 | 53 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 3459 | 36 |
SF | DSL | P | 26 | 39 | 56 | 41 |
0.0% | Wide Range · 66 | N/A | |
| 3460 | 36 |
SF | AA | P | 30 | 36 | 42 | 32 |
+0.1% | Low Risk · 36 | N/A | |
| 3461 | 36 |
STL | FCL | P | 28 | 38 | 48 | 36 |
-0.1% | Medium Risk · 56 | N/A | |
| 3462 | 36 |
TOR | High-A | CF | 26 | 37 | 48 | 44 |
0.0% | Low Risk · 36 | N/A | |
| 3463 | 36 |
MIA | FCL | P | 26 | 39 | 53 | 43 |
0.0% | Wide Range · 66 | N/A | |
| 3464 | 36 |
COL | DSL | P | 26 | 38 | 49 | 41 |
-0.5% | Wide Range · 62 | N/A | |
| 3465 | 36 |
ATH | Single-A | P | 27 | 39 | 55 | 43 |
+0.1% | Medium Risk · 55 | N/A | |
| 3466 | 36 |
ATH | High-A | CF | 28 | 37 | 45 | 28 |
0.0% | Low Risk · 40 | N/A | |
| 3467 | IL(Full Season)36 |
HOU | Single-A | PIL(Full Season) | 28 | 39 | 53 | 45 |
0.0% | Wide Range · 68 | N/A | |
| 3468 | 36 |
CLE | DSL | OF | 26 | 37 | 51 | 39 |
0.0% | Medium Risk · 56 | N/A | |
| 3469 | 36 |
CHC | DSL | P | 26 | 37 | 48 | 38 |
0.0% | Medium Risk · 56 | N/A | |
| 3470 | 36 |
SF | High-A | P | 28 | 37 | 50 | 38 |
0.0% | Medium Risk · 43 | N/A | |
| 3471 | 36 |
SF | DSL | IF | 26 | 36 | 46 | 39 |
-0.1% | Medium Risk · 51 | N/A | |
| 3472 | 36 |
NYY | FCL | P | 25 | 36 | 47 | 41 |
-0.3% | Medium Risk · 54 | N/A | |
| 3473 | 36 |
DET | AA | P | 28 | 34 | 41 | 40 |
0.0% | Low Risk · 19 | N/A | |
| 3474 | IL(Full Season)36 |
TEX | High-A | CFIL(Full Season) | 27 | 41 | 52 | 50 |
0.0% | High Risk · 79 | N/A | |
| 3475 | 36 |
MIL | DSL | P | 27 | 38 | 49 | 40 |
-0.5% | Wide Range · 66 | N/A | |
| 3476 | 36 |
KC | DSL | 1B | 25 | 36 | 47 | 38 |
0.0% | Medium Risk · 46 | N/A | |
| 3477 | 36 |
CIN | ACL | P | 27 | 37 | 46 | 33 |
0.0% | Medium Risk · 48 | N/A | |
| 3478 | 36 |
SF | DSL | OF | 26 | 36 | 46 | 38 |
-0.2% | Medium Risk · 51 | N/A | |
| 3479 | 36 |
NYY | DSL | P | 26 | 36 | 50 | 38 |
-0.5% | Medium Risk · 46 | N/A | |
| 3480 | 36 |
SF | High-A | P | 28 | 36 | 45 | 34 |
0.0% | Low Risk · 35 | N/A | |
| 3481 | 36 |
STL | DSL | OF | 25 | 40 | 51 | 45 |
0.0% | High Risk · 77 | N/A | |
| 3482 | 36 |
LAD | ACL | P | 26 | 40 | 51 | 44 |
-0.2% | High Risk · 76 | N/A | |
| 3483 | 36 |
HOU | DSL | P | 25 | 38 | 53 | 42 |
0.0% | Wide Range · 66 | N/A | |
| 3484 | 36 |
CIN | DSL | 2B | 27 | 40 | 54 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3485 | 36 |
CIN | DSL | OF | 25 | 37 | 48 | 41 |
-0.3% | Wide Range · 61 | N/A | |
| 3486 | 36 |
MIN | AAA | C | 29 | 34 | 39 | 39 |
0.0% | Low Risk · 21 | N/A | |
| 3487 | IL(Rehab)36 |
BAL | FCL | SSIL(Rehab) | 29 | 41 | 63 | 42 |
0.0% | Wide Range · 69 | N/A | |
| 3488 | 36 |
ATH | DSL | C | 25 | 36 | 46 | 38 |
0.0% | Medium Risk · 47 | N/A | |
| 3489 | IL(7-Day)36 |
CIN | Single-A | PIL(7-Day) | 26 | 36 | 45 | 38 |
0.0% | Low Risk · 36 | N/A | |
| 3490 | 36 |
SEA | ACL | P | 26 | 36 | 53 | 40 |
0.0% | Medium Risk · 54 | N/A | |
| 3491 | 36 |
ATL | FCL | P | 26 | 39 | 53 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 3492 | 36 |
HOU | High-A | P | 28 | 36 | 44 | 25 |
0.0% | Low Risk · 34 | N/A | |
| 3493 | 36 |
WSH | High-A | P | 27 | 39 | 50 | 44 |
0.0% | Wide Range · 62 | N/A | |
| 3494 | 36 |
NYY | Single-A | OF | 26 | 37 | 48 | 43 |
-0.2% | Medium Risk · 49 | N/A | |
| 3495 | 36 |
LAD | DSL | P | 25 | 36 | 47 | 39 |
0.0% | Medium Risk · 56 | N/A | |
| 3496 | 36 |
TEX | Single-A | P | 28 | 36 | 45 | 29 |
0.0% | Low Risk · 22 | N/A | |
| 3497 | 36 |
COL | DSL | P | 26 | 36 | 46 | 37 |
0.0% | Medium Risk · 46 | N/A | |
| 3498 | 36 |
MIA | High-A | C | 27 | 35 | 43 | 29 |
0.0% | Low Risk · 31 | N/A | |
| 3499 | 36 |
STL | Single-A | P | 28 | 36 | 45 | 31 |
0.0% | Low Risk · 36 | N/A | |
| 3500 | 36 |
CHC | Single-A | RF | 27 | 35 | 43 | 27 |
-0.1% | Low Risk · 26 | N/A | |
| 3501 | 36 |
DET | AA | OF | 27 | 33 | 40 | 46 |
+0.2% | Low Risk · 23 | N/A | |
| 3502 | 36 |
LAD | ACL | P | 25 | 40 | 50 | 44 |
-0.1% | High Risk · 76 | N/A | |
| 3503 | 36 |
TOR | AA | P | 30 | 36 | 41 | 28 |
-0.1% | Low Risk · 26 | N/A | |
| 3504 | 36 |
SF | ACL | P | 26 | 36 | 55 | 37 |
0.0% | Medium Risk · 50 | N/A | |
| 3505 | 36 |
TEX | DSL | IF | 25 | 36 | 46 | 38 |
0.0% | Medium Risk · 47 | N/A | |
| 3506 | 36 |
NYM | Single-A | P | 27 | 36 | 45 | 35 |
-0.1% | Medium Risk · 46 | N/A | |
| 3507 | 36 |
TB | High-A | RF | 28 | 36 | 44 | 28 |
0.0% | Low Risk · 35 | N/A | |
| 3508 | 36 |
CHC | High-A | SS | 26 | 35 | 43 | 37 |
0.0% | Low Risk · 24 | N/A | |
| 3509 | 36 |
COL | DSL | P | 26 | 38 | 50 | 41 |
-0.1% | Wide Range · 66 | N/A | |
| 3510 | 36 |
PHI | Single-A | C | 27 | 35 | 42 | 27 |
0.0% | Low Risk · 26 | N/A | |
| 3511 | 36 |
HOU | FCL | CF | 25 | 35 | 45 | 37 |
+0.1% | Medium Risk · 45 | N/A | |
| 3512 | 36 |
SEA | Single-A | 2B | 27 | 33 | 40 | 28 |
-0.2% | Low Risk · 12 | N/A | |
| 3513 | 36 |
COL | ACL | P | 27 | 39 | 52 | 40 |
0.0% | Wide Range · 66 | N/A | |
| 3514 | 36 |
BAL | DSL | IF | 25 | 36 | 46 | 39 |
-0.4% | Medium Risk · 51 | N/A | |
| 3515 | 36 |
ATH | DSL | P | 27 | 40 | 54 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3516 | 36 |
SF | ACL | P | 25 | 37 | 54 | 40 |
-0.2% | Medium Risk · 54 | N/A | |
| 3517 | 36 |
SEA | High-A | P | 27 | 36 | 46 | 36 |
0.0% | Low Risk · 29 | N/A | |
| 3518 | 36 |
CHC | DSL | OF | 25 | 36 | 48 | 41 |
-0.1% | Wide Range · 61 | N/A | |
| 3519 | 36 |
DET | DSL | OF | 25 | 38 | 51 | 42 |
0.0% | Wide Range · 62 | N/A | |
| 3520 | 36 |
MIN | Single-A | P | 26 | 34 | 42 | 33 |
-0.4% | Low Risk · 26 | N/A | |
| 3521 | 36 |
CWS | AAA | C | 26 | 33 | 41 | 48 |
+0.1% | Low Risk · 25 | N/A | |
| 3522 | 36 |
MIN | High-A | P | 28 | 36 | 45 | 32 |
0.0% | Low Risk · 34 | N/A | |
| 3523 | 36 |
CHC | AA | P | 26 | 33 | 40 | 48 |
-0.4% | Low Risk · 35 | N/A | |
| 3524 | 36 |
NYY | High-A | P | 28 | 40 | 56 | 45 |
+0.1% | Wide Range · 65 | N/A | |
| 3525 | 36 |
STL | DSL | P | 27 | 39 | 50 | 40 |
-0.2% | Wide Range · 66 | N/A | |
| 3526 | 36 |
TB | DSL | C | 25 | 37 | 51 | 43 |
-0.4% | Wide Range · 62 | N/A | |
| 3527 | 36 |
MIN | Single-A | P | 28 | 36 | 44 | 28 |
-0.1% | Low Risk · 38 | N/A | |
| 3528 | 36 |
ATL | FCL | P | 26 | 39 | 53 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 3529 | 36 |
MIL | DSL | P | 26 | 38 | 49 | 39 |
0.0% | Wide Range · 66 | N/A | |
| 3530 | IL(7-Day)36 |
TOR | Single-A | CIL(7-Day) | 25 | 37 | 48 | 45 |
0.0% | Medium Risk · 56 | N/A | |
| 3531 | 36 |
ATL | Single-A | P | 29 | 36 | 41 | 24 |
0.0% | Low Risk · 36 | N/A | |
| 3532 | 36 |
SD | AA | LF | 28 | 35 | 42 | 30 |
0.0% | Low Risk · 27 | N/A | |
| 3533 | 36 |
TOR | Single-A | P | 27 | 35 | 43 | 29 |
-0.4% | Low Risk · 22 | N/A | |
| 3534 | 36 |
MIL | Single-A | P | 27 | 36 | 43 | 30 |
0.0% | Low Risk · 36 | N/A | |
| 3535 | 36 |
SEA | AAA | 1B | 28 | 33 | 38 | 41 |
+0.1% | Low Risk · 22 | N/A | |
| 3536 | 36 |
CHC | DSL | P | 26 | 38 | 49 | 40 |
0.0% | Wide Range · 66 | N/A | |
| 3537 | 36 |
PIT | AA | RF | 27 | 37 | 47 | 46 |
+0.1% | Medium Risk · 52 | N/A | |
| 3538 | 36 |
LAD | DSL | P | 26 | 37 | 48 | 37 |
-0.3% | Medium Risk · 56 | N/A | |
| 3539 | 36 |
PIT | FCL | P | 25 | 39 | 50 | 44 |
-0.4% | High Risk · 76 | N/A | |
| 3540 | 36 |
TEX | ACL | CF | 26 | 36 | 46 | 35 |
-0.1% | Medium Risk · 53 | N/A | |
| 3541 | 36 |
CLE | ACL | IF | 27 | 36 | 45 | 30 |
0.0% | Medium Risk · 49 | N/A | |
| 3542 | 36 |
DET | Single-A | P | 27 | 38 | 52 | 41 |
0.0% | Medium Risk · 50 | N/A | |
| 3543 | 36 |
CHC | Single-A | P | 27 | 37 | 47 | 37 |
0.0% | Medium Risk · 44 | N/A | |
| 3544 | 36 |
COL | ACL | P | 26 | 35 | 44 | 37 |
-0.4% | Medium Risk · 46 | N/A | |
| 3545 | 36 |
BOS | DSL | OF | 25 | 35 | 45 | 35 |
-0.2% | Low Risk · 37 | N/A | |
| 3546 | 36 |
COL | ACL | SS | 26 | 36 | 46 | 36 |
0.0% | Medium Risk · 48 | N/A | |
| 3547 | 36 |
CWS | Single-A | P | 27 | 35 | 44 | 33 |
-0.2% | Low Risk · 36 | N/A | |
| 3548 | 36 |
ARI | ACL | P | 30 | 41 | 64 | 41 |
0.0% | Wide Range · 74 | N/A | |
| 3549 | 36 |
CHC | AA | P | 26 | 36 | 48 | 51 |
0.0% | Medium Risk · 47 | N/A | |
| 3550 | 36 |
CLE | DSL | SS | 25 | 36 | 47 | 39 |
+0.1% | Medium Risk · 56 | N/A | |
| 3551 | 36 |
CLE | DSL | P | 25 | 35 | 45 | 36 |
0.0% | Medium Risk · 46 | N/A | |
| 3552 | 35 |
COL | Single-A | P | 26 | 38 | 48 | 42 |
0.0% | Medium Risk · 54 | N/A | |
| 3553 | 35 |
COL | ACL | P | 26 | 40 | 56 | 43 |
0.0% | High Risk · 76 | N/A | |
| 3554 | 35 |
BOS | AAA | CF | 28 | 33 | 38 | 44 |
+0.1% | Low Risk · 24 | N/A | |
| 3555 | 35 |
BAL | High-A | P | 28 | 37 | 45 | 33 |
-0.2% | Medium Risk · 42 | N/A | |
| 3556 | 35 |
SF | High-A | P | 27 | 36 | 45 | 31 |
+0.2% | Low Risk · 34 | N/A | |
| 3557 | 35 |
ARI | Single-A | P | 27 | 35 | 42 | 26 |
+0.1% | Low Risk · 22 | N/A | |
| 3558 | 35 |
SD | Single-A | P | 28 | 37 | 45 | 33 |
0.0% | Low Risk · 36 | N/A | |
| 3559 | 35 |
LAA | High-A | SS | 27 | 34 | 41 | 26 |
0.0% | Low Risk · 19 | N/A | |
| 3560 | IL(Rehab)35 |
CIN | ACL | RFIL(Rehab) | 28 | 40 | 62 | 41 |
0.0% | Wide Range · 68 | N/A | |
| 3561 | 35 |
NYY | AAA | 1B | 27 | 33 | 40 | 43 |
0.0% | Low Risk · 23 | N/A | |
| 3562 | 35 |
DET | DSL | P | 26 | 40 | 54 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3563 | 35 |
MIL | High-A | P | 28 | 39 | 50 | 42 |
-0.1% | Medium Risk · 54 | N/A | |
| 3564 | 35 |
SF | DSL | P | 24 | 35 | 46 | 41 |
-0.3% | Wide Range · 60 | N/A | |
| 3565 | 35 |
COL | High-A | P | 26 | 34 | 42 | 33 |
-0.4% | Low Risk · 26 | N/A | |
| 3566 | 35 |
TOR | Single-A | SS | 26 | 38 | 49 | 44 |
-0.3% | Wide Range · 63 | N/A | |
| 3567 | 35 |
BAL | DSL | OF | 25 | 37 | 52 | 38 |
0.0% | Medium Risk · 56 | N/A | |
| 3568 | 35 |
ATL | FCL | OF | 26 | 36 | 46 | 36 |
0.0% | Medium Risk · 53 | N/A | |
| 3569 | 35 |
LAA | High-A | 2B | 26 | 38 | 48 | 43 |
-0.3% | Wide Range · 58 | N/A | |
| 3570 | 35 |
PHI | FCL | P | 26 | 37 | 49 | 35 |
0.0% | Medium Risk · 50 | N/A | |
| 3571 | 35 |
NYM | DSL | C | 25 | 37 | 47 | 39 |
-0.1% | Wide Range · 58 | N/A | |
| 3572 | 35 |
LAD | AAA | SS | 28 | 33 | 38 | 43 |
0.0% | Low Risk · 28 | N/A | |
| 3573 | 35 |
CHC | High-A | C | 28 | 40 | 56 | 46 |
-0.2% | Wide Range · 62 | N/A | |
| 3574 | 35 |
ATH | ACL | CF | 25 | 36 | 46 | 36 |
-0.4% | Medium Risk · 46 | N/A | |
| 3575 | 35 |
ATH | DSL | C | 24 | 35 | 47 | 39 |
0.0% | Medium Risk · 51 | N/A | |
| 3576 | 35 |
SD | AAA | P | 29 | 34 | 40 | 38 |
0.0% | Medium Risk · 43 | N/A | |
| 3577 | 35 |
PIT | DSL | C | 25 | 36 | 47 | 38 |
-0.1% | Medium Risk · 56 | N/A | |
| 3578 | 35 |
PHI | High-A | 2B | 26 | 36 | 45 | 38 |
0.0% | Low Risk · 37 | N/A | |
| 3579 | 35 |
LAA | High-A | C | 27 | 40 | 54 | 46 |
0.0% | Wide Range · 70 | N/A | |
| 3580 | 35 |
NYY | DSL | P | 25 | 38 | 52 | 41 |
-0.4% | Wide Range · 66 | N/A | |
| 3581 | 35 |
HOU | DSL | SS | 25 | 35 | 46 | 36 |
0.0% | Medium Risk · 42 | N/A | |
| 3582 | 35 |
NYM | Single-A | SS | 27 | 35 | 44 | 30 |
0.0% | Low Risk · 36 | N/A | |
| 3583 | IL(7-Day)35 |
ATH | Single-A | PIL(7-Day) | 27 | 39 | 53 | 43 |
0.0% | Wide Range · 70 | N/A | |
| 3584 | 35 |
STL | FCL | CF | 25 | 38 | 54 | 42 |
+0.1% | Wide Range · 70 | N/A | |
| 3585 | 35 |
SD | DSL | C | 25 | 37 | 50 | 42 |
0.0% | Wide Range · 62 | N/A | |
| 3586 | 35 |
BAL | DSL | P | 25 | 35 | 45 | 36 |
0.0% | Medium Risk · 46 | N/A | |
| 3587 | 35 |
SEA | AA | P | 25 | 33 | 41 | 46 |
0.0% | Low Risk · 29 | N/A | |
| 3588 | 35 |
CHC | DSL | SS | 25 | 38 | 50 | 41 |
0.0% | Wide Range · 70 | N/A | |
| 3589 | 35 |
ATL | High-A | P | 27 | 36 | 45 | 35 |
-0.3% | Medium Risk · 42 | N/A | |
| 3590 | 35 |
CIN | High-A | LF | 26 | 38 | 49 | 44 |
0.0% | Medium Risk · 57 | N/A | |
| 3591 | 35 |
BAL | DSL | IF | 25 | 35 | 46 | 38 |
0.0% | Medium Risk · 51 | N/A | |
| 3592 | 35 |
CLE | ACL | P | 26 | 39 | 52 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 3593 | 35 |
TB | DSL | SS | 25 | 38 | 49 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 3594 | 35 |
HOU | DSL | IF | 25 | 37 | 53 | 42 |
0.0% | Wide Range · 70 | N/A | |
| 3595 | 35 |
SEA | ACL | P | 26 | 37 | 48 | 38 |
0.0% | Medium Risk · 56 | N/A | |
| 3596 | 35 |
CWS | High-A | P | 27 | 34 | 41 | 33 |
0.0% | Low Risk · 27 | N/A | |
| 3597 | 35 |
PIT | DSL | P | 24 | 36 | 47 | 39 |
0.0% | Medium Risk · 56 | N/A | |
| 3598 | 35 |
SD | DSL | C | 25 | 36 | 46 | 37 |
-0.1% | Medium Risk · 53 | N/A | |
| 3599 | 35 |
CIN | High-A | C | 26 | 38 | 48 | 44 |
0.0% | Wide Range · 59 | N/A | |
| 3600 | IL(7-Day)35 |
TB | Single-A | PIL(7-Day) | 26 | 38 | 49 | 42 |
0.0% | Medium Risk · 56 | N/A | |
| 3601 | IL(60-Day)35 |
CLE | High-A | SSIL(60-Day) | 26 | 38 | 48 | 45 |
0.0% | Wide Range · 70 | N/A | |
| 3602 | 35 |
LAA | ACL | P | 27 | 38 | 49 | 35 |
-0.1% | Medium Risk · 56 | N/A | |
| 3603 | 35 |
CIN | AAA | C | 27 | 37 | 46 | 50 |
0.0% | Wide Range · 58 | N/A | |
| 3604 | 35 |
ATL | AAA | SS | 27 | 36 | 44 | 50 |
+0.2% | Low Risk · 40 | N/A | |
| 3605 | 35 |
NYM | Single-A | P | 27 | 36 | 44 | 29 |
0.0% | Low Risk · 36 | N/A | |
| 3606 | 35 |
CIN | AA | P | 28 | 38 | 48 | 46 |
0.0% | Wide Range · 64 | N/A | |
| 3607 | 35 |
MIA | DSL | OF | 25 | 36 | 46 | 37 |
0.0% | Medium Risk · 51 | N/A | |
| 3608 | 35 |
ATH | AA | P | 27 | 35 | 45 | 43 |
0.0% | Low Risk · 37 | N/A | |
| 3609 | 35 |
BOS | DSL | P | 26 | 38 | 59 | 38 |
0.0% | Wide Range · 66 | N/A | |
| 3610 | 35 |
TEX | Single-A | P | 26 | 37 | 50 | 41 |
0.0% | Medium Risk · 50 | N/A | |
| 3611 | 35 |
LAD | Single-A | P | 27 | 37 | 47 | 38 |
0.0% | Medium Risk · 45 | N/A | |
| 3612 | 35 |
PIT | DSL | SS | 25 | 36 | 47 | 37 |
0.0% | Medium Risk · 57 | N/A | |
| 3613 | 35 |
SEA | Single-A | P | 27 | 36 | 50 | 37 |
0.0% | Medium Risk · 44 | N/A | |
| 3614 | 35 |
SEA | AA | C | 25 | 33 | 41 | 47 |
0.0% | Low Risk · 34 | N/A | |
| 3615 | 35 |
MIN | AA | P | 30 | 37 | 52 | 51 |
0.0% | Medium Risk · 48 | N/A | |
| 3616 | 35 |
TOR | DSL | IF | 25 | 37 | 50 | 40 |
0.0% | Wide Range · 61 | N/A | |
| 3617 | 35 |
LAA | ACL | P | 26 | 35 | 44 | 31 |
0.0% | Medium Risk · 48 | N/A | |
| 3618 | 35 |
KC | DSL | C | 25 | 37 | 48 | 38 |
0.0% | Wide Range · 58 | N/A | |
| 3619 | 35 |
TOR | High-A | P | 27 | 37 | 47 | 39 |
-0.3% | Medium Risk · 52 | N/A | |
| 3620 | 35 |
HOU | FCL | P | 26 | 37 | 47 | 36 |
0.0% | Medium Risk · 56 | N/A | |
| 3621 | 35 |
CWS | ACL | P | 26 | 37 | 47 | 35 |
-0.4% | Medium Risk · 56 | N/A | |
| 3622 | 35 |
NYM | DSL | P | 24 | 36 | 46 | 39 |
0.0% | Medium Risk · 56 | N/A | |
| 3623 | 35 |
LAD | DSL | IF | 24 | 37 | 50 | 40 |
0.0% | Wide Range · 61 | N/A | |
| 3624 | 35 |
MIL | DSL | P | 26 | 36 | 52 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3625 | 35 |
MIL | Single-A | P | 26 | 39 | 50 | 44 |
0.0% | Wide Range · 69 | N/A | |
| 3626 | 35 |
DET | DSL | C | 25 | 38 | 49 | 40 |
-0.1% | Wide Range · 65 | N/A | |
| 3627 | 35 |
BOS | High-A | P | 25 | 36 | 47 | 41 |
-0.2% | Low Risk · 39 | N/A | |
| 3628 | 35 |
STL | High-A | 2B | 27 | 36 | 45 | 35 |
0.0% | Medium Risk · 48 | N/A | |
| 3629 | 35 |
NYM | DSL | P | 26 | 39 | 53 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3630 | 35 |
PIT | DSL | P | 26 | 39 | 53 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3631 | 35 |
PIT | FCL | P | 26 | 37 | 47 | 36 |
0.0% | Medium Risk · 56 | N/A | |
| 3632 | 35 |
TB | Single-A | 3B | 25 | 37 | 48 | 44 |
0.0% | Wide Range · 61 | N/A | |
| 3633 | 35 |
MIN | AA | 3B | 28 | 35 | 43 | 27 |
-0.1% | Low Risk · 35 | N/A | |
| 3634 | 35 |
ATH | AAA | 3B | 27 | 32 | 38 | 44 |
0.0% | Low Risk · 28 | N/A | |
| 3635 | 35 |
CHC | DSL | P | 24 | 35 | 47 | 38 |
0.0% | Medium Risk · 46 | N/A | |
| 3636 | 35 |
CLE | Single-A | P | 27 | 37 | 46 | 37 |
0.0% | Medium Risk · 44 | N/A | |
| 3637 | 35 |
COL | High-A | IF | 27 | 35 | 42 | 28 |
-0.3% | Low Risk · 35 | N/A | |
| 3638 | 35 |
ARI | DSL | IF | 26 | 37 | 47 | 36 |
0.0% | Medium Risk · 57 | N/A | |
| 3639 | 35 |
TB | FCL | OF | 25 | 36 | 46 | 35 |
-0.2% | Medium Risk · 46 | N/A | |
| 3640 | 35 |
TOR | FCL | SS | 25 | 35 | 44 | 34 |
-0.3% | Low Risk · 40 | N/A | |
| 3641 | 35 |
WSH | DSL | OF | 25 | 38 | 51 | 42 |
-0.1% | Wide Range · 72 | N/A | |
| 3642 | 35 |
BAL | FCL | C | 24 | 35 | 45 | 37 |
-0.1% | Medium Risk · 45 | N/A | |
| 3643 | 35 |
MIL | DSL | P | 24 | 34 | 44 | 36 |
0.0% | Medium Risk · 46 | N/A | |
| 3644 | 35 |
CWS | High-A | P | 25 | 37 | 48 | 43 |
0.0% | Medium Risk · 53 | N/A | |
| 3645 | 35 |
PIT | DSL | IF | 24 | 37 | 48 | 40 |
-0.1% | Wide Range · 61 | N/A | |
| 3646 | 35 |
KC | ACL | P | 25 | 37 | 48 | 40 |
-0.4% | Wide Range · 66 | N/A | |
| 3647 | 35 |
CLE | ACL | P | 26 | 37 | 58 | 36 |
+0.1% | Medium Risk · 50 | N/A | |
| 3648 | 35 |
SEA | DSL | C | 24 | 36 | 49 | 38 |
-0.2% | Medium Risk · 56 | N/A | |
| 3649 | 35 |
ATL | DSL | P | 25 | 39 | 50 | 44 |
0.0% | High Risk · 80 | N/A | |
| 3650 | 35 |
PHI | FCL | C | 25 | 37 | 48 | 41 |
+0.1% | Wide Range · 63 | N/A | |
| 3651 | 35 |
DET | Single-A | SS | 26 | 34 | 41 | 26 |
0.0% | Low Risk · 26 | N/A | |
| 3652 | 35 |
WSH | DSL | C | 25 | 38 | 50 | 42 |
0.0% | Wide Range · 71 | N/A | |
| 3653 | 35 |
SF | AAA | P | 28 | 35 | 43 | 41 |
-0.2% | Medium Risk · 43 | N/A | |
| 3654 | 35 |
SD | DSL | P | 24 | 37 | 49 | 41 |
0.0% | Wide Range · 66 | N/A | |
| 3655 | 35 |
ATH | ACL | P | 26 | 36 | 45 | 30 |
0.0% | Medium Risk · 48 | N/A | |
| 3656 | 35 |
WSH | High-A | LF | 25 | 35 | 45 | 39 |
0.0% | Medium Risk · 42 | N/A | |
| 3657 | IL(Rehab)35 |
PHI | Single-A | PIL(Rehab) | 25 | 37 | 50 | 43 |
0.0% | Wide Range · 58 | N/A | |
| 3658 | 35 |
SF | Single-A | P | 26 | 37 | 52 | 39 |
+0.1% | Medium Risk · 50 | N/A | |
| 3659 | 35 |
COL | DSL | P | 26 | 38 | 56 | 38 |
+0.2% | Wide Range · 66 | N/A | |
| 3660 | 35 |
WSH | High-A | 1B | 27 | 36 | 46 | 36 |
0.0% | Medium Risk · 48 | N/A | |
| 3661 | 35 |
SF | High-A | P | 27 | 36 | 45 | 33 |
0.0% | Medium Risk · 42 | N/A | |
| 3662 | 35 |
TEX | ACL | P | 26 | 41 | 58 | 42 |
0.0% | High Risk · 77 | N/A | |
| 3663 | IL(Rehab)35 |
CLE | ACL | 1BIL(Rehab) | 23 | 37 | 49 | 44 |
0.0% | Wide Range · 66 | N/A | |
| 3664 | 35 |
WSH | FCL | RF | 25 | 37 | 49 | 41 |
-0.3% | Wide Range · 72 | N/A | |
| 3665 | 35 |
COL | DSL | C | 25 | 35 | 46 | 37 |
0.0% | Medium Risk · 53 | N/A | |
| 3666 | 35 |
LAD | DSL | P | 25 | 37 | 49 | 39 |
0.0% | Wide Range · 66 | N/A | |
| 3667 | 35 |
STL | Single-A | P | 26 | 37 | 48 | 40 |
0.0% | Medium Risk · 54 | N/A | |
| 3668 | 35 |
TEX | DSL | OF | 24 | 36 | 47 | 39 |
-0.1% | Wide Range · 63 | N/A | |
| 3669 | 35 |
CLE | AAA | P | 28 | 35 | 42 | 35 |
0.0% | Low Risk · 33 | N/A | |
| 3670 | 35 |
TOR | AAA | RF | 29 | 34 | 40 | 40 |
-0.2% | Low Risk · 37 | N/A | |
| 3671 | 35 |
DET | AA | RF | 26 | 31 | 38 | 46 |
0.0% | Low Risk · 23 | N/A | |
| 3672 | 35 |
MIA | FCL | P | 27 | 38 | 52 | 35 |
-0.1% | Wide Range · 64 | N/A | |
| 3673 | IL(Rehab)35 |
SD | ACL | CIL(Rehab) | 24 | 37 | 48 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3674 | 35 |
MIA | DSL | 1B | 25 | 37 | 53 | 41 |
0.0% | Wide Range · 70 | N/A | |
| 3675 | 35 |
STL | Single-A | P | 27 | 36 | 45 | 35 |
0.0% | Medium Risk · 44 | N/A | |
| 3676 | 35 |
WSH | High-A | P | 27 | 35 | 43 | 35 |
0.0% | Low Risk · 36 | N/A | |
| 3677 | 35 |
MIA | DSL | P | 26 | 39 | 53 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3678 | 35 |
TB | FCL | P | 25 | 35 | 47 | 35 |
0.0% | Low Risk · 40 | N/A | |
| 3679 | 35 |
ATH | ACL | CF | 25 | 35 | 44 | 34 |
+0.1% | Low Risk · 40 | N/A | |
| 3680 | 35 |
DET | AAA | P | 27 | 34 | 42 | 41 |
-0.4% | Low Risk · 35 | N/A | |
| 3681 | 35 |
MIN | DSL | P | 25 | 37 | 48 | 39 |
0.0% | Wide Range · 66 | N/A | |
| 3682 | 35 |
MIL | DSL | P | 26 | 37 | 51 | 38 |
-0.1% | Wide Range · 66 | N/A | |
| 3683 | 35 |
ATH | ACL | P | 26 | 38 | 48 | 37 |
0.0% | Medium Risk · 57 | N/A | |
| 3684 | 35 |
KC | ACL | OF | 26 | 37 | 46 | 31 |
+0.1% | Medium Risk · 54 | N/A | |
| 3685 | 35 |
TB | DSL | P | 24 | 35 | 45 | 37 |
+0.1% | Medium Risk · 46 | N/A | |
| 3686 | 35 |
COL | High-A | C | 26 | 35 | 43 | 29 |
0.0% | Low Risk · 35 | N/A | |
| 3687 | 35 |
TB | AA | OF | 25 | 34 | 47 | 49 |
-0.6% | Low Risk · 39 | N/A | |
| 3688 | 35 |
CWS | ACL | P | 23 | 34 | 47 | 40 |
0.0% | Medium Risk · 54 | N/A | |
| 3689 | 35 |
NYY | DSL | CF | 24 | 37 | 50 | 42 |
0.0% | Wide Range · 62 | N/A | |
| 3690 | 35 |
MIL | DSL | SS | 24 | 36 | 47 | 40 |
0.0% | Wide Range · 61 | N/A | |
| 3691 | 35 |
DET | High-A | P | 26 | 40 | 51 | 48 |
0.0% | High Risk · 79 | N/A | |
| 3692 | 35 |
MIL | DSL | P | 25 | 38 | 54 | 39 |
0.0% | Wide Range · 66 | N/A | |
| 3693 | 35 |
KC | ACL | LF | 25 | 37 | 52 | 42 |
0.0% | Wide Range · 69 | N/A | |
| 3694 | 35 |
PHI | DSL | P | 24 | 37 | 48 | 41 |
0.0% | Wide Range · 66 | N/A | |
| 3695 | 35 |
ATL | DSL | OF | 24 | 37 | 49 | 39 |
0.0% | Medium Risk · 56 | N/A | |
| 3696 | 35 |
ARI | ACL | P | 26 | 37 | 48 | 36 |
0.0% | Medium Risk · 56 | N/A | |
| 3697 | 35 |
KC | DSL | P | 24 | 36 | 48 | 41 |
0.0% | Wide Range · 66 | N/A | |
| 3698 | 35 |
COL | High-A | P | 27 | 40 | 54 | 46 |
0.0% | High Risk · 77 | N/A | |
| 3699 | 35 |
PIT | High-A | P | 27 | 35 | 43 | 26 |
0.0% | Low Risk · 34 | N/A | |
| 3700 | 35 |
CWS | Single-A | CF | 25 | 37 | 47 | 42 |
+0.2% | Wide Range · 62 | N/A | |
| 3701 | 35 |
DET | DSL | 1B | 24 | 36 | 47 | 38 |
-0.3% | Medium Risk · 56 | N/A | |
| 3702 | 35 |
NYY | Single-A | P | 26 | 36 | 45 | 36 |
0.0% | Medium Risk · 44 | N/A | |
| 3703 | 35 |
COL | Single-A | P | 26 | 36 | 46 | 39 |
0.0% | Medium Risk · 54 | N/A | |
| 3704 | 35 |
WSH | FCL | C | 25 | 37 | 49 | 42 |
0.0% | Wide Range · 72 | N/A | |
| 3705 | 35 |
NYY | Single-A | P | 27 | 36 | 46 | 34 |
0.0% | Medium Risk · 44 | N/A | |
| 3706 | 35 |
TB | FCL | C | 25 | 35 | 46 | 36 |
0.0% | Medium Risk · 51 | N/A | |
| 3707 | 34 |
WSH | Single-A | P | 29 | 39 | 57 | 41 |
+0.1% | Medium Risk · 55 | N/A | |
| 3708 | 34 |
LAD | DSL | IF | 24 | 35 | 45 | 38 |
0.0% | Medium Risk · 51 | N/A | |
| 3709 | 34 |
MIN | FCL | P | 24 | 35 | 54 | 37 |
0.0% | Medium Risk · 50 | N/A | |
| 3710 | 34 |
PIT | AA | P | 27 | 33 | 39 | 37 |
0.0% | Low Risk · 20 | N/A | |
| 3711 | 34 |
DET | DSL | P | 24 | 35 | 50 | 40 |
0.0% | Wide Range · 60 | N/A | |
| 3712 | 34 |
COL | DSL | C | 23 | 35 | 46 | 38 |
0.0% | Medium Risk · 47 | N/A | |
| 3713 | 34 |
BAL | Single-A | P | 27 | 37 | 47 | 38 |
+0.6% | Medium Risk · 46 | N/A | |
| 3714 | 34 |
PHI | DSL | OF | 24 | 36 | 48 | 40 |
-0.1% | Wide Range · 65 | N/A | |
| 3715 | 34 |
ATH | Single-A | P | 26 | 35 | 54 | 48 |
0.0% | Low Risk · 42 | N/A | |
| 3716 | IL(7-Day)34 |
PIT | Single-A | PIL(7-Day) | 27 | 39 | 51 | 46 |
0.0% | Wide Range · 75 | N/A | |
| 3717 | 34 |
SF | DSL | 3B | 23 | 33 | 45 | 36 |
-0.2% | Low Risk · 40 | N/A | |
| 3718 | 34 |
LAA | High-A | P | 27 | 35 | 44 | 31 |
0.0% | Low Risk · 34 | N/A | |
| 3719 | 34 |
CLE | AA | P | 25 | 33 | 42 | 47 |
-0.1% | Low Risk · 41 | N/A | |
| 3720 | 34 |
DET | Single-A | C | 25 | 34 | 42 | 33 |
0.0% | Low Risk · 29 | N/A | |
| 3721 | 34 |
CIN | AA | 1B | 26 | 32 | 40 | 43 |
-0.2% | Low Risk · 23 | N/A | |
| 3722 | 34 |
MIA | DSL | P | 25 | 37 | 47 | 38 |
0.0% | Wide Range · 66 | N/A | |
| 3723 | IL(Rehab)34 |
PHI | Single-A | PIL(Rehab) | 27 | 36 | 48 | 37 |
0.0% | Medium Risk · 48 | N/A | |
| 3724 | 34 |
SD | DSL | P | 24 | 35 | 46 | 36 |
-0.3% | Medium Risk · 46 | N/A | |
| 3725 | 34 |
SEA | DSL | P | 25 | 36 | 49 | 35 |
-0.1% | Medium Risk · 46 | N/A | |
| 3726 | 34 |
TOR | DSL | IF | 24 | 36 | 47 | 40 |
0.0% | Wide Range · 61 | N/A | |
| 3727 | 34 |
SEA | High-A | CF | 26 | 32 | 40 | 38 |
+0.1% | Low Risk · 19 | N/A | |
| 3728 | 34 |
HOU | DSL | P | 25 | 39 | 53 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 3729 | 34 |
PHI | Single-A | P | 26 | 37 | 47 | 39 |
-0.2% | Medium Risk · 54 | N/A | |
| 3730 | 34 |
TOR | DSL | OF | 24 | 35 | 48 | 38 |
-0.2% | Medium Risk · 56 | N/A | |
| 3731 | 34 |
LAD | Single-A | P | 26 | 35 | 43 | 30 |
-0.1% | Low Risk · 36 | N/A | |
| 3732 | 34 |
SF | Single-A | P | 25 | 34 | 42 | 32 |
-0.1% | Low Risk · 26 | N/A | |
| 3733 | 34 |
CLE | ACL | P | 25 | 36 | 47 | 36 |
0.0% | Medium Risk · 56 | N/A | |
| 3734 | 34 |
CIN | DSL | OF | 24 | 35 | 46 | 36 |
+0.2% | Medium Risk · 53 | N/A | |
| 3735 | 34 |
SD | ACL | P | 26 | 36 | 49 | 37 |
0.0% | Wide Range · 64 | N/A | |
| 3736 | 34 |
STL | AA | 2B | 26 | 32 | 39 | 36 |
0.0% | Low Risk · 24 | N/A | |
| 3737 | 34 |
SD | DSL | SS | 24 | 35 | 46 | 39 |
0.0% | Wide Range · 61 | N/A | |
| 3738 | 34 |
ATH | DSL | P | 24 | 35 | 53 | 36 |
0.0% | Medium Risk · 50 | N/A | |
| 3739 | 34 |
HOU | FCL | P | 25 | 37 | 48 | 40 |
-0.1% | Wide Range · 70 | N/A | |
| 3740 | 34 |
HOU | High-A | P | 27 | 35 | 45 | 31 |
-0.4% | Low Risk · 37 | N/A | |
| 3741 | 34 |
CLE | DSL | P | 25 | 37 | 49 | 38 |
-0.4% | Wide Range · 66 | N/A | |
| 3742 | 34 |
PHI | DSL | 3B | 24 | 36 | 47 | 39 |
0.0% | Wide Range · 63 | N/A | |
| 3743 | 34 |
ATH | DSL | IF | 24 | 35 | 46 | 39 |
+0.1% | Wide Range · 61 | N/A | |
| 3744 | 34 |
MIA | Single-A | SS | 25 | 35 | 44 | 35 |
0.0% | Low Risk · 34 | N/A | |
| 3745 | 34 |
ATH | DSL | OF | 24 | 34 | 45 | 37 |
0.0% | Medium Risk · 46 | N/A | |
| 3746 | 34 |
TB | FCL | P | 25 | 37 | 49 | 38 |
0.0% | Wide Range · 66 | N/A | |
| 3747 | 34 |
CWS | AAA | P | 24 | 31 | 38 | 49 |
+0.1% | Low Risk · 25 | N/A | |
| 3748 | 34 |
MIA | Single-A | P | 26 | 36 | 46 | 37 |
0.0% | Medium Risk · 44 | N/A | |
| 3749 | 34 |
NYM | FCL | P | 24 | 35 | 46 | 39 |
-0.3% | Wide Range · 60 | N/A | |
| 3750 | 34 |
SEA | ACL | OF | 23 | 33 | 45 | 38 |
-0.2% | Medium Risk · 48 | N/A | |
| 3751 | 34 |
DET | DSL | P | 25 | 37 | 48 | 39 |
0.0% | Wide Range · 62 | N/A | |
| 3752 | 34 |
CWS | AA | OF | 27 | 39 | 49 | 48 |
+0.1% | Wide Range · 75 | N/A | |
| 3753 | 34 |
SD | DSL | C | 24 | 35 | 46 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3754 | IL(7-Day)34 |
COL | Single-A | PIL(7-Day) | 25 | 35 | 44 | 35 |
0.0% | Low Risk · 36 | N/A | |
| 3755 | 34 |
DET | High-A | P | 26 | 38 | 51 | 43 |
0.0% | Wide Range · 63 | N/A | |
| 3756 | 34 |
STL | DSL | P | 25 | 39 | 52 | 41 |
0.0% | High Risk · 76 | N/A | |
| 3757 | 34 |
SEA | ACL | P | 24 | 37 | 49 | 41 |
0.0% | Wide Range · 67 | N/A | |
| 3758 | 34 |
PIT | High-A | P | 27 | 35 | 42 | 26 |
-0.4% | Low Risk · 34 | N/A | |
| 3759 | 34 |
DET | DSL | P | 25 | 39 | 49 | 41 |
-0.2% | High Risk · 76 | N/A | |
| 3760 | 34 |
ATH | DSL | SS | 24 | 34 | 45 | 37 |
-0.4% | Medium Risk · 51 | N/A | |
| 3761 | 34 |
KC | DSL | P | 24 | 38 | 49 | 41 |
0.0% | High Risk · 76 | N/A | |
| 3762 | 34 |
BAL | DSL | P | 24 | 36 | 48 | 40 |
-0.1% | Wide Range · 66 | N/A | |
| 3763 | 34 |
TOR | Single-A | P | 25 | 34 | 42 | 29 |
0.0% | Low Risk · 22 | N/A | |
| 3764 | 34 |
CIN | Single-A | P | 27 | 36 | 45 | 35 |
0.0% | Medium Risk · 44 | N/A | |
| 3765 | 34 |
CWS | DSL | P | 23 | 37 | 49 | 42 |
0.0% | Wide Range · 67 | N/A | |
| 3766 | 34 |
HOU | DSL | SS | 25 | 36 | 46 | 36 |
0.0% | Medium Risk · 55 | N/A | |
| 3767 | 34 |
CWS | DSL | P | 24 | 35 | 46 | 36 |
0.0% | Medium Risk · 56 | N/A | |
| 3768 | 34 |
SD | DSL | IF | 24 | 34 | 45 | 37 |
-0.3% | Medium Risk · 51 | N/A | |
| 3769 | 34 |
NYM | Single-A | P | 26 | 36 | 46 | 34 |
0.0% | Medium Risk · 44 | N/A | |
| 3770 | IL(Rehab)34 |
BAL | Single-A | PIL(Rehab) | 23 | 34 | 45 | 41 |
-0.4% | Medium Risk · 44 | N/A | |
| 3771 | 34 |
NYY | DSL | P | 24 | 36 | 47 | 38 |
-0.1% | Wide Range · 66 | N/A | |
| 3772 | 34 |
MIL | DSL | OF | 24 | 36 | 48 | 40 |
0.0% | Wide Range · 62 | N/A | |
| 3773 | 34 |
PHI | Single-A | P | 27 | 36 | 46 | 35 |
0.0% | Medium Risk · 44 | N/A | |
| 3774 | 34 |
BAL | AA | C | 26 | 38 | 48 | 46 |
0.0% | Wide Range · 66 | N/A | |
| 3775 | 34 |
NYM | DSL | P | 24 | 35 | 47 | 38 |
0.0% | Medium Risk · 56 | N/A | |
| 3776 | 34 |
TEX | High-A | C | 25 | 36 | 46 | 41 |
0.0% | Wide Range · 58 | N/A | |
| 3777 | 34 |
CWS | ACL | P | 25 | 37 | 54 | 38 |
-0.1% | Wide Range · 64 | N/A | |
| 3778 | 34 |
TOR | FCL | P | 23 | 33 | 47 | 36 |
0.0% | Low Risk · 40 | N/A | |
| 3779 | 34 |
CHC | Single-A | SS | 26 | 38 | 53 | 43 |
0.0% | Wide Range · 70 | N/A | |
| 3780 | 34 |
ARI | DSL | OF | 23 | 36 | 48 | 40 |
-0.1% | Wide Range · 62 | N/A | |
| 3781 | 34 |
TOR | DSL | SS | 23 | 34 | 45 | 37 |
0.0% | Medium Risk · 51 | N/A | |
| 3782 | 34 |
DET | DSL | IF | 23 | 36 | 48 | 40 |
+0.2% | Wide Range · 62 | N/A | |
| 3783 | 34 |
LAD | ACL | OF | 24 | 35 | 46 | 37 |
0.0% | Wide Range · 58 | N/A | |
| 3784 | 34 |
BOS | FCL | P | 23 | 34 | 44 | 38 |
0.0% | Medium Risk · 50 | N/A | |
| 3785 | 34 |
TOR | DSL | P | 23 | 34 | 45 | 38 |
0.0% | Medium Risk · 56 | N/A | |
| 3786 | 34 |
LAA | DSL | OF | 23 | 34 | 45 | 36 |
+0.1% | Medium Risk · 47 | N/A | |
| 3787 | 34 |
COL | DSL | P | 25 | 38 | 52 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 3788 | 34 |
CIN | DSL | P | 24 | 38 | 49 | 41 |
-0.1% | High Risk · 76 | N/A | |
| 3789 | 34 |
TEX | DSL | 1B | 23 | 36 | 51 | 43 |
0.0% | Wide Range · 71 | N/A | |
| 3790 | 34 |
SD | DSL | P | 24 | 39 | 50 | 42 |
0.0% | High Risk · 78 | N/A | |
| 3791 | 34 |
NYM | DSL | OF | 24 | 35 | 46 | 35 |
+0.1% | Medium Risk · 53 | N/A | |
| 3792 | 34 |
WSH | Single-A | P | 24 | 35 | 45 | 39 |
0.0% | Low Risk · 40 | N/A | |
| 3793 | 34 |
DET | DSL | IF | 24 | 35 | 45 | 36 |
0.0% | Medium Risk · 51 | N/A | |
| 3794 | 34 |
CHC | AAA | P | 29 | 38 | 51 | 53 |
-0.9% | Wide Range · 73 | N/A | |
| 3795 | 34 |
ATH | High-A | P | 25 | 37 | 47 | 42 |
-0.2% | Wide Range · 62 | N/A | |
| 3796 | 34 |
CWS | ACL | P | 25 | 37 | 48 | 39 |
0.0% | Wide Range · 66 | N/A | |
| 3797 | 34 |
ATH | DSL | OF | 24 | 37 | 54 | 40 |
0.0% | Wide Range · 70 | N/A | |
| 3798 | 34 |
NYY | AA | P | 26 | 32 | 38 | 39 |
0.0% | Low Risk · 21 | N/A | |
| 3799 | 34 |
CWS | ACL | RF | 24 | 36 | 46 | 38 |
0.0% | Wide Range · 62 | N/A | |
| 3800 | 34 |
HOU | DSL | OF | 23 | 35 | 48 | 38 |
0.0% | Medium Risk · 56 | N/A | |
| 3801 | 34 |
NYY | AAA | C | 25 | 35 | 44 | 51 |
0.0% | Medium Risk · 48 | N/A | |
| 3802 | 34 |
DET | AAA | SS | 24 | 31 | 38 | 49 |
0.0% | Low Risk · 26 | N/A | |
| 3803 | 34 |
BAL | FCL | SS | 24 | 36 | 47 | 40 |
0.0% | Wide Range · 61 | N/A | |
| 3804 | 34 |
LAA | ACL | 3B | 25 | 35 | 45 | 34 |
+0.2% | Medium Risk · 55 | N/A | |
| 3805 | 34 |
PHI | FCL | P | 26 | 37 | 47 | 33 |
-0.1% | Medium Risk · 56 | N/A | |
| 3806 | 34 |
STL | Single-A | 2B | 24 | 36 | 47 | 42 |
-0.1% | Wide Range · 59 | N/A | |
| 3807 | 34 |
STL | DSL | IF | 24 | 37 | 49 | 41 |
0.0% | Wide Range · 72 | N/A | |
| 3808 | 34 |
PIT | High-A | P | 26 | 36 | 46 | 38 |
-0.1% | Medium Risk · 52 | N/A | |
| 3809 | 34 |
ATH | ACL | RF | 24 | 35 | 44 | 36 |
-0.1% | Medium Risk · 56 | N/A | |
| 3810 | 34 |
CHC | DSL | IF | 24 | 37 | 50 | 41 |
0.0% | Wide Range · 71 | N/A | |
| 3811 | 34 |
TEX | DSL | SS | 24 | 35 | 46 | 38 |
0.0% | Wide Range · 63 | N/A | |
| 3812 | 34 |
WSH | AAA | P | 25 | 32 | 39 | 43 |
0.0% | Low Risk · 37 | N/A | |
| 3813 | 34 |
SEA | DSL | P | 23 | 34 | 45 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3814 | 34 |
PIT | Single-A | P | 26 | 36 | 46 | 37 |
0.0% | Medium Risk · 45 | N/A | |
| 3815 | 34 |
WSH | AA | SS | 26 | 32 | 38 | 35 |
-0.6% | Low Risk · 19 | N/A | |
| 3816 | 34 |
MIA | AA | P | 26 | 32 | 39 | 38 |
0.0% | Low Risk · 21 | N/A | |
| 3817 | 34 |
MIL | High-A | P | 26 | 40 | 51 | 46 |
-25.0% | High Risk · 79 | N/A | |
| 3818 | 34 |
NYM | FCL | P | 25 | 37 | 48 | 38 |
-0.3% | Wide Range · 66 | N/A | |
| 3819 | 34 |
PHI | Single-A | P | 25 | 36 | 47 | 41 |
-0.1% | Wide Range · 65 | N/A | |
| 3820 | 34 |
KC | High-A | P | 26 | 34 | 42 | 26 |
0.0% | Low Risk · 34 | N/A | |
| 3821 | 34 |
MIL | Single-A | P | 23 | 35 | 46 | 41 |
+0.1% | Medium Risk · 54 | N/A | |
| 3822 | 34 |
CHC | AAA | P | 26 | 33 | 41 | 42 |
0.0% | Medium Risk · 45 | N/A | |
| 3823 | 34 |
TB | DSL | P | 22 | 34 | 44 | 39 |
-0.1% | Medium Risk · 56 | N/A | |
| 3824 | 34 |
ARI | DSL | P | 25 | 36 | 52 | 35 |
+0.1% | Medium Risk · 56 | N/A | |
| 3825 | 34 |
CLE | AA | P | 27 | 40 | 49 | 48 |
0.0% | High Risk · 79 | N/A | |
| 3826 | 34 |
TOR | DSL | P | 25 | 38 | 52 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 3827 | 34 |
CLE | DSL | P | 24 | 38 | 52 | 40 |
-0.2% | High Risk · 76 | N/A | |
| 3828 | 34 |
NYY | DSL | C | 24 | 36 | 56 | 40 |
0.0% | Wide Range · 70 | N/A | |
| 3829 | 34 |
NYY | AA | P | 30 | 36 | 52 | 49 |
0.0% | Medium Risk · 50 | N/A | |
| 3830 | IL(7-Day)34 |
NYM | Single-A | 3BIL(7-Day) | 24 | 34 | 44 | 39 |
0.0% | Low Risk · 41 | N/A | |
| 3831 | 34 |
DET | High-A | P | 25 | 34 | 42 | 30 |
+0.2% | Low Risk · 34 | N/A | |
| 3832 | 34 |
PHI | DSL | P | 24 | 38 | 48 | 41 |
0.0% | High Risk · 76 | N/A | |
| 3833 | 34 |
MIN | High-A | C | 24 | 36 | 47 | 42 |
0.0% | Medium Risk · 57 | N/A | |
| 3834 | 34 |
TOR | FCL | P | 25 | 36 | 48 | 35 |
0.0% | Medium Risk · 56 | N/A | |
| 3835 | 34 |
TB | DSL | P | 23 | 35 | 55 | 35 |
0.0% | Medium Risk · 50 | N/A | |
| 3836 | IL(60-Day)34 |
MIA | High-A | PIL(60-Day) | 24 | 38 | 49 | 46 |
0.0% | High Risk · 75 | N/A | |
| 3837 | 34 |
MIA | DSL | P | 23 | 35 | 47 | 39 |
0.0% | Wide Range · 66 | N/A | |
| 3838 | 34 |
MIL | DSL | OF | 23 | 34 | 45 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3839 | 34 |
CIN | DSL | P | 23 | 36 | 47 | 40 |
0.0% | Wide Range · 66 | N/A | |
| 3840 | 34 |
MIL | ACL | P | 25 | 36 | 47 | 37 |
0.0% | Medium Risk · 57 | N/A | |
| 3841 | 34 |
ATH | Single-A | P | 25 | 34 | 43 | 29 |
-0.2% | Low Risk · 22 | N/A | |
| 3842 | 34 |
TEX | AAA | RF | 26 | 31 | 36 | 42 |
0.0% | Low Risk · 24 | N/A | |
| 3843 | 33 |
TB | AAA | C | 28 | 33 | 38 | 39 |
0.0% | Low Risk · 31 | N/A | |
| 3844 | 33 |
MIL | ACL | P | 25 | 37 | 48 | 36 |
0.0% | Wide Range · 58 | N/A | |
| 3845 | 33 |
CIN | Single-A | P | 26 | 35 | 44 | 33 |
0.0% | Medium Risk · 44 | N/A | |
| 3846 | 33 |
HOU | AAA | P | 25 | 35 | 45 | 52 |
0.0% | Medium Risk · 50 | N/A | |
| 3847 | 33 |
BOS | DSL | P | 24 | 34 | 44 | 34 |
0.0% | Medium Risk · 46 | N/A | |
| 3848 | 33 |
PIT | FCL | P | 24 | 34 | 43 | 32 |
0.0% | Medium Risk · 46 | N/A | |
| 3849 | 33 |
WSH | DSL | OF | 23 | 35 | 46 | 38 |
0.0% | Wide Range · 63 | N/A | |
| 3850 | 33 |
CLE | DSL | SS | 23 | 35 | 45 | 38 |
-0.2% | Wide Range · 61 | N/A | |
| 3851 | 33 |
NYM | FCL | P | 25 | 35 | 45 | 31 |
0.0% | Medium Risk · 46 | N/A | |
| 3852 | 33 |
PHI | FCL | P | 25 | 39 | 56 | 42 |
0.0% | High Risk · 80 | N/A | |
| 3853 | 33 |
NYY | FCL | C | 23 | 38 | 48 | 43 |
-0.3% | High Risk · 77 | N/A | |
| 3854 | 33 |
ATH | Single-A | OF | 24 | 35 | 45 | 39 |
-0.5% | Wide Range · 60 | N/A | |
| 3855 | IL(60-Day)33 |
TOR | High-A | PIL(60-Day) | 25 | 37 | 48 | 45 |
0.0% | Wide Range · 74 | N/A | |
| 3856 | 33 |
COL | DSL | P | 23 | 35 | 45 | 35 |
0.0% | Medium Risk · 52 | N/A | |
| 3857 | 33 |
NYM | High-A | P | 26 | 34 | 41 | 27 |
0.0% | Low Risk · 34 | N/A | |
| 3858 | IL(Rehab)33 |
STL | Single-A | OFIL(Rehab) | 24 | 35 | 47 | 41 |
0.0% | Medium Risk · 53 | N/A | |
| 3859 | 33 |
HOU | High-A | P | 26 | 34 | 42 | 24 |
0.0% | Low Risk · 34 | N/A | |
| 3860 | 33 |
MIN | FCL | P | 24 | 36 | 47 | 38 |
0.0% | Wide Range · 66 | N/A | |
| 3861 | 33 |
CHC | ACL | P | 25 | 36 | 46 | 33 |
+0.1% | Medium Risk · 56 | N/A | |
| 3862 | 33 |
NYY | DSL | P | 24 | 35 | 45 | 36 |
0.0% | Medium Risk · 56 | N/A | |
| 3863 | 33 |
NYM | AAA | P | 26 | 35 | 44 | 50 |
0.0% | Medium Risk · 54 | N/A | |
| 3864 | 33 |
SD | DSL | P | 24 | 36 | 47 | 36 |
0.0% | Wide Range · 66 | N/A | |
| 3865 | 33 |
CLE | DSL | P | 23 | 34 | 44 | 35 |
-0.3% | Medium Risk · 46 | N/A | |
| 3866 | 33 |
KC | Single-A | P | 28 | 38 | 56 | 40 |
-0.3% | Wide Range · 64 | N/A | |
| 3867 | 33 |
TEX | Single-A | C | 23 | 35 | 45 | 40 |
0.0% | Medium Risk · 51 | N/A | |
| 3868 | 33 |
SEA | DSL | P | 24 | 38 | 52 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 3869 | 33 |
SF | DSL | SS | 24 | 38 | 52 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 3870 | 33 |
DET | FCL | LF | 24 | 34 | 44 | 34 |
-0.1% | Medium Risk · 51 | N/A | |
| 3871 | 33 |
MIA | DSL | C | 23 | 36 | 48 | 41 |
0.0% | Wide Range · 71 | N/A | |
| 3872 | 33 |
NYM | FCL | CF | 24 | 34 | 44 | 32 |
+0.1% | Medium Risk · 47 | N/A | |
| 3873 | 33 |
HOU | DSL | 3B | 23 | 34 | 43 | 35 |
-0.4% | Medium Risk · 51 | N/A | |
| 3874 | 33 |
CLE | High-A | P | 24 | 36 | 47 | 42 |
0.0% | Medium Risk · 53 | N/A | |
| 3875 | 33 |
MIL | DSL | P | 24 | 35 | 46 | 34 |
0.0% | Medium Risk · 56 | N/A | |
| 3876 | 33 |
CLE | DSL | P | 22 | 33 | 44 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3877 | 33 |
SEA | Single-A | CF | 25 | 33 | 40 | 26 |
0.0% | Low Risk · 28 | N/A | |
| 3878 | 33 |
TB | AA | C | 25 | 31 | 41 | 45 |
+0.3% | Low Risk · 25 | N/A | |
| 3879 | 33 |
ATH | ACL | C | 23 | 35 | 46 | 37 |
-0.1% | Medium Risk · 56 | N/A | |
| 3880 | 33 |
PIT | DSL | P | 23 | 35 | 47 | 39 |
-0.2% | Wide Range · 66 | N/A | |
| 3881 | 33 |
MIA | Single-A | P | 25 | 37 | 48 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 3882 | 33 |
PHI | FCL | RF | 24 | 36 | 55 | 37 |
0.0% | Wide Range · 59 | N/A | |
| 3883 | 33 |
SD | ACL | P | 24 | 35 | 51 | 36 |
0.0% | Medium Risk · 56 | N/A | |
| 3884 | 33 |
NYY | FCL | P | 25 | 40 | 51 | 43 |
-0.2% | High Risk · 82 | N/A | |
| 3885 | 33 |
BAL | AA | P | 26 | 35 | 44 | 37 |
0.0% | Medium Risk · 45 | N/A | |
| 3886 | 33 |
BOS | DSL | SS | 23 | 35 | 45 | 38 |
0.0% | Wide Range · 61 | N/A | |
| 3887 | 33 |
TOR | DSL | IF | 23 | 35 | 45 | 38 |
0.0% | Wide Range · 61 | N/A | |
| 3888 | 33 |
CHC | ACL | P | 25 | 35 | 44 | 30 |
0.0% | Medium Risk · 48 | N/A | |
| 3889 | 33 |
ATH | ACL | P | 24 | 36 | 55 | 36 |
+0.1% | Wide Range · 60 | N/A | |
| 3890 | 33 |
TEX | DSL | OF | 23 | 35 | 47 | 39 |
+0.1% | Wide Range · 62 | N/A | |
| 3891 | 33 |
ARI | DSL | OF | 23 | 35 | 46 | 38 |
+0.1% | Wide Range · 61 | N/A | |
| 3892 | 33 |
MIN | FCL | P | 24 | 35 | 46 | 36 |
0.0% | Wide Range · 70 | N/A | |
| 3893 | 33 |
PHI | Single-A | P | 25 | 37 | 51 | 40 |
0.0% | Wide Range · 64 | N/A | |
| 3894 | 33 |
KC | DSL | C | 23 | 35 | 46 | 39 |
-0.2% | Wide Range · 61 | N/A | |
| 3895 | 33 |
ATH | ACL | P | 23 | 37 | 50 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 3896 | 33 |
MIN | Single-A | P | 25 | 34 | 46 | 36 |
-0.1% | Medium Risk · 46 | N/A | |
| 3897 | 33 |
KC | AAA | C | 28 | 33 | 38 | 35 |
0.0% | Low Risk · 36 | N/A | |
| 3898 | 33 |
DET | Single-A | P | 24 | 34 | 44 | 37 |
+0.1% | Low Risk · 40 | N/A | |
| 3899 | 33 |
ATH | ACL | P | 25 | 36 | 52 | 36 |
-0.1% | Wide Range · 64 | N/A | |
| 3900 | 33 |
CLE | High-A | 2B | 25 | 34 | 43 | 33 |
0.0% | Medium Risk · 48 | N/A | |
| 3901 | 33 |
ATH | High-A | P | 25 | 34 | 42 | 32 |
0.0% | Low Risk · 29 | N/A | |
| 3902 | 33 |
DET | FCL | P | 25 | 36 | 52 | 36 |
0.0% | Wide Range · 64 | N/A | |
| 3903 | 33 |
PIT | DSL | P | 22 | 34 | 44 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3904 | 33 |
KC | Single-A | P | 25 | 34 | 43 | 28 |
-0.1% | Low Risk · 38 | N/A | |
| 3905 | 33 |
KC | Single-A | P | 25 | 35 | 44 | 31 |
0.0% | Medium Risk · 46 | N/A | |
| 3906 | 33 |
ATL | High-A | C | 25 | 32 | 39 | 28 |
-0.8% | Low Risk · 25 | N/A | |
| 3907 | 33 |
COL | ACL | 2B | 25 | 36 | 59 | 38 |
0.0% | Wide Range · 64 | N/A | |
| 3908 | 33 |
HOU | FCL | P | 24 | 34 | 45 | 35 |
-0.4% | Medium Risk · 56 | N/A | |
| 3909 | 33 |
NYY | DSL | C | 24 | 36 | 52 | 40 |
-0.2% | Wide Range · 71 | N/A | |
| 3910 | 33 |
BOS | High-A | P | 26 | 41 | 51 | 47 |
0.0% | High Risk · 80 | N/A | |
| 3911 | 33 |
NYM | DSL | 2B | 23 | 34 | 44 | 35 |
+0.1% | Medium Risk · 53 | N/A | |
| 3912 | 33 |
SD | DSL | OF | 23 | 36 | 49 | 40 |
0.0% | Wide Range · 70 | N/A | |
| 3913 | IL(7-Day)33 |
TOR | Single-A | PIL(7-Day) | 22 | 33 | 42 | 39 |
0.0% | Medium Risk · 50 | N/A | |
| 3914 | 33 |
KC | DSL | P | 24 | 36 | 53 | 37 |
0.0% | Wide Range · 66 | N/A | |
| 3915 | 33 |
PHI | DSL | P | 23 | 35 | 46 | 37 |
0.0% | Wide Range · 66 | N/A | |
| 3916 | 33 |
PHI | FCL | P | 24 | 35 | 46 | 37 |
0.0% | Wide Range · 66 | N/A | |
| 3917 | 33 |
KC | High-A | P | 26 | 35 | 44 | 32 |
+0.1% | Medium Risk · 42 | N/A | |
| 3918 | 33 |
ATL | AAA | P | 23 | 29 | 37 | 49 |
-0.2% | Low Risk · 26 | N/A | |
| 3919 | 33 |
TEX | High-A | P | 25 | 37 | 51 | 42 |
-0.1% | Wide Range · 63 | N/A | |
| 3920 | 33 |
LAA | ACL | C | 23 | 36 | 53 | 39 |
-0.1% | Wide Range · 64 | N/A | |
| 3921 | 33 |
KC | ACL | P | 25 | 36 | 51 | 35 |
0.0% | Wide Range · 64 | N/A | |
| 3922 | IL(7-Day)33 |
COL | Single-A | PIL(7-Day) | 25 | 34 | 44 | 35 |
0.0% | Medium Risk · 50 | N/A | |
| 3923 | IL(Rehab)33 |
HOU | FCL | 2BIL(Rehab) | 28 | 39 | 62 | 39 |
0.0% | Wide Range · 69 | N/A | |
| 3924 | 33 |
ARI | Single-A | P | 26 | 37 | 54 | 42 |
-0.5% | Wide Range · 69 | N/A | |
| 3925 | 33 |
SD | DSL | P | 24 | 39 | 52 | 42 |
0.0% | High Risk · 79 | N/A | |
| 3926 | 33 |
SF | AAA | IF | 25 | 35 | 45 | 52 |
-0.1% | Medium Risk · 54 | N/A | |
| 3927 | 33 |
STL | Single-A | P | 24 | 36 | 47 | 41 |
0.0% | Wide Range · 64 | N/A | |
| 3928 | 33 |
PHI | High-A | P | 24 | 35 | 46 | 42 |
0.0% | Wide Range · 62 | N/A | |
| 3929 | 33 |
MIL | DSL | P | 22 | 33 | 43 | 35 |
0.0% | Medium Risk · 46 | N/A | |
| 3930 | 33 |
PHI | DSL | P | 24 | 39 | 54 | 42 |
-0.3% | High Risk · 79 | N/A | |
| 3931 | 33 |
MIA | High-A | P | 26 | 35 | 43 | 31 |
0.0% | Medium Risk · 42 | N/A | |
| 3932 | 33 |
CIN | AA | 3B | 24 | 32 | 40 | 44 |
0.0% | Low Risk · 28 | N/A | |
| 3933 | 33 |
ATH | DSL | P | 23 | 35 | 45 | 35 |
0.0% | Medium Risk · 56 | N/A | |
| 3934 | 33 |
DET | FCL | P | 25 | 36 | 46 | 33 |
0.0% | Wide Range · 62 | N/A | |
| 3935 | 33 |
TB | FCL | C | 23 | 34 | 43 | 34 |
-0.1% | Medium Risk · 45 | N/A | |
| 3936 | 33 |
DET | DSL | C | 22 | 33 | 46 | 34 |
+0.1% | Low Risk · 40 | N/A | |
| 3937 | 33 |
TEX | High-A | P | 25 | 33 | 41 | 28 |
0.0% | Low Risk · 34 | N/A | |
| 3938 | 33 |
ATH | ACL | 1B | 23 | 36 | 50 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 3939 | 33 |
MIA | FCL | P | 25 | 36 | 48 | 36 |
-0.2% | Wide Range · 64 | N/A | |
| 3940 | 33 |
BAL | DSL | C | 22 | 34 | 45 | 37 |
-0.2% | Medium Risk · 56 | N/A | |
| 3941 | 33 |
NYM | DSL | 2B | 23 | 34 | 44 | 35 |
0.0% | Medium Risk · 53 | N/A | |
| 3942 | 33 |
SF | Single-A | P | 23 | 34 | 46 | 40 |
0.0% | Medium Risk · 42 | N/A | |
| 3943 | 33 |
PIT | DSL | OF | 23 | 36 | 54 | 39 |
0.0% | Wide Range · 70 | N/A | |
| 3944 | 33 |
PIT | FCL | C | 23 | 34 | 44 | 34 |
0.0% | Medium Risk · 54 | N/A | |
| 3945 | 33 |
NYM | DSL | P | 22 | 33 | 44 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 3946 | IL(Full Season)33 |
COL | High-A | PIL(Full Season) | 23 | 35 | 46 | 42 |
0.0% | Medium Risk · 56 | N/A | |
| 3947 | 33 |
ATH | AA | C | 24 | 33 | 43 | 47 |
0.0% | Low Risk · 42 | N/A | |
| 3948 | 33 |
COL | High-A | SS | 25 | 33 | 41 | 26 |
+0.1% | Low Risk · 35 | N/A | |
| 3949 | 33 |
KC | DSL | P | 22 | 33 | 43 | 36 |
-0.3% | Medium Risk · 46 | N/A | |
| 3950 | 33 |
HOU | AAA | P | 27 | 35 | 43 | 42 |
0.0% | Medium Risk · 52 | N/A | |
| 3951 | 33 |
NYM | DSL | C | 22 | 34 | 45 | 37 |
-0.1% | Medium Risk · 56 | N/A | |
| 3952 | 33 |
SEA | AAA | P | 24 | 30 | 39 | 46 |
-0.1% | Low Risk · 26 | N/A | |
| 3953 | 33 |
TOR | DSL | OF | 22 | 35 | 47 | 38 |
0.0% | Wide Range · 61 | N/A | |
| 3954 | 33 |
COL | DSL | P | 23 | 37 | 50 | 42 |
0.0% | High Risk · 80 | N/A | |
| 3955 | 33 |
PIT | DSL | P | 23 | 35 | 46 | 37 |
-0.3% | Wide Range · 66 | N/A | |
| 3956 | 33 |
PIT | FCL | P | 23 | 34 | 45 | 35 |
+0.2% | Medium Risk · 56 | N/A | |
| 3957 | 33 |
CWS | Single-A | P | 24 | 32 | 40 | 32 |
0.0% | Low Risk · 36 | N/A | |
| 3958 | 33 |
CIN | AA | P | 25 | 33 | 42 | 42 |
0.0% | Low Risk · 28 | N/A | |
| 3959 | 33 |
ATH | DSL | OF | 22 | 35 | 46 | 38 |
0.0% | Wide Range · 61 | N/A | |
| 3960 | 33 |
LAD | DSL | P | 23 | 34 | 44 | 35 |
0.0% | Medium Risk · 56 | N/A | |
| 3961 | 33 |
CWS | High-A | P | 25 | 34 | 43 | 33 |
-0.3% | Medium Risk · 42 | N/A | |
| 3962 | 33 |
ARI | AAA | P | 25 | 32 | 41 | 45 |
0.0% | Low Risk · 39 | N/A | |
| 3963 | 33 |
SEA | AAA | LF | 27 | 32 | 39 | 42 |
+0.1% | Low Risk · 39 | N/A | |
| 3964 | 33 |
NYY | FCL | P | 23 | 34 | 45 | 35 |
-0.4% | Medium Risk · 56 | N/A | |
| 3965 | 33 |
CIN | DSL | IF | 23 | 34 | 44 | 35 |
-0.1% | Medium Risk · 53 | N/A | |
| 3966 | 33 |
MIL | DSL | P | 23 | 35 | 47 | 37 |
-0.1% | Wide Range · 66 | N/A | |
| 3967 | 33 |
COL | ACL | P | 24 | 34 | 44 | 32 |
0.0% | Medium Risk · 56 | N/A | |
| 3968 | 33 |
MIN | DSL | P | 26 | 40 | 60 | 40 |
0.0% | High Risk · 80 | N/A | |
| 3969 | 33 |
LAD | DSL | IF | 23 | 37 | 51 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 3970 | 33 |
BAL | DSL | P | 23 | 37 | 51 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 3971 | 33 |
TEX | ACL | P | 23 | 35 | 52 | 36 |
0.0% | Wide Range · 60 | N/A | |
| 3972 | 33 |
TOR | AAA | P | 25 | 30 | 35 | 42 |
0.0% | Low Risk · 25 | N/A | |
| 3973 | 33 |
PHI | DSL | OF | 23 | 34 | 45 | 35 |
+0.4% | Medium Risk · 55 | N/A | |
| 3974 | IL(Rehab)32 |
SEA | ACL | 1BIL(Rehab) | 22 | 33 | 51 | 38 |
0.0% | Medium Risk · 55 | N/A | |
| 3975 | 32 |
CLE | ACL | P | 23 | 36 | 51 | 41 |
0.0% | Wide Range · 74 | N/A | |
| 3976 | 32 |
KC | ACL | C | 24 | 36 | 47 | 38 |
0.0% | Wide Range · 72 | N/A | |
| 3977 | 32 |
NYM | DSL | SS | 22 | 35 | 49 | 40 |
0.0% | Wide Range · 70 | N/A | |
| 3978 | 32 |
CHC | AA | C | 26 | 35 | 43 | 35 |
0.0% | Medium Risk · 45 | N/A | |
| 3979 | 32 |
BAL | DSL | P | 25 | 40 | 54 | 44 |
0.0% | High Risk · 91 | N/A | |
| 3980 | 32 |
PIT | FCL | P | 23 | 34 | 44 | 34 |
0.0% | Medium Risk · 56 | N/A | |
| 3981 | IL(60-Day)32 |
CWS | High-A | CIL(60-Day) | 23 | 34 | 45 | 41 |
0.0% | Medium Risk · 54 | N/A | |
| 3982 | 32 |
CHC | DSL | SS | 22 | 35 | 47 | 40 |
-0.1% | Wide Range · 71 | N/A | |
| 3983 | 32 |
CWS | ACL | P | 24 | 34 | 45 | 32 |
0.0% | Medium Risk · 50 | N/A | |
| 3984 | 32 |
ATH | High-A | P | 24 | 34 | 43 | 33 |
0.0% | Medium Risk · 42 | N/A | |
| 3985 | 32 |
NYY | DSL | P | 23 | 34 | 45 | 37 |
-0.1% | Wide Range · 66 | N/A | |
| 3986 | 32 |
ATL | FCL | OF | 24 | 34 | 43 | 30 |
+0.2% | Medium Risk · 54 | N/A | |
| 3987 | 32 |
CWS | DSL | C | 25 | 39 | 59 | 43 |
+0.1% | High Risk · 87 | N/A | |
| 3988 | 32 |
KC | ACL | P | 21 | 31 | 41 | 34 |
-0.1% | Low Risk · 40 | N/A | |
| 3989 | 32 |
ARI | DSL | P | 25 | 40 | 58 | 44 |
0.0% | High Risk · 91 | N/A | |
| 3990 | 32 |
CIN | ACL | P | 23 | 36 | 49 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 3991 | 32 |
LAA | DSL | P | 24 | 35 | 46 | 37 |
0.0% | Wide Range · 70 | N/A | |
| 3992 | 32 |
CHC | High-A | C | 23 | 34 | 44 | 39 |
0.0% | Medium Risk · 49 | N/A | |
| 3993 | 32 |
TOR | AA | C | 24 | 32 | 39 | 40 |
+0.2% | Low Risk · 28 | N/A | |
| 3994 | 32 |
SEA | ACL | C | 24 | 35 | 45 | 33 |
-0.3% | Wide Range · 62 | N/A | |
| 3995 | 32 |
PIT | AA | P | 26 | 34 | 48 | 50 |
0.0% | Medium Risk · 49 | N/A | |
| 3996 | 32 |
NYM | DSL | P | 22 | 37 | 47 | 42 |
0.0% | High Risk · 80 | N/A | |
| 3997 | 32 |
STL | Single-A | P | 24 | 33 | 41 | 30 |
0.0% | Low Risk · 36 | N/A | |
| 3998 | 32 |
SD | DSL | P | 22 | 33 | 47 | 34 |
0.0% | Medium Risk · 46 | N/A | |
| 3999 | 32 |
COL | DSL | SS | 22 | 34 | 45 | 36 |
0.0% | Wide Range · 63 | N/A | |
| 4000 | 32 |
MIN | DSL | P | 22 | 36 | 47 | 40 |
-0.2% | High Risk · 76 | N/A | |
| 4001 | 32 |
LAA | High-A | P | 24 | 35 | 47 | 40 |
-0.1% | Medium Risk · 55 | N/A | |
| 4002 | 32 |
CIN | ACL | P | 23 | 35 | 47 | 37 |
0.0% | Wide Range · 64 | N/A | |
| 4003 | 32 |
CLE | Single-A | P | 22 | 34 | 44 | 40 |
0.0% | Medium Risk · 54 | N/A | |
| 4004 | 32 |
COL | AA | OF | 24 | 31 | 43 | 46 |
0.0% | Low Risk · 40 | N/A | |
| 4005 | 32 |
SEA | ACL | C | 23 | 35 | 46 | 39 |
0.0% | Wide Range · 72 | N/A | |
| 4006 | 32 |
MIL | DSL | P | 21 | 32 | 43 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 4007 | 32 |
HOU | High-A | P | 24 | 34 | 45 | 38 |
+0.1% | Medium Risk · 52 | N/A | |
| 4008 | 32 |
CWS | AA | C | 26 | 33 | 41 | 28 |
0.0% | Low Risk · 37 | N/A | |
| 4009 | 32 |
NYY | FCL | CF | 23 | 34 | 45 | 34 |
0.0% | Medium Risk · 57 | N/A | |
| 4010 | 32 |
PHI | AAA | P | 25 | 29 | 36 | 47 |
-0.3% | Low Risk · 27 | N/A | |
| 4011 | IL(Rehab)32 |
TOR | Single-A | PIL(Rehab) | 25 | 33 | 41 | 24 |
0.0% | Low Risk · 40 | N/A | |
| 4012 | 32 |
MIL | ACL | P | 23 | 35 | 46 | 38 |
-0.4% | Wide Range · 66 | N/A | |
| 4013 | 32 |
ATL | DSL | SS | 23 | 37 | 50 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 4014 | 32 |
COL | Single-A | P | 24 | 35 | 50 | 37 |
0.0% | Medium Risk · 50 | N/A | |
| 4015 | 32 |
SD | ACL | P | 24 | 35 | 45 | 33 |
0.0% | Medium Risk · 56 | N/A | |
| 4016 | 32 |
CHC | DSL | P | 22 | 36 | 47 | 40 |
-0.4% | High Risk · 76 | N/A | |
| 4017 | 32 |
ATH | ACL | 2B | 23 | 32 | 41 | 29 |
-0.1% | Low Risk · 32 | N/A | |
| 4018 | 32 |
DET | DSL | C | 23 | 35 | 48 | 39 |
0.0% | Wide Range · 70 | N/A | |
| 4019 | 32 |
WSH | FCL | P | 24 | 34 | 44 | 32 |
-0.2% | Medium Risk · 56 | N/A | |
| 4020 | 32 |
CIN | Single-A | P | 24 | 33 | 41 | 25 |
-0.1% | Low Risk · 38 | N/A | |
| 4021 | 32 |
TEX | DSL | CF | 22 | 33 | 43 | 32 |
0.0% | Medium Risk · 46 | N/A | |
| 4022 | 32 |
LAA | DSL | P | 22 | 33 | 43 | 31 |
0.0% | Medium Risk · 42 | N/A | |
| 4023 | 32 |
COL | ACL | P | 23 | 35 | 46 | 36 |
0.0% | Wide Range · 66 | N/A | |
| 4024 | 32 |
STL | AAA | P | 25 | 34 | 43 | 46 |
0.0% | Medium Risk · 53 | N/A | |
| 4025 | 32 |
SEA | DSL | P | 23 | 34 | 46 | 35 |
0.0% | Medium Risk · 56 | N/A | |
| 4026 | 32 |
CLE | DSL | C | 23 | 34 | 44 | 35 |
-0.5% | Wide Range · 62 | N/A | |
| 4027 | 32 |
ATL | High-A | P | 25 | 34 | 43 | 30 |
-0.1% | Medium Risk · 42 | N/A | |
| 4028 | 32 |
KC | DSL | P | 22 | 34 | 45 | 38 |
0.0% | Wide Range · 66 | N/A | |
| 4029 | 32 |
BAL | FCL | P | 23 | 33 | 43 | 32 |
0.0% | Medium Risk · 56 | N/A | |
| 4030 | 32 |
TB | High-A | P | 21 | 32 | 43 | 41 |
0.0% | Low Risk · 41 | N/A | |
| 4031 | 32 |
ATH | High-A | P | 24 | 39 | 49 | 45 |
0.0% | High Risk · 79 | N/A | |
| 4032 | 32 |
PHI | High-A | P | 23 | 35 | 46 | 40 |
-0.4% | Wide Range · 62 | N/A | |
| 4033 | 32 |
WSH | High-A | P | 25 | 34 | 43 | 31 |
-0.6% | Medium Risk · 42 | N/A | |
| 4034 | 32 |
DET | DSL | SS | 21 | 32 | 43 | 33 |
0.0% | Low Risk · 40 | N/A | |
| 4035 | 32 |
SEA | DSL | IF | 22 | 36 | 47 | 42 |
0.0% | High Risk · 78 | N/A | |
| 4036 | 32 |
SEA | High-A | OF | 23 | 30 | 37 | 34 |
0.0% | Low Risk · 19 | N/A | |
| 4037 | 32 |
SF | DSL | P | 23 | 34 | 55 | 33 |
0.0% | Medium Risk · 50 | N/A | |
| 4038 | 32 |
ARI | Single-A | P | 24 | 35 | 48 | 39 |
0.0% | Wide Range · 64 | N/A | |
| 4039 | 32 |
TEX | DSL | 3B | 22 | 35 | 47 | 38 |
-6.0% | Wide Range · 62 | N/A | |
| 4040 | 32 |
ATL | AA | C | 23 | 29 | 36 | 42 |
-0.2% | Low Risk · 24 | N/A | |
| 4041 | 32 |
CHC | DSL | P | 22 | 34 | 52 | 36 |
0.0% | Wide Range · 64 | N/A | |
| 4042 | 32 |
CLE | DSL | P | 22 | 34 | 46 | 37 |
-0.1% | Wide Range · 66 | N/A | |
| 4043 | 32 |
COL | DSL | IF | 21 | 36 | 47 | 41 |
-0.1% | High Risk · 78 | N/A | |
| 4044 | 32 |
SD | AA | 3B | 24 | 30 | 36 | 34 |
-0.1% | Low Risk · 20 | N/A | |
| 4045 | 32 |
HOU | DSL | P | 23 | 36 | 50 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 4046 | 32 |
MIA | DSL | P | 23 | 36 | 50 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 4047 | 32 |
SEA | ACL | P | 22 | 35 | 47 | 40 |
0.0% | Wide Range · 67 | N/A | |
| 4048 | 32 |
TEX | DSL | P | 23 | 34 | 48 | 37 |
-0.1% | Wide Range · 70 | N/A | |
| 4049 | 32 |
ARI | ACL | P | 23 | 34 | 45 | 34 |
0.0% | Medium Risk · 56 | N/A | |
| 4050 | 32 |
COL | AA | C | 24 | 32 | 40 | 41 |
+0.2% | Medium Risk · 43 | N/A | |
| 4051 | 32 |
MIA | DSL | C | 21 | 35 | 47 | 39 |
0.0% | Wide Range · 64 | N/A | |
| 4052 | 32 |
NYM | AA | P | 24 | 31 | 42 | 43 |
0.0% | Low Risk · 37 | N/A | |
| 4053 | 32 |
HOU | Single-A | P | 22 | 33 | 44 | 39 |
0.0% | Medium Risk · 54 | N/A | |
| 4054 | IL(60-Day)32 |
CHC | Single-A | PIL(60-Day) | 24 | 39 | 49 | 46 |
0.0% | High Risk · 82 | N/A | |
| 4055 | 32 |
BAL | Single-A | P | 24 | 32 | 40 | 27 |
0.0% | Low Risk · 36 | N/A | |
| 4056 | 32 |
ARI | Single-A | C | 24 | 34 | 43 | 33 |
0.0% | Medium Risk · 50 | N/A | |
| 4057 | 32 |
HOU | FCL | P | 23 | 33 | 44 | 34 |
0.0% | Medium Risk · 56 | N/A | |
| 4058 | 32 |
WSH | DSL | C | 22 | 36 | 48 | 41 |
-0.2% | High Risk · 78 | N/A | |
| 4059 | 32 |
COL | DSL | C | 22 | 35 | 47 | 39 |
-0.2% | Wide Range · 72 | N/A | |
| 4060 | 32 |
MIL | DSL | P | 22 | 33 | 44 | 33 |
-0.1% | Medium Risk · 52 | N/A | |
| 4061 | 32 |
HOU | DSL | P | 20 | 31 | 42 | 37 |
0.0% | Wide Range · 60 | N/A | |
| 4062 | 32 |
PHI | High-A | P | 24 | 32 | 41 | 32 |
0.0% | Medium Risk · 42 | N/A | |
| 4063 | 32 |
WSH | FCL | 3B | 23 | 33 | 42 | 30 |
-0.1% | Medium Risk · 48 | N/A | |
| 4064 | 32 |
SEA | AA | P | 24 | 29 | 37 | 42 |
0.0% | Low Risk · 25 | N/A | |
| 4065 | 32 |
LAD | Single-A | P | 23 | 34 | 46 | 38 |
0.0% | Medium Risk · 54 | N/A | |
| 4066 | 32 |
CHC | DSL | P | 23 | 34 | 44 | 34 |
0.0% | Medium Risk · 56 | N/A | |
| 4067 | 32 |
COL | Single-A | P | 24 | 32 | 40 | 27 |
0.0% | Low Risk · 36 | N/A | |
| 4068 | 32 |
MIN | FCL | P | 22 | 36 | 47 | 40 |
0.0% | High Risk · 76 | N/A | |
| 4069 | 32 |
MIN | High-A | P | 24 | 32 | 40 | 28 |
0.0% | Low Risk · 35 | N/A | |
| 4070 | 32 |
BAL | AAA | P | 22 | 29 | 37 | 50 |
0.0% | Low Risk · 40 | N/A | |
| 4071 | 32 |
BOS | DSL | P | 22 | 34 | 49 | 37 |
0.0% | Wide Range · 70 | N/A | |
| 4072 | 32 |
CIN | DSL | P | 22 | 36 | 46 | 39 |
0.0% | High Risk · 76 | N/A | |
| 4073 | IL(7-Day)32 |
LAD | High-A | SSIL(7-Day) | 23 | 34 | 45 | 40 |
0.0% | Wide Range · 59 | N/A | |
| 4074 | 32 |
STL | FCL | P | 23 | 35 | 46 | 35 |
0.0% | Wide Range · 58 | N/A | |
| 4075 | 32 |
CHC | DSL | P | 22 | 34 | 48 | 37 |
0.0% | Wide Range · 70 | N/A | |
| 4076 | 32 |
MIA | Single-A | P | 24 | 35 | 46 | 40 |
0.0% | Wide Range · 65 | N/A | |
| 4077 | 32 |
ARI | ACL | P | 22 | 34 | 45 | 36 |
-0.3% | Wide Range · 66 | N/A | |
| 4078 | 32 |
MIL | ACL | P | 23 | 34 | 45 | 33 |
0.0% | Medium Risk · 56 | N/A | |
| 4079 | 32 |
CIN | DSL | 2B | 21 | 33 | 47 | 35 |
0.0% | Medium Risk · 56 | N/A | |
| 4080 | 32 |
ATH | DSL | P | 21 | 31 | 40 | 32 |
0.0% | Low Risk · 40 | N/A | |
| 4081 | 32 |
LAD | Single-A | P | 24 | 38 | 49 | 44 |
+0.1% | High Risk · 83 | N/A | |
| 4082 | 31 |
SD | ACL | P | 22 | 36 | 46 | 40 |
0.0% | High Risk · 76 | N/A | |
| 4083 | 31 |
NYY | DSL | CF | 22 | 35 | 47 | 39 |
-0.2% | Wide Range · 72 | N/A | |
| 4084 | 31 |
PIT | DSL | P | 21 | 35 | 46 | 40 |
-0.4% | High Risk · 76 | N/A | |
| 4085 | IL(Rehab)31 |
WSH | Single-A | PIL(Rehab) | 23 | 35 | 50 | 39 |
-0.1% | Wide Range · 58 | N/A | |
| 4086 | 31 |
SF | ACL | P | 22 | 33 | 47 | 34 |
0.0% | Medium Risk · 54 | N/A | |
| 4087 | 31 |
PIT | FCL | SS | 21 | 36 | 46 | 41 |
0.0% | High Risk · 77 | N/A | |
| 4088 | 31 |
CWS | DSL | P | 22 | 36 | 46 | 39 |
0.0% | High Risk · 76 | N/A | |
| 4089 | 31 |
TB | DSL | P | 25 | 37 | 59 | 38 |
0.0% | Wide Range · 74 | N/A | |
| 4090 | 31 |
SF | High-A | C | 23 | 34 | 44 | 40 |
0.0% | Wide Range · 58 | N/A | |
| 4091 | IL(7-Day)31 |
COL | Single-A | SSIL(7-Day) | 22 | 34 | 46 | 39 |
0.0% | Medium Risk · 55 | N/A | |
| 4092 | 31 |
HOU | DSL | P | 20 | 32 | 42 | 36 |
-0.3% | Medium Risk · 56 | N/A | |
| 4093 | 31 |
CWS | ACL | P | 22 | 33 | 44 | 35 |
0.0% | Wide Range · 60 | N/A | |
| 4094 | 31 |
WSH | FCL | P | 21 | 32 | 45 | 36 |
0.0% | Medium Risk · 54 | N/A | |
| 4095 | 31 |
TB | High-A | P | 24 | 33 | 42 | 32 |
0.0% | Medium Risk · 42 | N/A | |
| 4096 | 31 |
LAA | ACL | C | 21 | 34 | 46 | 39 |
0.0% | Wide Range · 72 | N/A | |
| 4097 | 31 |
KC | ACL | P | 23 | 34 | 46 | 33 |
0.0% | Medium Risk · 54 | N/A | |
| 4098 | 31 |
CIN | DSL | P | 22 | 31 | 42 | 31 |
-0.4% | Low Risk · 40 | N/A | |
| 4099 | 31 |
TOR | DSL | P | 21 | 36 | 47 | 41 |
-0.4% | High Risk · 80 | N/A | |
| 4100 | 31 |
NYY | DSL | OF | 22 | 33 | 44 | 36 |
+0.2% | Wide Range · 67 | N/A | |
| 4101 | 31 |
HOU | DSL | P | 22 | 34 | 45 | 36 |
-0.2% | Wide Range · 66 | N/A | |
| 4102 | 31 |
BAL | DSL | P | 22 | 33 | 45 | 34 |
-0.2% | Medium Risk · 56 | N/A | |
| 4103 | 31 |
ARI | DSL | P | 21 | 32 | 43 | 35 |
0.0% | Medium Risk · 56 | N/A | |
| 4104 | 31 |
CWS | ACL | P | 25 | 41 | 51 | 45 |
-0.1% | High Risk · 94 | N/A | |
| 4105 | 31 |
DET | High-A | P | 21 | 30 | 41 | 45 |
0.0% | Low Risk · 42 | N/A | |
| 4106 | 31 |
ATL | FCL | P | 22 | 35 | 48 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 4107 | 31 |
STL | FCL | 3B | 22 | 34 | 45 | 34 |
-0.1% | Wide Range · 59 | N/A | |
| 4108 | 31 |
BAL | DSL | P | 22 | 34 | 45 | 34 |
0.0% | Medium Risk · 56 | N/A | |
| 4109 | 31 |
PHI | Single-A | P | 24 | 32 | 41 | 28 |
0.0% | Low Risk · 36 | N/A | |
| 4110 | 31 |
CHC | ACL | P | 23 | 35 | 46 | 36 |
-0.1% | Wide Range · 70 | N/A | |
| 4111 | 31 |
CIN | ACL | C | 22 | 35 | 52 | 37 |
0.0% | Wide Range · 64 | N/A | |
| 4112 | 31 |
ATH | High-A | P | 24 | 33 | 42 | 30 |
+0.2% | Medium Risk · 42 | N/A | |
| 4113 | 31 |
CLE | DSL | P | 22 | 36 | 50 | 38 |
0.0% | High Risk · 76 | N/A | |
| 4114 | 31 |
PHI | AAA | C | 23 | 29 | 37 | 46 |
+0.1% | Low Risk · 27 | N/A | |
| 4115 | 31 |
HOU | DSL | P | 22 | 36 | 47 | 39 |
-0.2% | High Risk · 76 | N/A | |
| 4116 | IL(Rehab)31 |
TB | FCL | 1BIL(Rehab) | 22 | 35 | 49 | 42 |
0.0% | Wide Range · 63 | N/A | |
| 4117 | 31 |
CWS | DSL | P | 24 | 39 | 52 | 43 |
0.0% | High Risk · 91 | N/A | |
| 4118 | 31 |
PIT | DSL | OF | 21 | 34 | 46 | 38 |
0.0% | Wide Range · 72 | N/A | |
| 4119 | 31 |
KC | ACL | 3B | 21 | 33 | 44 | 36 |
0.0% | Wide Range · 61 | N/A | |
| 4120 | 31 |
CHC | DSL | P | 21 | 32 | 42 | 33 |
0.0% | Medium Risk · 46 | N/A | |
| 4121 | 31 |
DET | DSL | SS | 21 | 31 | 45 | 33 |
+0.1% | Low Risk · 40 | N/A | |
| 4122 | 31 |
CLE | DSL | P | 21 | 34 | 46 | 38 |
0.0% | Wide Range · 66 | N/A | |
| 4123 | 31 |
SD | Single-A | P | 22 | 34 | 45 | 39 |
-0.1% | Wide Range · 64 | N/A | |
| 4124 | 31 |
COL | DSL | OF | 21 | 32 | 43 | 33 |
0.0% | Medium Risk · 51 | N/A | |
| 4125 | 31 |
STL | FCL | 2B | 23 | 33 | 42 | 28 |
0.0% | Medium Risk · 49 | N/A | |
| 4126 | 31 |
ATH | Single-A | C | 22 | 34 | 45 | 40 |
0.0% | Wide Range · 59 | N/A | |
| 4127 | 31 |
PIT | DSL | P | 22 | 33 | 44 | 36 |
-0.1% | Wide Range · 66 | N/A | |
| 4128 | 31 |
PIT | FCL | P | 22 | 33 | 45 | 35 |
0.0% | Wide Range · 64 | N/A | |
| 4129 | 31 |
MIN | DSL | P | 22 | 37 | 51 | 39 |
0.0% | High Risk · 77 | N/A | |
| 4130 | 31 |
MIL | ACL | P | 22 | 34 | 45 | 35 |
0.0% | Wide Range · 66 | N/A | |
| 4131 | 31 |
BAL | High-A | P | 21 | 31 | 44 | 43 |
0.0% | Low Risk · 38 | N/A | |
| 4132 | 31 |
NYM | AA | SS | 22 | 32 | 41 | 47 |
0.0% | Medium Risk · 43 | N/A | |
| 4133 | 31 |
LAA | DSL | C | 21 | 33 | 44 | 37 |
0.0% | Wide Range · 61 | N/A | |
| 4134 | 31 |
DET | DSL | P | 21 | 35 | 45 | 39 |
0.0% | High Risk · 76 | N/A | |
| 4135 | 31 |
CHC | DSL | IF | 21 | 32 | 43 | 33 |
+0.1% | Medium Risk · 53 | N/A | |
| 4136 | 31 |
MIN | FCL | C | 21 | 33 | 43 | 35 |
0.0% | Medium Risk · 55 | N/A | |
| 4137 | 31 |
BAL | DSL | P | 21 | 32 | 43 | 35 |
0.0% | Wide Range · 60 | N/A | |
| 4138 | 31 |
KC | AA | P | 23 | 31 | 40 | 39 |
0.0% | Low Risk · 35 | N/A | |
| 4139 | 31 |
PHI | AA | P | 21 | 29 | 40 | 48 |
-0.3% | Low Risk · 34 | N/A | |
| 4140 | 31 |
SD | DSL | OF | 21 | 36 | 47 | 41 |
0.0% | High Risk · 78 | N/A | |
| 4141 | 31 |
SF | DSL | IF | 22 | 33 | 43 | 34 |
0.0% | Wide Range · 60 | N/A | |
| 4142 | 31 |
TB | AA | C | 23 | 30 | 38 | 38 |
0.0% | Low Risk · 28 | N/A | |
| 4143 | 31 |
WSH | AA | P | 24 | 30 | 38 | 37 |
0.0% | Low Risk · 31 | N/A | |
| 4144 | 31 |
PHI | FCL | P | 23 | 33 | 43 | 31 |
-0.1% | Medium Risk · 56 | N/A | |
| 4145 | 31 |
DET | DSL | P | 21 | 35 | 48 | 41 |
0.0% | Wide Range · 59 | N/A | |
| 4146 | 31 |
BOS | AA | P | 23 | 29 | 37 | 36 |
0.0% | Low Risk · 21 | N/A | |
| 4147 | 31 |
STL | AA | P | 25 | 32 | 40 | 28 |
0.0% | Low Risk · 37 | N/A | |
| 4148 | 31 |
BAL | DSL | SS | 21 | 33 | 45 | 35 |
0.0% | Medium Risk · 56 | N/A | |
| 4149 | 31 |
CWS | AA | P | 26 | 34 | 48 | 48 |
0.0% | Wide Range · 62 | N/A | |
| 4150 | 31 |
NYY | High-A | P | 23 | 34 | 44 | 39 |
-0.2% | Wide Range · 62 | N/A | |
| 4151 | 31 |
MIL | DSL | P | 22 | 33 | 43 | 32 |
-0.4% | Medium Risk · 56 | N/A | |
| 4152 | 31 |
BAL | High-A | P | 23 | 37 | 49 | 43 |
+0.2% | High Risk · 77 | N/A | |
| 4153 | 31 |
SF | DSL | LF | 20 | 30 | 41 | 33 |
-0.1% | Medium Risk · 45 | N/A | |
| 4154 | 31 |
MIA | DSL | SS | 21 | 35 | 47 | 39 |
0.0% | High Risk · 75 | N/A | |
| 4155 | 31 |
TB | AA | P | 23 | 29 | 36 | 38 |
0.0% | Low Risk · 22 | N/A | |
| 4156 | 31 |
BAL | High-A | P | 23 | 35 | 46 | 40 |
0.0% | Wide Range · 63 | N/A | |
| 4157 | 31 |
NYM | DSL | SS | 21 | 35 | 46 | 40 |
0.0% | High Risk · 78 | N/A | |
| 4158 | 31 |
TEX | High-A | SS | 22 | 33 | 43 | 38 |
+0.1% | Wide Range · 58 | N/A | |
| 4159 | 31 |
SEA | Single-A | C | 23 | 31 | 39 | 26 |
0.0% | Low Risk · 33 | N/A | |
| 4160 | 31 |
DET | AA | P | 21 | 28 | 41 | 52 |
-0.1% | Low Risk · 31 | N/A | |
| 4161 | 31 |
DET | DSL | C | 21 | 34 | 51 | 39 |
0.0% | Wide Range · 71 | N/A | |
| 4162 | 31 |
NYY | DSL | P | 21 | 36 | 47 | 40 |
0.0% | High Risk · 77 | N/A | |
| 4163 | 31 |
PIT | FCL | P | 22 | 34 | 45 | 34 |
0.0% | Wide Range · 64 | N/A | |
| 4164 | 31 |
CIN | Single-A | P | 21 | 33 | 44 | 39 |
0.0% | Medium Risk · 55 | N/A | |
| 4165 | 31 |
NYM | AA | P | 22 | 29 | 44 | 54 |
-0.1% | Medium Risk · 45 | N/A | |
| 4166 | 31 |
SEA | DSL | P | 22 | 35 | 49 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 4167 | 31 |
HOU | FCL | 2B | 21 | 34 | 47 | 38 |
0.0% | Wide Range · 69 | N/A | |
| 4168 | 31 |
CIN | DSL | C | 22 | 34 | 45 | 35 |
0.0% | Wide Range · 72 | N/A | |
| 4169 | 31 |
SF | DSL | P | 22 | 33 | 46 | 33 |
-0.4% | Medium Risk · 56 | N/A | |
| 4170 | 31 |
TB | DSL | P | 22 | 33 | 43 | 32 |
0.0% | Medium Risk · 56 | N/A | |
| 4171 | 31 |
PIT | FCL | P | 22 | 33 | 43 | 30 |
-0.4% | Medium Risk · 56 | N/A | |
| 4172 | 31 |
MIA | DSL | P | 22 | 36 | 49 | 38 |
-0.2% | High Risk · 80 | N/A | |
| 4173 | 31 |
KC | DSL | IF | 21 | 34 | 52 | 38 |
-0.1% | Wide Range · 70 | N/A | |
| 4174 | 31 |
TOR | DSL | P | 21 | 35 | 50 | 40 |
0.0% | High Risk · 80 | N/A | |
| 4175 | 31 |
MIA | DSL | P | 21 | 35 | 45 | 38 |
0.0% | High Risk · 76 | N/A | |
| 4176 | 31 |
CHC | ACL | P | 23 | 34 | 45 | 35 |
-0.3% | Wide Range · 70 | N/A | |
| 4177 | 31 |
STL | Single-A | C | 21 | 33 | 43 | 37 |
0.0% | Medium Risk · 51 | N/A | |
| 4178 | 31 |
CHC | DSL | P | 22 | 33 | 46 | 32 |
-0.5% | Medium Risk · 56 | N/A | |
| 4179 | 31 |
HOU | DSL | IF | 20 | 32 | 43 | 35 |
-0.1% | Wide Range · 61 | N/A | |
| 4180 | 31 |
TB | High-A | P | 21 | 31 | 42 | 42 |
-0.1% | Low Risk · 42 | N/A | |
| 4181 | 31 |
NYY | DSL | C | 21 | 36 | 48 | 41 |
0.0% | High Risk · 86 | N/A | |
| 4182 | 31 |
WSH | DSL | P | 22 | 33 | 49 | 33 |
0.0% | Medium Risk · 56 | N/A | |
| 4183 | 31 |
TEX | AA | SS | 23 | 29 | 36 | 41 |
0.0% | Low Risk · 25 | N/A | |
| 4184 | 31 |
TB | FCL | P | 22 | 34 | 48 | 34 |
0.0% | Wide Range · 64 | N/A | |
| 4185 | 31 |
CHC | DSL | P | 22 | 37 | 48 | 43 |
-0.1% | High Risk · 90 | N/A | |
| 4186 | 31 |
KC | AA | P | 25 | 29 | 35 | 32 |
0.0% | Low Risk · 34 | N/A | |
| 4187 | 31 |
TEX | ACL | P | 23 | 34 | 45 | 33 |
0.0% | Wide Range · 64 | N/A | |
| 4188 | 31 |
MIA | DSL | OF | 20 | 34 | 46 | 39 |
0.0% | Wide Range · 71 | N/A | |
| 4189 | 31 |
WSH | FCL | P | 22 | 33 | 43 | 34 |
0.0% | Wide Range · 64 | N/A | |
| 4190 | 31 |
KC | DSL | P | 21 | 32 | 49 | 33 |
0.0% | Medium Risk · 50 | N/A | |
| 4191 | 31 |
ATH | AA | C | 22 | 29 | 37 | 42 |
0.0% | Low Risk · 31 | N/A | |
| 4192 | 31 |
LAD | ACL | P | 22 | 32 | 45 | 29 |
0.0% | Low Risk · 40 | N/A | |
| 4193 | 31 |
COL | DSL | P | 20 | 34 | 45 | 38 |
0.0% | High Risk · 76 | N/A | |
| 4194 | 30 |
TB | DSL | OF | 20 | 34 | 46 | 39 |
0.0% | Wide Range · 71 | N/A | |
| 4195 | 30 |
BOS | Single-A | P | 23 | 33 | 42 | 32 |
0.0% | Medium Risk · 44 | N/A | |
| 4196 | 30 |
SD | DSL | P | 22 | 34 | 45 | 36 |
0.0% | Wide Range · 67 | N/A | |
| 4197 | 30 |
TEX | High-A | P | 23 | 37 | 49 | 43 |
+0.1% | High Risk · 79 | N/A | |
| 4198 | 30 |
ATL | Single-A | P | 23 | 34 | 44 | 37 |
0.0% | Medium Risk · 55 | N/A | |
| 4199 | IL(7-Day)30 |
CWS | AA | OFIL(7-Day) | 22 | 30 | 44 | 48 |
0.0% | Low Risk · 39 | N/A | |
| 4200 | 30 |
PIT | DSL | P | 23 | 39 | 52 | 43 |
0.0% | High Risk · 93 | N/A | |
| 4201 | 30 |
PIT | DSL | OF | 22 | 34 | 46 | 37 |
+0.1% | Wide Range · 72 | N/A | |
| 4202 | 30 |
DET | DSL | P | 21 | 32 | 47 | 34 |
-0.1% | Medium Risk · 56 | N/A | |
| 4203 | 30 |
WSH | FCL | IF | 21 | 32 | 43 | 33 |
+0.1% | Medium Risk · 55 | N/A | |
| 4204 | 30 |
NYM | AA | 1B | 24 | 30 | 36 | 35 |
-0.7% | Low Risk · 30 | N/A | |
| 4205 | 30 |
SF | DSL | P | 20 | 30 | 42 | 36 |
-0.1% | Medium Risk · 54 | N/A | |
| 4206 | IL(7-Day)30 |
LAD | Single-A | PIL(7-Day) | 22 | 33 | 45 | 40 |
0.0% | Wide Range · 70 | N/A | |
| 4207 | 30 |
CLE | AAA | P | 22 | 29 | 36 | 40 |
0.0% | Low Risk · 25 | N/A | |
| 4208 | 30 |
BAL | DSL | OF | 21 | 34 | 50 | 37 |
-0.2% | Wide Range · 70 | N/A | |
| 4209 | 30 |
BAL | FCL | OF | 21 | 33 | 45 | 36 |
-0.1% | Wide Range · 72 | N/A | |
| 4210 | 30 |
BOS | Single-A | P | 23 | 33 | 41 | 29 |
0.0% | Medium Risk · 44 | N/A | |
| 4211 | 30 |
BAL | High-A | P | 23 | 32 | 41 | 29 |
+0.1% | Medium Risk · 42 | N/A | |
| 4212 | 30 |
CHC | DSL | OF | 20 | 33 | 45 | 37 |
0.0% | Wide Range · 70 | N/A | |
| 4213 | 30 |
ARI | DSL | C | 21 | 34 | 47 | 37 |
0.0% | Wide Range · 70 | N/A | |
| 4214 | 30 |
DET | DSL | P | 21 | 32 | 47 | 32 |
0.0% | Medium Risk · 50 | N/A | |
| 4215 | 30 |
NYY | DSL | P | 20 | 34 | 45 | 38 |
0.0% | High Risk · 76 | N/A | |
| 4216 | 30 |
CLE | DSL | C | 21 | 34 | 51 | 37 |
0.0% | Wide Range · 70 | N/A | |
| 4217 | 30 |
ATH | Single-A | P | 22 | 33 | 45 | 39 |
0.0% | Wide Range · 64 | N/A | |
| 4218 | 30 |
TEX | DSL | C | 22 | 34 | 53 | 36 |
-0.5% | Wide Range · 70 | N/A | |
| 4219 | 30 |
DET | FCL | P | 22 | 37 | 56 | 42 |
0.0% | High Risk · 88 | N/A | |
| 4220 | 30 |
CIN | Single-A | C | 22 | 30 | 38 | 26 |
0.0% | Low Risk · 33 | N/A | |
| 4221 | 30 |
LAD | DSL | P | 21 | 32 | 43 | 35 |
0.0% | Wide Range · 66 | N/A | |
| 4222 | IL(7-Day)30 |
KC | AAA | PIL(7-Day) | 24 | 36 | 45 | 53 |
0.0% | High Risk · 78 | N/A | |
| 4223 | IL(Rehab)30 |
BAL | FCL | SSIL(Rehab) | 23 | 35 | 57 | 38 |
0.0% | Wide Range · 69 | N/A | |
| 4224 | 30 |
MIA | DSL | C | 21 | 34 | 48 | 41 |
-0.3% | Wide Range · 59 | N/A | |
| 4225 | 30 |
SD | Single-A | P | 23 | 32 | 39 | 22 |
-0.1% | Low Risk · 36 | N/A | |
| 4226 | 30 |
ATL | AA | P | 23 | 29 | 36 | 36 |
0.0% | Low Risk · 22 | N/A | |
| 4227 | 30 |
MIA | Single-A | P | 23 | 38 | 49 | 44 |
0.0% | High Risk · 82 | N/A | |
| 4228 | 30 |
SEA | High-A | P | 21 | 31 | 45 | 44 |
0.0% | Medium Risk · 53 | N/A | |
| 4229 | 30 |
MIL | DSL | P | 21 | 33 | 50 | 34 |
0.0% | Wide Range · 64 | N/A | |
| 4230 | 30 |
SF | DSL | IF | 21 | 34 | 51 | 36 |
0.0% | Wide Range · 70 | N/A | |
| 4231 | 30 |
MIN | High-A | P | 23 | 33 | 43 | 37 |
+0.1% | Medium Risk · 54 | N/A | |
| 4232 | 30 |
MIA | DSL | P | 22 | 36 | 55 | 39 |
0.0% | High Risk · 80 | N/A | |
| 4233 | 30 |
TB | FCL | P | 22 | 31 | 40 | 29 |
0.0% | Medium Risk · 56 | N/A | |
| 4234 | 30 |
CLE | DSL | P | 22 | 33 | 46 | 34 |
-0.2% | Wide Range · 66 | N/A | |
| 4235 | 30 |
CHC | ACL | C | 21 | 32 | 43 | 34 |
0.0% | Wide Range · 60 | N/A | |
| 4236 | 30 |
STL | FCL | P | 22 | 33 | 44 | 35 |
-0.1% | Wide Range · 70 | N/A | |
| 4237 | 30 |
KC | DSL | C | 21 | 34 | 46 | 38 |
0.0% | Wide Range · 73 | N/A | |
| 4238 | 30 |
DET | FCL | C | 21 | 33 | 44 | 36 |
0.0% | Wide Range · 65 | N/A | |
| 4239 | 30 |
PHI | FCL | P | 23 | 39 | 50 | 43 |
0.0% | High Risk · 93 | N/A | |
| 4240 | 30 |
SEA | AA | 2B | 24 | 31 | 38 | 34 |
-0.1% | Medium Risk · 44 | N/A | |
| 4241 | 30 |
CHC | Single-A | P | 25 | 38 | 53 | 42 |
-0.5% | High Risk · 81 | N/A | |
| 4242 | 30 |
SF | AAA | P | 22 | 30 | 37 | 40 |
0.0% | Low Risk · 37 | N/A | |
| 4243 | 30 |
ATH | ACL | P | 25 | 37 | 59 | 36 |
0.0% | Wide Range · 74 | N/A | |
| 4244 | 30 |
HOU | AAA | SS | 22 | 29 | 37 | 37 |
0.0% | Low Risk · 27 | N/A | |
| 4245 | 30 |
TB | DSL | P | 20 | 35 | 45 | 39 |
-0.1% | High Risk · 80 | N/A | |
| 4246 | 30 |
SEA | ACL | P | 20 | 31 | 45 | 34 |
0.0% | Medium Risk · 50 | N/A | |
| 4247 | 30 |
CHC | AA | P | 30 | 35 | 52 | 49 |
0.0% | Wide Range · 61 | N/A | |
| 4248 | 30 |
LAA | DSL | P | 21 | 33 | 45 | 35 |
-0.4% | Wide Range · 70 | N/A | |
| 4249 | 30 |
ATL | High-A | P | 20 | 28 | 39 | 46 |
0.0% | Low Risk · 32 | N/A | |
| 4250 | 30 |
DET | FCL | P | 22 | 33 | 44 | 34 |
0.0% | Wide Range · 64 | N/A | |
| 4251 | 30 |
HOU | DSL | P | 23 | 38 | 57 | 42 |
0.0% | High Risk · 94 | N/A | |
| 4252 | 30 |
LAD | ACL | P | 21 | 33 | 44 | 34 |
0.0% | Wide Range · 64 | N/A | |
| 4253 | 30 |
BAL | DSL | P | 21 | 35 | 45 | 38 |
-0.2% | High Risk · 76 | N/A | |
| 4254 | 30 |
NYM | FCL | OF | 21 | 33 | 43 | 33 |
0.0% | Wide Range · 62 | N/A | |
| 4255 | 30 |
BAL | DSL | OF | 20 | 33 | 45 | 37 |
-0.1% | Wide Range · 70 | N/A | |
| 4256 | 30 |
MIA | High-A | P | 20 | 31 | 42 | 40 |
0.0% | Medium Risk · 54 | N/A | |
| 4257 | 30 |
SD | AA | P | 24 | 31 | 39 | 35 |
0.0% | Medium Risk · 43 | N/A | |
| 4258 | 30 |
MIL | ACL | C | 21 | 32 | 43 | 35 |
0.0% | Wide Range · 66 | N/A | |
| 4259 | 30 |
BAL | FCL | P | 22 | 32 | 42 | 28 |
0.0% | Wide Range · 62 | N/A | |
| 4260 | 30 |
TOR | DSL | P | 20 | 34 | 45 | 38 |
0.0% | High Risk · 76 | N/A | |
| 4261 | 30 |
CLE | ACL | P | 23 | 38 | 52 | 43 |
0.0% | High Risk · 93 | N/A | |
| 4262 | 30 |
HOU | AA | P | 23 | 30 | 39 | 38 |
0.0% | Low Risk · 36 | N/A | |
| 4263 | 30 |
BOS | DSL | P | 22 | 37 | 48 | 41 |
0.0% | High Risk · 90 | N/A | |
| 4264 | 30 |
NYM | DSL | P | 21 | 33 | 44 | 35 |
-0.1% | Wide Range · 70 | N/A | |
| 4265 | 30 |
MIA | DSL | SS | 20 | 33 | 45 | 38 |
-0.3% | Wide Range · 71 | N/A | |
| 4266 | 30 |
SD | AAA | P | 23 | 35 | 45 | 53 |
-0.4% | Wide Range · 75 | N/A | |
| 4267 | 30 |
WSH | Single-A | C | 22 | 34 | 50 | 38 |
0.0% | Wide Range · 61 | N/A | |
| 4268 | 30 |
MIA | DSL | P | 21 | 33 | 44 | 34 |
0.0% | Wide Range · 66 | N/A | |
| 4269 | 30 |
HOU | High-A | C | 21 | 28 | 36 | 35 |
+0.1% | Low Risk · 21 | N/A | |
| 4270 | 30 |
TOR | DSL | P | 21 | 35 | 50 | 40 |
0.0% | High Risk · 81 | N/A | |
| 4271 | 30 |
ATL | AA | P | 23 | 30 | 41 | 38 |
0.0% | Low Risk · 33 | N/A | |
| 4272 | 30 |
PHI | DSL | P | 23 | 38 | 52 | 42 |
0.0% | High Risk · 93 | N/A | |
| 4273 | 30 |
TEX | DSL | P | 21 | 32 | 43 | 35 |
0.0% | Wide Range · 66 | N/A | |
| 4274 | 30 |
TEX | DSL | P | 21 | 32 | 45 | 34 |
0.0% | Wide Range · 60 | N/A | |
| 4275 | 30 |
SEA | DSL | P | 20 | 32 | 43 | 36 |
+0.1% | Wide Range · 70 | N/A | |
| 4276 | 30 |
CWS | High-A | P | 22 | 37 | 46 | 44 |
-0.6% | High Risk · 80 | N/A | |
| 4277 | 30 |
KC | DSL | P | 20 | 32 | 43 | 36 |
0.0% | Wide Range · 70 | N/A | |
| 4278 | 30 |
SEA | DSL | C | 20 | 33 | 46 | 37 |
0.0% | Wide Range · 71 | N/A | |
| 4279 | 30 |
SD | ACL | P | 21 | 34 | 45 | 38 |
0.0% | High Risk · 76 | N/A | |
| 4280 | 30 |
NYY | Single-A | C | 22 | 33 | 46 | 36 |
0.0% | Medium Risk · 55 | N/A | |
| 4281 | 30 |
TEX | ACL | P | 22 | 32 | 42 | 30 |
0.0% | Medium Risk · 50 | N/A | |
| 4282 | 30 |
CHC | ACL | P | 22 | 33 | 47 | 33 |
0.0% | Wide Range · 64 | N/A | |
| 4283 | 30 |
WSH | Single-A | 3B | 22 | 31 | 39 | 24 |
0.0% | Low Risk · 37 | N/A | |
| 4284 | 30 |
ARI | DSL | C | 20 | 34 | 46 | 38 |
0.0% | High Risk · 75 | N/A | |
| 4285 | 30 |
SD | DSL | P | 20 | 32 | 43 | 34 |
0.0% | Wide Range · 66 | N/A | |
| 4286 | 30 |
KC | DSL | P | 20 | 32 | 43 | 35 |
0.0% | Wide Range · 70 | N/A | |
| 4287 | 30 |
SEA | AA | P | 25 | 34 | 47 | 47 |
0.0% | Wide Range · 71 | N/A | |
| 4288 | 30 |
NYY | DSL | P | 21 | 33 | 44 | 34 |
-0.1% | Wide Range · 66 | N/A | |
| 4289 | 30 |
TB | FCL | SS | 20 | 32 | 44 | 36 |
0.0% | Wide Range · 64 | N/A | |
| 4290 | 30 |
SD | DSL | P | 21 | 32 | 42 | 32 |
0.0% | Medium Risk · 56 | N/A | |
| 4291 | 30 |
CWS | DSL | P | 21 | 35 | 45 | 37 |
0.0% | High Risk · 76 | N/A | |
| 4292 | IL(Rehab)30 |
CWS | ACL | CIL(Rehab) | 22 | 34 | 56 | 36 |
0.0% | Wide Range · 68 | N/A | |
| 4293 | 30 |
BAL | DSL | P | 20 | 33 | 44 | 38 |
0.0% | High Risk · 76 | N/A | |
| 4294 | 30 |
SF | DSL | IF | 21 | 36 | 51 | 40 |
0.0% | High Risk · 86 | N/A | |
| 4295 | IL(7-Day)30 |
HOU | High-A | PIL(7-Day) | 22 | 34 | 45 | 41 |
0.0% | Wide Range · 69 | N/A | |
| 4296 | 30 |
CIN | ACL | P | 20 | 33 | 47 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 4297 | 30 |
TEX | DSL | C | 20 | 33 | 46 | 38 |
-0.2% | High Risk · 75 | N/A | |
| 4298 | 30 |
ATH | ACL | P | 20 | 32 | 43 | 34 |
-0.3% | Wide Range · 64 | N/A | |
| 4299 | 30 |
SEA | AA | P | 21 | 28 | 35 | 42 |
-0.1% | Low Risk · 25 | N/A | |
| 4300 | IL(Rehab)30 |
MIL | ACL | PIL(Rehab) | 20 | 34 | 49 | 39 |
0.0% | High Risk · 78 | N/A | |
| 4301 | 30 |
MIN | FCL | P | 22 | 32 | 43 | 28 |
0.0% | Medium Risk · 56 | N/A | |
| 4302 | 30 |
SEA | AAA | LF | 26 | 33 | 48 | 55 |
0.0% | Medium Risk · 48 | N/A | |
| 4303 | 30 |
TOR | Single-A | C | 22 | 31 | 40 | 29 |
0.0% | Medium Risk · 50 | N/A | |
| 4304 | 30 |
SF | Single-A | P | 22 | 31 | 39 | 26 |
+0.3% | Low Risk · 36 | N/A | |
| 4305 | 30 |
LAD | AAA | P | 23 | 32 | 45 | 47 |
-0.2% | Medium Risk · 56 | N/A | |
| 4306 | 30 |
HOU | AAA | P | 24 | 32 | 40 | 36 |
-0.1% | Medium Risk · 45 | N/A | |
| 4307 | 29 |
ATH | ACL | P | 21 | 33 | 43 | 32 |
0.0% | Medium Risk · 56 | N/A | |
| 4308 | 29 |
ATH | ACL | P | 22 | 33 | 44 | 31 |
-0.1% | Wide Range · 64 | N/A | |
| 4309 | 29 |
SD | AA | C | 22 | 30 | 39 | 37 |
0.0% | Low Risk · 36 | N/A | |
| 4310 | 29 |
HOU | AAA | P | 23 | 28 | 34 | 44 |
0.0% | Low Risk · 28 | N/A | |
| 4311 | 29 |
SF | AAA | 1B | 23 | 27 | 33 | 41 |
0.0% | Low Risk · 26 | N/A | |
| 4312 | 29 |
SEA | ACL | P | 21 | 33 | 44 | 33 |
0.0% | Wide Range · 64 | N/A | |
| 4313 | 29 |
HOU | DSL | P | 20 | 32 | 43 | 35 |
0.0% | Wide Range · 70 | N/A | |
| 4314 | 29 |
LAD | DSL | P | 20 | 29 | 39 | 32 |
-0.1% | Low Risk · 40 | N/A | |
| 4315 | 29 |
NYY | DSL | P | 22 | 33 | 46 | 33 |
0.0% | Wide Range · 70 | N/A | |
| 4316 | 29 |
SF | AAA | P | 22 | 30 | 38 | 45 |
-0.7% | Medium Risk · 56 | N/A | |
| 4317 | 29 |
BAL | Single-A | P | 20 | 32 | 43 | 38 |
0.0% | Wide Range · 64 | N/A | |
| 4318 | 29 |
NYY | AA | P | 24 | 30 | 41 | 36 |
0.0% | Medium Risk · 45 | N/A | |
| 4319 | 29 |
ATL | AA | P | 23 | 32 | 43 | 38 |
-0.1% | Medium Risk · 52 | N/A | |
| 4320 | 29 |
ATL | Single-A | SS | 21 | 30 | 38 | 25 |
+0.2% | Low Risk · 33 | N/A | |
| 4321 | IL(Rehab)29 |
LAD | ACL | PIL(Rehab) | 23 | 37 | 57 | 40 |
0.0% | High Risk · 88 | N/A | |
| 4322 | 29 |
ARI | DSL | P | 22 | 33 | 46 | 34 |
0.0% | Wide Range · 70 | N/A | |
| 4323 | 29 |
MIA | FCL | P | 21 | 32 | 44 | 31 |
0.0% | Medium Risk · 50 | N/A | |
| 4324 | 29 |
LAA | ACL | P | 22 | 34 | 51 | 35 |
-0.1% | Wide Range · 74 | N/A | |
| 4325 | 29 |
CHC | High-A | 3B | 21 | 33 | 44 | 40 |
-0.4% | Wide Range · 64 | N/A | |
| 4326 | IL(Rehab)29 |
STL | Single-A | PIL(Rehab) | 21 | 32 | 45 | 39 |
0.0% | Wide Range · 59 | N/A | |
| 4327 | 29 |
NYM | High-A | 3B | 21 | 32 | 42 | 38 |
-0.3% | Medium Risk · 54 | N/A | |
| 4328 | 29 |
LAA | AA | 1B | 21 | 30 | 38 | 42 |
0.0% | Low Risk · 38 | N/A | |
| 4329 | 29 |
WSH | AA | RF | 23 | 28 | 35 | 28 |
0.0% | Low Risk · 20 | N/A | |
| 4330 | 29 |
BAL | DSL | P | 20 | 34 | 48 | 37 |
0.0% | High Risk · 76 | N/A | |
| 4331 | 29 |
BOS | FCL | P | 22 | 33 | 44 | 34 |
-0.3% | Wide Range · 70 | N/A | |
| 4332 | 29 |
BOS | DSL | CF | 20 | 33 | 44 | 35 |
0.0% | Wide Range · 65 | N/A | |
| 4333 | 29 |
SD | DSL | P | 20 | 34 | 45 | 40 |
0.0% | High Risk · 80 | N/A | |
| 4334 | 29 |
CHC | DSL | P | 21 | 35 | 49 | 36 |
0.0% | High Risk · 80 | N/A | |
| 4335 | 29 |
MIN | FCL | P | 22 | 33 | 44 | 33 |
-0.1% | Wide Range · 70 | N/A | |
| 4336 | IL(60-Day)29 |
ARI | AA | PIL(60-Day) | 22 | 35 | 44 | 45 |
0.0% | High Risk · 76 | N/A | |
| 4337 | 29 |
PIT | AA | P | 22 | 31 | 43 | 45 |
0.0% | Medium Risk · 53 | N/A | |
| 4338 | IL(Rehab)29 |
DET | FCL | SSIL(Rehab) | 21 | 33 | 55 | 36 |
0.0% | Wide Range · 68 | N/A | |
| 4339 | 29 |
DET | DSL | C | 20 | 33 | 46 | 38 |
0.0% | High Risk · 75 | N/A | |
| 4340 | 29 |
ATH | DSL | P | 20 | 34 | 45 | 39 |
0.0% | High Risk · 80 | N/A | |
| 4341 | 29 |
TEX | ACL | C | 20 | 33 | 45 | 38 |
0.0% | Wide Range · 71 | N/A | |
| 4342 | 29 |
ARI | Single-A | P | 22 | 32 | 42 | 33 |
0.0% | Medium Risk · 45 | N/A | |
| 4343 | 29 |
TB | DSL | P | 20 | 31 | 46 | 32 |
0.0% | Medium Risk · 50 | N/A | |
| 4344 | 29 |
MIL | DSL | P | 21 | 32 | 46 | 32 |
-0.1% | Medium Risk · 56 | N/A | |
| 4345 | 29 |
NYM | FCL | P | 21 | 32 | 45 | 33 |
0.0% | Wide Range · 64 | N/A | |
| 4346 | 29 |
PIT | Single-A | P | 22 | 30 | 39 | 25 |
0.0% | Low Risk · 36 | N/A | |
| 4347 | 29 |
LAA | Single-A | P | 22 | 34 | 46 | 36 |
-0.1% | Medium Risk · 56 | N/A | |
| 4348 | 29 |
MIN | FCL | P | 20 | 31 | 44 | 33 |
-0.3% | Medium Risk · 54 | N/A | |
| 4349 | 29 |
LAD | DSL | P | 20 | 31 | 45 | 32 |
0.0% | Medium Risk · 54 | N/A | |
| 4350 | 29 |
CHC | DSL | OF | 21 | 33 | 44 | 35 |
0.0% | Wide Range · 72 | N/A | |
| 4351 | IL(Rehab)29 |
BAL | FCL | PIL(Rehab) | 20 | 34 | 45 | 39 |
0.0% | High Risk · 78 | N/A | |
| 4352 | 29 |
LAD | AAA | P | 23 | 31 | 40 | 44 |
0.0% | Medium Risk · 54 | N/A | |
| 4353 | 29 |
COL | DSL | P | 20 | 31 | 43 | 35 |
-0.3% | Wide Range · 66 | N/A | |
| 4354 | 29 |
NYY | DSL | C | 20 | 34 | 47 | 39 |
-0.2% | High Risk · 76 | N/A | |
| 4355 | 29 |
LAD | High-A | C | 21 | 31 | 48 | 42 |
0.0% | Medium Risk · 46 | N/A | |
| 4356 | 29 |
COL | AA | P | 21 | 28 | 36 | 41 |
0.0% | Low Risk · 36 | N/A | |
| 4357 | 29 |
HOU | FCL | OF | 20 | 34 | 46 | 39 |
0.0% | High Risk · 78 | N/A | |
| 4358 | 29 |
BOS | AAA | 2B | 22 | 30 | 38 | 40 |
-0.1% | Low Risk · 39 | N/A | |
| 4359 | 29 |
MIN | DSL | P | 21 | 36 | 47 | 40 |
0.0% | High Risk · 90 | N/A | |
| 4360 | 29 |
BOS | DSL | CF | 20 | 32 | 44 | 37 |
0.0% | Wide Range · 71 | N/A | |
| 4361 | 29 |
TEX | Single-A | P | 21 | 30 | 39 | 29 |
0.0% | Medium Risk · 44 | N/A | |
| 4362 | 29 |
SEA | Single-A | OF | 22 | 30 | 38 | 22 |
0.0% | Low Risk · 37 | N/A | |
| 4363 | 29 |
MIN | DSL | P | 20 | 31 | 42 | 31 |
0.0% | Medium Risk · 56 | N/A | |
| 4364 | IL(Rehab)29 |
BOS | FCL | SSIL(Rehab) | 21 | 33 | 55 | 36 |
0.0% | Wide Range · 68 | N/A | |
| 4365 | 29 |
ARI | DSL | P | 20 | 30 | 41 | 34 |
0.0% | Medium Risk · 56 | N/A | |
| 4366 | 29 |
BOS | FCL | C | 20 | 33 | 44 | 38 |
0.0% | High Risk · 77 | N/A | |
| 4367 | 29 |
SD | Single-A | P | 22 | 31 | 40 | 29 |
0.0% | Medium Risk · 44 | N/A | |
| 4368 | 29 |
SEA | Single-A | P | 22 | 36 | 49 | 42 |
-0.1% | High Risk · 81 | N/A | |
| 4369 | 29 |
LAA | DSL | C | 20 | 33 | 47 | 37 |
-0.1% | High Risk · 75 | N/A | |
| 4370 | 29 |
TB | Single-A | P | 21 | 33 | 48 | 37 |
0.0% | Wide Range · 64 | N/A | |
| 4371 | 29 |
BAL | DSL | IF | 20 | 33 | 43 | 37 |
+0.2% | High Risk · 77 | N/A | |
| 4372 | 29 |
BOS | FCL | P | 21 | 32 | 43 | 31 |
0.0% | Wide Range · 64 | N/A | |
| 4373 | 29 |
CWS | High-A | P | 22 | 31 | 40 | 28 |
-0.2% | Medium Risk · 42 | N/A | |
| 4374 | 29 |
LAA | Single-A | P | 22 | 36 | 47 | 42 |
-0.3% | High Risk · 83 | N/A | |
| 4375 | 29 |
NYM | DSL | P | 21 | 35 | 52 | 36 |
0.0% | High Risk · 80 | N/A | |
| 4376 | IL(Rehab)29 |
MIN | Single-A | PIL(Rehab) | 23 | 38 | 48 | 44 |
0.0% | High Risk · 88 | N/A | |
| 4377 | 29 |
NYM | High-A | P | 23 | 33 | 51 | 47 |
0.0% | Wide Range · 63 | N/A | |
| 4378 | 29 |
TB | AA | P | 24 | 31 | 46 | 51 |
-0.1% | Medium Risk · 53 | N/A | |
| 4379 | 29 |
WSH | DSL | OF | 20 | 33 | 45 | 37 |
0.0% | Wide Range · 71 | N/A | |
| 4380 | 29 |
SEA | DSL | P | 20 | 31 | 42 | 35 |
0.0% | Wide Range · 70 | N/A | |
| 4381 | 29 |
MIL | DSL | C | 20 | 33 | 45 | 37 |
0.0% | High Risk · 75 | N/A | |
| 4382 | 29 |
SF | DSL | P | 20 | 28 | 38 | 32 |
-0.1% | Low Risk · 40 | N/A | |
| 4383 | 29 |
DET | DSL | SS | 20 | 33 | 45 | 37 |
0.0% | High Risk · 75 | N/A | |
| 4384 | 29 |
TOR | DSL | P | 21 | 37 | 48 | 41 |
0.0% | High Risk · 91 | N/A | |
| 4385 | 29 |
STL | FCL | C | 20 | 32 | 43 | 36 |
0.0% | Wide Range · 70 | N/A | |
| 4386 | 29 |
COL | ACL | C | 20 | 32 | 46 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 4387 | 29 |
SEA | ACL | P | 20 | 32 | 46 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 4388 | 29 |
TOR | FCL | P | 20 | 32 | 46 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 4389 | 29 |
SD | ACL | P | 20 | 32 | 46 | 42 |
0.0% | Wide Range · 59 | N/A | |
| 4390 | 29 |
TEX | Single-A | P | 20 | 26 | 36 | 44 |
0.0% | Low Risk · 27 | N/A | |
| 4391 | 29 |
MIL | DSL | P | 21 | 32 | 42 | 30 |
0.0% | Medium Risk · 56 | N/A | |
| 4392 | 29 |
PHI | AAA | P | 21 | 28 | 37 | 42 |
0.0% | Low Risk · 26 | N/A | |
| 4393 | 29 |
DET | AA | P | 22 | 29 | 38 | 35 |
0.0% | Low Risk · 32 | N/A | |
| 4394 | 29 |
TOR | DSL | C | 20 | 33 | 46 | 38 |
0.0% | High Risk · 75 | N/A | |
| 4395 | 29 |
LAA | DSL | P | 20 | 33 | 43 | 37 |
-0.1% | High Risk · 76 | N/A | |
| 4396 | 29 |
SEA | High-A | P | 21 | 32 | 42 | 35 |
0.0% | Medium Risk · 53 | N/A | |
| 4397 | 29 |
SF | ACL | CF | 21 | 32 | 42 | 31 |
+0.1% | Wide Range · 62 | N/A | |
| 4398 | 29 |
CWS | Single-A | OF | 20 | 32 | 43 | 37 |
0.0% | Wide Range · 59 | N/A | |
| 4399 | 29 |
NYY | FCL | P | 21 | 32 | 41 | 28 |
0.0% | Wide Range · 62 | N/A | |
| 4400 | 29 |
BAL | DSL | IF | 20 | 31 | 42 | 34 |
+0.1% | Wide Range · 70 | N/A | |
| 4401 | 29 |
STL | Single-A | P | 22 | 36 | 48 | 41 |
0.0% | High Risk · 81 | N/A | |
| 4402 | 29 |
TOR | DSL | P | 20 | 34 | 45 | 39 |
0.0% | High Risk · 80 | N/A | |
| 4403 | 29 |
CLE | DSL | P | 21 | 32 | 44 | 33 |
-0.2% | Wide Range · 70 | N/A | |
| 4404 | 29 |
BOS | DSL | P | 20 | 31 | 42 | 31 |
0.0% | Wide Range · 60 | N/A | |
| 4405 | IL(Rehab)29 |
STL | Single-A | PIL(Rehab) | 25 | 36 | 53 | 39 |
0.0% | Wide Range · 72 | N/A | |
| 4406 | IL(7-Day)29 |
TB | AAA | 2BIL(7-Day) | 22 | 31 | 41 | 44 |
0.0% | Wide Range · 64 | N/A | |
| 4407 | 29 |
SEA | DSL | P | 20 | 29 | 42 | 33 |
0.0% | Medium Risk · 50 | N/A | |
| 4408 | 29 |
TEX | DSL | P | 20 | 30 | 45 | 31 |
0.0% | Medium Risk · 50 | N/A | |
| 4409 | 29 |
SD | ACL | P | 21 | 34 | 51 | 34 |
0.0% | Wide Range · 74 | N/A | |
| 4410 | 29 |
STL | FCL | P | 21 | 32 | 43 | 32 |
+0.4% | Wide Range · 64 | N/A | |
| 4411 | 29 |
DET | FCL | P | 20 | 30 | 40 | 28 |
0.0% | Low Risk · 40 | N/A | |
| 4412 | 29 |
CIN | High-A | P | 22 | 32 | 40 | 28 |
+0.1% | Medium Risk · 42 | N/A | |
| 4413 | 29 |
MIN | AA | P | 22 | 30 | 42 | 41 |
-0.1% | Medium Risk · 44 | N/A | |
| 4414 | 29 |
STL | FCL | LF | 20 | 31 | 41 | 34 |
-0.2% | Wide Range · 64 | N/A | |
| 4415 | 29 |
CWS | ACL | OF | 20 | 32 | 43 | 34 |
+0.1% | Wide Range · 70 | N/A | |
| 4416 | 29 |
MIN | AAA | P | 22 | 29 | 36 | 36 |
+0.2% | Low Risk · 34 | N/A | |
| 4417 | 29 |
CIN | ACL | P | 22 | 38 | 48 | 43 |
0.0% | High Risk · 94 | N/A | |
| 4418 | 29 |
PIT | DSL | P | 20 | 33 | 43 | 37 |
0.0% | High Risk · 80 | N/A | |
| 4419 | 29 |
NYY | DSL | SS | 20 | 33 | 46 | 37 |
-0.3% | High Risk · 75 | N/A | |
| 4420 | 29 |
BAL | Single-A | P | 22 | 31 | 40 | 28 |
0.0% | Medium Risk · 44 | N/A | |
| 4421 | 28 |
TOR | DSL | P | 20 | 30 | 41 | 36 |
+0.1% | Wide Range · 70 | N/A | |
| 4422 | 28 |
PHI | AAA | P | 24 | 30 | 36 | 31 |
-0.7% | Medium Risk · 45 | N/A | |
| 4423 | 28 |
NYM | DSL | P | 20 | 34 | 47 | 37 |
-0.1% | High Risk · 80 | N/A | |
| 4424 | 28 |
CLE | DSL | P | 23 | 37 | 57 | 39 |
0.0% | High Risk · 91 | N/A | |
| 4425 | 28 |
LAA | ACL | P | 20 | 32 | 42 | 32 |
0.0% | Wide Range · 64 | N/A | |
| 4426 | 28 |
ARI | High-A | P | 21 | 35 | 46 | 42 |
0.0% | High Risk · 79 | N/A | |
| 4427 | 28 |
PHI | DSL | IF | 20 | 33 | 43 | 37 |
0.0% | High Risk · 77 | N/A | |
| 4428 | 28 |
NYM | DSL | P | 20 | 30 | 41 | 33 |
0.0% | Wide Range · 60 | N/A | |
| 4429 | 28 |
TEX | DSL | P | 21 | 34 | 46 | 35 |
0.0% | High Risk · 80 | N/A | |
| 4430 | 28 |
BAL | Single-A | P | 20 | 31 | 42 | 38 |
-0.3% | Wide Range · 68 | N/A | |
| 4431 | 28 |
MIA | AA | P | 22 | 33 | 43 | 46 |
-0.3% | Wide Range · 71 | N/A | |
| 4432 | 28 |
ATH | Single-A | P | 22 | 30 | 37 | 21 |
0.0% | Low Risk · 36 | N/A | |
| 4433 | 28 |
LAD | ACL | P | 21 | 33 | 47 | 34 |
+0.1% | Wide Range · 65 | N/A | |
| 4434 | 28 |
HOU | DSL | P | 21 | 37 | 55 | 41 |
0.0% | High Risk · 93 | N/A | |
| 4435 | 28 |
LAA | ACL | P | 21 | 32 | 43 | 32 |
0.0% | Wide Range · 70 | N/A | |
| 4436 | 28 |
COL | ACL | P | 22 | 36 | 56 | 37 |
0.0% | High Risk · 84 | N/A | |
| 4437 | 28 |
SF | DSL | P | 20 | 33 | 47 | 38 |
0.0% | High Risk · 80 | N/A | |
| 4438 | 28 |
ATL | Single-A | P | 20 | 31 | 42 | 37 |
0.0% | Wide Range · 64 | N/A | |
| 4439 | 28 |
STL | FCL | C | 20 | 32 | 44 | 36 |
0.0% | Wide Range · 69 | N/A | |
| 4440 | 28 |
DET | Single-A | P | 24 | 33 | 52 | 43 |
0.0% | Medium Risk · 51 | N/A | |
| 4441 | 28 |
MIA | AA | P | 21 | 27 | 33 | 33 |
0.0% | Low Risk · 22 | N/A | |
| 4442 | 28 |
CWS | AA | P | 21 | 27 | 34 | 33 |
0.0% | Low Risk · 22 | N/A | |
| 4443 | 28 |
DET | AAA | P | 20 | 26 | 33 | 46 |
0.0% | Low Risk · 29 | N/A | |
| 4444 | 28 |
CIN | ACL | P | 20 | 32 | 45 | 32 |
+0.2% | Wide Range · 64 | N/A | |
| 4445 | 28 |
ARI | ACL | P | 22 | 38 | 50 | 43 |
0.0% | High Risk · 94 | N/A | |
| 4446 | 28 |
COL | DSL | P | 20 | 33 | 44 | 37 |
+0.1% | High Risk · 77 | N/A | |
| 4447 | 28 |
COL | ACL | P | 20 | 33 | 53 | 36 |
0.0% | Wide Range · 74 | N/A | |
| 4448 | 28 |
BOS | DSL | CF | 20 | 31 | 42 | 33 |
0.0% | Wide Range · 67 | N/A | |
| 4449 | 28 |
BAL | DSL | IF | 20 | 31 | 43 | 34 |
+0.2% | Wide Range · 72 | N/A | |
| 4450 | 28 |
LAA | AAA | C | 20 | 26 | 33 | 44 |
+0.2% | Low Risk · 28 | N/A | |
| 4451 | 28 |
STL | High-A | P | 21 | 30 | 44 | 36 |
-0.3% | Medium Risk · 44 | N/A | |
| 4452 | 28 |
TOR | AAA | C | 20 | 26 | 37 | 49 |
+0.1% | Low Risk · 31 | N/A | |
| 4453 | 28 |
NYM | AA | SS | 21 | 27 | 34 | 31 |
-0.2% | Low Risk · 26 | N/A | |
| 4454 | 28 |
ATL | DSL | P | 20 | 32 | 46 | 41 |
0.0% | Wide Range · 59 | N/A | |
| 4455 | 28 |
DET | DSL | P | 20 | 32 | 46 | 41 |
0.0% | Wide Range · 59 | N/A | |
| 4456 | 28 |
NYY | AAA | P | 22 | 33 | 44 | 52 |
-0.1% | Wide Range · 75 | N/A | |
| 4457 | 28 |
ATL | DSL | P | 22 | 38 | 48 | 42 |
0.0% | High Risk · 94 | N/A | |
| 4458 | IL(Rehab)28 |
CHC | ACL | PIL(Rehab) | 20 | 31 | 47 | 33 |
0.0% | Wide Range · 64 | N/A | |
| 4459 | 28 |
SEA | ACL | OF | 20 | 31 | 49 | 35 |
0.0% | Wide Range · 64 | N/A | |
| 4460 | 28 |
NYM | FCL | P | 21 | 33 | 46 | 35 |
0.0% | Wide Range · 74 | N/A | |
| 4461 | 28 |
WSH | DSL | C | 20 | 31 | 43 | 35 |
0.0% | Wide Range · 70 | N/A | |
| 4462 | 28 |
TEX | DSL | P | 20 | 31 | 42 | 32 |
-0.3% | Wide Range · 70 | N/A | |
| 4463 | 28 |
HOU | DSL | P | 20 | 33 | 43 | 38 |
-0.2% | High Risk · 80 | N/A | |
| 4464 | 28 |
LAD | ACL | P | 20 | 33 | 46 | 34 |
-0.1% | Wide Range · 74 | N/A | |
| 4465 | 28 |
NYM | DSL | P | 20 | 35 | 48 | 41 |
-0.1% | High Risk · 91 | N/A | |
| 4466 | 28 |
SD | DSL | P | 20 | 31 | 42 | 33 |
0.0% | Wide Range · 70 | N/A | |
| 4467 | 28 |
CLE | ACL | P | 21 | 33 | 49 | 34 |
0.0% | Wide Range · 74 | N/A | |
| 4468 | 28 |
PIT | DSL | P | 20 | 28 | 39 | 32 |
-0.3% | Medium Risk · 50 | N/A | |
| 4469 | 28 |
TEX | AAA | P | 20 | 31 | 41 | 49 |
-0.1% | Wide Range · 64 | N/A | |
| 4470 | 28 |
CWS | AA | P | 20 | 30 | 40 | 47 |
0.0% | Wide Range · 61 | N/A | |
| 4471 | 28 |
TOR | DSL | P | 21 | 36 | 50 | 40 |
0.0% | High Risk · 91 | N/A | |
| 4472 | 28 |
TEX | DSL | P | 20 | 34 | 46 | 35 |
0.0% | High Risk · 80 | N/A | |
| 4473 | 28 |
TEX | DSL | IF | 20 | 33 | 45 | 37 |
0.0% | High Risk · 79 | N/A | |
| 4474 | 28 |
CIN | ACL | P | 21 | 32 | 42 | 31 |
+0.2% | Wide Range · 64 | N/A | |
| 4475 | 28 |
MIL | DSL | P | 20 | 30 | 41 | 34 |
-0.2% | Wide Range · 70 | N/A | |
| 4476 | 28 |
ARI | DSL | P | 20 | 32 | 43 | 36 |
-0.1% | High Risk · 76 | N/A | |
| 4477 | 28 |
DET | FCL | P | 20 | 32 | 47 | 34 |
-0.3% | Wide Range · 74 | N/A | |
| 4478 | 28 |
CWS | ACL | P | 20 | 31 | 44 | 28 |
0.0% | Medium Risk · 56 | N/A | |
| 4479 | 28 |
STL | FCL | P | 20 | 33 | 44 | 39 |
-0.4% | High Risk · 80 | N/A | |
| 4480 | 28 |
ATL | Single-A | C | 20 | 30 | 40 | 33 |
0.0% | Medium Risk · 44 | N/A | |
| 4481 | 28 |
TEX | DSL | P | 21 | 36 | 51 | 40 |
0.0% | High Risk · 91 | N/A | |
| 4482 | 28 |
SF | DSL | P | 20 | 33 | 49 | 38 |
-0.3% | High Risk · 80 | N/A | |
| 4483 | 28 |
CHC | ACL | P | 21 | 32 | 43 | 32 |
-0.1% | Wide Range · 65 | N/A | |
| 4484 | 28 |
MIA | AAA | P | 20 | 31 | 41 | 49 |
0.0% | Wide Range · 64 | N/A | |
| 4485 | 28 |
DET | Single-A | P | 20 | 29 | 38 | 25 |
+0.1% | Low Risk · 36 | N/A | |
| 4486 | 28 |
SEA | AA | C | 20 | 26 | 32 | 39 |
+0.1% | Low Risk · 26 | N/A | |
| 4487 | 28 |
LAD | High-A | P | 20 | 34 | 45 | 41 |
0.0% | High Risk · 77 | N/A | |
| 4488 | IL(7-Day)28 |
BAL | Single-A | PIL(7-Day) | 21 | 35 | 48 | 41 |
0.0% | High Risk · 85 | N/A | |
| 4489 | 28 |
LAD | DSL | P | 20 | 30 | 41 | 34 |
+0.1% | Wide Range · 70 | N/A | |
| 4490 | 28 |
TB | DSL | P | 20 | 32 | 54 | 35 |
0.0% | Wide Range · 74 | N/A | |
| 4491 | 28 |
CHC | DSL | C | 20 | 32 | 43 | 36 |
0.0% | High Risk · 75 | N/A | |
| 4492 | IL(Rehab)28 |
BAL | FCL | PIL(Rehab) | 20 | 31 | 46 | 34 |
0.0% | Wide Range · 68 | N/A | |
| 4493 | 28 |
SEA | ACL | P | 20 | 33 | 43 | 36 |
-0.4% | High Risk · 80 | N/A | |
| 4494 | 28 |
SD | ACL | 2B | 20 | 30 | 41 | 32 |
0.0% | Wide Range · 61 | N/A | |
| 4495 | 28 |
COL | DSL | P | 20 | 34 | 46 | 39 |
0.0% | High Risk · 90 | N/A | |
| 4496 | 28 |
TEX | ACL | P | 20 | 32 | 44 | 33 |
0.0% | Wide Range · 65 | N/A | |
| 4497 | 28 |
TB | DSL | P | 20 | 34 | 52 | 37 |
0.0% | High Risk · 81 | N/A | |
| 4498 | 28 |
NYM | DSL | P | 21 | 35 | 54 | 40 |
-0.3% | High Risk · 94 | N/A | |
| 4499 | 28 |
SF | ACL | P | 20 | 32 | 50 | 31 |
-0.1% | Wide Range · 64 | N/A | |
| 4500 | 28 |
TB | DSL | P | 20 | 30 | 43 | 30 |
-0.1% | Medium Risk · 50 | N/A | |
| 4501 | 28 |
CHC | DSL | P | 21 | 36 | 52 | 38 |
0.0% | High Risk · 90 | N/A | |
| 4502 | 28 |
MIA | Single-A | P | 21 | 33 | 46 | 36 |
+0.1% | Wide Range · 65 | N/A | |
| 4503 | 28 |
SD | ACL | C | 20 | 29 | 39 | 30 |
0.0% | Medium Risk · 45 | N/A | |
| 4504 | 28 |
TOR | AAA | P | 20 | 28 | 37 | 44 |
0.0% | Medium Risk · 47 | N/A | |
| 4505 | 28 |
KC | AA | 2B | 21 | 27 | 34 | 29 |
+0.1% | Low Risk · 29 | N/A | |
| 4506 | 28 |
CWS | DSL | OF | 20 | 33 | 45 | 39 |
0.0% | High Risk · 80 | N/A | |
| 4507 | 28 |
SF | DSL | OF | 20 | 33 | 46 | 37 |
0.0% | High Risk · 76 | N/A | |
| 4508 | 28 |
KC | DSL | P | 20 | 34 | 46 | 40 |
0.0% | High Risk · 90 | N/A | |
| 4509 | 28 |
SEA | AA | OF | 21 | 27 | 33 | 31 |
-0.1% | Low Risk · 22 | N/A | |
| 4510 | 28 |
TOR | DSL | P | 21 | 37 | 52 | 41 |
0.0% | High Risk · 93 | N/A | |
| 4511 | 28 |
KC | DSL | SS | 20 | 32 | 45 | 34 |
0.0% | Wide Range · 70 | N/A | |
| 4512 | 28 |
BAL | DSL | P | 21 | 35 | 55 | 37 |
0.0% | High Risk · 81 | N/A | |
| 4513 | 28 |
TEX | DSL | P | 20 | 30 | 45 | 29 |
0.0% | Medium Risk · 50 | N/A | |
| 4514 | 28 |
TEX | ACL | P | 20 | 30 | 43 | 28 |
0.0% | Medium Risk · 50 | N/A | |
| 4515 | 28 |
NYM | AA | P | 21 | 29 | 43 | 49 |
0.0% | Medium Risk · 52 | N/A | |
| 4516 | 28 |
ATH | ACL | P | 20 | 34 | 45 | 38 |
-0.1% | High Risk · 82 | N/A | |
| 4517 | 28 |
PIT | FCL | P | 20 | 31 | 42 | 32 |
0.0% | Wide Range · 70 | N/A | |
| 4518 | 28 |
MIA | FCL | P | 20 | 31 | 42 | 31 |
0.0% | Wide Range · 64 | N/A | |
| 4519 | 28 |
NYM | FCL | P | 20 | 32 | 43 | 34 |
+0.3% | Wide Range · 74 | N/A | |
| 4520 | 28 |
CIN | High-A | P | 21 | 30 | 39 | 29 |
-0.7% | Medium Risk · 44 | N/A | |
| 4521 | 28 |
CWS | DSL | P | 20 | 36 | 47 | 41 |
-0.1% | High Risk · 93 | N/A | |
| 4522 | 28 |
STL | DSL | P | 20 | 32 | 45 | 38 |
0.0% | High Risk · 80 | N/A | |
| 4523 | 28 |
PIT | DSL | P | 20 | 30 | 43 | 33 |
0.0% | Wide Range · 64 | N/A | |
| 4524 | 28 |
KC | ACL | OF | 20 | 30 | 40 | 27 |
0.0% | Medium Risk · 57 | N/A | |
| 4525 | IL(Rehab)28 |
TB | FCL | PIL(Rehab) | 22 | 36 | 56 | 38 |
0.0% | High Risk · 81 | N/A | |
| 4526 | 28 |
KC | DSL | P | 20 | 30 | 41 | 33 |
-0.1% | Wide Range · 66 | N/A | |
| 4527 | 28 |
PHI | AA | C | 22 | 28 | 35 | 26 |
0.0% | Low Risk · 28 | N/A | |
| 4528 | 28 |
SEA | AA | P | 20 | 27 | 36 | 37 |
0.0% | Low Risk · 25 | N/A | |
| 4529 | 28 |
CIN | DSL | C | 20 | 32 | 43 | 36 |
+0.1% | High Risk · 75 | N/A | |
| 4530 | 28 |
TB | Single-A | P | 20 | 31 | 41 | 33 |
-0.2% | Medium Risk · 55 | N/A | |
| 4531 | 28 |
TB | DSL | IF | 20 | 30 | 41 | 33 |
0.0% | Wide Range · 70 | N/A | |
| 4532 | 28 |
LAD | DSL | OF | 20 | 33 | 47 | 37 |
+0.1% | High Risk · 76 | N/A | |
| 4533 | 27 |
HOU | Single-A | P | 21 | 35 | 44 | 42 |
-0.2% | High Risk · 84 | N/A | |
| 4534 | 27 |
PHI | DSL | P | 20 | 35 | 48 | 38 |
0.0% | High Risk · 90 | N/A | |
| 4535 | 27 |
STL | DSL | P | 21 | 37 | 47 | 41 |
0.0% | High Risk · 94 | N/A | |
| 4536 | 27 |
CLE | AAA | P | 22 | 29 | 44 | 53 |
0.0% | Medium Risk · 55 | N/A | |
| 4537 | 27 |
PIT | DSL | IF | 20 | 31 | 42 | 34 |
-0.1% | Wide Range · 70 | N/A | |
| 4538 | 27 |
SEA | High-A | P | 21 | 31 | 49 | 46 |
+0.1% | Wide Range · 63 | N/A | |
| 4539 | 27 |
NYM | AA | LF | 20 | 27 | 36 | 46 |
0.0% | Low Risk · 38 | N/A | |
| 4540 | 27 |
NYM | DSL | P | 20 | 35 | 46 | 40 |
0.0% | High Risk · 91 | N/A | |
| 4541 | 27 |
KC | High-A | P | 21 | 34 | 43 | 42 |
-0.5% | High Risk · 80 | N/A | |
| 4542 | 27 |
ARI | DSL | P | 20 | 35 | 46 | 40 |
0.0% | High Risk · 91 | N/A | |
| 4543 | 27 |
WSH | AA | P | 21 | 30 | 43 | 46 |
0.0% | Wide Range · 59 | N/A | |
| 4544 | 27 |
BOS | DSL | P | 20 | 34 | 45 | 39 |
0.0% | High Risk · 90 | N/A | |
| 4545 | 27 |
BAL | FCL | P | 20 | 31 | 41 | 30 |
-0.2% | Wide Range · 70 | N/A | |
| 4546 | 27 |
COL | ACL | P | 21 | 33 | 55 | 34 |
+0.2% | Wide Range · 74 | N/A | |
| 4547 | 27 |
TOR | DSL | SS | 20 | 32 | 43 | 36 |
0.0% | High Risk · 75 | N/A | |
| 4548 | 27 |
DET | DSL | LF | 20 | 32 | 50 | 34 |
-0.1% | Wide Range · 70 | N/A | |
| 4549 | 27 |
ARI | ACL | P | 21 | 33 | 55 | 35 |
0.0% | Wide Range · 74 | N/A | |
| 4550 | 27 |
CIN | AAA | P | 21 | 29 | 36 | 39 |
-0.6% | Medium Risk · 47 | N/A | |
| 4551 | 27 |
ATL | DSL | P | 20 | 32 | 43 | 36 |
-0.1% | High Risk · 80 | N/A | |
| 4552 | 27 |
DET | Single-A | C | 20 | 30 | 39 | 30 |
+0.1% | Medium Risk · 50 | N/A | |
| 4553 | 27 |
WSH | AA | P | 21 | 29 | 37 | 33 |
0.0% | Medium Risk · 43 | N/A | |
| 4554 | 27 |
HOU | DSL | OF | 20 | 30 | 40 | 31 |
0.0% | Wide Range · 60 | N/A | |
| 4555 | IL(Rehab)27 |
COL | ACL | PIL(Rehab) | 22 | 35 | 56 | 35 |
0.0% | High Risk · 78 | N/A | |
| 4556 | 27 |
LAA | DSL | P | 20 | 36 | 48 | 40 |
+0.1% | High Risk · 93 | N/A | |
| 4557 | 27 |
CIN | AAA | 2B | 21 | 26 | 31 | 42 |
+0.1% | Low Risk · 33 | N/A | |
| 4558 | 27 |
COL | DSL | P | 20 | 34 | 48 | 40 |
-0.1% | High Risk · 94 | N/A | |
| 4559 | 27 |
HOU | High-A | C | 20 | 30 | 40 | 34 |
+0.1% | Medium Risk · 55 | N/A | |
| 4560 | 27 |
ATH | ACL | 3B | 20 | 30 | 40 | 28 |
-0.2% | Medium Risk · 54 | N/A | |
| 4561 | 27 |
PHI | DSL | P | 21 | 36 | 47 | 40 |
-0.1% | High Risk · 93 | N/A | |
| 4562 | 27 |
WSH | Single-A | P | 20 | 29 | 40 | 35 |
0.0% | Medium Risk · 54 | N/A | |
| 4563 | 27 |
BAL | FCL | P | 20 | 26 | 41 | 44 |
0.0% | Medium Risk · 52 | N/A | |
| 4564 | 27 |
TB | FCL | P | 20 | 29 | 40 | 33 |
0.0% | Wide Range · 64 | N/A | |
| 4565 | 27 |
LAA | ACL | OF | 20 | 31 | 49 | 33 |
0.0% | Wide Range · 64 | N/A | |
| 4566 | 27 |
STL | FCL | P | 20 | 32 | 43 | 33 |
0.0% | Wide Range · 74 | N/A | |
| 4567 | 27 |
SEA | High-A | P | 20 | 27 | 38 | 35 |
0.0% | Low Risk · 33 | N/A | |
| 4568 | 27 |
KC | DSL | P | 20 | 35 | 54 | 40 |
-0.2% | High Risk · 94 | N/A | |
| 4569 | 27 |
BOS | DSL | P | 20 | 35 | 47 | 40 |
0.0% | High Risk · 93 | N/A | |
| 4570 | 27 |
TOR | AA | P | 26 | 32 | 48 | 48 |
0.0% | Wide Range · 62 | N/A | |
| 4571 | 27 |
ATH | ACL | P | 20 | 32 | 43 | 32 |
0.0% | Wide Range · 71 | N/A | |
| 4572 | 27 |
CIN | DSL | C | 20 | 31 | 43 | 36 |
0.0% | High Risk · 75 | N/A | |
| 4573 | 27 |
CIN | DSL | P | 20 | 31 | 42 | 35 |
0.0% | High Risk · 76 | N/A | |
| 4574 | 27 |
LAD | AAA | 2B | 20 | 28 | 38 | 49 |
0.0% | Medium Risk · 48 | N/A | |
| 4575 | 27 |
SF | DSL | P | 20 | 31 | 44 | 32 |
0.0% | Wide Range · 70 | N/A | |
| 4576 | 27 |
ATL | AA | C | 20 | 30 | 40 | 44 |
0.0% | Medium Risk · 52 | N/A | |
| 4577 | 27 |
WSH | DSL | P | 20 | 36 | 47 | 40 |
0.0% | High Risk · 93 | N/A | |
| 4578 | 27 |
BAL | FCL | P | 20 | 34 | 48 | 39 |
-0.3% | High Risk · 90 | N/A | |
| 4579 | 27 |
MIN | Single-A | SS | 20 | 30 | 41 | 35 |
-0.1% | Wide Range · 60 | N/A | |
| 4580 | 27 |
MIL | DSL | P | 20 | 31 | 42 | 32 |
0.0% | Wide Range · 67 | N/A | |
| 4581 | 27 |
WSH | DSL | P | 20 | 30 | 41 | 33 |
-0.1% | Wide Range · 70 | N/A | |
| 4582 | 27 |
SEA | DSL | SS | 20 | 32 | 42 | 35 |
0.0% | High Risk · 75 | N/A | |
| 4583 | 27 |
TEX | AA | P | 20 | 26 | 34 | 38 |
0.0% | Low Risk · 26 | N/A | |
| 4584 | 27 |
WSH | Single-A | P | 20 | 31 | 42 | 35 |
-0.2% | Wide Range · 64 | N/A | |
| 4585 | 27 |
SF | ACL | RF | 20 | 30 | 40 | 26 |
0.0% | Wide Range · 63 | N/A | |
| 4586 | 27 |
CHC | DSL | P | 21 | 36 | 48 | 41 |
0.0% | High Risk · 94 | N/A | |
| 4587 | 27 |
LAA | DSL | SS | 20 | 33 | 44 | 38 |
-0.1% | High Risk · 80 | N/A | |
| 4588 | 27 |
COL | AA | CF | 26 | 32 | 48 | 53 |
0.0% | Wide Range · 61 | N/A | |
| 4589 | 27 |
ARI | DSL | C | 20 | 31 | 42 | 36 |
-0.1% | High Risk · 77 | N/A | |
| 4590 | 27 |
CIN | DSL | P | 20 | 34 | 45 | 38 |
0.0% | High Risk · 90 | N/A | |
| 4591 | 27 |
BOS | DSL | P | 20 | 34 | 45 | 39 |
0.0% | High Risk · 90 | N/A | |
| 4592 | 27 |
TB | AAA | P | 23 | 29 | 36 | 35 |
0.0% | Medium Risk · 48 | N/A | |
| 4593 | 27 |
NYY | AAA | P | 20 | 26 | 34 | 42 |
-0.2% | Low Risk · 40 | N/A | |
| 4594 | 27 |
PIT | AAA | C | 20 | 29 | 38 | 41 |
-0.4% | Medium Risk · 54 | N/A | |
| 4595 | 27 |
SD | AAA | C | 20 | 27 | 34 | 33 |
+0.2% | Low Risk · 39 | N/A | |
| 4596 | 27 |
KC | DSL | P | 20 | 34 | 45 | 38 |
-0.4% | High Risk · 90 | N/A | |
| 4597 | IL(7-Day)27 |
TOR | FCL | PIL(7-Day) | 20 | 36 | 50 | 42 |
0.0% | High Risk · 97 | N/A | |
| 4598 | 27 |
BOS | FCL | P | 20 | 30 | 40 | 31 |
-0.4% | Wide Range · 64 | N/A | |
| 4599 | 27 |
LAD | ACL | P | 21 | 36 | 48 | 41 |
0.0% | High Risk · 94 | N/A | |
| 4600 | 27 |
COL | DSL | P | 20 | 32 | 42 | 35 |
0.0% | High Risk · 80 | N/A | |
| 4601 | 27 |
KC | ACL | P | 20 | 31 | 42 | 33 |
-0.4% | Wide Range · 74 | N/A | |
| 4602 | 27 |
MIA | DSL | P | 20 | 30 | 41 | 32 |
-0.4% | Wide Range · 70 | N/A | |
| 4603 | 27 |
ARI | AA | C | 20 | 28 | 39 | 45 |
-0.2% | Medium Risk · 52 | N/A | |
| 4604 | 27 |
STL | DSL | P | 20 | 34 | 45 | 38 |
-0.1% | High Risk · 90 | N/A | |
| 4605 | 27 |
WSH | FCL | P | 20 | 29 | 43 | 28 |
0.0% | Medium Risk · 50 | N/A | |
| 4606 | 27 |
ATL | AA | P | 20 | 26 | 38 | 50 |
-0.1% | Medium Risk · 51 | N/A | |
| 4607 | 27 |
DET | AA | P | 20 | 25 | 33 | 47 |
-0.3% | Medium Risk · 42 | N/A | |
| 4608 | 27 |
SD | DSL | P | 20 | 35 | 52 | 38 |
0.0% | High Risk · 90 | N/A | |
| 4609 | 27 |
SD | DSL | P | 20 | 33 | 45 | 34 |
0.0% | High Risk · 80 | N/A | |
| 4610 | 27 |
KC | Single-A | P | 20 | 31 | 41 | 35 |
-0.7% | Wide Range · 64 | N/A | |
| 4611 | 27 |
KC | DSL | OF | 20 | 30 | 41 | 33 |
+0.1% | Wide Range · 70 | N/A | |
| 4612 | 27 |
TB | AA | P | 20 | 28 | 38 | 35 |
-0.1% | Low Risk · 32 | N/A | |
| 4613 | 27 |
ATL | FCL | P | 20 | 30 | 42 | 35 |
0.0% | Wide Range · 74 | N/A | |
| 4614 | 27 |
MIL | DSL | P | 20 | 36 | 46 | 41 |
0.0% | High Risk · 94 | N/A | |
| 4615 | 27 |
SD | AAA | P | 21 | 28 | 36 | 28 |
0.0% | Medium Risk · 44 | N/A | |
| 4616 | 27 |
BOS | DSL | P | 20 | 35 | 50 | 39 |
0.0% | High Risk · 94 | N/A | |
| 4617 | 27 |
CIN | AA | P | 20 | 30 | 38 | 39 |
0.0% | Medium Risk · 51 | N/A | |
| 4618 | 27 |
SD | ACL | OF | 20 | 30 | 40 | 28 |
0.0% | Wide Range · 65 | N/A | |
| 4619 | IL(7-Day)27 |
PHI | AAA | PIL(7-Day) | 22 | 34 | 44 | 52 |
0.0% | High Risk · 81 | N/A | |
| 4620 | IL(Rehab)27 |
STL | High-A | PIL(Rehab) | 20 | 28 | 40 | 43 |
0.0% | Medium Risk · 51 | N/A | |
| 4621 | 27 |
LAA | ACL | RF | 20 | 31 | 42 | 33 |
0.0% | High Risk · 75 | N/A | |
| 4622 | 27 |
KC | DSL | P | 20 | 31 | 42 | 35 |
0.0% | High Risk · 76 | N/A | |
| 4623 | 27 |
ARI | DSL | P | 20 | 32 | 54 | 33 |
0.0% | Wide Range · 74 | N/A | |
| 4624 | 27 |
DET | FCL | P | 20 | 34 | 45 | 40 |
-0.5% | High Risk · 91 | N/A | |
| 4625 | 27 |
STL | DSL | P | 20 | 32 | 43 | 36 |
0.0% | High Risk · 80 | N/A | |
| 4626 | 27 |
CLE | ACL | P | 20 | 30 | 41 | 30 |
0.0% | Wide Range · 64 | N/A | |
| 4627 | 27 |
MIA | DSL | P | 20 | 36 | 46 | 41 |
-0.3% | High Risk · 94 | N/A | |
| 4628 | 27 |
ARI | DSL | OF | 20 | 32 | 44 | 35 |
0.0% | High Risk · 75 | N/A | |
| 4629 | 27 |
TB | DSL | P | 20 | 34 | 46 | 39 |
0.0% | High Risk · 91 | N/A | |
| 4630 | 27 |
SD | DSL | P | 20 | 36 | 46 | 41 |
0.0% | High Risk · 94 | N/A | |
| 4631 | 27 |
CHC | AAA | P | 23 | 30 | 45 | 52 |
0.0% | Medium Risk · 56 | N/A | |
| 4632 | 27 |
TEX | AA | OF | 20 | 27 | 40 | 50 |
0.0% | Medium Risk · 45 | N/A | |
| 4633 | 27 |
KC | DSL | P | 20 | 33 | 44 | 38 |
0.0% | High Risk · 90 | N/A | |
| 4634 | 27 |
NYY | DSL | P | 20 | 32 | 45 | 34 |
0.0% | High Risk · 80 | N/A | |
| 4635 | 27 |
SF | DSL | P | 20 | 30 | 45 | 27 |
0.0% | Medium Risk · 50 | N/A | |
| 4636 | 27 |
PIT | DSL | C | 20 | 31 | 42 | 35 |
0.0% | High Risk · 75 | N/A | |
| 4637 | 27 |
BAL | FCL | C | 20 | 30 | 42 | 34 |
-0.1% | Wide Range · 69 | N/A | |
| 4638 | 27 |
CHC | DSL | P | 20 | 30 | 41 | 32 |
-0.4% | Wide Range · 70 | N/A | |
| 4639 | 27 |
SD | DSL | P | 20 | 30 | 40 | 31 |
0.0% | Wide Range · 70 | N/A | |
| 4640 | 27 |
SEA | AA | C | 20 | 28 | 38 | 46 |
0.0% | Medium Risk · 46 | N/A | |
| 4641 | 27 |
NYM | FCL | P | 20 | 32 | 50 | 35 |
0.0% | Wide Range · 74 | N/A | |
| 4642 | 26 |
COL | ACL | P | 20 | 30 | 41 | 30 |
0.0% | Wide Range · 64 | N/A | |
| 4643 | 26 |
COL | AAA | P | 20 | 27 | 35 | 35 |
-0.2% | Medium Risk · 47 | N/A | |
| 4644 | 26 |
CLE | DSL | P | 20 | 33 | 44 | 37 |
0.0% | High Risk · 79 | N/A | |
| 4645 | 26 |
TOR | AAA | P | 21 | 32 | 43 | 50 |
0.0% | Wide Range · 75 | N/A | |
| 4646 | 26 |
TB | FCL | P | 20 | 29 | 42 | 28 |
0.0% | Medium Risk · 50 | N/A | |
| 4647 | 26 |
SEA | AA | 2B | 20 | 25 | 31 | 40 |
-0.3% | Low Risk · 28 | N/A | |
| 4648 | 26 |
COL | DSL | P | 20 | 34 | 45 | 39 |
-0.1% | High Risk · 91 | N/A | |
| 4649 | 26 |
TOR | DSL | P | 20 | 32 | 44 | 34 |
-0.1% | High Risk · 80 | N/A | |
| 4650 | 26 |
NYM | DSL | P | 20 | 31 | 42 | 36 |
0.0% | High Risk · 80 | N/A | |
| 4651 | 26 |
TOR | DSL | P | 20 | 30 | 41 | 31 |
0.0% | Wide Range · 70 | N/A | |
| 4652 | 26 |
STL | DSL | P | 20 | 33 | 43 | 36 |
0.0% | High Risk · 81 | N/A | |
| 4653 | 26 |
KC | DSL | P | 20 | 30 | 44 | 31 |
0.0% | Wide Range · 64 | N/A | |
| 4654 | 26 |
MIN | High-A | P | 20 | 28 | 36 | 32 |
-6.3% | Medium Risk · 43 | N/A | |
| 4655 | 26 |
COL | ACL | P | 20 | 30 | 41 | 30 |
-0.1% | Wide Range · 64 | N/A | |
| 4656 | 26 |
KC | ACL | P | 20 | 30 | 40 | 30 |
0.0% | Wide Range · 64 | N/A | |
| 4657 | 26 |
ATH | AA | P | 21 | 30 | 38 | 37 |
-0.5% | Medium Risk · 51 | N/A | |
| 4658 | 26 |
LAD | ACL | P | 20 | 36 | 46 | 41 |
-0.3% | High Risk · 94 | N/A | |
| 4659 | 26 |
ARI | DSL | P | 20 | 29 | 40 | 31 |
0.0% | Wide Range · 70 | N/A | |
| 4660 | 26 |
CWS | AAA | P | 21 | 28 | 36 | 34 |
-0.8% | Medium Risk · 48 | N/A | |
| 4661 | 26 |
STL | High-A | P | 20 | 34 | 43 | 41 |
-0.4% | High Risk · 80 | N/A | |
| 4662 | 26 |
TOR | DSL | C | 20 | 31 | 41 | 33 |
+0.1% | High Risk · 77 | N/A | |
| 4663 | 26 |
CLE | DSL | P | 20 | 29 | 40 | 32 |
0.0% | Wide Range · 70 | N/A | |
| 4664 | IL(Rehab)26 |
MIN | FCL | PIL(Rehab) | 20 | 33 | 54 | 35 |
0.0% | High Risk · 78 | N/A | |
| 4665 | 26 |
ATH | DSL | P | 20 | 35 | 50 | 39 |
+0.2% | High Risk · 93 | N/A | |
| 4666 | 26 |
MIL | ACL | P | 20 | 31 | 42 | 32 |
-0.1% | Wide Range · 74 | N/A | |
| 4667 | IL(Rehab)26 |
HOU | FCL | OFIL(Rehab) | 20 | 30 | 47 | 34 |
0.0% | Wide Range · 68 | N/A | |
| 4668 | 26 |
NYM | DSL | P | 20 | 35 | 46 | 39 |
0.0% | High Risk · 93 | N/A | |
| 4669 | 26 |
TEX | DSL | SS | 20 | 33 | 44 | 38 |
-0.1% | High Risk · 87 | N/A | |
| 4670 | 26 |
MIL | DSL | C | 20 | 30 | 47 | 31 |
0.0% | Wide Range · 64 | N/A | |
| 4671 | 26 |
WSH | DSL | P | 20 | 27 | 37 | 27 |
0.0% | Low Risk · 40 | N/A | |
| 4672 | 26 |
TB | FCL | P | 20 | 31 | 44 | 34 |
0.0% | Wide Range · 74 | N/A | |
| 4673 | 26 |
ATL | DSL | P | 20 | 33 | 45 | 39 |
0.0% | High Risk · 91 | N/A | |
| 4674 | 26 |
KC | DSL | P | 20 | 31 | 41 | 37 |
-0.1% | High Risk · 80 | N/A | |
| 4675 | 26 |
CIN | AA | P | 20 | 24 | 31 | 40 |
0.0% | Low Risk · 27 | N/A | |
| 4676 | 26 |
NYY | DSL | P | 20 | 34 | 45 | 39 |
0.0% | High Risk · 91 | N/A | |
| 4677 | 26 |
CIN | High-A | C | 20 | 25 | 33 | 28 |
-0.3% | Low Risk · 24 | N/A | |
| 4678 | 26 |
MIA | DSL | P | 20 | 33 | 44 | 36 |
+0.1% | High Risk · 82 | N/A | |
| 4679 | 26 |
TEX | DSL | OF | 20 | 32 | 44 | 38 |
0.0% | High Risk · 87 | N/A | |
| 4680 | 26 |
NYY | DSL | P | 20 | 34 | 48 | 38 |
-0.4% | High Risk · 91 | N/A | |
| 4681 | 26 |
TB | DSL | P | 20 | 28 | 39 | 28 |
0.0% | Medium Risk · 50 | N/A | |
| 4682 | 26 |
BAL | DSL | P | 20 | 31 | 41 | 36 |
-0.4% | High Risk · 80 | N/A | |
| 4683 | 26 |
NYM | Single-A | 1B | 20 | 31 | 42 | 36 |
+0.1% | Wide Range · 66 | N/A | |
| 4684 | 26 |
LAD | DSL | P | 20 | 31 | 42 | 33 |
0.0% | High Risk · 80 | N/A | |
| 4685 | 26 |
DET | High-A | OF | 22 | 31 | 50 | 47 |
0.0% | Wide Range · 71 | N/A | |
| 4686 | 26 |
HOU | DSL | SS | 20 | 32 | 44 | 37 |
-0.1% | High Risk · 86 | N/A | |
| 4687 | 26 |
TB | DSL | P | 21 | 35 | 55 | 36 |
0.0% | High Risk · 90 | N/A | |
| 4688 | 26 |
SF | DSL | P | 20 | 27 | 38 | 30 |
0.0% | Medium Risk · 50 | N/A | |
| 4689 | 26 |
MIN | High-A | P | 20 | 26 | 37 | 32 |
+0.2% | Low Risk · 33 | N/A | |
| 4690 | 26 |
BOS | DSL | P | 20 | 33 | 44 | 38 |
0.0% | High Risk · 90 | N/A | |
| 4691 | 26 |
ATL | High-A | P | 20 | 27 | 35 | 34 |
0.0% | Medium Risk · 43 | N/A | |
| 4692 | 26 |
ARI | DSL | P | 20 | 36 | 48 | 40 |
0.0% | High Risk · 94 | N/A | |
| 4693 | 26 |
MIN | FCL | P | 20 | 27 | 37 | 30 |
-0.1% | Medium Risk · 54 | N/A | |
| 4694 | 26 |
NYM | DSL | P | 20 | 28 | 39 | 33 |
-0.1% | Wide Range · 70 | N/A | |
| 4695 | 26 |
COL | DSL | P | 20 | 33 | 44 | 37 |
0.0% | High Risk · 90 | N/A | |
| 4696 | 26 |
CWS | DSL | P | 20 | 35 | 45 | 40 |
0.0% | High Risk · 94 | N/A | |
| 4697 | IL(Rehab)26 |
CWS | ACL | OFIL(Rehab) | 20 | 30 | 44 | 42 |
0.0% | Wide Range · 65 | N/A | |
| 4698 | IL(Rehab)26 |
LAD | ACL | SSIL(Rehab) | 20 | 30 | 47 | 33 |
0.0% | Wide Range · 68 | N/A | |
| 4699 | 26 |
MIA | AAA | C | 21 | 28 | 43 | 51 |
0.0% | Medium Risk · 55 | N/A | |
| 4700 | 26 |
COL | ACL | P | 20 | 34 | 53 | 35 |
-0.3% | High Risk · 84 | N/A | |
| 4701 | IL(Rehab)26 |
SD | High-A | PIL(Rehab) | 21 | 28 | 49 | 47 |
0.0% | Medium Risk · 57 | N/A | |
| 4702 | 26 |
BOS | DSL | P | 20 | 33 | 44 | 38 |
0.0% | High Risk · 90 | N/A | |
| 4703 | 26 |
TOR | DSL | OF | 20 | 32 | 43 | 38 |
0.0% | High Risk · 87 | N/A | |
| 4704 | 26 |
HOU | DSL | P | 20 | 35 | 45 | 40 |
0.0% | High Risk · 94 | N/A | |
| 4705 | 26 |
KC | DSL | P | 20 | 34 | 45 | 39 |
0.0% | High Risk · 93 | N/A | |
| 4706 | 26 |
CWS | High-A | P | 20 | 29 | 48 | 45 |
0.0% | Wide Range · 64 | N/A | |
| 4707 | 26 |
DET | AA | P | 20 | 27 | 38 | 48 |
0.0% | Medium Risk · 53 | N/A | |
| 4708 | 26 |
DET | DSL | P | 20 | 32 | 50 | 32 |
-0.1% | High Risk · 80 | N/A | |
| 4709 | 26 |
MIA | DSL | P | 20 | 30 | 47 | 31 |
-0.2% | Wide Range · 74 | N/A | |
| 4710 | 26 |
LAD | DSL | OF | 20 | 30 | 40 | 32 |
0.0% | High Risk · 76 | N/A | |
| 4711 | 26 |
WSH | DSL | OF | 20 | 32 | 43 | 38 |
0.0% | High Risk · 87 | N/A | |
| 4712 | 26 |
DET | DSL | P | 21 | 36 | 55 | 39 |
0.0% | High Risk · 100 | N/A | |
| 4713 | 26 |
TB | FCL | P | 20 | 28 | 39 | 29 |
0.0% | Medium Risk · 50 | N/A | |
| 4714 | 26 |
NYY | DSL | P | 20 | 34 | 47 | 39 |
0.0% | High Risk · 93 | N/A | |
| 4715 | 26 |
TOR | DSL | P | 20 | 32 | 43 | 38 |
0.0% | High Risk · 90 | N/A | |
| 4716 | 26 |
BOS | AA | P | 23 | 31 | 45 | 46 |
0.0% | Wide Range · 65 | N/A | |
| 4717 | 26 |
ARI | DSL | P | 20 | 31 | 42 | 34 |
0.0% | High Risk · 80 | N/A | |
| 4718 | 26 |
KC | AA | LF | 20 | 26 | 32 | 28 |
+0.1% | Low Risk · 30 | N/A | |
| 4719 | 26 |
ARI | AA | P | 20 | 27 | 34 | 27 |
0.0% | Low Risk · 31 | N/A | |
| 4720 | 26 |
HOU | FCL | RF | 20 | 32 | 48 | 35 |
0.0% | High Risk · 80 | N/A | |
| 4721 | 26 |
TOR | FCL | OF | 20 | 30 | 46 | 32 |
0.0% | Wide Range · 64 | N/A | |
| 4722 | 26 |
MIN | DSL | P | 20 | 35 | 52 | 39 |
0.0% | High Risk · 100 | N/A | |
| 4723 | IL(Rehab)26 |
ATL | FCL | PIL(Rehab) | 20 | 31 | 43 | 35 |
0.0% | High Risk · 78 | N/A | |
| 4724 | 25 |
PHI | DSL | P | 20 | 33 | 44 | 38 |
-0.3% | High Risk · 91 | N/A | |
| 4725 | 25 |
SD | DSL | P | 20 | 32 | 43 | 37 |
-0.1% | High Risk · 90 | N/A | |
| 4726 | 25 |
COL | DSL | OF | 20 | 30 | 41 | 35 |
0.0% | High Risk · 78 | N/A | |
| 4727 | 25 |
LAA | AA | P | 22 | 28 | 44 | 48 |
0.0% | Medium Risk · 54 | N/A | |
| 4728 | 25 |
LAA | AA | 2B | 20 | 26 | 33 | 28 |
0.0% | Low Risk · 36 | N/A | |
| 4729 | 25 |
WSH | DSL | IF | 20 | 32 | 43 | 36 |
-0.1% | High Risk · 86 | N/A | |
| 4730 | 25 |
CLE | DSL | P | 20 | 32 | 43 | 36 |
-0.1% | High Risk · 82 | N/A | |
| 4731 | 25 |
MIN | Single-A | P | 20 | 29 | 39 | 31 |
0.0% | Medium Risk · 54 | N/A | |
| 4732 | 25 |
COL | ACL | C | 20 | 28 | 39 | 29 |
0.0% | Medium Risk · 55 | N/A | |
| 4733 | 25 |
ARI | ACL | P | 20 | 30 | 43 | 29 |
0.0% | Wide Range · 64 | N/A | |
| 4734 | 25 |
HOU | AA | P | 20 | 25 | 34 | 38 |
0.0% | Low Risk · 27 | N/A | |
| 4735 | 25 |
SEA | AA | P | 20 | 24 | 30 | 37 |
0.0% | Low Risk · 27 | N/A | |
| 4736 | IL(60-Day)25 |
ATL | High-A | PIL(60-Day) | 22 | 30 | 50 | 46 |
0.0% | Wide Range · 75 | N/A | |
| 4737 | 25 |
CIN | High-A | P | 20 | 26 | 34 | 32 |
0.0% | Low Risk · 33 | N/A | |
| 4738 | 25 |
ATH | Single-A | C | 20 | 29 | 40 | 33 |
0.0% | Wide Range · 58 | N/A | |
| 4739 | 25 |
DET | DSL | P | 20 | 29 | 40 | 31 |
0.0% | Wide Range · 70 | N/A | |
| 4740 | 25 |
MIN | AA | P | 20 | 25 | 33 | 33 |
0.0% | Low Risk · 23 | N/A | |
| 4741 | 25 |
LAA | High-A | C | 20 | 25 | 33 | 32 |
-0.1% | Low Risk · 30 | N/A | |
| 4742 | 25 |
MIA | DSL | P | 20 | 31 | 46 | 33 |
-0.1% | High Risk · 80 | N/A | |
| 4743 | 25 |
MIA | DSL | P | 20 | 35 | 45 | 40 |
0.0% | High Risk · 94 | N/A | |
| 4744 | IL(Rehab)25 |
STL | FCL | PIL(Rehab) | 20 | 32 | 54 | 35 |
-0.1% | High Risk · 79 | N/A | |
| 4745 | 25 |
MIA | DSL | SS | 20 | 29 | 39 | 30 |
0.0% | Wide Range · 67 | N/A | |
| 4746 | 25 |
NYM | AA | P | 23 | 29 | 45 | 49 |
0.0% | Wide Range · 64 | N/A | |
| 4747 | 25 |
PIT | AA | P | 20 | 27 | 34 | 26 |
-0.3% | Medium Risk · 43 | N/A | |
| 4748 | 25 |
DET | FCL | P | 20 | 29 | 41 | 35 |
0.0% | Wide Range · 74 | N/A | |
| 4749 | 25 |
CWS | Single-A | P | 20 | 30 | 42 | 34 |
0.0% | Wide Range · 65 | N/A | |
| 4750 | 25 |
COL | DSL | P | 20 | 33 | 44 | 38 |
0.0% | High Risk · 91 | N/A | |
| 4751 | 25 |
MIL | ACL | C | 20 | 33 | 53 | 35 |
-0.4% | High Risk · 81 | N/A | |
| 4752 | 25 |
SEA | ACL | 2B | 20 | 30 | 48 | 32 |
0.0% | Wide Range · 65 | N/A | |
| 4753 | IL(7-Day)25 |
WSH | Single-A | PIL(7-Day) | 21 | 34 | 49 | 40 |
0.0% | High Risk · 87 | N/A | |
| 4754 | 25 |
TOR | FCL | P | 20 | 32 | 42 | 33 |
-0.1% | High Risk · 80 | N/A | |
| 4755 | 25 |
NYY | DSL | P | 20 | 35 | 54 | 38 |
0.0% | High Risk · 95 | N/A | |
| 4756 | 25 |
CWS | ACL | P | 20 | 28 | 38 | 24 |
0.0% | Medium Risk · 50 | N/A | |
| 4757 | 25 |
MIA | AA | P | 20 | 27 | 37 | 34 |
+0.1% | Medium Risk · 45 | N/A | |
| 4758 | 25 |
BAL | AA | P | 22 | 28 | 44 | 48 |
0.0% | Medium Risk · 55 | N/A | |
| 4759 | 25 |
MIA | AAA | P | 20 | 27 | 42 | 45 |
0.0% | Medium Risk · 50 | N/A | |
| 4760 | IL(Rehab)25 |
CIN | ACL | PIL(Rehab) | 20 | 31 | 51 | 34 |
0.0% | High Risk · 78 | N/A | |
| 4761 | 25 |
ATL | DSL | C | 20 | 31 | 42 | 36 |
0.0% | High Risk · 78 | N/A | |
| 4762 | IL(7-Day)25 |
WSH | Single-A | PIL(7-Day) | 20 | 32 | 43 | 41 |
0.0% | High Risk · 87 | N/A | |
| 4763 | 25 |
NYM | DSL | P | 20 | 34 | 44 | 40 |
+0.1% | High Risk · 94 | N/A | |
| 4764 | 25 |
SF | ACL | P | 20 | 29 | 41 | 31 |
+0.1% | Wide Range · 74 | N/A | |
| 4765 | 25 |
NYY | FCL | P | 20 | 28 | 39 | 30 |
0.0% | Wide Range · 64 | N/A | |
| 4766 | 25 |
LAD | AA | P | 20 | 27 | 38 | 45 |
-0.3% | Wide Range · 62 | N/A | |
| 4767 | 25 |
BOS | FCL | P | 20 | 35 | 45 | 40 |
-0.4% | High Risk · 94 | N/A | |
| 4768 | 25 |
NYM | FCL | P | 20 | 32 | 43 | 37 |
0.0% | High Risk · 90 | N/A | |
| 4769 | 25 |
MIN | DSL | P | 20 | 30 | 40 | 29 |
0.0% | Wide Range · 70 | N/A | |
| 4770 | 25 |
MIA | AAA | SS | 20 | 26 | 33 | 31 |
0.0% | Low Risk · 34 | N/A | |
| 4771 | 25 |
TOR | DSL | P | 20 | 34 | 48 | 38 |
0.0% | High Risk · 93 | N/A | |
| 4772 | 25 |
SEA | AAA | 1B | 20 | 28 | 37 | 41 |
+0.2% | Medium Risk · 56 | N/A | |
| 4773 | 25 |
ATL | DSL | P | 20 | 28 | 42 | 27 |
-0.1% | Medium Risk · 54 | N/A | |
| 4774 | 25 |
CLE | DSL | P | 20 | 33 | 44 | 37 |
0.0% | High Risk · 91 | N/A | |
| 4775 | IL(Rehab)25 |
PHI | FCL | PIL(Rehab) | 20 | 33 | 54 | 37 |
0.0% | High Risk · 92 | N/A | |
| 4776 | 25 |
BAL | DSL | IF | 20 | 32 | 43 | 37 |
0.0% | High Risk · 87 | N/A | |
| 4777 | 25 |
TOR | FCL | P | 20 | 28 | 39 | 29 |
0.0% | Wide Range · 64 | N/A | |
| 4778 | 25 |
PIT | DSL | P | 20 | 33 | 45 | 38 |
0.0% | High Risk · 93 | N/A | |
| 4779 | 25 |
TEX | Single-A | P | 20 | 32 | 42 | 39 |
0.0% | High Risk · 82 | N/A | |
| 4780 | IL(Rehab)25 |
CLE | ACL | PIL(Rehab) | 20 | 32 | 53 | 33 |
0.0% | High Risk · 78 | N/A | |
| 4781 | 25 |
DET | DSL | P | 20 | 33 | 44 | 37 |
-0.3% | High Risk · 91 | N/A | |
| 4782 | 25 |
DET | DSL | C | 20 | 30 | 40 | 34 |
-0.2% | High Risk · 75 | N/A | |
| 4783 | 25 |
BAL | DSL | C | 20 | 32 | 43 | 38 |
+0.1% | High Risk · 91 | N/A | |
| 4784 | IL(7-Day)25 |
CIN | AA | CIL(7-Day) | 20 | 27 | 37 | 44 |
0.0% | Wide Range · 61 | N/A | |
| 4785 | 25 |
CIN | Single-A | P | 20 | 33 | 45 | 39 |
0.0% | High Risk · 82 | N/A | |
| 4786 | 25 |
ATL | FCL | P | 20 | 29 | 40 | 28 |
-0.1% | Wide Range · 64 | N/A | |
| 4787 | 25 |
BOS | DSL | P | 20 | 29 | 40 | 29 |
-0.1% | Wide Range · 70 | N/A | |
| 4788 | 25 |
CLE | AA | P | 20 | 27 | 35 | 34 |
0.0% | Medium Risk · 51 | N/A | |
| 4789 | 25 |
CWS | ACL | P | 20 | 33 | 47 | 33 |
-0.4% | High Risk · 85 | N/A | |
| 4790 | 25 |
MIL | ACL | P | 20 | 29 | 39 | 26 |
0.0% | Wide Range · 64 | N/A | |
| 4791 | 25 |
TEX | AAA | C | 20 | 24 | 30 | 32 |
-0.3% | Low Risk · 26 | N/A | |
| 4792 | 25 |
ARI | AA | P | 20 | 27 | 36 | 34 |
0.0% | Low Risk · 40 | N/A | |
| 4793 | 25 |
TOR | DSL | P | 20 | 29 | 40 | 29 |
0.0% | Wide Range · 70 | N/A | |
| 4794 | 25 |
COL | AA | P | 20 | 26 | 34 | 30 |
0.0% | Medium Risk · 45 | N/A | |
| 4795 | 25 |
MIA | Single-A | P | 20 | 33 | 45 | 38 |
0.0% | High Risk · 82 | N/A | |
| 4796 | 25 |
TB | DSL | P | 20 | 34 | 44 | 39 |
0.0% | High Risk · 94 | N/A | |
| 4797 | 25 |
NYY | DSL | P | 20 | 28 | 41 | 29 |
0.0% | Wide Range · 60 | N/A | |
| 4798 | 25 |
SF | DSL | P | 20 | 34 | 54 | 37 |
0.0% | High Risk · 94 | N/A | |
| 4799 | 25 |
TOR | FCL | P | 20 | 28 | 39 | 30 |
0.0% | Wide Range · 64 | N/A | |
| 4800 | 25 |
MIL | ACL | P | 20 | 33 | 44 | 39 |
0.0% | High Risk · 93 | N/A | |
| 4801 | 25 |
TB | DSL | P | 20 | 32 | 44 | 36 |
0.0% | High Risk · 90 | N/A | |
| 4802 | 25 |
CHC | ACL | P | 20 | 28 | 41 | 29 |
0.0% | Wide Range · 64 | N/A | |
| 4803 | 25 |
PIT | DSL | P | 20 | 30 | 41 | 35 |
-0.4% | High Risk · 80 | N/A | |
| 4804 | 25 |
CWS | DSL | P | 20 | 32 | 43 | 37 |
-0.4% | High Risk · 91 | N/A | |
| 4805 | 25 |
LAA | DSL | P | 20 | 31 | 43 | 33 |
0.0% | High Risk · 80 | N/A | |
| 4806 | 25 |
TEX | ACL | P | 20 | 30 | 48 | 30 |
0.0% | Wide Range · 74 | N/A | |
| 4807 | IL(7-Day)25 |
TOR | Single-A | CIL(7-Day) | 20 | 31 | 41 | 38 |
0.0% | High Risk · 81 | N/A | |
| 4808 | 25 |
MIA | DSL | P | 20 | 27 | 38 | 31 |
-0.2% | Wide Range · 64 | N/A | |
| 4809 | 25 |
SF | DSL | OF | 20 | 31 | 43 | 36 |
0.0% | High Risk · 87 | N/A | |
| 4810 | 25 |
LAD | DSL | P | 20 | 28 | 40 | 30 |
0.0% | Wide Range · 70 | N/A | |
| 4811 | 25 |
PHI | FCL | P | 20 | 28 | 39 | 27 |
0.0% | Wide Range · 64 | N/A | |
| 4812 | IL(Rehab)24 |
NYM | FCL | PIL(Rehab) | 21 | 33 | 55 | 35 |
0.0% | High Risk · 81 | N/A | |
| 4813 | 24 |
SF | DSL | P | 20 | 29 | 45 | 27 |
0.0% | Wide Range · 60 | N/A | |
| 4814 | 24 |
CIN | DSL | P | 20 | 29 | 40 | 29 |
-0.1% | Wide Range · 70 | N/A | |
| 4815 | 24 |
NYM | DSL | P | 20 | 34 | 44 | 39 |
0.0% | High Risk · 94 | N/A | |
| 4816 | 24 |
CLE | DSL | P | 20 | 32 | 43 | 37 |
0.0% | High Risk · 91 | N/A | |
| 4817 | 24 |
MIN | DSL | P | 20 | 31 | 42 | 36 |
0.0% | High Risk · 81 | N/A | |
| 4818 | 24 |
WSH | Single-A | P | 20 | 31 | 44 | 37 |
0.0% | High Risk · 79 | N/A | |
| 4819 | 24 |
ARI | DSL | P | 20 | 29 | 40 | 33 |
0.0% | High Risk · 80 | N/A | |
| 4820 | 24 |
CLE | DSL | P | 20 | 32 | 44 | 37 |
-0.4% | High Risk · 91 | N/A | |
| 4821 | 24 |
ATL | DSL | P | 20 | 32 | 43 | 37 |
0.0% | High Risk · 91 | N/A | |
| 4822 | 24 |
TOR | FCL | P | 20 | 29 | 43 | 31 |
0.0% | Wide Range · 74 | N/A | |
| 4823 | 24 |
MIN | DSL | P | 20 | 31 | 42 | 35 |
0.0% | High Risk · 82 | N/A | |
| 4824 | 24 |
BAL | Single-A | P | 20 | 30 | 41 | 37 |
-0.3% | High Risk · 79 | N/A | |
| 4825 | 24 |
PIT | DSL | P | 20 | 28 | 39 | 30 |
0.0% | Wide Range · 70 | N/A | |
| 4826 | 24 |
MIA | DSL | P | 20 | 30 | 40 | 33 |
0.0% | High Risk · 80 | N/A | |
| 4827 | 24 |
BOS | DSL | C | 20 | 29 | 42 | 31 |
0.0% | Wide Range · 70 | N/A | |
| 4828 | 24 |
SF | AAA | P | 20 | 27 | 38 | 42 |
0.0% | Medium Risk · 57 | N/A | |
| 4829 | 24 |
KC | DSL | P | 20 | 27 | 37 | 27 |
-0.3% | Medium Risk · 50 | N/A | |
| 4830 | 24 |
WSH | AA | P | 20 | 23 | 30 | 38 |
0.0% | Low Risk · 27 | N/A | |
| 4831 | 24 |
NYY | FCL | P | 20 | 30 | 48 | 31 |
-0.1% | Wide Range · 74 | N/A | |
| 4832 | 24 |
DET | DSL | OF | 20 | 28 | 38 | 27 |
0.0% | Wide Range · 60 | N/A | |
| 4833 | 24 |
SEA | AAA | P | 20 | 27 | 42 | 48 |
+0.2% | Wide Range · 60 | N/A | |
| 4834 | 24 |
CHC | DSL | P | 20 | 31 | 42 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4835 | 24 |
BAL | DSL | P | 20 | 29 | 46 | 32 |
-0.1% | Wide Range · 74 | N/A | |
| 4836 | 24 |
CLE | DSL | P | 20 | 28 | 39 | 31 |
0.0% | Wide Range · 70 | N/A | |
| 4837 | 24 |
HOU | FCL | P | 20 | 28 | 39 | 28 |
0.0% | Wide Range · 64 | N/A | |
| 4838 | 24 |
KC | DSL | P | 20 | 26 | 37 | 28 |
-0.3% | Medium Risk · 50 | N/A | |
| 4839 | 24 |
DET | DSL | P | 20 | 32 | 44 | 37 |
-0.2% | High Risk · 91 | N/A | |
| 4840 | 24 |
SEA | Single-A | P | 20 | 29 | 40 | 34 |
0.0% | Wide Range · 66 | N/A | |
| 4841 | 24 |
BAL | AA | P | 20 | 27 | 38 | 38 |
0.0% | Medium Risk · 53 | N/A | |
| 4842 | 24 |
CIN | DSL | P | 20 | 34 | 47 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4843 | 24 |
DET | High-A | P | 20 | 26 | 37 | 38 |
-0.2% | Medium Risk · 44 | N/A | |
| 4844 | 24 |
BAL | DSL | P | 20 | 32 | 45 | 37 |
-0.5% | High Risk · 94 | N/A | |
| 4845 | 24 |
CIN | DSL | P | 20 | 32 | 43 | 36 |
-0.1% | High Risk · 90 | N/A | |
| 4846 | 24 |
NYY | FCL | P | 20 | 29 | 43 | 27 |
0.0% | Wide Range · 64 | N/A | |
| 4847 | 24 |
LAD | DSL | IF | 20 | 29 | 39 | 30 |
-0.4% | High Risk · 76 | N/A | |
| 4848 | 24 |
CLE | DSL | C | 20 | 30 | 43 | 34 |
-0.1% | High Risk · 76 | N/A | |
| 4849 | 24 |
ATH | ACL | P | 20 | 32 | 43 | 37 |
0.0% | High Risk · 91 | N/A | |
| 4850 | 24 |
ATH | DSL | IF | 20 | 28 | 39 | 30 |
0.0% | Wide Range · 72 | N/A | |
| 4851 | 24 |
STL | AAA | LF | 20 | 23 | 29 | 35 |
0.0% | Low Risk · 32 | N/A | |
| 4852 | 24 |
SD | DSL | P | 20 | 31 | 43 | 36 |
0.0% | High Risk · 90 | N/A | |
| 4853 | 24 |
STL | FCL | P | 20 | 29 | 40 | 32 |
+0.1% | Wide Range · 74 | N/A | |
| 4854 | 24 |
CIN | AAA | P | 20 | 25 | 32 | 34 |
-0.1% | Low Risk · 36 | N/A | |
| 4855 | 24 |
COL | AA | C | 20 | 27 | 37 | 42 |
0.0% | Medium Risk · 53 | N/A | |
| 4856 | 24 |
BOS | DSL | P | 20 | 33 | 44 | 38 |
0.0% | High Risk · 93 | N/A | |
| 4857 | 24 |
CLE | DSL | P | 20 | 32 | 44 | 38 |
0.0% | High Risk · 93 | N/A | |
| 4858 | 24 |
BOS | DSL | P | 20 | 32 | 43 | 36 |
0.0% | High Risk · 91 | N/A | |
| 4859 | 24 |
CHC | High-A | P | 20 | 31 | 41 | 38 |
0.0% | High Risk · 79 | N/A | |
| 4860 | 24 |
MIL | AA | P | 20 | 26 | 37 | 41 |
0.0% | Medium Risk · 43 | N/A | |
| 4861 | 24 |
SF | ACL | P | 20 | 27 | 37 | 26 |
0.0% | Medium Risk · 50 | N/A | |
| 4862 | 24 |
CHC | DSL | P | 20 | 29 | 40 | 34 |
0.0% | High Risk · 80 | N/A | |
| 4863 | 24 |
ATL | DSL | P | 20 | 33 | 44 | 39 |
0.0% | High Risk · 94 | N/A | |
| 4864 | IL(Rehab)24 |
CLE | ACL | PIL(Rehab) | 20 | 33 | 54 | 34 |
0.0% | High Risk · 88 | N/A | |
| 4865 | 24 |
LAA | ACL | P | 20 | 29 | 42 | 28 |
0.0% | Wide Range · 60 | N/A | |
| 4866 | 24 |
PIT | DSL | OF | 20 | 32 | 43 | 37 |
0.0% | High Risk · 89 | N/A | |
| 4867 | 24 |
CWS | AA | P | 20 | 28 | 38 | 43 |
-0.1% | Wide Range · 71 | N/A | |
| 4868 | 24 |
LAD | DSL | P | 20 | 32 | 43 | 37 |
0.0% | High Risk · 91 | N/A | |
| 4869 | 24 |
KC | DSL | P | 20 | 29 | 46 | 31 |
0.0% | Wide Range · 74 | N/A | |
| 4870 | 24 |
ATL | DSL | P | 20 | 29 | 40 | 29 |
0.0% | Wide Range · 70 | N/A | |
| 4871 | IL(Rehab)24 |
ATH | ACL | PIL(Rehab) | 20 | 30 | 49 | 33 |
0.0% | High Risk · 78 | N/A | |
| 4872 | 24 |
BOS | DSL | P | 20 | 31 | 41 | 33 |
0.0% | High Risk · 81 | N/A | |
| 4873 | 24 |
TB | FCL | P | 20 | 29 | 40 | 30 |
0.0% | Wide Range · 74 | N/A | |
| 4874 | 24 |
COL | DSL | P | 20 | 33 | 43 | 39 |
0.0% | High Risk · 94 | N/A | |
| 4875 | 24 |
SF | DSL | P | 20 | 31 | 42 | 36 |
0.0% | High Risk · 90 | N/A | |
| 4876 | 24 |
BOS | FCL | P | 20 | 32 | 44 | 38 |
0.0% | High Risk · 93 | N/A | |
| 4877 | 24 |
CHC | DSL | 2B | 20 | 29 | 39 | 32 |
-0.6% | High Risk · 75 | N/A | |
| 4878 | 24 |
MIN | AA | P | 20 | 27 | 42 | 45 |
+0.1% | Wide Range · 62 | N/A | |
| 4879 | 24 |
MIN | DSL | P | 20 | 33 | 43 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4880 | 24 |
HOU | DSL | P | 20 | 29 | 39 | 32 |
0.0% | High Risk · 80 | N/A | |
| 4881 | 24 |
BAL | DSL | 2B | 20 | 29 | 41 | 32 |
0.0% | High Risk · 75 | N/A | |
| 4882 | 24 |
SF | DSL | P | 20 | 33 | 43 | 39 |
0.0% | High Risk · 94 | N/A | |
| 4883 | 24 |
TEX | ACL | P | 20 | 29 | 39 | 23 |
0.0% | Wide Range · 64 | N/A | |
| 4884 | 24 |
CHC | DSL | SS | 20 | 30 | 41 | 35 |
0.0% | High Risk · 86 | N/A | |
| 4885 | 24 |
CIN | AA | P | 20 | 26 | 37 | 44 |
-0.1% | Wide Range · 63 | N/A | |
| 4886 | IL(Rehab)24 |
HOU | FCL | CIL(Rehab) | 20 | 28 | 46 | 34 |
0.0% | Wide Range · 71 | N/A | |
| 4887 | 24 |
WSH | DSL | P | 20 | 33 | 43 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4888 | 24 |
SD | ACL | P | 20 | 30 | 48 | 32 |
0.0% | High Risk · 75 | N/A | |
| 4889 | 24 |
LAD | DSL | P | 20 | 33 | 43 | 39 |
0.0% | High Risk · 94 | N/A | |
| 4890 | 24 |
DET | FCL | C | 20 | 27 | 37 | 27 |
0.0% | Medium Risk · 56 | N/A | |
| 4891 | 24 |
ATH | ACL | P | 20 | 28 | 39 | 28 |
0.0% | Wide Range · 64 | N/A | |
| 4892 | IL(Full Season)24 |
ARI | Single-A | PIL(Full Season) | 20 | 33 | 44 | 43 |
-0.5% | High Risk · 100 | N/A | |
| 4893 | 24 |
SD | DSL | P | 20 | 29 | 40 | 31 |
0.0% | High Risk · 80 | N/A | |
| 4894 | 24 |
TOR | DSL | P | 20 | 32 | 43 | 36 |
0.0% | High Risk · 91 | N/A | |
| 4895 | 24 |
CIN | DSL | IF | 20 | 31 | 42 | 36 |
-0.2% | High Risk · 91 | N/A | |
| 4896 | 24 |
STL | AAA | P | 20 | 30 | 42 | 49 |
0.0% | High Risk · 78 | N/A | |
| 4897 | 24 |
COL | DSL | P | 20 | 32 | 43 | 35 |
-0.3% | High Risk · 90 | N/A | |
| 4898 | 24 |
SF | DSL | P | 20 | 30 | 44 | 33 |
0.0% | High Risk · 80 | N/A | |
| 4899 | 24 |
MIL | DSL | P | 20 | 31 | 42 | 36 |
-0.1% | High Risk · 91 | N/A | |
| 4900 | 24 |
ATL | AA | P | 20 | 25 | 34 | 36 |
-0.2% | Low Risk · 39 | N/A | |
| 4901 | 24 |
PIT | FCL | P | 20 | 33 | 43 | 39 |
-0.2% | High Risk · 94 | N/A | |
| 4902 | 24 |
NYM | AA | P | 20 | 27 | 37 | 45 |
0.0% | Wide Range · 64 | N/A | |
| 4903 | 24 |
ATL | DSL | P | 20 | 34 | 45 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4904 | 24 |
SD | Single-A | P | 20 | 28 | 39 | 33 |
-0.1% | Wide Range · 65 | N/A | |
| 4905 | 24 |
ATL | FCL | P | 20 | 28 | 40 | 30 |
0.0% | Wide Range · 74 | N/A | |
| 4906 | 24 |
CHC | ACL | P | 20 | 26 | 36 | 23 |
-0.1% | Medium Risk · 56 | N/A | |
| 4907 | 24 |
CLE | DSL | P | 20 | 29 | 40 | 33 |
-0.3% | High Risk · 80 | N/A | |
| 4908 | 23 |
NYM | DSL | P | 20 | 31 | 41 | 34 |
0.0% | High Risk · 82 | N/A | |
| 4909 | 23 |
WSH | Single-A | C | 20 | 27 | 39 | 33 |
0.0% | Wide Range · 60 | N/A | |
| 4910 | 23 |
BOS | DSL | P | 20 | 32 | 43 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4911 | 23 |
CWS | DSL | P | 20 | 33 | 52 | 36 |
0.0% | High Risk · 94 | N/A | |
| 4912 | 23 |
PHI | DSL | P | 20 | 31 | 42 | 35 |
0.0% | High Risk · 90 | N/A | |
| 4913 | 23 |
LAD | DSL | P | 20 | 32 | 44 | 37 |
+0.3% | High Risk · 93 | N/A | |
| 4914 | 23 |
SEA | DSL | P | 20 | 31 | 42 | 36 |
-0.2% | High Risk · 91 | N/A | |
| 4915 | 23 |
NYY | DSL | P | 20 | 34 | 46 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4916 | 23 |
LAD | DSL | P | 20 | 33 | 43 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4917 | 23 |
BOS | DSL | OF | 20 | 30 | 41 | 36 |
+0.1% | High Risk · 87 | N/A | |
| 4918 | 23 |
KC | DSL | P | 20 | 28 | 38 | 32 |
-0.2% | High Risk · 80 | N/A | |
| 4919 | 23 |
BAL | AA | P | 20 | 26 | 35 | 38 |
-0.1% | Medium Risk · 53 | N/A | |
| 4920 | 23 |
CIN | ACL | P | 20 | 34 | 54 | 38 |
0.0% | High Risk · 100 | N/A | |
| 4921 | 23 |
NYY | FCL | P | 20 | 27 | 39 | 31 |
+0.2% | Wide Range · 74 | N/A | |
| 4922 | 23 |
PIT | FCL | P | 20 | 27 | 38 | 27 |
-0.3% | Wide Range · 64 | N/A | |
| 4923 | 23 |
CLE | DSL | P | 20 | 33 | 43 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4924 | 23 |
KC | DSL | P | 20 | 31 | 42 | 35 |
0.0% | High Risk · 90 | N/A | |
| 4925 | 23 |
KC | DSL | P | 20 | 32 | 43 | 37 |
0.0% | High Risk · 93 | N/A | |
| 4926 | 23 |
LAA | ACL | P | 20 | 33 | 43 | 39 |
0.0% | High Risk · 94 | N/A | |
| 4927 | 23 |
TEX | DSL | P | 20 | 32 | 43 | 37 |
-0.5% | High Risk · 93 | N/A | |
| 4928 | 23 |
ATH | DSL | P | 20 | 33 | 43 | 38 |
-0.3% | High Risk · 94 | N/A | |
| 4929 | 23 |
LAA | DSL | P | 20 | 30 | 41 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4930 | 23 |
ATL | DSL | P | 20 | 32 | 43 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4931 | 23 |
MIN | High-A | P | 20 | 26 | 40 | 37 |
0.0% | Medium Risk · 56 | N/A | |
| 4932 | 23 |
HOU | DSL | P | 20 | 32 | 48 | 35 |
0.0% | High Risk · 91 | N/A | |
| 4933 | 23 |
LAA | High-A | 1B | 20 | 25 | 36 | 41 |
-0.1% | Medium Risk · 45 | N/A | |
| 4934 | 23 |
WSH | High-A | C | 20 | 25 | 34 | 34 |
0.0% | Medium Risk · 43 | N/A | |
| 4935 | 23 |
SD | DSL | P | 20 | 32 | 42 | 38 |
-0.2% | High Risk · 94 | N/A | |
| 4936 | 23 |
PHI | Single-A | P | 20 | 30 | 41 | 37 |
0.0% | High Risk · 81 | N/A | |
| 4937 | 23 |
PIT | AA | P | 20 | 26 | 34 | 26 |
0.0% | Medium Risk · 43 | N/A | |
| 4938 | 23 |
ARI | ACL | C | 20 | 27 | 39 | 29 |
0.0% | Wide Range · 66 | N/A | |
| 4939 | 23 |
HOU | DSL | LF | 20 | 30 | 46 | 34 |
-0.4% | High Risk · 86 | N/A | |
| 4940 | 23 |
CLE | DSL | P | 20 | 32 | 46 | 36 |
0.0% | High Risk · 95 | N/A | |
| 4941 | 23 |
CIN | AA | P | 20 | 26 | 36 | 43 |
0.0% | Medium Risk · 51 | N/A | |
| 4942 | 23 |
CLE | AA | P | 20 | 27 | 37 | 41 |
0.0% | Wide Range · 63 | N/A | |
| 4943 | 23 |
ARI | DSL | P | 20 | 30 | 47 | 34 |
-0.2% | High Risk · 88 | N/A | |
| 4944 | 23 |
BOS | DSL | P | 20 | 33 | 43 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4945 | 23 |
NYY | FCL | P | 20 | 30 | 44 | 33 |
0.0% | High Risk · 84 | N/A | |
| 4946 | 23 |
CLE | DSL | P | 20 | 29 | 39 | 32 |
-0.2% | High Risk · 80 | N/A | |
| 4947 | 23 |
NYY | DSL | P | 20 | 31 | 51 | 32 |
0.0% | High Risk · 84 | N/A | |
| 4948 | 23 |
NYM | FCL | P | 20 | 26 | 36 | 23 |
0.0% | Medium Risk · 56 | N/A | |
| 4949 | 23 |
LAD | DSL | P | 20 | 32 | 42 | 38 |
0.0% | High Risk · 94 | N/A | |
| 4950 | 23 |
CIN | DSL | P | 20 | 32 | 43 | 37 |
-0.1% | High Risk · 93 | N/A | |
| 4951 | 23 |
TB | DSL | P | 20 | 31 | 42 | 36 |
0.0% | High Risk · 91 | N/A | |
| 4952 | 23 |
WSH | DSL | P | 20 | 32 | 43 | 35 |
-0.1% | High Risk · 91 | N/A | |
| 4953 | 23 |
CWS | DSL | P | 20 | 33 | 47 | 36 |
0.0% | High Risk · 100 | N/A | |
| 4954 | 23 |
SEA | DSL | P | 20 | 29 | 39 | 31 |
+0.3% | High Risk · 80 | N/A | |
| 4955 | 23 |
TEX | ACL | P | 20 | 26 | 37 | 29 |
+0.1% | Wide Range · 64 | N/A | |
| 4956 | 23 |
SEA | DSL | C | 20 | 27 | 40 | 30 |
0.0% | Wide Range · 69 | N/A | |
| 4957 | 23 |
PIT | DSL | P | 20 | 27 | 38 | 28 |
-0.1% | Wide Range · 70 | N/A | |
| 4958 | 23 |
CIN | DSL | P | 20 | 29 | 42 | 31 |
0.0% | High Risk · 80 | N/A | |
| 4959 | 23 |
CHC | DSL | P | 20 | 28 | 45 | 29 |
0.0% | Wide Range · 74 | N/A | |
| 4960 | 23 |
MIL | High-A | C | 20 | 24 | 35 | 38 |
+0.1% | Medium Risk · 43 | N/A | |
| 4961 | 23 |
CLE | DSL | P | 20 | 28 | 39 | 34 |
-0.1% | High Risk · 80 | N/A | |
| 4962 | 23 |
PIT | DSL | P | 20 | 33 | 48 | 36 |
0.0% | High Risk · 100 | N/A | |
| 4963 | 23 |
ATH | High-A | P | 20 | 24 | 35 | 30 |
0.0% | Low Risk · 34 | N/A | |
| 4964 | 23 |
BAL | AA | P | 20 | 26 | 35 | 34 |
-0.2% | Medium Risk · 53 | N/A | |
| 4965 | 23 |
SD | DSL | P | 20 | 30 | 42 | 36 |
0.0% | High Risk · 91 | N/A | |
| 4966 | 23 |
STL | AA | P | 20 | 27 | 37 | 41 |
0.0% | Wide Range · 63 | N/A | |
| 4967 | IL(Rehab)23 |
NYY | Single-A | PIL(Rehab) | 20 | 27 | 46 | 43 |
0.0% | Wide Range · 70 | N/A | |
| 4968 | 23 |
SD | DSL | P | 20 | 31 | 42 | 36 |
0.0% | High Risk · 91 | N/A | |
| 4969 | 23 |
PHI | DSL | P | 20 | 31 | 44 | 34 |
0.0% | High Risk · 90 | N/A | |
| 4970 | 23 |
ARI | DSL | OF | 20 | 30 | 41 | 35 |
0.0% | High Risk · 85 | N/A | |
| 4971 | 23 |
CHC | DSL | P | 20 | 28 | 39 | 31 |
0.0% | High Risk · 80 | N/A | |
| 4972 | 23 |
MIA | DSL | P | 20 | 32 | 42 | 37 |
0.0% | High Risk · 94 | N/A | |
| 4973 | 23 |
CWS | AAA | 2B | 20 | 23 | 30 | 38 |
-0.4% | Low Risk · 38 | N/A | |
| 4974 | 23 |
LAD | DSL | P | 20 | 30 | 41 | 36 |
0.0% | High Risk · 91 | N/A | |
| 4975 | 23 |
PHI | Single-A | 1B | 20 | 26 | 37 | 33 |
0.0% | Wide Range · 62 | N/A | |
| 4976 | 23 |
SD | DSL | P | 20 | 26 | 37 | 28 |
0.0% | Wide Range · 64 | N/A | |
| 4977 | 23 |
COL | ACL | 1B | 20 | 27 | 41 | 32 |
0.0% | Wide Range · 70 | N/A | |
| 4978 | 23 |
CLE | AAA | P | 20 | 25 | 33 | 26 |
-0.1% | Medium Risk · 47 | N/A | |
| 4979 | 23 |
CWS | DSL | P | 20 | 32 | 42 | 37 |
-0.1% | High Risk · 94 | N/A | |
| 4980 | 23 |
MIN | AA | P | 20 | 25 | 34 | 34 |
0.0% | Medium Risk · 47 | N/A | |
| 4981 | 23 |
CIN | DSL | P | 20 | 30 | 41 | 36 |
-0.2% | High Risk · 94 | N/A | |
| 4982 | 23 |
CHC | ACL | P | 20 | 27 | 37 | 24 |
0.0% | Wide Range · 64 | N/A | |
| 4983 | 23 |
CHC | ACL | P | 20 | 31 | 51 | 34 |
+0.1% | High Risk · 88 | N/A | |
| 4984 | 23 |
NYM | FCL | P | 20 | 26 | 36 | 23 |
-0.4% | Medium Risk · 56 | N/A | |
| 4985 | 23 |
CLE | DSL | P | 20 | 30 | 41 | 34 |
0.0% | High Risk · 90 | N/A | |
| 4986 | 22 |
NYY | AA | P | 20 | 24 | 33 | 37 |
0.0% | Medium Risk · 54 | N/A | |
| 4987 | 22 |
NYM | FCL | P | 20 | 30 | 41 | 33 |
-0.1% | High Risk · 84 | N/A | |
| 4988 | 22 |
CIN | DSL | C | 20 | 28 | 39 | 33 |
-0.4% | High Risk · 84 | N/A | |
| 4989 | 22 |
MIA | AA | P | 20 | 23 | 31 | 35 |
0.0% | Low Risk · 39 | N/A | |
| 4990 | 22 |
CIN | DSL | P | 20 | 30 | 41 | 34 |
0.0% | High Risk · 90 | N/A | |
| 4991 | 22 |
TOR | FCL | SS | 20 | 27 | 40 | 30 |
0.0% | Wide Range · 69 | N/A | |
| 4992 | 22 |
HOU | High-A | P | 20 | 25 | 38 | 42 |
-0.1% | Wide Range · 63 | N/A | |
| 4993 | 22 |
STL | DSL | P | 20 | 32 | 47 | 36 |
0.0% | High Risk · 100 | N/A | |
| 4994 | 22 |
KC | DSL | P | 20 | 30 | 42 | 34 |
-0.1% | High Risk · 90 | N/A | |
| 4995 | 22 |
NYM | DSL | P | 20 | 32 | 42 | 37 |
0.0% | High Risk · 94 | N/A | |
| 4996 | 22 |
ARI | ACL | P | 20 | 28 | 39 | 29 |
-0.2% | Wide Range · 74 | N/A | |
| 4997 | 22 |
NYM | DSL | P | 20 | 29 | 39 | 31 |
-0.5% | High Risk · 80 | N/A | |
| 4998 | 22 |
HOU | FCL | P | 20 | 25 | 35 | 26 |
0.0% | Medium Risk · 54 | N/A | |
| 4999 | 22 |
TEX | DSL | P | 20 | 29 | 40 | 31 |
0.0% | High Risk · 80 | N/A | |
| 5000 | 22 |
COL | High-A | P | 20 | 26 | 35 | 31 |
0.0% | Medium Risk · 51 | N/A | |
| 5001 | 22 |
DET | DSL | P | 20 | 28 | 38 | 32 |
0.0% | High Risk · 80 | N/A | |
| 5002 | 22 |
DET | DSL | P | 20 | 28 | 38 | 31 |
+0.1% | High Risk · 80 | N/A | |
| 5003 | 22 |
HOU | DSL | P | 20 | 28 | 38 | 31 |
0.0% | High Risk · 80 | N/A | |
| 5004 | 22 |
NYY | DSL | P | 20 | 28 | 44 | 28 |
-0.1% | Wide Range · 74 | N/A | |
| 5005 | 22 |
BOS | DSL | C | 20 | 27 | 38 | 31 |
0.0% | High Risk · 75 | N/A | |
| 5006 | 22 |
CWS | DSL | SS | 20 | 27 | 37 | 30 |
-0.2% | High Risk · 77 | N/A | |
| 5007 | 22 |
MIN | FCL | P | 20 | 29 | 40 | 33 |
0.0% | High Risk · 84 | N/A | |
| 5008 | IL(7-Day)22 |
STL | Single-A | PIL(7-Day) | 20 | 27 | 38 | 34 |
0.0% | Wide Range · 71 | N/A | |
| 5009 | 22 |
MIN | High-A | P | 20 | 24 | 35 | 40 |
0.0% | Medium Risk · 49 | N/A | |
| 5010 | 22 |
LAA | DSL | P | 20 | 29 | 40 | 35 |
0.0% | High Risk · 90 | N/A | |
| 5011 | 22 |
CLE | ACL | P | 20 | 29 | 47 | 31 |
-6.6% | High Risk · 75 | N/A | |
| 5012 | 22 |
LAD | DSL | P | 20 | 32 | 47 | 36 |
+0.1% | High Risk · 100 | N/A | |
| 5013 | 22 |
CIN | High-A | P | 20 | 24 | 34 | 35 |
-0.2% | Medium Risk · 48 | N/A | |
| 5014 | 22 |
CWS | DSL | P | 20 | 32 | 42 | 37 |
-0.4% | High Risk · 94 | N/A | |
| 5015 | IL(60-Day)22 |
CHC | AA | PIL(60-Day) | 20 | 29 | 40 | 45 |
0.0% | High Risk · 84 | N/A | |
| 5016 | 22 |
MIA | AA | P | 20 | 27 | 38 | 42 |
0.0% | Wide Range · 72 | N/A | |
| 5017 | 22 |
ATH | ACL | OF | 20 | 27 | 39 | 29 |
0.0% | Wide Range · 64 | N/A | |
| 5018 | 22 |
CHC | DSL | P | 20 | 30 | 41 | 35 |
0.0% | High Risk · 91 | N/A | |
| 5019 | 22 |
BAL | DSL | P | 20 | 32 | 49 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5020 | 22 |
ARI | DSL | P | 20 | 30 | 41 | 35 |
+0.1% | High Risk · 91 | N/A | |
| 5021 | 22 |
NYY | FCL | P | 20 | 27 | 38 | 25 |
0.0% | Wide Range · 64 | N/A | |
| 5022 | 22 |
CIN | AA | 1B | 20 | 22 | 29 | 28 |
0.0% | Low Risk · 33 | N/A | |
| 5023 | 22 |
CLE | DSL | P | 20 | 33 | 45 | 37 |
0.0% | High Risk · 94 | N/A | |
| 5024 | 22 |
NYM | DSL | P | 20 | 30 | 41 | 35 |
-0.4% | High Risk · 91 | N/A | |
| 5025 | 22 |
PHI | AAA | P | 20 | 26 | 42 | 49 |
0.0% | Medium Risk · 58 | N/A | |
| 5026 | 22 |
CWS | AAA | P | 20 | 24 | 31 | 32 |
0.0% | Low Risk · 36 | N/A | |
| 5027 | 22 |
WSH | Single-A | P | 20 | 24 | 34 | 30 |
0.0% | Medium Risk · 45 | N/A | |
| 5028 | 22 |
TOR | AAA | 2B | 20 | 22 | 28 | 31 |
0.0% | Low Risk · 35 | N/A | |
| 5029 | 22 |
ATL | DSL | P | 20 | 31 | 43 | 36 |
0.0% | High Risk · 93 | N/A | |
| 5030 | 22 |
LAD | AAA | C | 20 | 24 | 34 | 46 |
-0.1% | Medium Risk · 54 | N/A | |
| 5031 | 22 |
SEA | AA | P | 20 | 22 | 30 | 31 |
+0.3% | Medium Risk · 45 | N/A | |
| 5032 | 22 |
HOU | DSL | P | 20 | 29 | 41 | 36 |
0.0% | High Risk · 94 | N/A | |
| 5033 | 22 |
STL | DSL | C | 20 | 28 | 39 | 33 |
-0.1% | High Risk · 84 | N/A | |
| 5034 | 22 |
PHI | DSL | P | 20 | 32 | 51 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5035 | 22 |
MIN | High-A | P | 20 | 30 | 39 | 38 |
+0.2% | High Risk · 81 | N/A | |
| 5036 | 22 |
ATH | DSL | P | 20 | 30 | 41 | 34 |
+0.1% | High Risk · 91 | N/A | |
| 5037 | 22 |
ATH | ACL | P | 20 | 28 | 43 | 28 |
0.0% | Wide Range · 74 | N/A | |
| 5038 | IL(Rehab)22 |
CHC | ACL | PIL(Rehab) | 20 | 31 | 52 | 34 |
0.0% | High Risk · 92 | N/A | |
| 5039 | 22 |
TEX | DSL | P | 20 | 28 | 39 | 30 |
0.0% | High Risk · 80 | N/A | |
| 5040 | 22 |
WSH | AA | P | 22 | 26 | 44 | 48 |
0.0% | Wide Range · 67 | N/A | |
| 5041 | 22 |
TOR | DSL | P | 20 | 26 | 40 | 31 |
0.0% | Wide Range · 74 | N/A | |
| 5042 | 22 |
DET | AA | C | 20 | 23 | 31 | 35 |
-0.1% | Low Risk · 41 | N/A | |
| 5043 | 22 |
PIT | AAA | P | 20 | 23 | 29 | 27 |
+0.3% | Low Risk · 35 | N/A | |
| 5044 | 22 |
DET | Single-A | P | 20 | 31 | 44 | 36 |
0.0% | High Risk · 82 | N/A | |
| 5045 | 22 |
BOS | DSL | P | 20 | 30 | 42 | 35 |
0.0% | High Risk · 93 | N/A | |
| 5046 | 22 |
SF | DSL | P | 20 | 29 | 40 | 36 |
-0.1% | High Risk · 94 | N/A | |
| 5047 | IL(Rehab)22 |
WSH | FCL | SSIL(Rehab) | 20 | 27 | 41 | 31 |
0.0% | Wide Range · 73 | N/A | |
| 5048 | 22 |
CHC | AA | 2B | 20 | 26 | 39 | 44 |
0.0% | Wide Range · 67 | N/A | |
| 5049 | 22 |
TB | DSL | P | 20 | 27 | 37 | 30 |
-0.1% | High Risk · 80 | N/A | |
| 5050 | 22 |
SD | AAA | P | 20 | 21 | 28 | 36 |
-0.3% | Low Risk · 31 | N/A | |
| 5051 | 22 |
CWS | DSL | P | 20 | 30 | 42 | 35 |
0.0% | High Risk · 91 | N/A | |
| 5052 | 22 |
BOS | DSL | P | 20 | 30 | 42 | 35 |
-0.4% | High Risk · 93 | N/A | |
| 5053 | IL(Rehab)22 |
BOS | Single-A | PIL(Rehab) | 20 | 29 | 40 | 37 |
-0.3% | High Risk · 85 | N/A | |
| 5054 | 22 |
SEA | ACL | C | 20 | 26 | 38 | 29 |
0.0% | Wide Range · 69 | N/A | |
| 5055 | IL(Rehab)22 |
COL | ACL | OFIL(Rehab) | 20 | 29 | 40 | 35 |
0.0% | High Risk · 89 | N/A | |
| 5056 | 22 |
MIL | ACL | P | 20 | 27 | 38 | 28 |
0.0% | Wide Range · 74 | N/A | |
| 5057 | 22 |
MIN | DSL | P | 20 | 31 | 41 | 37 |
0.0% | High Risk · 94 | N/A | |
| 5058 | 22 |
SD | ACL | P | 20 | 25 | 35 | 19 |
0.0% | Medium Risk · 56 | N/A | |
| 5059 | 22 |
NYM | AA | P | 20 | 20 | 31 | 47 |
0.0% | Low Risk · 36 | N/A | |
| 5060 | 22 |
NYM | DSL | P | 20 | 31 | 42 | 36 |
0.0% | High Risk · 100 | N/A | |
| 5061 | 22 |
CHC | Single-A | C | 20 | 28 | 39 | 34 |
0.0% | High Risk · 77 | N/A | |
| 5062 | 22 |
DET | DSL | P | 20 | 25 | 35 | 24 |
0.0% | Medium Risk · 50 | N/A | |
| 5063 | 22 |
HOU | DSL | P | 20 | 29 | 40 | 36 |
0.0% | High Risk · 94 | N/A | |
| 5064 | 22 |
WSH | FCL | P | 20 | 27 | 42 | 29 |
0.0% | Wide Range · 74 | N/A | |
| 5065 | 22 |
TOR | DSL | P | 20 | 31 | 41 | 37 |
0.0% | High Risk · 94 | N/A | |
| 5066 | 22 |
MIL | DSL | OF | 20 | 29 | 41 | 35 |
0.0% | High Risk · 92 | N/A | |
| 5067 | 22 |
TEX | AAA | P | 20 | 21 | 29 | 37 |
0.0% | Low Risk · 29 | N/A | |
| 5068 | 22 |
ARI | DSL | SS | 20 | 29 | 40 | 34 |
0.0% | High Risk · 87 | N/A | |
| 5069 | 22 |
SD | DSL | P | 20 | 28 | 38 | 29 |
0.0% | High Risk · 80 | N/A | |
| 5070 | 22 |
ATL | DSL | P | 20 | 29 | 41 | 35 |
0.0% | High Risk · 94 | N/A | |
| 5071 | 22 |
DET | DSL | P | 20 | 30 | 44 | 35 |
0.0% | High Risk · 94 | N/A | |
| 5072 | IL(Rehab)22 |
MIN | FCL | PIL(Rehab) | 20 | 28 | 41 | 32 |
-0.1% | High Risk · 79 | N/A | |
| 5073 | 22 |
PIT | DSL | P | 20 | 24 | 35 | 27 |
-0.3% | Wide Range · 64 | N/A | |
| 5074 | 21 |
TOR | AA | P | 21 | 25 | 43 | 47 |
0.0% | Wide Range · 58 | N/A | |
| 5075 | 21 |
STL | DSL | P | 20 | 30 | 41 | 34 |
0.0% | High Risk · 91 | N/A | |
| 5076 | 21 |
NYM | DSL | P | 20 | 27 | 38 | 30 |
-0.1% | High Risk · 80 | N/A | |
| 5077 | 21 |
CWS | ACL | P | 20 | 24 | 40 | 29 |
-0.1% | Medium Risk · 51 | N/A | |
| 5078 | 21 |
LAD | DSL | P | 20 | 31 | 41 | 36 |
0.0% | High Risk · 94 | N/A | |
| 5079 | 21 |
NYM | DSL | P | 20 | 31 | 42 | 35 |
0.0% | High Risk · 93 | N/A | |
| 5080 | 21 |
MIL | DSL | P | 20 | 31 | 41 | 36 |
0.0% | High Risk · 94 | N/A | |
| 5081 | 21 |
MIA | AA | P | 20 | 23 | 32 | 36 |
-0.2% | Medium Risk · 51 | N/A | |
| 5082 | 21 |
MIN | AAA | P | 20 | 20 | 29 | 50 |
0.0% | Low Risk · 39 | N/A | |
| 5083 | 21 |
CIN | AA | P | 20 | 23 | 30 | 30 |
0.0% | Medium Risk · 47 | N/A | |
| 5084 | 21 |
SF | AA | P | 20 | 24 | 32 | 29 |
0.0% | Medium Risk · 45 | N/A | |
| 5085 | 21 |
NYY | DSL | C | 20 | 29 | 40 | 33 |
0.0% | High Risk · 87 | N/A | |
| 5086 | IL(Rehab)21 |
BAL | Single-A | LFIL(Rehab) | 20 | 27 | 46 | 40 |
0.0% | Wide Range · 74 | N/A | |
| 5087 | 21 |
CWS | High-A | P | 20 | 25 | 35 | 39 |
0.0% | Wide Range · 59 | N/A | |
| 5088 | 21 |
ATL | DSL | P | 20 | 29 | 41 | 34 |
0.0% | High Risk · 91 | N/A | |
| 5089 | 21 |
CHC | AA | 3B | 20 | 22 | 30 | 30 |
+0.1% | Low Risk · 32 | N/A | |
| 5090 | 21 |
NYM | DSL | P | 20 | 29 | 41 | 35 |
0.0% | High Risk · 94 | N/A | |
| 5091 | 21 |
TB | DSL | P | 20 | 24 | 35 | 23 |
0.0% | Medium Risk · 50 | N/A | |
| 5092 | 21 |
SF | AAA | P | 20 | 23 | 30 | 30 |
0.0% | Medium Risk · 48 | N/A | |
| 5093 | IL(7-Day)21 |
COL | AA | 3BIL(7-Day) | 22 | 28 | 44 | 50 |
0.0% | High Risk · 81 | N/A | |
| 5094 | 21 |
KC | High-A | C | 20 | 24 | 35 | 41 |
0.0% | Wide Range · 60 | N/A | |
| 5095 | 21 |
KC | DSL | P | 20 | 31 | 44 | 37 |
0.0% | High Risk · 100 | N/A | |
| 5096 | 21 |
TB | DSL | P | 20 | 31 | 41 | 36 |
0.0% | High Risk · 94 | N/A | |
| 5097 | IL(Rehab)21 |
DET | FCL | OFIL(Rehab) | 20 | 29 | 47 | 31 |
+0.1% | High Risk · 84 | N/A | |
| 5098 | 21 |
COL | DSL | P | 20 | 28 | 40 | 36 |
-0.2% | High Risk · 94 | N/A | |
| 5099 | 21 |
SF | ACL | OF | 20 | 28 | 46 | 28 |
0.0% | Wide Range · 73 | N/A | |
| 5100 | 21 |
NYY | FCL | P | 20 | 32 | 45 | 37 |
0.0% | High Risk · 100 | N/A | |
| 5101 | 21 |
TEX | DSL | P | 20 | 29 | 40 | 34 |
-0.2% | High Risk · 91 | N/A | |
| 5102 | IL(Rehab)21 |
TB | FCL | OFIL(Rehab) | 20 | 26 | 38 | 29 |
0.0% | Wide Range · 68 | N/A | |
| 5103 | 21 |
CWS | AA | P | 20 | 24 | 36 | 40 |
0.0% | Medium Risk · 58 | N/A | |
| 5104 | 21 |
ARI | AAA | P | 20 | 28 | 37 | 48 |
+0.1% | High Risk · 79 | N/A | |
| 5105 | 21 |
ATL | AA | SS | 20 | 23 | 33 | 42 |
0.0% | Medium Risk · 43 | N/A | |
| 5106 | 21 |
ATL | DSL | P | 20 | 31 | 41 | 37 |
0.0% | High Risk · 94 | N/A | |
| 5107 | 21 |
CLE | DSL | P | 20 | 31 | 42 | 36 |
0.0% | High Risk · 94 | N/A | |
| 5108 | 21 |
MIN | FCL | P | 20 | 26 | 38 | 28 |
-0.3% | Wide Range · 74 | N/A | |
| 5109 | 21 |
COL | AA | P | 20 | 25 | 34 | 32 |
-0.2% | Medium Risk · 46 | N/A | |
| 5110 | 21 |
LAA | High-A | P | 20 | 24 | 35 | 41 |
0.0% | Wide Range · 63 | N/A | |
| 5111 | 21 |
CLE | DSL | P | 20 | 31 | 42 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5112 | 21 |
SD | AAA | P | 20 | 21 | 28 | 33 |
-0.1% | Low Risk · 40 | N/A | |
| 5113 | 21 |
KC | DSL | P | 20 | 29 | 40 | 33 |
-0.6% | High Risk · 90 | N/A | |
| 5114 | 21 |
WSH | FCL | P | 20 | 26 | 38 | 24 |
0.0% | Wide Range · 64 | N/A | |
| 5115 | 21 |
KC | ACL | 2B | 20 | 28 | 39 | 33 |
0.0% | High Risk · 85 | N/A | |
| 5116 | 21 |
PIT | High-A | P | 20 | 24 | 34 | 32 |
0.0% | Medium Risk · 51 | N/A | |
| 5117 | 21 |
SEA | ACL | P | 20 | 30 | 50 | 30 |
0.0% | High Risk · 84 | N/A | |
| 5118 | 21 |
KC | DSL | P | 20 | 29 | 41 | 35 |
-0.2% | High Risk · 93 | N/A | |
| 5119 | 21 |
CIN | DSL | P | 20 | 31 | 45 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5120 | 21 |
NYM | Single-A | C | 20 | 27 | 37 | 33 |
0.0% | High Risk · 75 | N/A | |
| 5121 | 21 |
MIN | FCL | P | 20 | 27 | 43 | 28 |
0.0% | Wide Range · 75 | N/A | |
| 5122 | 21 |
COL | DSL | P | 20 | 31 | 41 | 36 |
0.0% | High Risk · 94 | N/A | |
| 5123 | 21 |
CWS | DSL | C | 20 | 29 | 40 | 34 |
0.0% | High Risk · 91 | N/A | |
| 5124 | 21 |
CIN | AA | P | 20 | 23 | 31 | 33 |
-0.1% | Medium Risk · 45 | N/A | |
| 5125 | IL(Rehab)21 |
STL | FCL | OFIL(Rehab) | 20 | 28 | 39 | 33 |
0.0% | High Risk · 83 | N/A | |
| 5126 | 21 |
ARI | AA | C | 20 | 22 | 31 | 39 |
-0.3% | Medium Risk · 44 | N/A | |
| 5127 | 21 |
CIN | DSL | P | 20 | 27 | 37 | 30 |
0.0% | High Risk · 80 | N/A | |
| 5128 | 21 |
BAL | DSL | P | 20 | 25 | 36 | 25 |
0.0% | Wide Range · 64 | N/A | |
| 5129 | 21 |
SEA | DSL | P | 20 | 32 | 50 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5130 | 21 |
CIN | ACL | P | 20 | 26 | 37 | 25 |
0.0% | Wide Range · 64 | N/A | |
| 5131 | 21 |
PHI | AA | P | 20 | 21 | 28 | 30 |
0.0% | Low Risk · 28 | N/A | |
| 5132 | IL(Rehab)21 |
PIT | FCL | PIL(Rehab) | 20 | 31 | 50 | 32 |
0.0% | High Risk · 82 | N/A | |
| 5133 | 21 |
CWS | ACL | P | 20 | 31 | 54 | 31 |
0.0% | High Risk · 87 | N/A | |
| 5134 | 21 |
NYM | DSL | P | 20 | 29 | 40 | 35 |
0.0% | High Risk · 94 | N/A | |
| 5135 | IL(Rehab)21 |
PHI | FCL | SSIL(Rehab) | 20 | 26 | 38 | 29 |
0.0% | Wide Range · 68 | N/A | |
| 5136 | 21 |
HOU | DSL | P | 20 | 31 | 46 | 36 |
0.0% | High Risk · 100 | N/A | |
| 5137 | IL(Rehab)21 |
BOS | FCL | PIL(Rehab) | 20 | 30 | 48 | 34 |
0.0% | High Risk · 92 | N/A | |
| 5138 | 21 |
BOS | DSL | P | 20 | 26 | 37 | 25 |
0.0% | Wide Range · 70 | N/A | |
| 5139 | 21 |
CLE | AA | P | 20 | 23 | 31 | 31 |
0.0% | Medium Risk · 47 | N/A | |
| 5140 | 21 |
SD | Single-A | P | 20 | 29 | 38 | 35 |
-0.1% | High Risk · 82 | N/A | |
| 5141 | 21 |
KC | Single-A | P | 20 | 29 | 39 | 35 |
-0.3% | High Risk · 82 | N/A | |
| 5142 | 21 |
TB | DSL | P | 20 | 27 | 38 | 29 |
-0.1% | High Risk · 80 | N/A | |
| 5143 | 21 |
LAD | DSL | P | 20 | 29 | 40 | 34 |
+0.1% | High Risk · 94 | N/A | |
| 5144 | 21 |
TB | FCL | P | 20 | 24 | 35 | 27 |
0.0% | Wide Range · 64 | N/A | |
| 5145 | 21 |
MIL | DSL | P | 20 | 31 | 47 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5146 | 21 |
DET | DSL | IF | 20 | 28 | 39 | 32 |
+0.1% | High Risk · 86 | N/A | |
| 5147 | 21 |
KC | DSL | SS | 20 | 26 | 37 | 29 |
0.0% | High Risk · 75 | N/A | |
| 5148 | 21 |
ATL | AA | P | 20 | 24 | 33 | 31 |
0.0% | Medium Risk · 52 | N/A | |
| 5149 | 21 |
SD | ACL | C | 20 | 27 | 53 | 37 |
0.0% | Wide Range · 75 | N/A | |
| 5150 | 21 |
CLE | ACL | P | 20 | 26 | 40 | 27 |
-0.1% | Wide Range · 74 | N/A | |
| 5151 | 21 |
LAD | ACL | P | 20 | 31 | 46 | 35 |
-0.4% | High Risk · 99 | N/A | |
| 5152 | 21 |
TB | DSL | P | 20 | 26 | 37 | 29 |
+0.4% | High Risk · 80 | N/A | |
| 5153 | 21 |
ATH | High-A | P | 20 | 22 | 31 | 33 |
0.0% | Medium Risk · 45 | N/A | |
| 5154 | 21 |
CIN | DSL | P | 20 | 27 | 37 | 29 |
0.0% | High Risk · 80 | N/A | |
| 5155 | 21 |
TB | DSL | P | 20 | 27 | 37 | 29 |
-0.4% | High Risk · 80 | N/A | |
| 5156 | 21 |
WSH | AA | P | 20 | 25 | 36 | 42 |
-0.1% | Wide Range · 73 | N/A | |
| 5157 | IL(7-Day)21 |
WSH | Single-A | PIL(7-Day) | 20 | 29 | 40 | 36 |
0.0% | High Risk · 87 | N/A | |
| 5158 | 21 |
DET | High-A | P | 20 | 28 | 38 | 37 |
+0.3% | High Risk · 81 | N/A | |
| 5159 | 20 |
MIA | DSL | P | 20 | 32 | 45 | 37 |
0.0% | High Risk · 100 | N/A | |
| 5160 | 20 |
SD | DSL | P | 20 | 29 | 48 | 32 |
0.0% | High Risk · 88 | N/A | |
| 5161 | 20 |
MIN | DSL | P | 20 | 29 | 41 | 34 |
0.0% | High Risk · 93 | N/A | |
| 5162 | 20 |
TOR | DSL | P | 20 | 33 | 48 | 36 |
-0.4% | High Risk · 100 | N/A | |
| 5163 | 20 |
NYM | AAA | P | 20 | 23 | 32 | 44 |
0.0% | Wide Range · 60 | N/A | |
| 5164 | 20 |
TB | AA | P | 20 | 22 | 29 | 32 |
0.0% | Low Risk · 38 | N/A | |
| 5165 | 20 |
CIN | DSL | P | 20 | 27 | 38 | 29 |
-0.3% | High Risk · 80 | N/A | |
| 5166 | 20 |
NYM | FCL | P | 20 | 26 | 37 | 28 |
0.0% | Wide Range · 74 | N/A | |
| 5167 | 20 |
SEA | DSL | P | 20 | 30 | 41 | 35 |
-0.1% | High Risk · 94 | N/A | |
| 5168 | 20 |
MIA | FCL | P | 20 | 32 | 45 | 37 |
0.0% | High Risk · 100 | N/A | |
| 5169 | 20 |
ARI | DSL | P | 20 | 31 | 49 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5170 | 20 |
PHI | AA | 3B | 20 | 22 | 29 | 31 |
0.0% | Medium Risk · 50 | N/A | |
| 5171 | 20 |
BAL | DSL | P | 20 | 30 | 41 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5172 | IL(7-Day)20 |
NYM | AA | PIL(7-Day) | 20 | 28 | 38 | 44 |
0.0% | High Risk · 80 | N/A | |
| 5173 | IL(Rehab)20 |
BOS | FCL | PIL(Rehab) | 20 | 29 | 44 | 33 |
0.0% | High Risk · 92 | N/A | |
| 5174 | 20 |
TB | DSL | P | 20 | 27 | 42 | 31 |
-0.2% | High Risk · 84 | N/A | |
| 5175 | 20 |
SF | ACL | SS | 20 | 26 | 36 | 29 |
0.0% | High Risk · 80 | N/A | |
| 5176 | 20 |
ARI | DSL | P | 20 | 30 | 42 | 35 |
-2.9% | High Risk · 100 | N/A | |
| 5177 | 20 |
BAL | FCL | P | 20 | 26 | 38 | 27 |
+0.2% | Wide Range · 74 | N/A | |
| 5178 | 20 |
CWS | DSL | P | 20 | 30 | 43 | 35 |
+0.2% | High Risk · 100 | N/A | |
| 5179 | 20 |
SF | DSL | P | 20 | 28 | 42 | 32 |
0.0% | High Risk · 88 | N/A | |
| 5180 | 20 |
TOR | DSL | P | 20 | 24 | 35 | 25 |
0.0% | Wide Range · 64 | N/A | |
| 5181 | 20 |
NYY | FCL | P | 20 | 25 | 36 | 24 |
0.0% | Wide Range · 64 | N/A | |
| 5182 | 20 |
MIL | DSL | P | 20 | 30 | 43 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5183 | IL(Rehab)20 |
TOR | Single-A | OFIL(Rehab) | 20 | 22 | 35 | 40 |
0.0% | Medium Risk · 48 | N/A | |
| 5184 | 20 |
KC | ACL | P | 20 | 30 | 42 | 35 |
+0.1% | High Risk · 99 | N/A | |
| 5185 | 20 |
MIN | DSL | P | 20 | 31 | 45 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5186 | 20 |
BAL | DSL | P | 20 | 26 | 41 | 26 |
0.0% | Wide Range · 74 | N/A | |
| 5187 | 20 |
MIL | DSL | P | 20 | 31 | 45 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5188 | 20 |
NYM | DSL | P | 20 | 32 | 44 | 36 |
0.0% | High Risk · 100 | N/A | |
| 5189 | 20 |
STL | FCL | P | 20 | 29 | 41 | 36 |
0.0% | High Risk · 100 | N/A | |
| 5190 | 20 |
NYY | DSL | C | 20 | 28 | 39 | 32 |
-0.1% | High Risk · 91 | N/A | |
| 5191 | 20 |
SD | ACL | P | 20 | 32 | 45 | 36 |
-0.4% | High Risk · 100 | N/A | |
| 5192 | 20 |
CLE | DSL | P | 20 | 29 | 44 | 32 |
0.0% | High Risk · 94 | N/A | |
| 5193 | IL(Rehab)20 |
DET | FCL | PIL(Rehab) | 20 | 28 | 39 | 34 |
-0.1% | High Risk · 92 | N/A | |
| 5194 | 20 |
WSH | FCL | P | 20 | 27 | 38 | 33 |
0.0% | High Risk · 88 | N/A | |
| 5195 | 20 |
ATH | DSL | P | 20 | 29 | 40 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5196 | 20 |
BAL | DSL | P | 20 | 30 | 40 | 35 |
0.0% | High Risk · 94 | N/A | |
| 5197 | 20 |
PHI | FCL | C | 20 | 26 | 40 | 28 |
0.0% | Wide Range · 73 | N/A | |
| 5198 | 20 |
CHC | ACL | P | 20 | 32 | 44 | 36 |
0.0% | High Risk · 100 | N/A | |
| 5199 | 20 |
SF | DSL | P | 20 | 30 | 46 | 34 |
-0.1% | High Risk · 100 | N/A | |
| 5200 | 20 |
COL | DSL | P | 20 | 25 | 36 | 27 |
0.0% | Wide Range · 74 | N/A | |
| 5201 | 20 |
SF | DSL | P | 20 | 24 | 35 | 24 |
0.0% | Wide Range · 64 | N/A | |
| 5202 | 20 |
KC | AA | P | 20 | 24 | 34 | 42 |
0.0% | Wide Range · 62 | N/A | |
| 5203 | 20 |
PHI | DSL | P | 20 | 30 | 43 | 35 |
-0.1% | High Risk · 100 | N/A | |
| 5204 | 20 |
STL | Single-A | P | 20 | 28 | 48 | 39 |
0.0% | High Risk · 76 | N/A | |
| 5205 | 20 |
TEX | Single-A | P | 20 | 29 | 38 | 34 |
0.0% | High Risk · 82 | N/A | |
| 5206 | 20 |
SF | AA | C | 20 | 24 | 35 | 41 |
0.0% | Wide Range · 69 | N/A | |
| 5207 | 20 |
DET | High-A | P | 20 | 22 | 32 | 33 |
+0.4% | Medium Risk · 49 | N/A | |
| 5208 | 20 |
NYY | DSL | P | 20 | 30 | 40 | 35 |
0.0% | High Risk · 94 | N/A | |
| 5209 | 20 |
PIT | DSL | P | 20 | 29 | 40 | 33 |
0.0% | High Risk · 95 | N/A | |
| 5210 | 20 |
LAA | High-A | P | 20 | 23 | 34 | 39 |
0.0% | Wide Range · 64 | N/A | |
| 5211 | 20 |
DET | DSL | P | 20 | 28 | 40 | 34 |
0.0% | High Risk · 93 | N/A | |
| 5212 | 20 |
SEA | DSL | P | 20 | 28 | 40 | 34 |
-0.1% | High Risk · 93 | N/A | |
| 5213 | 20 |
PIT | DSL | P | 20 | 27 | 38 | 34 |
0.0% | High Risk · 94 | N/A | |
| 5214 | 20 |
CLE | DSL | SS | 20 | 27 | 41 | 32 |
0.0% | High Risk · 85 | N/A | |
| 5215 | 20 |
ATL | FCL | P | 20 | 28 | 39 | 33 |
0.0% | High Risk · 90 | N/A | |
| 5216 | 20 |
LAA | ACL | 2B | 20 | 28 | 43 | 32 |
0.0% | High Risk · 89 | N/A | |
| 5217 | 20 |
BOS | AA | RF | 20 | 22 | 33 | 44 |
0.0% | Wide Range · 61 | N/A | |
| 5218 | 20 |
CIN | DSL | SS | 20 | 27 | 38 | 32 |
0.0% | High Risk · 85 | N/A | |
| 5219 | 20 |
KC | DSL | IF | 20 | 27 | 38 | 32 |
+0.1% | High Risk · 91 | N/A | |
| 5220 | 20 |
SD | DSL | P | 20 | 24 | 35 | 23 |
+0.1% | Wide Range · 64 | N/A | |
| 5221 | 20 |
SEA | ACL | P | 20 | 28 | 45 | 29 |
0.0% | High Risk · 84 | N/A | |
| 5222 | 20 |
NYY | DSL | P | 20 | 27 | 43 | 31 |
+0.2% | High Risk · 88 | N/A | |
| 5223 | 20 |
CIN | ACL | P | 20 | 28 | 40 | 31 |
0.0% | High Risk · 85 | N/A | |
| 5224 | 20 |
ARI | DSL | P | 20 | 29 | 39 | 35 |
0.0% | High Risk · 94 | N/A | |
| 5225 | 20 |
DET | AA | P | 20 | 20 | 28 | 35 |
0.0% | Low Risk · 41 | N/A | |
| 5226 | 20 |
SD | High-A | P | 20 | 23 | 32 | 34 |
0.0% | Medium Risk · 54 | N/A | |
| 5227 | 19 |
CIN | DSL | P | 20 | 29 | 39 | 35 |
0.0% | High Risk · 94 | N/A | |
| 5228 | 19 |
ATL | DSL | P | 20 | 29 | 39 | 34 |
-0.1% | High Risk · 94 | N/A | |
| 5229 | 19 |
KC | AAA | RF | 20 | 22 | 42 | 53 |
-0.3% | Medium Risk · 55 | N/A | |
| 5230 | 19 |
CWS | AAA | 2B | 20 | 20 | 28 | 37 |
0.0% | Low Risk · 37 | N/A | |
| 5231 | 19 |
CIN | AA | P | 20 | 25 | 36 | 41 |
0.0% | Wide Range · 74 | N/A | |
| 5232 | 19 |
MIA | DSL | P | 20 | 31 | 47 | 34 |
-0.1% | High Risk · 100 | N/A | |
| 5233 | 19 |
MIL | DSL | P | 20 | 29 | 41 | 35 |
-2.8% | High Risk · 100 | N/A | |
| 5234 | 19 |
PIT | FCL | P | 20 | 30 | 47 | 32 |
-0.3% | High Risk · 98 | N/A | |
| 5235 | 19 |
HOU | FCL | OF | 20 | 27 | 39 | 33 |
0.0% | High Risk · 88 | N/A | |
| 5236 | 19 |
STL | DSL | P | 20 | 30 | 43 | 33 |
-0.3% | High Risk · 100 | N/A | |
| 5237 | 19 |
LAA | ACL | CF | 20 | 29 | 41 | 35 |
0.0% | High Risk · 97 | N/A | |
| 5238 | 19 |
TEX | AA | P | 20 | 22 | 38 | 39 |
0.0% | Medium Risk · 56 | N/A | |
| 5239 | 19 |
KC | DSL | P | 20 | 29 | 41 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5240 | 19 |
TOR | Single-A | P | 20 | 22 | 31 | 29 |
0.0% | Medium Risk · 53 | N/A | |
| 5241 | 19 |
BAL | DSL | P | 20 | 31 | 42 | 35 |
-0.1% | High Risk · 100 | N/A | |
| 5242 | 19 |
BOS | DSL | P | 20 | 28 | 39 | 33 |
-0.1% | High Risk · 94 | N/A | |
| 5243 | 19 |
MIA | DSL | P | 20 | 25 | 37 | 26 |
-0.2% | Wide Range · 74 | N/A | |
| 5244 | 19 |
MIA | AAA | P | 20 | 24 | 36 | 44 |
0.0% | Wide Range · 69 | N/A | |
| 5245 | 19 |
DET | DSL | P | 20 | 24 | 34 | 23 |
-0.2% | Wide Range · 60 | N/A | |
| 5246 | 19 |
DET | AA | P | 20 | 22 | 34 | 46 |
-0.1% | Medium Risk · 57 | N/A | |
| 5247 | IL(Rehab)19 |
ARI | ACL | PIL(Rehab) | 20 | 30 | 50 | 32 |
0.0% | High Risk · 93 | N/A | |
| 5248 | 19 |
CHC | ACL | P | 20 | 31 | 44 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5249 | 19 |
BAL | DSL | P | 20 | 24 | 34 | 24 |
0.0% | Wide Range · 64 | N/A | |
| 5250 | 19 |
ATL | High-A | P | 20 | 22 | 33 | 32 |
0.0% | Medium Risk · 43 | N/A | |
| 5251 | 19 |
SEA | DSL | P | 20 | 29 | 41 | 33 |
-0.1% | High Risk · 100 | N/A | |
| 5252 | 19 |
LAD | DSL | P | 20 | 29 | 44 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5253 | 19 |
LAD | DSL | P | 20 | 23 | 34 | 23 |
+0.1% | Wide Range · 64 | N/A | |
| 5254 | 19 |
NYY | FCL | C | 20 | 28 | 40 | 36 |
0.0% | High Risk · 100 | N/A | |
| 5255 | 19 |
ATH | DSL | P | 20 | 28 | 40 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5256 | IL(Rehab)19 |
TB | FCL | PIL(Rehab) | 20 | 25 | 37 | 30 |
0.0% | High Risk · 78 | N/A | |
| 5257 | 19 |
NYM | DSL | P | 20 | 29 | 39 | 34 |
0.0% | High Risk · 94 | N/A | |
| 5258 | 19 |
MIN | AA | CF | 20 | 22 | 29 | 26 |
0.0% | Medium Risk · 48 | N/A | |
| 5259 | 19 |
PIT | DSL | P | 20 | 29 | 40 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5260 | 19 |
MIA | FCL | P | 20 | 29 | 42 | 34 |
0.0% | High Risk · 99 | N/A | |
| 5261 | 19 |
LAA | ACL | SS | 20 | 29 | 40 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5262 | 19 |
LAD | DSL | P | 20 | 30 | 49 | 31 |
+0.1% | High Risk · 98 | N/A | |
| 5263 | 19 |
LAD | ACL | P | 20 | 28 | 39 | 32 |
0.0% | High Risk · 90 | N/A | |
| 5264 | 19 |
PIT | AA | P | 21 | 27 | 43 | 47 |
0.0% | High Risk · 83 | N/A | |
| 5265 | 19 |
WSH | DSL | P | 20 | 27 | 44 | 30 |
0.0% | High Risk · 88 | N/A | |
| 5266 | IL(Full Season)19 |
ARI | Single-A | PIL(Full Season) | 20 | 30 | 44 | 37 |
0.0% | High Risk · 99 | N/A | |
| 5267 | 19 |
BOS | Single-A | P | 20 | 27 | 36 | 34 |
0.0% | High Risk · 82 | N/A | |
| 5268 | 19 |
BOS | High-A | P | 20 | 22 | 32 | 30 |
-0.3% | Medium Risk · 53 | N/A | |
| 5269 | 19 |
MIN | FCL | P | 20 | 30 | 40 | 36 |
0.0% | High Risk · 100 | N/A | |
| 5270 | 19 |
KC | DSL | P | 20 | 27 | 39 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5271 | 19 |
COL | ACL | P | 20 | 23 | 39 | 42 |
0.0% | Wide Range · 69 | N/A | |
| 5272 | IL(Rehab)19 |
SF | ACL | PIL(Rehab) | 20 | 26 | 38 | 30 |
0.0% | High Risk · 79 | N/A | |
| 5273 | 19 |
SEA | DSL | P | 20 | 28 | 39 | 34 |
-19.5% | High Risk · 94 | N/A | |
| 5274 | 19 |
CLE | AAA | P | 20 | 21 | 29 | 26 |
-0.8% | Medium Risk · 48 | N/A | |
| 5275 | 19 |
TOR | DSL | P | 20 | 27 | 40 | 32 |
0.0% | High Risk · 94 | N/A | |
| 5276 | 19 |
NYM | DSL | P | 20 | 27 | 38 | 33 |
0.0% | High Risk · 94 | N/A | |
| 5277 | 19 |
HOU | DSL | P | 20 | 28 | 39 | 34 |
-0.1% | High Risk · 100 | N/A | |
| 5278 | 19 |
PIT | DSL | P | 20 | 28 | 38 | 34 |
-0.2% | High Risk · 94 | N/A | |
| 5279 | 19 |
NYY | DSL | CF | 20 | 27 | 38 | 31 |
-0.1% | High Risk · 91 | N/A | |
| 5280 | 19 |
SF | AA | P | 20 | 22 | 33 | 41 |
0.0% | Wide Range · 65 | N/A | |
| 5281 | 19 |
WSH | DSL | P | 20 | 28 | 39 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5282 | 19 |
BAL | DSL | P | 20 | 30 | 41 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5283 | 19 |
WSH | FCL | P | 20 | 26 | 37 | 32 |
-0.3% | High Risk · 88 | N/A | |
| 5284 | 19 |
CIN | DSL | P | 20 | 30 | 44 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5285 | 19 |
SD | ACL | P | 20 | 30 | 50 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5286 | 19 |
HOU | DSL | P | 20 | 26 | 38 | 32 |
0.0% | High Risk · 94 | N/A | |
| 5287 | 18 |
CIN | DSL | P | 20 | 28 | 39 | 33 |
-0.1% | High Risk · 100 | N/A | |
| 5288 | 18 |
STL | FCL | P | 20 | 25 | 36 | 25 |
0.0% | Wide Range · 74 | N/A | |
| 5289 | 18 |
COL | AA | SS | 20 | 21 | 28 | 22 |
-0.1% | Medium Risk · 46 | N/A | |
| 5290 | 18 |
NYM | AAA | P | 20 | 24 | 42 | 51 |
0.0% | Wide Range · 75 | N/A | |
| 5291 | 18 |
ATH | DSL | P | 20 | 30 | 44 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5292 | 18 |
SD | AA | 2B | 20 | 22 | 32 | 40 |
0.0% | Wide Range · 62 | N/A | |
| 5293 | 18 |
KC | DSL | P | 20 | 28 | 39 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5294 | 18 |
LAD | ACL | P | 20 | 28 | 40 | 31 |
+0.2% | High Risk · 90 | N/A | |
| 5295 | 18 |
PIT | DSL | P | 20 | 28 | 38 | 34 |
0.0% | High Risk · 94 | N/A | |
| 5296 | 18 |
ATH | High-A | P | 20 | 21 | 31 | 32 |
0.0% | Medium Risk · 52 | N/A | |
| 5297 | 18 |
CIN | ACL | 3B | 20 | 26 | 37 | 31 |
0.0% | High Risk · 89 | N/A | |
| 5298 | 18 |
CIN | DSL | P | 20 | 24 | 35 | 27 |
0.0% | High Risk · 80 | N/A | |
| 5299 | 18 |
BOS | DSL | P | 20 | 25 | 35 | 26 |
0.0% | High Risk · 80 | N/A | |
| 5300 | 18 |
NYY | DSL | P | 20 | 28 | 39 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5301 | 18 |
MIL | DSL | P | 20 | 30 | 42 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5302 | 18 |
ARI | DSL | P | 20 | 28 | 38 | 34 |
0.0% | High Risk · 94 | N/A | |
| 5303 | 18 |
NYM | AAA | P | 20 | 20 | 27 | 30 |
-0.3% | Low Risk · 42 | N/A | |
| 5304 | 18 |
PHI | DSL | IF | 20 | 27 | 39 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5305 | 18 |
TOR | FCL | C | 20 | 28 | 40 | 35 |
-0.4% | High Risk · 100 | N/A | |
| 5306 | 18 |
BOS | FCL | P | 20 | 29 | 40 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5307 | 18 |
PIT | AA | P | 20 | 21 | 29 | 28 |
+0.1% | Medium Risk · 49 | N/A | |
| 5308 | 18 |
COL | DSL | P | 20 | 29 | 41 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5309 | 18 |
CHC | AAA | C | 20 | 23 | 33 | 44 |
0.0% | Wide Range · 73 | N/A | |
| 5310 | 18 |
MIA | DSL | OF | 20 | 27 | 39 | 31 |
0.0% | High Risk · 95 | N/A | |
| 5311 | 18 |
SEA | AAA | P | 20 | 18 | 24 | 40 |
0.0% | Low Risk · 36 | N/A | |
| 5312 | IL(Rehab)18 |
CLE | ACL | PIL(Rehab) | 20 | 24 | 35 | 29 |
0.0% | High Risk · 78 | N/A | |
| 5313 | 18 |
TB | DSL | OF | 20 | 24 | 35 | 25 |
0.0% | Wide Range · 69 | N/A | |
| 5314 | 18 |
NYY | DSL | P | 20 | 29 | 44 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5315 | 18 |
LAA | DSL | P | 20 | 27 | 39 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5316 | 18 |
SF | AA | P | 20 | 20 | 40 | 47 |
0.0% | Medium Risk · 54 | N/A | |
| 5317 | 18 |
CLE | DSL | P | 20 | 27 | 38 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5318 | 18 |
LAD | DSL | P | 20 | 29 | 43 | 32 |
-0.1% | High Risk · 100 | N/A | |
| 5319 | 18 |
BOS | FCL | P | 20 | 27 | 38 | 30 |
0.0% | High Risk · 90 | N/A | |
| 5320 | 18 |
CHC | DSL | 2B | 20 | 23 | 35 | 26 |
0.0% | Wide Range · 70 | N/A | |
| 5321 | 18 |
KC | DSL | P | 20 | 23 | 34 | 25 |
0.0% | Wide Range · 74 | N/A | |
| 5322 | IL(Rehab)18 |
WSH | FCL | 1BIL(Rehab) | 20 | 24 | 45 | 36 |
0.0% | High Risk · 78 | N/A | |
| 5323 | 18 |
MIN | AA | P | 20 | 20 | 28 | 28 |
0.0% | Medium Risk · 49 | N/A | |
| 5324 | 18 |
WSH | DSL | C | 20 | 26 | 37 | 31 |
-0.3% | High Risk · 91 | N/A | |
| 5325 | 18 |
MIL | DSL | P | 20 | 28 | 40 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5326 | 18 |
NYM | DSL | P | 20 | 28 | 39 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5327 | 18 |
SD | DSL | P | 20 | 28 | 40 | 34 |
+0.2% | High Risk · 100 | N/A | |
| 5328 | 18 |
CLE | AA | P | 20 | 23 | 34 | 41 |
0.0% | Wide Range · 74 | N/A | |
| 5329 | 18 |
WSH | DSL | P | 20 | 29 | 43 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5330 | 18 |
SF | DSL | P | 20 | 28 | 39 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5331 | 18 |
MIA | FCL | P | 20 | 28 | 40 | 35 |
0.0% | High Risk · 100 | N/A | |
| 5332 | 18 |
COL | Single-A | P | 20 | 26 | 36 | 33 |
+0.1% | High Risk · 82 | N/A | |
| 5333 | 18 |
COL | High-A | 2B | 20 | 21 | 32 | 37 |
0.0% | Wide Range · 68 | N/A | |
| 5334 | 18 |
MIA | DSL | P | 20 | 29 | 42 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5335 | 18 |
LAD | DSL | P | 20 | 29 | 39 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5336 | 18 |
PHI | AA | P | 20 | 22 | 33 | 41 |
0.0% | Wide Range · 74 | N/A | |
| 5337 | 18 |
CIN | DSL | P | 20 | 28 | 39 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5338 | 18 |
ARI | DSL | P | 20 | 23 | 34 | 25 |
+0.1% | Wide Range · 74 | N/A | |
| 5339 | IL(Rehab)18 |
BOS | FCL | PIL(Rehab) | 20 | 27 | 44 | 30 |
0.0% | High Risk · 92 | N/A | |
| 5340 | IL(Rehab)18 |
BAL | FCL | PIL(Rehab) | 20 | 28 | 43 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5341 | 18 |
LAD | DSL | P | 20 | 27 | 38 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5342 | 18 |
ATH | DSL | P | 20 | 27 | 39 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5343 | 17 |
BAL | DSL | P | 20 | 28 | 40 | 33 |
-0.2% | High Risk · 100 | N/A | |
| 5344 | IL(Rehab)17 |
NYY | Single-A | PIL(Rehab) | 20 | 23 | 46 | 42 |
-0.2% | Wide Range · 75 | N/A | |
| 5345 | 17 |
WSH | AA | P | 20 | 24 | 33 | 42 |
0.0% | High Risk · 76 | N/A | |
| 5346 | 17 |
BAL | DSL | P | 20 | 25 | 39 | 29 |
0.0% | High Risk · 88 | N/A | |
| 5347 | 17 |
HOU | FCL | P | 20 | 25 | 47 | 36 |
-0.1% | High Risk · 83 | N/A | |
| 5348 | 17 |
WSH | DSL | P | 20 | 27 | 38 | 32 |
-0.1% | High Risk · 100 | N/A | |
| 5349 | 17 |
MIL | DSL | P | 20 | 27 | 39 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5350 | 17 |
DET | AA | C | 20 | 20 | 33 | 45 |
0.0% | Wide Range · 65 | N/A | |
| 5351 | IL(7-Day)17 |
BAL | High-A | PIL(7-Day) | 20 | 26 | 36 | 36 |
0.0% | High Risk · 87 | N/A | |
| 5352 | 17 |
STL | DSL | P | 20 | 28 | 39 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5353 | 17 |
KC | DSL | OF | 20 | 27 | 38 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5354 | 17 |
DET | DSL | P | 20 | 28 | 44 | 32 |
-0.1% | High Risk · 100 | N/A | |
| 5355 | 17 |
COL | ACL | IF | 20 | 23 | 35 | 26 |
0.0% | Wide Range · 73 | N/A | |
| 5356 | 17 |
BAL | DSL | P | 20 | 27 | 40 | 31 |
-0.1% | High Risk · 94 | N/A | |
| 5357 | 17 |
CIN | ACL | P | 20 | 27 | 42 | 29 |
-0.3% | High Risk · 90 | N/A | |
| 5358 | 17 |
LAA | ACL | OF | 20 | 25 | 37 | 30 |
0.0% | High Risk · 85 | N/A | |
| 5359 | 17 |
LAD | DSL | P | 20 | 29 | 39 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5360 | 17 |
CLE | ACL | 2B | 20 | 26 | 37 | 31 |
+0.1% | High Risk · 94 | N/A | |
| 5361 | IL(Rehab)17 |
DET | FCL | CIL(Rehab) | 20 | 25 | 36 | 29 |
0.0% | High Risk · 83 | N/A | |
| 5362 | 17 |
SD | AAA | P | 20 | 19 | 29 | 32 |
-0.3% | Low Risk · 40 | N/A | |
| 5363 | 17 |
SD | ACL | P | 20 | 29 | 41 | 33 |
-0.4% | High Risk · 100 | N/A | |
| 5364 | 17 |
BOS | DSL | P | 20 | 27 | 39 | 33 |
+0.2% | High Risk · 100 | N/A | |
| 5365 | 17 |
ATH | ACL | P | 20 | 28 | 43 | 31 |
-0.1% | High Risk · 99 | N/A | |
| 5366 | 17 |
TB | DSL | P | 20 | 23 | 34 | 24 |
-0.1% | Wide Range · 74 | N/A | |
| 5367 | 17 |
PHI | High-A | 1B | 20 | 21 | 32 | 37 |
-0.3% | Wide Range · 69 | N/A | |
| 5368 | 17 |
NYM | AA | P | 20 | 23 | 36 | 43 |
0.0% | High Risk · 78 | N/A | |
| 5369 | 17 |
STL | AA | P | 20 | 21 | 35 | 44 |
0.0% | Wide Range · 70 | N/A | |
| 5370 | 17 |
LAA | ACL | 3B | 20 | 25 | 37 | 29 |
0.0% | High Risk · 85 | N/A | |
| 5371 | 17 |
LAA | AA | OF | 20 | 20 | 28 | 32 |
+0.2% | Medium Risk · 51 | N/A | |
| 5372 | 17 |
SEA | ACL | SS | 20 | 24 | 35 | 29 |
-0.5% | High Risk · 85 | N/A | |
| 5373 | 17 |
PHI | DSL | P | 20 | 29 | 43 | 33 |
-0.2% | High Risk · 100 | N/A | |
| 5374 | 17 |
KC | ACL | P | 20 | 27 | 39 | 33 |
0.0% | High Risk · 99 | N/A | |
| 5375 | 17 |
SD | AAA | 2B | 20 | 17 | 24 | 38 |
-0.1% | Low Risk · 36 | N/A | |
| 5376 | IL(Rehab)17 |
LAA | ACL | PIL(Rehab) | 20 | 26 | 41 | 31 |
0.0% | High Risk · 92 | N/A | |
| 5377 | 17 |
NYM | DSL | P | 20 | 28 | 38 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5378 | 17 |
TB | DSL | P | 20 | 24 | 35 | 30 |
-0.3% | High Risk · 88 | N/A | |
| 5379 | 17 |
ARI | DSL | P | 20 | 23 | 34 | 23 |
-0.2% | Wide Range · 74 | N/A | |
| 5380 | 17 |
KC | ACL | P | 20 | 29 | 40 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5381 | 17 |
PIT | DSL | P | 20 | 28 | 42 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5382 | 17 |
TEX | High-A | P | 20 | 25 | 42 | 42 |
0.0% | High Risk · 79 | N/A | |
| 5383 | 17 |
ARI | AA | P | 20 | 26 | 35 | 43 |
0.0% | High Risk · 89 | N/A | |
| 5384 | 17 |
SEA | ACL | 2B | 20 | 24 | 34 | 27 |
0.0% | High Risk · 80 | N/A | |
| 5385 | 17 |
SD | ACL | C | 20 | 25 | 36 | 29 |
0.0% | High Risk · 85 | N/A | |
| 5386 | 17 |
SF | DSL | P | 20 | 29 | 42 | 33 |
-0.1% | High Risk · 100 | N/A | |
| 5387 | 17 |
LAD | DSL | P | 20 | 28 | 40 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5388 | IL(Full Season)17 |
ATL | Single-A | PIL(Full Season) | 20 | 27 | 38 | 36 |
0.0% | High Risk · 99 | N/A | |
| 5389 | 17 |
HOU | DSL | P | 20 | 27 | 39 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5390 | 17 |
CIN | ACL | P | 20 | 27 | 39 | 34 |
0.0% | High Risk · 100 | N/A | |
| 5391 | 17 |
SF | DSL | P | 20 | 26 | 38 | 32 |
+0.1% | High Risk · 100 | N/A | |
| 5392 | 17 |
HOU | DSL | P | 20 | 26 | 38 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5393 | 17 |
KC | DSL | P | 20 | 26 | 37 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5394 | 17 |
TOR | DSL | P | 20 | 28 | 43 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5395 | 17 |
MIL | DSL | P | 20 | 25 | 36 | 31 |
-0.2% | High Risk · 94 | N/A | |
| 5396 | 17 |
COL | ACL | P | 20 | 25 | 37 | 30 |
0.0% | High Risk · 88 | N/A | |
| 5397 | 17 |
DET | AA | 2B | 20 | 17 | 24 | 32 |
0.0% | Low Risk · 32 | N/A | |
| 5398 | 17 |
TEX | DSL | P | 20 | 26 | 41 | 28 |
-0.1% | High Risk · 89 | N/A | |
| 5399 | 17 |
CLE | DSL | P | 20 | 27 | 39 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5400 | 16 |
TOR | DSL | P | 20 | 24 | 36 | 29 |
0.0% | High Risk · 88 | N/A | |
| 5401 | 16 |
NYM | DSL | P | 20 | 27 | 39 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5402 | 16 |
WSH | DSL | P | 20 | 26 | 37 | 30 |
0.0% | High Risk · 94 | N/A | |
| 5403 | 16 |
CLE | DSL | P | 20 | 27 | 38 | 32 |
-0.1% | High Risk · 100 | N/A | |
| 5404 | 16 |
CLE | DSL | P | 20 | 26 | 37 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5405 | IL(Rehab)16 |
BAL | FCL | PIL(Rehab) | 20 | 28 | 49 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5406 | 16 |
ATL | DSL | P | 20 | 27 | 38 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5407 | 16 |
ATH | DSL | P | 20 | 28 | 40 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5408 | 16 |
NYY | DSL | P | 20 | 27 | 44 | 29 |
0.0% | High Risk · 98 | N/A | |
| 5409 | 16 |
SD | High-A | P | 20 | 24 | 42 | 42 |
+0.2% | High Risk · 78 | N/A | |
| 5410 | 16 |
LAA | ACL | 2B | 20 | 24 | 35 | 27 |
0.0% | High Risk · 79 | N/A | |
| 5411 | 16 |
TOR | Single-A | P | 20 | 21 | 36 | 37 |
0.0% | Wide Range · 68 | N/A | |
| 5412 | 16 |
SD | DSL | P | 20 | 26 | 37 | 31 |
-0.5% | High Risk · 100 | N/A | |
| 5413 | 16 |
NYM | DSL | P | 20 | 27 | 39 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5414 | 16 |
LAA | DSL | P | 20 | 27 | 39 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5415 | 16 |
WSH | FCL | P | 20 | 26 | 39 | 31 |
-0.3% | High Risk · 98 | N/A | |
| 5416 | 16 |
ATH | DSL | P | 20 | 29 | 42 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5417 | IL(7-Day)16 |
PHI | AA | PIL(7-Day) | 20 | 23 | 33 | 41 |
0.0% | High Risk · 80 | N/A | |
| 5418 | 16 |
DET | DSL | P | 20 | 27 | 38 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5419 | 16 |
TEX | AAA | P | 20 | 19 | 30 | 36 |
0.0% | Medium Risk · 50 | N/A | |
| 5420 | 16 |
BOS | DSL | P | 20 | 27 | 37 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5421 | 16 |
LAD | DSL | P | 20 | 27 | 38 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5422 | 16 |
DET | DSL | P | 20 | 27 | 38 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5423 | 16 |
CIN | DSL | P | 20 | 26 | 38 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5424 | 16 |
SF | DSL | P | 20 | 27 | 48 | 28 |
0.0% | High Risk · 98 | N/A | |
| 5425 | 16 |
SF | DSL | P | 20 | 26 | 38 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5426 | 16 |
TB | AA | P | 20 | 20 | 29 | 28 |
-0.3% | Medium Risk · 55 | N/A | |
| 5427 | 16 |
LAA | AAA | P | 20 | 19 | 27 | 27 |
0.0% | Medium Risk · 50 | N/A | |
| 5428 | 16 |
MIA | DSL | P | 20 | 28 | 39 | 32 |
-0.1% | High Risk · 100 | N/A | |
| 5429 | 16 |
BOS | DSL | P | 20 | 26 | 37 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5430 | 16 |
BOS | DSL | P | 20 | 28 | 41 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5431 | 16 |
BOS | DSL | P | 20 | 26 | 40 | 30 |
0.0% | High Risk · 98 | N/A | |
| 5432 | 16 |
CHC | DSL | P | 20 | 27 | 37 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5433 | 16 |
ATH | AAA | P | 20 | 22 | 31 | 44 |
0.0% | High Risk · 78 | N/A | |
| 5434 | 16 |
NYY | DSL | P | 20 | 27 | 39 | 32 |
-0.4% | High Risk · 100 | N/A | |
| 5435 | 16 |
ARI | AA | P | 20 | 21 | 30 | 32 |
+0.1% | Medium Risk · 56 | N/A | |
| 5436 | 16 |
SEA | DSL | P | 20 | 26 | 37 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5437 | 16 |
SD | DSL | P | 20 | 24 | 35 | 28 |
0.0% | High Risk · 88 | N/A | |
| 5438 | 16 |
SF | ACL | P | 20 | 26 | 42 | 29 |
0.0% | High Risk · 98 | N/A | |
| 5439 | 16 |
PIT | DSL | P | 20 | 25 | 39 | 28 |
0.0% | High Risk · 89 | N/A | |
| 5440 | 16 |
HOU | High-A | P | 20 | 22 | 33 | 35 |
0.0% | Wide Range · 73 | N/A | |
| 5441 | 16 |
NYY | DSL | P | 20 | 25 | 37 | 31 |
-0.1% | High Risk · 100 | N/A | |
| 5442 | IL(Rehab)16 |
LAD | ACL | PIL(Rehab) | 20 | 25 | 43 | 32 |
-0.1% | High Risk · 95 | N/A | |
| 5443 | 16 |
CIN | DSL | P | 20 | 27 | 37 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5444 | 16 |
DET | DSL | SS | 20 | 25 | 37 | 31 |
-0.2% | High Risk · 100 | N/A | |
| 5445 | 16 |
COL | DSL | P | 20 | 27 | 37 | 33 |
-0.1% | High Risk · 100 | N/A | |
| 5446 | 16 |
SEA | ACL | P | 20 | 26 | 37 | 31 |
0.0% | High Risk · 99 | N/A | |
| 5447 | 16 |
DET | AA | P | 20 | 18 | 25 | 30 |
0.0% | Medium Risk · 52 | N/A | |
| 5448 | 16 |
PIT | AAA | 2B | 20 | 20 | 29 | 36 |
-0.7% | Wide Range · 64 | N/A | |
| 5449 | 16 |
HOU | High-A | P | 20 | 20 | 29 | 29 |
0.0% | Medium Risk · 54 | N/A | |
| 5450 | 16 |
PIT | DSL | P | 20 | 26 | 38 | 31 |
-0.3% | High Risk · 100 | N/A | |
| 5451 | 16 |
MIA | FCL | P | 20 | 26 | 41 | 28 |
0.0% | High Risk · 90 | N/A | |
| 5452 | 16 |
BOS | DSL | P | 20 | 27 | 37 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5453 | 16 |
HOU | DSL | P | 20 | 25 | 36 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5454 | 15 |
LAD | ACL | P | 20 | 27 | 41 | 30 |
0.0% | High Risk · 99 | N/A | |
| 5455 | 15 |
STL | DSL | 1B | 20 | 25 | 37 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5456 | 15 |
ATL | FCL | P | 20 | 25 | 37 | 28 |
0.0% | High Risk · 90 | N/A | |
| 5457 | 15 |
SEA | DSL | P | 20 | 27 | 39 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5458 | 15 |
HOU | FCL | SS | 20 | 25 | 36 | 30 |
-0.4% | High Risk · 95 | N/A | |
| 5459 | 15 |
CLE | DSL | P | 20 | 26 | 37 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5460 | 15 |
PIT | DSL | P | 20 | 25 | 37 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5461 | 15 |
MIA | FCL | P | 20 | 26 | 38 | 30 |
0.0% | High Risk · 99 | N/A | |
| 5462 | 15 |
ARI | DSL | P | 20 | 25 | 36 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5463 | 15 |
SEA | Single-A | P | 20 | 24 | 41 | 37 |
0.0% | High Risk · 88 | N/A | |
| 5464 | 15 |
LAD | DSL | P | 20 | 26 | 37 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5465 | 15 |
DET | DSL | P | 20 | 26 | 37 | 30 |
-0.1% | High Risk · 100 | N/A | |
| 5466 | 15 |
TEX | ACL | P | 20 | 25 | 37 | 27 |
0.0% | High Risk · 89 | N/A | |
| 5467 | 15 |
LAD | ACL | P | 20 | 27 | 37 | 32 |
+0.1% | High Risk · 100 | N/A | |
| 5468 | 15 |
DET | DSL | P | 20 | 26 | 38 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5469 | 15 |
ARI | DSL | P | 20 | 26 | 41 | 28 |
0.0% | High Risk · 98 | N/A | |
| 5470 | 15 |
MIL | DSL | P | 20 | 25 | 36 | 30 |
-0.1% | High Risk · 100 | N/A | |
| 5471 | 15 |
HOU | DSL | P | 20 | 27 | 37 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5472 | 15 |
ARI | AA | 3B | 20 | 18 | 29 | 40 |
-0.2% | Wide Range · 59 | N/A | |
| 5473 | 15 |
COL | DSL | P | 20 | 26 | 37 | 32 |
-0.3% | High Risk · 100 | N/A | |
| 5474 | 15 |
KC | AAA | C | 20 | 19 | 29 | 42 |
0.0% | Wide Range · 72 | N/A | |
| 5475 | 15 |
WSH | Single-A | P | 20 | 22 | 36 | 37 |
0.0% | High Risk · 77 | N/A | |
| 5476 | 15 |
WSH | FCL | P | 20 | 20 | 38 | 29 |
0.0% | Wide Range · 75 | N/A | |
| 5477 | 15 |
LAD | DSL | P | 20 | 26 | 37 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5478 | 15 |
SF | High-A | P | 20 | 21 | 32 | 38 |
+0.1% | Wide Range · 75 | N/A | |
| 5479 | 15 |
MIN | AAA | P | 20 | 18 | 24 | 29 |
-0.2% | Medium Risk · 53 | N/A | |
| 5480 | 15 |
NYY | DSL | P | 20 | 27 | 41 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5481 | 15 |
PIT | DSL | P | 20 | 25 | 37 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5482 | 15 |
CWS | DSL | P | 20 | 27 | 37 | 32 |
+0.3% | High Risk · 100 | N/A | |
| 5483 | 15 |
BAL | DSL | P | 20 | 27 | 42 | 29 |
0.0% | High Risk · 99 | N/A | |
| 5484 | 15 |
ATH | DSL | P | 20 | 26 | 43 | 29 |
0.0% | High Risk · 98 | N/A | |
| 5485 | 15 |
PHI | DSL | P | 20 | 26 | 37 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5486 | 15 |
LAA | ACL | 1B | 20 | 24 | 36 | 30 |
-0.5% | High Risk · 95 | N/A | |
| 5487 | IL(Rehab)15 |
BAL | FCL | PIL(Rehab) | 20 | 24 | 36 | 27 |
0.0% | High Risk · 88 | N/A | |
| 5488 | 15 |
ATH | DSL | P | 20 | 26 | 38 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5489 | 15 |
ARI | DSL | P | 20 | 25 | 37 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5490 | IL(60-Day)15 |
SF | AA | PIL(60-Day) | 20 | 20 | 30 | 42 |
0.0% | High Risk · 78 | N/A | |
| 5491 | 15 |
CWS | DSL | P | 20 | 27 | 37 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5492 | 15 |
CIN | DSL | P | 20 | 27 | 38 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5493 | 15 |
PIT | DSL | P | 20 | 25 | 36 | 30 |
+0.2% | High Risk · 100 | N/A | |
| 5494 | 15 |
BOS | FCL | P | 20 | 27 | 40 | 31 |
-0.1% | High Risk · 100 | N/A | |
| 5495 | 15 |
CHC | AA | P | 20 | 24 | 34 | 42 |
0.0% | High Risk · 89 | N/A | |
| 5496 | 15 |
TB | DSL | P | 20 | 25 | 37 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5497 | 15 |
SF | DSL | P | 20 | 27 | 41 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5498 | 15 |
STL | DSL | P | 20 | 26 | 37 | 32 |
-0.3% | High Risk · 100 | N/A | |
| 5499 | 15 |
CIN | DSL | P | 20 | 27 | 37 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5500 | 15 |
DET | DSL | P | 20 | 26 | 42 | 28 |
0.0% | High Risk · 98 | N/A | |
| 5501 | IL(Rehab)15 |
TB | FCL | CIL(Rehab) | 20 | 23 | 35 | 28 |
0.0% | High Risk · 89 | N/A | |
| 5502 | 15 |
HOU | DSL | P | 20 | 25 | 37 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5503 | 15 |
WSH | DSL | P | 20 | 26 | 37 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5504 | 15 |
CHC | ACL | P | 20 | 26 | 41 | 28 |
0.0% | High Risk · 98 | N/A | |
| 5505 | 15 |
HOU | DSL | P | 20 | 24 | 36 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5506 | 15 |
TEX | DSL | P | 20 | 26 | 36 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5507 | IL(Rehab)15 |
CLE | ACL | 2BIL(Rehab) | 20 | 21 | 40 | 33 |
+0.1% | High Risk · 78 | N/A | |
| 5508 | 15 |
LAA | AA | P | 20 | 19 | 42 | 50 |
0.0% | Wide Range · 68 | N/A | |
| 5509 | 14 |
TOR | DSL | P | 20 | 26 | 36 | 32 |
0.0% | High Risk · 100 | N/A | |
| 5510 | 14 |
DET | AAA | P | 20 | 15 | 24 | 32 |
-0.2% | Low Risk · 36 | N/A | |
| 5511 | 14 |
TEX | DSL | P | 20 | 26 | 36 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5512 | 14 |
CHC | DSL | P | 20 | 23 | 35 | 26 |
+0.1% | High Risk · 88 | N/A | |
| 5513 | 14 |
DET | FCL | C | 20 | 22 | 33 | 25 |
0.0% | High Risk · 79 | N/A | |
| 5514 | 14 |
PHI | AA | P | 20 | 21 | 30 | 41 |
0.0% | High Risk · 78 | N/A | |
| 5515 | 14 |
SD | ACL | P | 20 | 22 | 33 | 28 |
0.0% | High Risk · 88 | N/A | |
| 5516 | 14 |
HOU | DSL | P | 20 | 25 | 37 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5517 | 14 |
WSH | FCL | P | 20 | 25 | 38 | 29 |
0.0% | High Risk · 98 | N/A | |
| 5518 | 14 |
SF | DSL | P | 20 | 22 | 33 | 27 |
0.0% | High Risk · 88 | N/A | |
| 5519 | 14 |
SF | DSL | P | 20 | 26 | 36 | 31 |
+0.1% | High Risk · 100 | N/A | |
| 5520 | 14 |
BOS | DSL | P | 20 | 24 | 36 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5521 | 14 |
MIN | DSL | P | 20 | 25 | 37 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5522 | 14 |
WSH | DSL | P | 20 | 22 | 34 | 25 |
-0.2% | High Risk · 84 | N/A | |
| 5523 | 14 |
NYM | Single-A | 2B | 20 | 19 | 30 | 34 |
0.0% | Wide Range · 69 | N/A | |
| 5524 | IL(Rehab)14 |
PIT | FCL | PIL(Rehab) | 20 | 27 | 46 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5525 | 14 |
ATL | FCL | P | 20 | 26 | 36 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5526 | IL(Rehab)14 |
PHI | FCL | PIL(Rehab) | 20 | 23 | 35 | 28 |
0.0% | High Risk · 92 | N/A | |
| 5527 | 14 |
KC | AAA | P | 20 | 17 | 25 | 26 |
-0.5% | Medium Risk · 53 | N/A | |
| 5528 | 14 |
NYY | FCL | P | 20 | 26 | 40 | 29 |
0.0% | High Risk · 99 | N/A | |
| 5529 | 14 |
CHC | DSL | P | 20 | 25 | 38 | 28 |
0.0% | High Risk · 98 | N/A | |
| 5530 | 14 |
PIT | Single-A | P | 20 | 17 | 27 | 23 |
-0.2% | Medium Risk · 49 | N/A | |
| 5531 | IL(Rehab)14 |
SD | ACL | PIL(Rehab) | 20 | 24 | 36 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5532 | 14 |
HOU | AA | 2B | 20 | 15 | 24 | 27 |
0.0% | Medium Risk · 43 | N/A | |
| 5533 | 14 |
DET | FCL | P | 20 | 24 | 35 | 26 |
+0.1% | High Risk · 90 | N/A | |
| 5534 | 14 |
CIN | ACL | P | 20 | 22 | 33 | 28 |
+0.1% | High Risk · 88 | N/A | |
| 5535 | 14 |
HOU | DSL | P | 20 | 24 | 36 | 28 |
0.0% | High Risk · 93 | N/A | |
| 5536 | 14 |
TEX | DSL | P | 20 | 25 | 42 | 27 |
0.0% | High Risk · 98 | N/A | |
| 5537 | 14 |
MIN | AAA | P | 20 | 20 | 41 | 49 |
0.0% | High Risk · 76 | N/A | |
| 5538 | 14 |
PIT | DSL | P | 20 | 25 | 38 | 29 |
-0.1% | High Risk · 100 | N/A | |
| 5539 | 14 |
WSH | DSL | P | 20 | 24 | 36 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5540 | 14 |
PIT | DSL | P | 20 | 24 | 35 | 29 |
+0.3% | High Risk · 100 | N/A | |
| 5541 | 14 |
TB | DSL | P | 20 | 25 | 36 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5542 | 14 |
CHC | ACL | OF | 20 | 23 | 34 | 26 |
-0.1% | High Risk · 89 | N/A | |
| 5543 | IL(Rehab)14 |
CLE | ACL | PIL(Rehab) | 20 | 24 | 36 | 27 |
0.0% | High Risk · 92 | N/A | |
| 5544 | 14 |
NYY | DSL | P | 20 | 25 | 36 | 30 |
+0.1% | High Risk · 100 | N/A | |
| 5545 | 14 |
WSH | DSL | P | 20 | 25 | 37 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5546 | 14 |
CIN | DSL | P | 20 | 23 | 35 | 25 |
0.0% | High Risk · 85 | N/A | |
| 5547 | 14 |
COL | DSL | P | 20 | 24 | 35 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5548 | 14 |
CWS | High-A | P | 20 | 22 | 33 | 38 |
-0.1% | High Risk · 87 | N/A | |
| 5549 | 14 |
CHC | AA | P | 20 | 18 | 27 | 33 |
-0.5% | Wide Range · 58 | N/A | |
| 5550 | 14 |
MIN | DSL | P | 20 | 24 | 36 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5551 | 13 |
TOR | DSL | P | 20 | 25 | 35 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5552 | 13 |
CIN | AA | P | 20 | 20 | 34 | 45 |
0.0% | High Risk · 82 | N/A | |
| 5553 | 13 |
HOU | DSL | P | 20 | 23 | 34 | 26 |
0.0% | High Risk · 94 | N/A | |
| 5554 | 13 |
TEX | AA | P | 20 | 18 | 28 | 36 |
0.0% | Wide Range · 68 | N/A | |
| 5555 | 13 |
ARI | DSL | P | 20 | 26 | 44 | 27 |
+0.1% | High Risk · 99 | N/A | |
| 5556 | 13 |
BOS | AAA | P | 20 | 16 | 25 | 27 |
+0.1% | Medium Risk · 53 | N/A | |
| 5557 | 13 |
TB | DSL | P | 20 | 25 | 42 | 29 |
-0.1% | High Risk · 100 | N/A | |
| 5558 | 13 |
LAD | ACL | P | 20 | 25 | 38 | 28 |
-0.1% | High Risk · 99 | N/A | |
| 5559 | 13 |
CIN | DSL | P | 20 | 26 | 37 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5560 | IL(7-Day)13 |
DET | FCL | PIL(7-Day) | 20 | 24 | 36 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5561 | 13 |
BAL | DSL | P | 20 | 24 | 36 | 27 |
-0.4% | High Risk · 98 | N/A | |
| 5562 | 13 |
PIT | FCL | P | 20 | 22 | 33 | 26 |
0.0% | High Risk · 88 | N/A | |
| 5563 | IL(Rehab)13 |
NYM | FCL | PIL(Rehab) | 20 | 24 | 39 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5564 | 13 |
HOU | DSL | P | 20 | 25 | 35 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5565 | 13 |
KC | DSL | P | 20 | 24 | 36 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5566 | 13 |
HOU | DSL | P | 20 | 25 | 36 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5567 | 13 |
TOR | DSL | P | 20 | 23 | 34 | 25 |
-0.1% | High Risk · 89 | N/A | |
| 5568 | IL(Rehab)13 |
NYM | FCL | PIL(Rehab) | 20 | 26 | 43 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5569 | 13 |
ARI | DSL | P | 20 | 25 | 35 | 30 |
+0.1% | High Risk · 100 | N/A | |
| 5570 | 13 |
CIN | DSL | P | 20 | 21 | 32 | 26 |
0.0% | High Risk · 88 | N/A | |
| 5571 | 13 |
KC | DSL | C | 20 | 23 | 35 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5572 | 13 |
TEX | DSL | P | 20 | 25 | 41 | 28 |
-0.5% | High Risk · 100 | N/A | |
| 5573 | 13 |
ARI | DSL | P | 20 | 23 | 37 | 27 |
0.0% | High Risk · 98 | N/A | |
| 5574 | 13 |
PHI | High-A | 1B | 20 | 17 | 28 | 36 |
0.0% | Wide Range · 72 | N/A | |
| 5575 | 13 |
TEX | ACL | P | 20 | 26 | 39 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5576 | 13 |
MIN | DSL | P | 20 | 24 | 36 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5577 | 13 |
ATL | FCL | P | 20 | 24 | 35 | 30 |
0.0% | High Risk · 100 | N/A | |
| 5578 | 13 |
MIA | FCL | P | 20 | 25 | 39 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5579 | 13 |
KC | DSL | P | 20 | 21 | 32 | 26 |
0.0% | High Risk · 88 | N/A | |
| 5580 | 13 |
TB | DSL | P | 20 | 23 | 35 | 29 |
-0.2% | High Risk · 100 | N/A | |
| 5581 | IL(60-Day)13 |
MIA | AA | PIL(60-Day) | 20 | 20 | 30 | 40 |
0.0% | High Risk · 86 | N/A | |
| 5582 | 13 |
SD | AAA | P | 20 | 16 | 25 | 23 |
0.0% | Medium Risk · 51 | N/A | |
| 5583 | 13 |
PIT | DSL | P | 20 | 23 | 35 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5584 | 12 |
CIN | DSL | P | 20 | 23 | 35 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5585 | 12 |
ARI | ACL | P | 20 | 23 | 34 | 27 |
-0.1% | High Risk · 98 | N/A | |
| 5586 | 12 |
WSH | FCL | P | 20 | 24 | 36 | 27 |
0.0% | High Risk · 98 | N/A | |
| 5587 | 12 |
MIL | DSL | P | 20 | 25 | 38 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5588 | 12 |
WSH | FCL | P | 20 | 18 | 34 | 42 |
0.0% | Wide Range · 74 | N/A | |
| 5589 | 12 |
BOS | DSL | P | 20 | 25 | 38 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5590 | 12 |
SF | DSL | P | 20 | 24 | 34 | 29 |
+0.1% | High Risk · 100 | N/A | |
| 5591 | IL(Rehab)12 |
COL | ACL | PIL(Rehab) | 20 | 21 | 44 | 35 |
0.0% | High Risk · 90 | N/A | |
| 5592 | 12 |
SF | DSL | P | 20 | 23 | 35 | 28 |
-0.3% | High Risk · 100 | N/A | |
| 5593 | 12 |
CLE | DSL | P | 20 | 23 | 37 | 26 |
+0.3% | High Risk · 98 | N/A | |
| 5594 | 12 |
TB | DSL | P | 20 | 20 | 31 | 25 |
0.0% | High Risk · 88 | N/A | |
| 5595 | 12 |
NYM | DSL | P | 20 | 24 | 39 | 27 |
-0.4% | High Risk · 99 | N/A | |
| 5596 | 12 |
MIA | DSL | P | 20 | 24 | 35 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5597 | 12 |
TEX | High-A | P | 20 | 21 | 33 | 38 |
0.0% | High Risk · 89 | N/A | |
| 5598 | IL(7-Day)12 |
MIA | AA | CIL(7-Day) | 20 | 18 | 28 | 39 |
0.0% | High Risk · 79 | N/A | |
| 5599 | 12 |
DET | DSL | P | 20 | 24 | 34 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5600 | 12 |
BOS | DSL | P | 20 | 24 | 35 | 29 |
+0.1% | High Risk · 100 | N/A | |
| 5601 | 12 |
SD | DSL | P | 20 | 24 | 34 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5602 | 12 |
KC | DSL | P | 20 | 24 | 35 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5603 | 12 |
NYY | DSL | P | 20 | 24 | 34 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5604 | 12 |
NYM | Single-A | P | 20 | 22 | 36 | 36 |
-0.4% | High Risk · 90 | N/A | |
| 5605 | 12 |
BAL | DSL | P | 20 | 23 | 36 | 27 |
0.0% | High Risk · 99 | N/A | |
| 5606 | IL(60-Day)12 |
BOS | AAA | PIL(60-Day) | 20 | 20 | 30 | 44 |
-0.8% | High Risk · 90 | N/A | |
| 5607 | IL(Rehab)12 |
WSH | FCL | PIL(Rehab) | 20 | 21 | 44 | 34 |
0.0% | High Risk · 90 | N/A | |
| 5608 | 12 |
MIA | AAA | P | 20 | 18 | 32 | 48 |
0.0% | High Risk · 78 | N/A | |
| 5609 | 12 |
SF | DSL | P | 20 | 23 | 37 | 25 |
-0.4% | High Risk · 98 | N/A | |
| 5610 | 12 |
TEX | DSL | P | 20 | 22 | 34 | 26 |
0.0% | High Risk · 98 | N/A | |
| 5611 | 12 |
SF | DSL | C | 20 | 21 | 32 | 25 |
0.0% | High Risk · 94 | N/A | |
| 5612 | 12 |
BAL | Single-A | P | 20 | 22 | 35 | 35 |
-0.5% | High Risk · 89 | N/A | |
| 5613 | 12 |
BAL | DSL | P | 20 | 23 | 36 | 26 |
-0.3% | High Risk · 99 | N/A | |
| 5614 | 11 |
ATH | AA | P | 20 | 13 | 26 | 41 |
-0.4% | Wide Range · 59 | N/A | |
| 5615 | 11 |
MIA | DSL | P | 20 | 24 | 41 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5616 | 11 |
CLE | ACL | P | 20 | 23 | 36 | 26 |
-0.2% | High Risk · 99 | N/A | |
| 5617 | 11 |
TEX | DSL | P | 20 | 21 | 32 | 23 |
0.0% | High Risk · 89 | N/A | |
| 5618 | IL(7-Day)11 |
STL | AAA | PIL(7-Day) | 20 | 17 | 39 | 50 |
-0.3% | Wide Range · 74 | N/A | |
| 5619 | IL(Rehab)11 |
NYY | FCL | PIL(Rehab) | 20 | 20 | 41 | 33 |
0.0% | High Risk · 89 | N/A | |
| 5620 | IL(Rehab)11 |
TB | FCL | OFIL(Rehab) | 20 | 21 | 33 | 26 |
0.0% | High Risk · 90 | N/A | |
| 5621 | 11 |
ARI | DSL | P | 20 | 23 | 37 | 25 |
0.0% | High Risk · 98 | N/A | |
| 5622 | 11 |
SEA | ACL | P | 20 | 25 | 39 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5623 | 11 |
BAL | DSL | P | 20 | 23 | 36 | 25 |
-0.1% | High Risk · 98 | N/A | |
| 5624 | 11 |
TB | FCL | P | 20 | 21 | 32 | 25 |
-0.1% | High Risk · 90 | N/A | |
| 5625 | 11 |
NYY | DSL | P | 20 | 24 | 40 | 27 |
0.0% | High Risk · 100 | N/A | |
| 5626 | 11 |
LAD | ACL | P | 20 | 24 | 37 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5627 | 11 |
SD | DSL | P | 20 | 20 | 31 | 22 |
0.0% | High Risk · 88 | N/A | |
| 5628 | 11 |
LAD | DSL | P | 20 | 22 | 34 | 26 |
-0.2% | High Risk · 99 | N/A | |
| 5629 | 11 |
KC | High-A | P | 20 | 22 | 36 | 40 |
0.0% | High Risk · 92 | N/A | |
| 5630 | 11 |
TOR | DSL | P | 20 | 23 | 34 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5631 | 11 |
ATH | ACL | P | 20 | 23 | 38 | 27 |
-0.1% | High Risk · 100 | N/A | |
| 5632 | 11 |
HOU | AAA | SS | 20 | 16 | 35 | 51 |
0.0% | Wide Range · 74 | N/A | |
| 5633 | 11 |
DET | DSL | P | 20 | 23 | 35 | 27 |
-0.1% | High Risk · 100 | N/A | |
| 5634 | 11 |
HOU | DSL | P | 20 | 22 | 33 | 27 |
-0.3% | High Risk · 100 | N/A | |
| 5635 | 11 |
BAL | AAA | P | 20 | 15 | 26 | 36 |
0.0% | Wide Range · 63 | N/A | |
| 5636 | 11 |
BAL | AA | P | 20 | 22 | 34 | 43 |
-0.1% | High Risk · 95 | N/A | |
| 5637 | IL(Rehab)11 |
COL | ACL | PIL(Rehab) | 20 | 24 | 38 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5638 | IL(Rehab)11 |
TOR | FCL | PIL(Rehab) | 20 | 24 | 38 | 27 |
0.0% | High Risk · 100 | N/A | |
| 5639 | 11 |
LAA | ACL | P | 20 | 23 | 33 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5640 | 11 |
DET | DSL | P | 20 | 24 | 38 | 27 |
+0.2% | High Risk · 100 | N/A | |
| 5641 | 11 |
BAL | DSL | P | 20 | 21 | 32 | 25 |
0.0% | High Risk · 98 | N/A | |
| 5642 | 11 |
HOU | AAA | 2B | 20 | 10 | 22 | 31 |
0.0% | Low Risk · 39 | N/A | |
| 5643 | 11 |
NYM | FCL | P | 20 | 23 | 35 | 27 |
-0.2% | High Risk · 100 | N/A | |
| 5644 | IL(Rehab)11 |
PHI | FCL | PIL(Rehab) | 20 | 24 | 38 | 27 |
0.0% | High Risk · 100 | N/A | |
| 5645 | 10 |
WSH | High-A | C | 20 | 18 | 29 | 36 |
-0.1% | High Risk · 84 | N/A | |
| 5646 | 10 |
TEX | DSL | P | 20 | 23 | 35 | 27 |
+0.1% | High Risk · 100 | N/A | |
| 5647 | 10 |
TOR | DSL | P | 20 | 22 | 33 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5648 | 10 |
TOR | DSL | P | 20 | 21 | 33 | 26 |
0.0% | High Risk · 99 | N/A | |
| 5649 | 10 |
ATH | AAA | P | 20 | 14 | 23 | 25 |
0.0% | Medium Risk · 56 | N/A | |
| 5650 | 10 |
SD | AAA | P | 20 | 16 | 27 | 41 |
-0.2% | Wide Range · 74 | N/A | |
| 5651 | 10 |
CHC | ACL | P | 20 | 23 | 36 | 28 |
0.0% | High Risk · 100 | N/A | |
| 5652 | 10 |
KC | AA | P | 20 | 20 | 29 | 40 |
0.0% | High Risk · 92 | N/A | |
| 5653 | 10 |
WSH | High-A | P | 20 | 21 | 33 | 39 |
-0.5% | High Risk · 92 | N/A | |
| 5654 | 10 |
CLE | ACL | P | 20 | 22 | 34 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5655 | 10 |
ARI | High-A | P | 20 | 20 | 30 | 36 |
0.0% | High Risk · 89 | N/A | |
| 5656 | 10 |
NYY | DSL | P | 20 | 20 | 32 | 25 |
0.0% | High Risk · 98 | N/A | |
| 5657 | IL(60-Day)10 |
COL | AAA | PIL(60-Day) | 20 | 18 | 28 | 43 |
0.0% | High Risk · 90 | N/A | |
| 5658 | 10 |
DET | DSL | P | 20 | 21 | 33 | 24 |
0.0% | High Risk · 98 | N/A | |
| 5659 | IL(Rehab)10 |
CLE | ACL | PIL(Rehab) | 20 | 23 | 38 | 28 |
-0.5% | High Risk · 100 | N/A | |
| 5660 | IL(Rehab)10 |
SF | ACL | PIL(Rehab) | 20 | 20 | 44 | 35 |
0.0% | High Risk · 92 | N/A | |
| 5661 | 10 |
SF | Single-A | P | 20 | 18 | 29 | 33 |
0.0% | High Risk · 88 | N/A | |
| 5662 | 10 |
ATH | AA | P | 20 | 21 | 30 | 41 |
0.0% | High Risk · 93 | N/A | |
| 5663 | 10 |
SD | DSL | P | 20 | 23 | 35 | 27 |
0.0% | High Risk · 100 | N/A | |
| 5664 | 10 |
WSH | FCL | P | 20 | 20 | 32 | 25 |
0.0% | High Risk · 98 | N/A | |
| 5665 | 10 |
CWS | ACL | P | 20 | 23 | 35 | 27 |
0.0% | High Risk · 100 | N/A | |
| 5666 | 10 |
LAD | DSL | P | 20 | 23 | 38 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5667 | 10 |
NYM | AAA | P | 20 | 13 | 27 | 43 |
0.0% | Wide Range · 72 | N/A | |
| 5668 | IL(Rehab)9 |
DET | FCL | PIL(Rehab) | 20 | 20 | 41 | 33 |
0.0% | High Risk · 100 | N/A | |
| 5669 | 9 |
LAA | DSL | P | 20 | 23 | 38 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5670 | 9 |
BOS | DSL | P | 20 | 21 | 33 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5671 | 9 |
ARI | DSL | P | 20 | 21 | 33 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5672 | 9 |
SF | DSL | P | 20 | 20 | 31 | 24 |
0.0% | High Risk · 98 | N/A | |
| 5673 | 9 |
TOR | Single-A | C | 20 | 17 | 28 | 33 |
+0.1% | High Risk · 85 | N/A | |
| 5674 | 9 |
SEA | DSL | P | 20 | 21 | 32 | 25 |
+0.2% | High Risk · 100 | N/A | |
| 5675 | IL(Rehab)9 |
MIN | FCL | PIL(Rehab) | 20 | 20 | 32 | 25 |
0.0% | High Risk · 100 | N/A | |
| 5676 | 9 |
LAD | DSL | P | 20 | 23 | 38 | 25 |
-0.1% | High Risk · 100 | N/A | |
| 5677 | 9 |
TOR | DSL | P | 20 | 22 | 32 | 26 |
-0.1% | High Risk · 100 | N/A | |
| 5678 | 9 |
HOU | High-A | P | 20 | 12 | 25 | 23 |
-0.1% | Medium Risk · 53 | N/A | |
| 5679 | 9 |
MIN | FCL | P | 20 | 22 | 34 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5680 | 9 |
LAA | ACL | 3B | 20 | 16 | 38 | 34 |
0.0% | High Risk · 81 | N/A | |
| 5681 | 8 |
PHI | AA | 2B | 20 | 14 | 26 | 35 |
0.0% | Wide Range · 73 | N/A | |
| 5682 | 8 |
DET | DSL | P | 20 | 19 | 31 | 23 |
0.0% | High Risk · 98 | N/A | |
| 5683 | 8 |
SF | DSL | P | 20 | 19 | 30 | 23 |
-0.1% | High Risk · 98 | N/A | |
| 5684 | IL(Rehab)8 |
HOU | FCL | PIL(Rehab) | 20 | 21 | 31 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5685 | IL(Rehab)8 |
BAL | FCL | PIL(Rehab) | 20 | 21 | 32 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5686 | IL(Rehab)8 |
CLE | ACL | SSIL(Rehab) | 20 | 19 | 30 | 26 |
0.0% | High Risk · 94 | N/A | |
| 5687 | IL(Rehab)8 |
TB | FCL | PIL(Rehab) | 20 | 17 | 37 | 33 |
0.0% | High Risk · 91 | N/A | |
| 5688 | 8 |
TEX | DSL | P | 20 | 20 | 30 | 25 |
0.0% | High Risk · 100 | N/A | |
| 5689 | 8 |
TEX | AAA | P | 20 | 14 | 27 | 45 |
0.0% | High Risk · 75 | N/A | |
| 5690 | 7 |
ARI | DSL | P | 20 | 20 | 32 | 23 |
+0.1% | High Risk · 100 | N/A | |
| 5691 | 7 |
TOR | DSL | P | 20 | 20 | 31 | 23 |
0.0% | High Risk · 100 | N/A | |
| 5692 | IL(Rehab)7 |
ARI | ACL | PIL(Rehab) | 20 | 18 | 30 | 25 |
0.0% | High Risk · 100 | N/A | |
| 5693 | IL(Rehab)7 |
HOU | FCL | PIL(Rehab) | 20 | 20 | 30 | 25 |
0.0% | High Risk · 100 | N/A | |
| 5694 | 7 |
NYY | DSL | P | 20 | 20 | 32 | 23 |
0.0% | High Risk · 100 | N/A | |
| 5695 | IL(Rehab)7 |
CHC | ACL | PIL(Rehab) | 20 | 18 | 37 | 29 |
0.0% | High Risk · 100 | N/A | |
| 5696 | IL(7-Day)6 |
BOS | AA | PIL(7-Day) | 20 | 18 | 28 | 40 |
0.0% | High Risk · 99 | N/A | |
| 5697 | IL(Rehab)6 |
BAL | High-A | PIL(Rehab) | 20 | 17 | 30 | 39 |
-0.1% | High Risk · 97 | N/A | |
| 5698 | IL(Rehab)6 |
SD | ACL | PIL(Rehab) | 20 | 19 | 30 | 25 |
0.0% | High Risk · 100 | N/A | |
| 5699 | 6 |
DET | DSL | P | 20 | 20 | 30 | 23 |
0.0% | High Risk · 100 | N/A | |
| 5700 | 6 |
BAL | FCL | P | 20 | 17 | 40 | 34 |
-0.3% | High Risk · 100 | N/A | |
| 5701 | 6 |
PHI | AAA | P | 20 | 17 | 27 | 42 |
0.0% | High Risk · 97 | N/A | |
| 5702 | 6 |
MIA | AA | P | 20 | 14 | 26 | 39 |
0.0% | High Risk · 84 | N/A | |
| 5703 | 5 |
DET | DSL | P | 20 | 18 | 29 | 23 |
0.0% | High Risk · 100 | N/A | |
| 5704 | 5 |
SF | AA | P | 20 | 15 | 38 | 51 |
0.0% | High Risk · 88 | N/A | |
| 5705 | 5 |
PHI | AAA | P | 20 | 11 | 27 | 50 |
0.0% | Wide Range · 75 | N/A | |
| 5706 | 5 |
TB | DSL | P | 20 | 18 | 29 | 22 |
0.0% | High Risk · 100 | N/A | |
| 5707 | IL(Rehab)4 |
SEA | ACL | PIL(Rehab) | 20 | 15 | 32 | 31 |
0.0% | High Risk · 100 | N/A | |
| 5708 | IL(Rehab)4 |
TOR | FCL | PIL(Rehab) | 20 | 13 | 29 | 31 |
0.0% | High Risk · 92 | N/A | |
| 5709 | 4 |
SD | DSL | P | 20 | 15 | 33 | 27 |
0.0% | High Risk · 100 | N/A | |
| 5710 | 3 |
WSH | FCL | P | 20 | 14 | 27 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5711 | 3 |
MIN | AA | P | 20 | 13 | 28 | 43 |
0.0% | High Risk · 90 | N/A | |
| 5712 | 3 |
NYY | AA | OF | 20 | 9 | 23 | 30 |
+0.1% | Medium Risk · 53 | N/A | |
| 5713 | 1 |
WSH | FCL | P | 20 | 13 | 27 | 27 |
0.0% | High Risk · 100 | N/A | |
| 5714 | 1 |
SF | AA | P | 20 | 9 | 24 | 30 |
0.0% | Wide Range · 70 | N/A | |
| 5715 | IL(Rehab)1 |
KC | ACL | PIL(Rehab) | 20 | 9 | 26 | 26 |
0.0% | High Risk · 100 | N/A | |
| 5716 | IL(7-Day)1 |
BAL | AA | PIL(7-Day) | 20 | 8 | 25 | 43 |
0.0% | High Risk · 100 | N/A | |
| 5717 | 1 |
NYM | AA | P | 20 | 8 | 23 | 37 |
0.0% | High Risk · 77 | N/A | |
| 5718 | 1 |
SD | AA | P | 20 | 7 | 23 | 41 |
0.0% | High Risk · 100 | N/A | |
| 5719 | 1 |
CHC | ACL | P | 20 | 7 | 25 | 28 |
0.0% | High Risk · 92 | N/A |
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong Public Top 100 pressure based on the current model profile.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Strong baseline profile, but current performance is lagging.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Recent model signal weakened; watch the next run for confirmation.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current model profile is worth tracking against the next run.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Interesting signal, but model confidence is still developing.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.
Current performance is running ahead of the longer-term baseline.